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Abstract for whole thesis  
 
Background 
Estimates of Paediatric HIV are essential for planning national HIV programs.  Although 
there is a large amount of empirical data on the prevalence of adult HIV from antenatal 
clinics and national surveys there is very little HIV data for children, necessitating 
estimates based on knowledge of: HIV infection in pregnant women; transmission rates 
among pregnant and breastfeeding women according to their treatment status; and 
survival of infants infected in different ways.  It is essential that these inputs into 
estimating paediatric HIV are as accurate as possible as there is little empirical data to 
calibrate the final estimates of prevalence of paediatric HIV.   Currently there are gaps in 
the understanding of some of the inputs needed to estimate paediatric HIV and a 
potential to improve estimates as new data become available, particularly as more 
widespread availability of antiretroviral treatment changes the circumstances in which 
children become infected. 
 
Aims and Objectives 
The aim of the research is to improve and fill gaps in knowledge about the HIV epidemic 
and thereby improve estimates of paediatric HIV.  Objectives include improving 
estimates of survival of infected children, exploring the acquisition of HIV by women in 
relation to incidence during pregnancy, furthering understanding of the impact of HIV on 
fertility and understanding the biases inherent in different data sources. 
 
Implications 
The new empirical evidence and rigorous methods developed to evaluate the inputs 
needed to estimate the number of children born to HIV positive women and the 
prevalence of paediatric HIV will produce more reliable HIV epidemic projections, and 
will improve information available to policy makers and programme planners.  
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LSHTM London School of Hygiene and Tropical Medicine 
MTCT   Mother-to-Child Transmission 
NIMR  National Institute for Medical Research 
PCR  Polymerase chain reaction 
PMTCT  Prevention of Mother-to-Child Transmission 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
UNAIDS Joint United Nations Programme on HIV/AIDS 
VCT   Voluntary Counselling and testing 
WHO   World Health Organisation  
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1 Introduction to thesis 
 
 
1.1 Background 
Estimating the number of children born to HIV positive mothers and living with HIV is 
essential for providing reliable estimates of the magnitude and trend of the paediatric 
epidemic.  These estimates are needed for national programme planning, policy 
formulation and resource allocation 1, 2.  Most populations with a generalised HIV 
epidemic in sub Saharan Africa have very limited population-based data to estimate 
paediatric HIV.  HIV prevalence is usually measured using data from antenatal clinic 
surveillance and, where available, national HIV surveys such as Demographic Health 
Surveys 3.  Best estimates of age specific fertility within a country come from the United 
Nations, Department of Economic and Social Affairs, Population Division, who fit trend 
lines to data sources that are available for each country, such as census data and 
demographic and health surveys, and, in more developed countries, vital registration 
data.   From these starting points, in order to estimate the number of children born to HIV 
positive women, we also need to understand differences in fertility between HIV positive 
and negative women.  To estimate the number of infected children born to HIV positive 
mothers, mother to child transmission probabilities are required. Finally, to estimate the 
number of children living with HIV by age who were infected through MTCT we need to 
know their survival pattern from time of infection.  These estimates are needed to 
estimate and project the HIV epidemic and are used in models such as the UNAIDS 
Spectrum model which is used by national programs and UNAIDS to prepare annual 
estimates of the status of the HIV epidemic worldwide 4. 
 
Through my work prior to this PhD on both paediatric and adult survival from HIV, with 
colleagues at the London School of Hygiene and Tropical Medicine 5-7, I became involved 
with the UNAIDS reference group on estimates, modelling and projections8.  What 
quickly became evident at that time was the paucity of empirical evidence on which to 
base the estimates and projections of the HIV epidemic, particularly for paediatric HIV.  
I have been involved with ALPHA (Analysing Longitudinal Population-based HIV/AIDS 
data on Africa), a network of HIV longitudinal surveillance studies9 (see page 21) from 
its inception in 2005, which opened up a new pool of data that could help provide 
empirical data on the HIV epidemic.  My involvement with the ALPHA network and other 
work using large nationally representative surveys10, 11 led me to the work in this PhD 
which aims to improve and update empirical evidence to inform the estimates and 
projections of the HIV epidemic.   
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This PhD will focus on the three distinct aspects of paediatric HIV calculations: paediatric 
survival from HIV; mother to child transmission rates and differences in fertility by HIV 
status.   
 
 
1.2 Overarching Rationale  
Inputs into the estimates of the number of children born to HIV positive women and the 
prevalence of paediatric HIV have often been based on very small amounts of empirical 
evidence.  Over the years more data have become available which gives the opportunity 
to update, improve and assess levels, patterns and changes over time.  It is particularly 
important to capture change, as since around 2005 antiretroviral treatment began to be 
rolled out in sub-Saharan Africa, with some countries now having very high coverage.   
Fertility of HIV positive women compared to HIV negative women is a key input into 
estimates of the number of children born to HIV positive women, but there is no 
consensus on the impact of ART on fertility.  It is essential to try to measure any changes 
and understand the underlying dynamics in order to be able to provide accurate 
estimates for national HIV programs of the number of children born to HIV positive 
women and the prevalence of paediatric HIV. 
 
 
1.3 Overview of Data  
This section highlights the new data that became available prior to this PhD that 
underpins this PhD and gave rise to the objectives set out in section 1.4 of this chapter  
 
1.3.1 Pooled Clinical Trial and cohort study data  
This dataset is a pooled dataset of clinical and cohort study data from sub Saharan Africa 
prior to the introduction of infant antiretroviral treatment. It is a child based data set with 
follow up from birth, including timing of HIV infection and survival status along with the 
HIV status of the mother and breastfeeding patterns.  At the time of creating the pooled 
dataset, the trials represented the vast majority of the clinical research studies performed 
since the mid 90’s on the African continent on the prevention of mother-to-child 
transmission of HIV (PMTCT). 
 
The dataset was prepared by the University of Bordeaux and is described in detail 
elsewhere12, 13  (chapter 3, page 52). In brief, data from 12 clinical trials and cohort 
studies in Southern, Eastern and Western Africa were combined into the same dataset.  
Interventions in these studies included various peripartum antiretroviral prophylactic 
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regimens14-22, vitamin A23, and birth canal cleansing24.  Most of the study sites (n=8) were 
located in reference hospitals of capital or large cities; three studies were based in 
antenatal care clinics, or a mixture of the two, and one in a mixture of both urban and 
rural settings. The median follow up time ranged from 300 to 1096 days, and studies 
tested for HIV infection in children at regular intervals in the first 18 months.    
 
1.3.1.1 Candidate’s role in data preparation  
All the data in this data set are secondary data.  I was part of the preliminary talks 
about preparation of the pooled dataset and contributed to the discussions about what 
needed to be included.  Bordeaux University collated the dataset and produce the final 
version.   I prepared the dataset for the analysis in this PhD. 
 
1.3.2 ALPHA network data 
The ALPHA network is a network of ten community based, longitudinal HIV studies in 
Eastern and Southern Africa9.  Data for this PhD comes from six of the study sites from 
Uganda (2), Tanzania (1), Malawi (1), Zimbabwe (1) and South Africa (1) (Figure 1.1). 
Table 1.1 summarises the study sites.  Study start dates range from 1989 in Masaka to 
2002 in Karonga.   
Figure 1.1: ALPHA network study sites, green circles are the study sites used in this PhD 
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Table 1.1: Description of the ALPHA Network study sites used in this PhD (Abridged from Reniers et 
al9) 
Name  Short Name  Institutional affiliation 
URL 
Kyamulibwa General 
Population Cohort  
Masaka MRC/UVRI Research Unit on AIDS 
http://www.mrcuganda.org/research/research-
site/kyamulibwa-field-station 
Rakai Community 
Cohort Study  
Rakai Rakai Health Sciences Program, Uganda Virus Research 
 Institute / Makerere University 
http://www.rhsp.org 
Magu Household 
Demographic  
Surveillance System 
Kisesa Tazama Project, Tanzania National Institute  
for Medical Research  
http://www.tazamaproject.org/ 
Karonga Health and 
Demographic 
Surveillance System 
Karonga Malawi Epidemiology and Intervention Research Unit 
(MEIRU), London School of Hygiene 
 and Tropical Medicine  
http://www.lshtm.ac.uk/eph/ide/research/kps/ 
Manicaland HIV/STD 
Prevention Project 
Manicaland Biomedical Research and Training 
 Institute (Harare), and Imperial College (London) 
http://www.manicalandhivproject.org/ 
Africa Centre 
Demographic 
Information System 
(ACDIS) 
uMkhanyakude Africa Centre for Population Health 
www.africacentre.ac.za/ 
   
Name  Location, Country Demographic 
surveillance: 
start/frequency  
Serological  
survey: 
start/frequency  
Kyamulibwa General 
Population Cohort  
Kalungu District 
(formerly Masaka), 
Uganda 
1989: 
Annual 
1989: 
Annual. Every 2 years 
from 2012 
Rakai Community 
Cohort Study  
Rakai District, Uganda 1995: 
Every 12-16 months 
1995: 
Every 12-16 months 
Magu Household 
Demographic  
Surveillance System 
Magu District 
(Mwanza Region), 
Tanzania 
1994: 
1-2 times per year 
1994: 
 Approx. every 3 years 
Karonga Health and 
Demographic 
Surveillance System 
Karonga District, 
Malawi 
2002: 
Continuous 
Annual survey from 
2007 to 2011. New 
residents and 
individuals with long 
test interval since 2012 
Manicaland HIV/STD 
Prevention Project 
Manicaland Province, 
Zimbabwe 
1998: 
Every 2-3 years 
2002: 
Every 2-3 years 
Africa Centre 
Demographic 
Information System 
(ACDIS) 
uMkhanyakude 
(formely Hlabisa) 
Discrict, South Africa  
2000:  
bi-annual 
2003-2004:  
Annual 
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1.3.2.1 Overview of Study sites 
This section gives a brief description of each of the study sites used in this PhD outlining 
the main features of each study site in relation to the collection of demographic and HIV 
testing data.   
Karonga 
The Karonga Demographic Surveillance Study (DSS) is located in rural northern Malawi; 
it was established in 2002 and has a total population of around 35,000.  The demographic 
surveillance data have been continuously collected using key informants, who are trained 
to record vital events and movements within their cluster of households25.   Population-
based HIV testing in the DSS based on voluntary counselling and testing (VCT) was 
undertaken in four annual rounds from 2007-2011 25 and average adult HIV prevalence 
between these dates was 8% 26.   
Kisesa 
The Kisesa DSS is located in Mwanza in north western Tanzania and was established 
in 1994. It is predominately rural with a small trading centre on the main road from 
Mwanza City to the Kenyan border and has a population of around 34,000. The average 
HIV prevalence between 1994 and 2010 was 6% 27.  The frequency of the DSS has 
varied but is approximately once or twice a year.  HIV surveys are done separately to 
the demographic surveillance rounds, with the data linked afterwards using unique 
identifiers.  Temporary village clinics are used to which people are transported from their 
homes.  Prior to the availability of antiretroviral therapy, testing protocols used informed 
consent without disclosure, so that participants did not learn the results of the HIV 
research tests, however with the advent of ART, sites began to offer full pre-test and 
post-test counselling to the participants during the data collection round.  Participants 
are still not obliged take part in the counselling or to learn their results.   
Manicaland 
The Manicaland study in Zimbabwe was established in 1998. A prospective household 
census (population size approximately 37,000) and general population cohort survey 
(10,000-12,000) were initiated in 12 geographically distinct study sites spread across 
three districts, with follow-up rounds conducted every 2 or 3 years. The Manicaland study 
sites comprise of two small towns, four agricultural estates, two roadside settlements 
and four subsistence farming areas. Overall adult HIV prevalence was around 25% in 
the late 1990s and has declined steadily to around 15% in 2012-13 28.  HIV testing is 
conducted only for research purposes 29. 
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Masaka 
The Masaka DSS is located in rural south west Uganda and was established in 1989.  
Its initial population was around 10,000 which then increased to 18,000 when 10 villages 
were added to the census area30, 31.  Average HIV prevalence between 1989 and 2011 
was 8% 32. DSS data are collected through an annual household census, and through 
key informants who register births and deaths on a monthly basis. HIV testing was 
undertaken annually until 2011, with biennial surveys conducted subsequently. HIV test 
results are reported back to respondents if requested.    
Rakai 
The Rakai Health Sciences Program runs the Rakai Community Cohort Study (RCCS), 
with an adult population of between 12,000-16,000. Data were collected from 1999 with 
adult HIV prevalence in 2002/03 reported to be 11.4 % 33.  In Rakai the HIV surveys were 
done separately to the demographic surveillance rounds.  Samples were taken in the 
home and tested at the field laboratory then returned by a community based counsellor 
to those participants requesting the results.  The data were linked afterwards using 
unique identifiers. 
uMkhanyakude 
The African Health Research Institute (AHRI), formally known as Africa Centre, 
demographic surveillance study was established in 2000 in uMkhanyakude, in rural 
KwaZulu-Natal, South Africa; each round covers approximately 90,000 resident and non-
resident household members in approximately 12,000 households, with a key-household 
respondent 34.  Individual HIV surveillance for resident adults (≥15 years) was added in 
2003 and adult HIV prevalence in 2012 was around 28% and annual incidence in the 15-
50 year age group for women was about 5% 35.  DSS data are collected every six months, 
and the HIV serosurveys are conducted every year.  Participants can obtain their HIV 
test results from counselling centres in the research area 34.  
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1.3.2.2 ALPHA Data format 
Each study site provides standardised data that conforms to data specifications provided 
by ALPHA.  Specifications used in this PhD are as follows (See appendix 1) 
1. DSS residency episodes: entry and exit date, entry type (baseline, birth or in-
migration) and exit type (still present in study site, death, out-migration, loss to 
follow up) for calculating person-years of observation and dates of death 
2. HIV test data: dates and results of HIV tests for the classification of individuals 
by HIV status and tracking of any changes in this status over time 
3. Birth Records: Dates of delivery of lives births (and stillbirths if recorded) 
1.3.2.3 Candidate’s role in data preparation  
I did not play any role in collecting primary data but was the lead in the ALPHA team 
involved with producing the data specifications sites needed for harmonising data.  I 
translated the Kisesa site data into the standard format and also advised other ALPHA 
sites on the production of the ALPHA specifications.  I pooled the site specific 
standardised data from the ALPHA sites and prepared it for analysis.  
  
26 
 
1.3.3 Demographic and Health surveys 
Demographic and Health surveys (DHS) and AIDS indicator surveys (AIS) are nationally 
representative surveys that use standard questionnaires to collect data over a large 
range of countries within and outside sub-Saharan Africa36.    Data collected include data 
on fertility, family planning, maternal and child health, gender, malaria, and nutrition 
along with socio-demographic background characteristics.  Since 2001 HIV testing has 
been undertaken in selected DHS surveys.  The HIV testing was on a sub sample of the 
DHS and was generally done so the power was adequate to measure HIV prevalence in 
15-49 year olds disaggregated by sex and urban and rural residence. Details of the 
survey methodology for HIV testing is provided elsewhere37. 
Table 1.2 shows the DHS and AIS from Sub-Saharan Africa used in this PhD along with 
the sample number and HIV prevalence. 
1.3.3.1 Candidate role in data preparation  
I did not play any role in collecting primary data or producing the final country datasets.  
With permission from the DHS program I download the data for multiple surveys, 
standardised and pooled them and prepared the final dataset ready for analysis. 
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Table 1.2: DHS and AIS used in PhD 
Region Survey Year n 
HIV prevalence 
Women 15-49 
 (95% CI)* 
Southern Africa     
  
Lesotho 2004 3030 26.3 (24.5-28.2) 
  Lesotho 2009 3778 26.7 (25.0-28.6) 
  Lesotho 2014 3175 29.7 (27.7-31.8) 
  Namibia 2013 4051 16.9 (15.4-18.4) 
  Swaziland 2006-07 4424 31.1 (29.4-32.9) 
  Zimbabwe 2005-06 6947 21.1 (19.7-22.6) 
  Zimbabwe 2010-11 7313 17.7 (16.6-18.8) 
  Zimbabwe 2015 8667 16.7 (15.6-17.8) 
East and Mid Africa     
  
Burundi 2010 4533 1.7 (1.4-2.1) 
  Kenya 2003 3151 8.7 (7.6-10.0) 
  Kenya 2008-09 3641 8.0 (6.8-9.3) 
  Malawi 2004 2686 13.3 (12.0-14.8) 
  Malawi 2010 7091 12.9 (11.8-14.1) 
 
 
Malawi 2015-16 7737 10.8 (9.9-11.7) 
  Rwanda 2005 5641 3.6 (3.1-4.2) 
  Rwanda 2010 6917 3.7 (3.3-4.2) 
  Rwanda 2014-15 6752 3.6 (3.2-4.1) 
  Tanzania 2007-08 8179 6.6 (5.9-7.4) 
  Tanzania 2011-12 9756 6.2 (5.6-6.8) 
  Zambia 2007 5502 16.1 (14.7-17.5) 
  Zambia 2013-14 14719 15.1 (14.2-16.0) 
West and Central Africa and Ethiopia    
  
Burkina 2003 4086 1.5 (1.2-2.0) 
  Burkina 2010 8298 1.2 (0.9-1.5) 
  Cameroon 2004 5128 6.6 (5.9-7.4) 
  Cameroon 2011 7221 5.6 (5.0-6.3) 
  Chad 2014-15 5656 1.8 (1.4-2.2) 
  Cote Ivoire 2005 4413 6.4 (5.5-7.5) 
  Cote Ivoire 2011-12 4509 4.6 (3.9-5.4) 
  DRC 2007 4492 1.6 (1.2-2.2) 
  DRC 2013-14 9264 1.6 (1.2-2.2) 
  Ethiopia 2005 5736 1.9 (1.4-2.4) 
  Ethiopia 2011 14695 1.9 (1.5-2.3) 
  Gabon 2012 5459 5.8 (4.7-7.1) 
  Gambia 2013 4089 2.1 (1.6-2.8) 
  Ghana 2003 5097 2.3 (1.9-2.8) 
  Guinea 2005 3742 1.9 (1.4-2.6) 
  Guinea 2012 4622 2.1 (1.7-2.6) 
  Liberia 2007 6382 1.8 (1.4-2.1) 
  Liberia 2013 4397 2.0 (1.5-2.8) 
  Mali 2006 4528 1.4 (1.0-2.0) 
  Mali 2012-13 4806 1.3 (1.0-1.8) 
  Niger 2006 4406 0.6 (0.4-0.9) 
  Niger 2012 5000 0.4 (0.2-0.5) 
  Sao Tome 2009 2378 1.3 (0.8-2.0) 
  Senegal 2005 4229 0.7 (0.4-1.0) 
  Senegal 2010-11 5326 0.6 (0.4-0.8) 
  Sierra Leone 2008 3448 1.7 (1.3-2.3) 
  Sierra Leone 2013 7695 1.7 (1.3-2.0) 
    Togo 2013-14 4737 3.1 (2.6-3.7) 
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1.4 Overall aim and objectives 
The overall aim of this research is, in light of the availability of new data, to make use of 
empirical evidence to improve estimates of the number of children born to HIV positive 
women and hence improve estimates of the prevalence of paediatric HIV in populations 
with generalised HIV epidemics.   
The objectives are as follows: 
Objective 1: describe different patterns of paediatric survival by timing of HIV infection, 
using data from pooled clinical trial and cohort study data. 
Objective 2: investigate population level risk of acquisition of HIV in pregnant women, 
using longitudinal data from the ALPHA network. 
Objective 3: investigate whether there is an impact of ART on fertility at the population 
level, using longitudinal data from the ALPHA network. 
Objective 4: estimate the population impact of HIV on fertility and examine the effect of 
duration of infection on fertility and whether this is independent of age using longitudinal 
data from the ALPHA network.  
Objective 5: estimate the population impact of HIV on fertility and investigate if there are 
variations by region, urban and rural residence and ART coverage using cross sectional 
data from demographic and health surveys. 
Objective 6:  investigate possible biases affecting the analysis of the impact of HIV on 
fertility that arise from the use of retrospective data such as DHS or prospective data, 
such as ALPHA network 
Objective 7: identify how behaviour contributes to HIV subfertility to gain a better 
understanding of the contribution it makes to differences in fertility by HIV status 
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1.5 Overview of methods 
The methods used to answer the objectives of this PhD are described in detail in each 
chapter.   This section gives an overview of these methods by the objectives outlined in 
section 1.4. 
 
Objective 1: describe different patterns of paediatric survival by timing of HIV infection, 
using data from pooled clinical trial and cohort study data. 
 
Data from 12 clinical trials and cohort studies in Southern, Eastern and Western Africa 
with data on child survival in the absence of antiretroviral therapy were included in a 
pooled analysis where all the data was combined into the same dataset.  Along with data 
on child survival with follow up from birth by timing of HIV infection and survival status 
each dataset also included data the HIV status of the mother and breastfeeding patterns.   
Most study sites (n = 8) were situated in reference hospitals of capital or large cities; 
three studies were based in antenatal care clinics, or a mixture of the two, and one in a 
mixture of both urban and rural settings.  The median follow up time ranged from 300 to 
1096 days, and studies tested at regular intervals in the first 18 months. 
 
Kaplan-Meier analysis was used to calculate survival curves of children by timing of 
infection.  Date of infection was taken to be the midpoint between the last negative test 
and the first positive HIV test (antibody or PCR depending on age).  Where there was no 
negative test for those infected early, the midpoint between birth and first positive test 
was taken.  A sensitivity analysis was undertaken to assess how results varied according 
to the date imputed.   
 
The net survival probability, , if HIV-related mortality is the only operative cause of 
death, was calculated from the proportions of HIV-infected children surviving to age x, 
, and the proportion of uninfected children surviving to age x, , using the 
usual relationship for cause deleted life tables: 
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To make the distribution of the HIV-negative children similar to that of the HIV-infected 
children, the HIV-negative ones were weighted so that their distribution by entry into 
observation, study group, and timing of start of risk exposure matched those of the HIV-
infected children.    
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The double Weibull provides a good functional representation of paediatric survival curve 
as it allows for initial high mortality followed by rising mortality at later time points 6, 38, 
taking the form: 
 
[ ]{ } ( ) [ ]{ }21 21 exp1exp)( µµ λpiλpi xxxlA ⋅−⋅−+⋅−⋅=  
 
Where lA(x) is the survival at time x from HIV/AIDS. By studying the empirical curves 
depicting net survival by time since infection we used the double Weibull curve to 
produce functional representations of the net survival post infection of children for 
different times of infection, in the perinatal period and during early and late breastfeeding.   
  
Objective 2: investigate population level risk of acquisition of HIV in pregnant women, 
using longitudinal data from the ALPHA network. 
Data from the ALPHA network was used as outlined in section 1.3.2.  For this objective 
I used data from six of the sites Karonga, Kisesa, Masaka, Rakai, Manicaland and 
uMkhanyukude.  Data collection was sufficiently similar to allow pooled analyses, with 
allowance for unobserved heterogeneity between sites. 
 
Women of reproductive age (15- 49 years old) were eligible for inclusion in the analysis.  
Person-years of observation for each woman were split into time not-pregnant, pregnant 
and one year postpartum.  For a woman to be included in the analysis she must have 
had at least two HIV tests, the first of which must have been negative to allow observation 
of any sero-conversion. Follow-up time started from the date of the first negative test and 
lasted until exit at the date of their last test or at the date of sero- conversion, if earlier.    
Time between HIV surveillance tests varies across the different sites ranging from annual 
to three year inter-test intervals; further, a person might miss a surveillance round thus 
extending the period between tests.  For all study sites, the interval between HIV tests is 
longer than a full gestation pregnancy, and we cannot be sure whether the sero-
conversion occurred before, during or after the pregnancy period.  To allow for this 
uncertainty, the analysis was repeated 100 times, each time with the estimated sero-
conversion date assigned at a random point between the last negative and first positive 
dates, rates and crude and adjusted hazard rate ratios (HRR) were calculated using 
piecewise exponential regression, so that age (grouped into conventional five year age 
groups), pregnancy status and calendar time could be treated as time-varying factors.  
Rates and the log of the hazard rate ratios from the imputations were combined using 
Rubin’s rules 39 to give confidence intervals that reflect the uncertainty about the exact 
date of sero-conversion.  The crude hazard rate ratios converged at around 20 
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imputations with the adjusted rate ratios taking 30 to 40 imputations to converge to stable 
values.  
 
Objective 3: investigate whether there is an impact of ART on fertility at the population 
level, using longitudinal data from the ALPHA network. 
Data from the ALPHA network was used as outlined in section 1.3.2.  Fertility data that 
span the pre-ART era and the time of introduction and widespread use of ART that were 
needed to complete the objective above were available from four of these community-
based demographic and HIV surveillance sites: Kisesa, Masaka, Rakai and 
uMkhanyukude. The population included in this analysis is women of reproductive age 
(15-44) living in the surveillance areas between the time point corresponding to five years 
before ART was introduced, to the last date for which data were available for each site 
up to 2015.   
 
All live births to women aged 15–44 years old while under observation in the study were 
included in the analysis, classified by mother’s age, area of residence and HIV status at 
time of the birth, and by ART availability in the community.   Women aged 45-49 year 
olds were not included to create the standard fertility analysis grouping of 15-49 years 
as there were very few births to HIV positive women at this age.   
 
I used Poisson regression to calculate age adjusted fertility rate ratios over time by HIV 
status, and investigated the interaction between ART period and HIV status to ascertain 
whether trends over time were different for HIV positive and negative women.   I adjust 
for age and area of residence in this analysis to control for any changes in the 
composition of the study site that may have occurred between the pre and post ART 
periods.   The analysis was performed separately for each site and pooled across sites 
where appropriate, the pooled results were adjusted by study site. 
 
Objective 4: estimate the population impact of HIV on fertility and examine the effect of 
duration of infection on fertility and whether this is independent of age using longitudinal 
data from the ALPHA network. 
 
Data from the ALPHA network was used as outlined in section 1.3.2.  Fertility data from 
the pre-ART era that were needed to complete the objective above were available from 
three of the community-based demographic and HIV surveillance sites: Kisesa, Masaka 
and Manicaland. 
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Calculating the fertility rate by duration of HIV infection requires data about when a 
woman seroconverted, which is not exactly observed. I generated 100 imputations for 
the date of seroconversion for each HIV-positive woman. For women who are observed 
HIV-negative in one survey round and HIV-positive in a subsequent round 
(‘seroconverters’), I imputed dates of seroconversion from a uniform distribution between 
the dates of the last negative and first HIV positive test.   For women who were already 
HIV positive the first time they were tested in the cohort (‘prevalent cases’), I imputed 
100 seroconversion dates from a distribution determined by the convolution of the age-
specific HIV incidence rates and the probability of surviving from seroconversion until the 
woman’s latest age at interview.  
 
Person time and live births of women of reproductive age (15- 49 years old) who had 
ever tested for HIV in the studies were eligible for inclusion in the analysis.  HIV negative 
person-time for women with no subsequent positive test was assumed to last for up to 
five years past their last negative test, the exact cut-off point was determined by the HIV 
incidence rates in the sites, defined as the time at which the cumulated probability of 
becoming infected following the last negative test reached 5%.  Data for each cohort 
were censored at the start of ART introduction (Kisesa March 2005, Masaka January 
2004, Manicaland June 2005), in order to estimate the intrinsic relationship between HIV 
and fertility before the availability of antiretroviral therapy.  For women ever testing HIV 
positive imputed seroconversion dates were used to assign person-time by HIV status.  
The imputed duration of infection is defined as 0 for HIV-negative, and is treated as a 
continuous variable in years following sero-conversion. Fertility rate ratios (FRR) by HIV 
status and duration of infection are calculated using piecewise exponential regression 
allowing for clustering of births in each women, adjusting for age-specific fertility in each 
site and a log-linear trend in fertility over calendar time centred on the year 2001.   The 
analysis was repeated 100 times using independently imputed sero conversion dates.  
The log of the hazard rate ratios from the imputations were combined using Rubin’s rules 
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conversion.   
 
Objective 5: estimate the population impact of HIV on fertility and investigate if there are 
variations by region, urban and rural residence and ART coverage using cross sectional 
data from demographic and health surveys.    
 
Data from 48 Demographic and Health Surveys (DHS) and AIDS indicator surveys (AIS) 
conducted in 27 sub-Saharan African countries between 2003 and 2016 were used, in 
which both full birth histories and HIV testing outcomes were available 40.  DHS and AIS 
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are nationally representative household surveys 40. All analyses account for the two-
stage cluster sampling survey design and use the HIV weights provided by DHS. In 
pooled analysis, surveys are re-weighted so that each survey contributes equally toward 
the analysis. 
 
Each woman respondent was asked birth history questions for up to 20 births, beginning 
with the most recent. Dates of birth of the women and children are given in months and 
years, the day of birth was assigned to be the midpoint of the month.  
 
Initially I analysed fertility rates by HIV status during the three years prior to the interview. 
This cut-off was used in previous studies41, 42 to balance the benefits of maximizing the 
person-years of observation while seeking to minimize maternal survivorship bias, recall 
bias and misclassification of HIV status over the three preceding years43. However, I 
report results adjusted for the first year prior to the survey due to evidence of persistence 
of these biases when using data from longer than a year prior to the survey (see section 
7.2, which shows this analysis). I used the standard demographic definition of age-
specific fertility rates (ASFR):  
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I then estimated the fertility rate ratios in the general population.  Subsequently, I 
restricted the analysis to person years after first sex to assess the extent to which 
variation in age at first sex explains fertility differences among HIV positive women and 
HIV negative women in the younger age groups. I assumed sexual debut occurred on 
the date corresponding to the midpoint of the reported age at first sex (which is reported 
as an integer age). Age at first sex was changed to nine months before the reported date 
of first birth if this was earlier than the midpoint of reported age at first sex. 
 
I used exponential regression to investigate the interaction between HIV status and five-
year age group, place of residence, region and ART coverage with respect to their 
impacts on fertility. Each analysis was adjusted for country and survey year. The analysis 
was repeated excluding person time prior to first sex. The multivariate Wald test was 
used to assess significance of interaction terms. The first model includes only the 
interaction between age and HIV status controlled for country and year of survey. 
Subsequent models include the effect of place of residence, region and national ART 
coverage and the interactions between them and age and HIV status.  
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All models included the three-way interaction between year before the survey, five year 
age group and HIV status. Results are reported for the first year before the interview 
date.  
 
Objective 6:  investigate possible biases affecting the analysis of the impact of HIV on 
fertility that arise from the use of retrospective data such as DHS or prospective data, 
such as ALPHA network. 
 
The methods used for this objective are the same as for objective 5. 
 
Objective 7: identify how behaviour contributes to HIV subfertility to gain a better 
understanding of the contribution it makes to differences in fertility by HIV status. 
 
I analysed data from 46 Demographic and Health surveys (DHS) and AIDS indicator 
surveys (AIS) from 26 countries in sub-Saharan Africa that included both HIV testing 
data and questions about recent sexual intercourse and current contraceptive use.  Four 
surveys with HIV testing (Tanzania 2008 and 2012, Cote D’Ivoire 2005 and Uganda 
2011) were excluded as they did not include questions on current contraceptive use. 
 
Outcome variables  
Exposure to sex: I created a binary variable “had recent sexual intercourse” defined as 
reporting having had sexual intercourse in the last four weeks.   
 
Married: Marital status was defined as a binary outcome: currently married (including 
cohabiting couples) and not currently married. 
 
Modern Contraceptive use: Modern contraceptive use conformed to the DHS definition 
and included the pill, IUD, injections, diaphragm, condom, female sterilization, male 
sterilization, implants, female condom, Foam/Jelly and lactational amenorrhea.  I 
restricted lactational amenorrhea to be included only if it was within six months of the 
birth. 
 
Exposure to pregnancy: A binary outcome “exposure to pregnancy” was calculated as 
those who reported recent intercourse and reported not to be currently using any modern 
contraceptive. This definition assumes that current contraceptive use was constant in the 
4 weeks prior to the survey.   
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Condom use: This binary outcome defined as women reporting currently using condoms 
among women who had reported recent sex and currently using a modern contraceptive. 
 
Fertility Rates: This is measured using the retrospective birth histories and calculated as 
births per person year in the three years preceding the survey. 
 
Explanatory variables 
Other variables included  women’s HIV status at the time of the survey, five-year age 
group at time of survey, calendar year, place of residence (urban/rural), geographic 
region, and national female ART coverage in the year of the survey drawn from UNAIDS 
estimates14 and stratified into categories <20%, 20-49%, and >50%.  Region was 
grouped into Southern (Zimbabwe, Lesotho, Swaziland and Namibia), East and Mid 
Africa (Tanzania, Kenya, Uganda, Rwanda, Burundi, Malawi and Zambia) and West and 
Central Africa with Ethiopia (Table 1). HIV epidemics in the East and Mid African 
countries occurred earlier than in Southern Africa. West and central Africa along with 
Ethiopia have lower prevalence and their HIV transmission is likely to be more 
concentrated in high risk groups.  
 
Women who were pregnant at the time of the survey (9.0% across all surveys); those 
infected with HIV-2 (0.04%); and those whose HIV test was indeterminate (0.02%) were 
excluded from the analysis.  
 
Data analysis  
For each outcome variable, I used log Poisson regression44 to estimate the interaction 
between HIV status and five-year age group, place of residence, region and national 
ART coverage for the outcome variables recent sex, recent exposure to pregnancy, and 
fertility rate45. Each model was adjusted for country and survey year.  Relative exposure 
to pregnancy by HIV status were compared to the fertility rate ratios by HIV status in 
order to estimate how much of the reduced fertility in HIV positive women compared to 
HIV negative women at the population level could be attributed to less exposure to sex. 
For regressions of fertility rate, fertility data for the three years before the survey were 
modelled, with an additional categorical variable for each year before the survey 
interacted with the age groups below 25 years and above 25 years45. Estimated fertility 
rate ratios by HIV status pertain to estimated fertility rate for the year preceding the 
survey.  
 
The log Poisson model was chosen for a number of reasons.  Normally one might choose 
a logistic regression model, however this would give odds ratios which I could not have 
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later compared to rate ratios of fertility, therefore a relative risk was preferable.  The 
literature suggest a number of  methods of obtaining risk ratios that can be used when 
the event is common as it is in the case of this paper.  Two suggestions are the log 
binomial regression model and the other a log Poisson regression model with a robust 
error variance. In the case of this analysis as stated in the literature, a common problem 
with the log binomial regression is that the models did not converge so could not be used.  
An alternative to the log binomial method is a modified Poisson regression first put 
forward by Zou44 who suggests using a Poisson model with robust error variances.  Since 
then there has been various literature looking at the reliability of estimates using the 
Robust Poisson model, concluding that in general it gives reasonable estimates of the 
risk ratio, although sometimes leads to slightly larger standard errors than the log 
binomial46, therefore is in fact more conservative.   
 
I further analysed the outcomes of modern contraceptive use and marital status using 
the same log Poisson regression models in order to evaluate the extent to which 
differences in exposure to pregnancy between HIV positive and HIV negative women 
were mediated by differences in these intermediate outcomes. Finally, I investigate 
differences in contraceptive type between HIV positive and HIV negative women and the 
potential implications of this for contraceptive efficacy.  I assess differences in type of 
modern contraceptives used between HIV positive and HIV negative women by 
analysing differences in condom use among women who reported having recent sex and 
currently using a modern contraceptive.   
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1.6 Structure of the thesis 
This thesis is presented in research paper style, including five published and one 
submitted academic papers (A-F), an extract from one academic paper, a report, and 
three additional chapters including this introductory chapter, a literature review and final 
discussion.   
I present the work in the chronological order in which it was done: first the Paediatric 
survival from HIV infection in the absence of ART, second whether there are differences 
in acquisition of HIV in pregnant compared to non-pregnant women which could affect 
the mother to child transmission rates, finally looking at differences in fertility between 
HIV positive and HIV negative women, and how this changes in the era of ART. 
A short introductory section is provided before each of the papers A-F, briefly outlining 
the rationale for the paper, and linking it to the findings and material presented in 
preceding chapters if relevant.      
Chapter 2: Literature review on Child survival, HIV acquisition in pregnancy and Fertility 
and HIV in era of ART 
Chapter 3: Research paper (paper A): “Net survival of perinatally and postnatally HIV-
infected children: A pooled analysis of individual data from sub-Saharan Africa.”  This 
chapter also includes an extract from another research paper that extends this work and 
a further unpublished report produced for UNAIDS. 
Chapter 4: Research paper B: “Is the risk of HIV acquisition increased during and 
immediately after pregnancy?  A secondary analysis of pooled HIV community-based 
studies from the ALPHA network”. 
Chapter 5: Research paper C: “Measuring the Impact of antiretroviral therapy roll-out on 
population level fertility in three African countries” 
Chapter 6: Research paper D: “The effects of HIV on fertility by infection duration: 
evidence from African population cohorts before ART availability” 
Chapter 7: Research paper E: “The relationship between HIV and fertility in the era of 
antiretroviral therapy in sub Saharan Africa – Evidence from 49 Demographic & Health 
Surveys” 
This chapter also includes an expanded version of the supplementary materials for 
research paper E which is an analysis of bias when using cross sectional surveys to look 
at the impact of HIV on fertility 
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Chapter 8: Research paper F: “Relative patterns of sexual activity and fertility among 
HIV positive and negative women – evidence from 46 DHS” 
Chapter 9: Final discussion of the work done in the PhD 
Table 1.3: Sources of data used in each paper presented in this thesis  
 Paper Title ALPHA DHS Clinical 
Trials 
 Brief Literature review on Fertility and HIV in era of ART    
A Net survival of perinatally and postnatally HIV-infected 
children: A pooled analysis of individual data from sub-
Saharan Africa 
  X 
 Research (report for UNAIDS) an update to the paediatric 
curve 
 X X 
B “Is the risk of HIV acquisition increased during and 
immediately after pregnancy?  A secondary analysis of pooled 
HIV community-based studies from the ALPHA network”. 
X   
C 
 “Measuring the Impact of antiretroviral therapy roll-out on 
population level fertility in three African countries” 
X   
D “The effects of HIV on fertility by infection duration: evidence 
from African population cohorts before ART availability”   
X   
E 
 “The relationship between HIV and fertility in the era of 
antiretroviral therapy in sub Saharan Africa – Evidence from 
49 Demographic & Health Surveys” 
 X  
 Expanded version of the supplementary materials for research 
paper E which is an analysis of bias when using cross 
sectional surveys to look at the impact of  HIV on fertility 
X X  
F 
 “Relative patterns of sexual activity and fertility among HIV 
positive and negative women – evidence from 46 DHS” 
 X  
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2 Literature review  
 
2.1 Introduction 
This literature review first describes the Spectrum AIDS impact module (AIM) to give an 
example of how estimates of paediatric AIDS are calculated.  The following sections then 
go on to describe the current literature that informs the assumptions in these models and 
evidence that could be utilised to further refine these assumptions.  
2.2 The Spectrum AIDS impact module (AIM) 
The Spectrum AIDS impact module (AIM)  is part of Spectrum, an established model 
used by UNAIDS  that has generated global AIDS estimates since 199947.  This module 
estimates the number of children newly infected with HIV each year and then progresses 
them through survival schedules as they age to estimate AIDS deaths and numbers of 
children living with HIV by age, until they reach 15 years old, when they move to the adult 
model.  Figure 2.1 shows the flow of the module highlighting different inputs, 
assumptions and calculations made, starting from the input of demographic data ending 
with the number of AIDS related deaths among children. 
Figure 2.1: Paediatric HIV Calculations in Spectrum AIDS Impact Module (Reproduced from Mahy et 
al48 under the creative commons attribution - Non Commercial – No Derivatives License 4.0.) 
 
  
The assumptions made in this module and other models that estimate paediatric HIV  
which are relevant to this PhD are those on fertility adjustments, relating to differences 
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in fertility of HIV positive and HIV negative women; mother to child transmission rates; 
and disease progression among children not receiving ART.  
2.3 Estimating the survival of HIV infected children 
Prior to antiretroviral treatment it was estimated that in breastfeeding populations 
between 25% and 45% of children born to HIV positive mothers would become infected 
through mother to child transmission with 30%-50% of these infections occurring during 
breastfeeding 49.  To estimate the effect that the HIV epidemic will have on population 
level child mortality, a schedule of age specific “net” mortality - mortality as if HIV was 
the only cause of death - is needed.  This schedule can then be paired with age specific 
mortality patterns of uninfected children child mortality schedule to obtain expected 
mortality of HIV infected children given differing background mortality rates. 
Survival of HIV positive children infected around birth in the absence of antiretroviral 
treatment is described by a double Weibul distribution; this distribution is used as it can 
describe initial high mortality in “fast progressors” directly after birth representing those 
infected in utero, peri-partum and intrapartum along with “slow progressors”, those 
infected during breastfeeding.  This curve has been used in the UNAIDS Spectrum model 
from 2002 after being recommended by the reference group on estimates, modelling and 
projections 50.  The curve was originally modelled on data from seven cohort studies that 
provided survival data on HIV positive children50, it assumed in the absence of other 
information that no child HIV infected at birth would survive beyond fifteen years.  
Following this study, further data from longitudinal studies became available to improve 
the fitting of this curve, although many of these studies did not have the HIV status of the 
child but only the HIV status of the mother, necessitating the use of indirect techniques 
to estimate the survival of children assumed to be infected with HIV.  With this later data 
Marston et al6 estimated an improved survival schedule, using the same double Weibul 
function as previously used, retaining the assumption that no child infected through 
MTCT would survive beyond 15 years.   
Later, further evidence emerged from a pooled analysis showing that the mortality two 
years following HIV infection was lower for children who acquired HIV via breastfeeding 
compared to those with perinatal infection51, confirming the slow and fast progressors 
theorised in previous estimates of net paediatric survival.  With this evidence and the 
newly available data from clinical trials, that provided information on the HIV status of 
children from birth with accurate estimates of the timing of HIV infection, Marston et al13 
(Presented in this thesis, chapter 3) estimated separate representations of survival for 
children infected with HIV early; in utero, peri partum and intrapartum and during 
breastfeeding.  Also with increasing evidence indicating children surviving beyond 15 
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years who were infected through mother to child transmission from national HIV 
prevalence surveys, assumptions in the updated curves also included an assumption 
that the “slow progressors” would have a survival pattern similar to that of adults infected 
at young ages5, 7 meaning that the slow progressors would be assumed to have a median 
survival of around 14 years.   The resulting estimated net survival schedules gave a 
median survival of 1.09 years for those infected perinatally compared to 9.24 years for 
those infected through breastfeeding, this compares to the previous median survival of 
2.08 years using the previous schedule that provided only one curve to represent all 
infected children irrespective of timing of infection.  It was agreed later that there was 
adequate data to break down the survival schedules further by timing of infection through 
breastfeeding, this resulted in 4 survival schedules, one for perinatal infection as before 
and three for postnatal infection at 0-180 days, 181-365 days and 365+ days, giving 
median survival of 1.1, 6.4, 11.5 and 14.1 years after infection respectively52 (Presented 
in this thesis, chapter 3).     
2.4 HIV Acquisition in Pregnancy  
Fertility rates are high in many sub-Saharan African countries and, therefore, a significant 
proportion of woman-years are spent pregnant53. Evidence regarding the risk of 
acquisition of HIV infection at and shortly after the time of pregnancy is conflicting54-60. 
An increased risk of HIV acquisition in pregnant women has implications for health 
services as the increased viral load in acute infection would expose the foetus to higher 
risk of in utero mother-to-child transmission61. It would also have implications for HIV 
epidemic modelling as estimates for paediatric HIV would need to be revised upwards.  
A number of prospective studies from Eastern and Southern Africa have assessed the 
risk of HIV incidence during pregnancy. A multisite study of sero-discordant couples 
found that HIV incidence was, in univariate analysis, two-fold higher in pregnant than in 
not-pregnant women; however, after adjusting for age, unprotected sex in last month, 
and contraceptive use, the risk difference was reduced and was no longer statistically 
significant57. A similar study in Uganda restricted to married sero-discordant couples 
reported a non-significant increase in the HIV acquisition rate in pregnant women54. 
Other studies included women regardless of the partner’s HIV status; in a Ugandan study 
of sexually-active women the risk of HIV-1 acquisition was doubled during pregnancy54. 
However, in an HIV prevention trial enrolling women from a number of health services 
and community venues in southern Africa there was no increased risk of HIV-1 in 
pregnant women59. A study in Uganda and Zimbabwe, in which women from family 
planning sites were enrolled, found no overall increased risk of HIV acquisition in 
pregnant women in the pooled analysis, and after adjusting for covariates, actually 
showed some evidence of a protective pregnancy effect in one of the study sites56. 
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Further studies have shown a possible increased HIV incidence during pregnancy62-64, 
others showed a risk comparable to the general population of a similar age65, 66. A 
number of studies have investigated HIV incidence in the postpartum period, again with 
somewhat conflicting results. In Malawi, a prospective study of women enrolled after 
delivery found HIV acquisition was increased in the first year postpartum, decreasing 
subsequently60; this was also the case in Zimbabwe58 and Rwanda55. The authors of the 
latter study suggested that the decrease could be partly due to a cohort selection bias 
with those remaining uninfected for longer having a lower risk of infection. Other studies 
have not reported an increased risk in the postpartum period54, 67.  
The rate of HIV acquisition and differences between pregnant, postpartum and non-
pregnant women at a population level will depend not only on the risk of infection per 
sexual act with an HIV positive partner, but also on the level of discordance in pregnant 
and non-pregnant couples and the differences in sexual behaviour between these 
groups. Therefore, results from the studies outlined above cannot be generalised to all 
women in the population, which are needed for national estimates of paediatric HIV. 
To assess the population level differences in HIV acquisition Marston et al68 (Presented 
in this PhD, chapter 4) used community based cohort data from six study sites to estimate 
differences in HIV acquisition by pregnancy status.  This study found that HIV acquisition 
at a population level was lower in pregnant women than non-pregnant women (hazard 
rate ratio 0.79, 95%CI 0.70-0.89) and that there was no evidence of a difference in HIV 
acquisition rates in post-partum women compared to women who were not pregnant.  
These findings were attributed to pregnant women being more likely to be concordant 
with their partner during their pregnancy and in the post-partum period.  A later study 
from South Africa 69 using updated data from one of the sites in Marston et al68 (Chapter 
4) further corroborated these findings showing pregnancy to have a protective effect on 
HIV acquisition with no significant difference in the postpartum period when compared 
to HIV negative women.  There has been continued interest in the area of HIV acquisition 
in pregnancy which often fails to separate the population level from the individual level70, 
71
 which will be discussed in the final discussion section (section 9.2) 
2.5 Impact of HIV on fertility 
In order to estimate the number of children born to HIV positive women, we need to 
understand differences in fertility between HIV positive and negative women and how 
this can vary over populations and time.  Estimating the number of pregnant women is 
the first calculation made when estimating paediatric HIV, therefore this directly impacts 
on all later estimates, PMTCT need, paediatric ART need and numbers of HIV positive 
children surviving to adulthood.  It is widely anticipated that ART scale-up will lessen the 
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subfertility of HIV positive women, which would lead to an increase in the number of HIV 
positive pregnant women.  This section assesses the current literature on the impact of 
HIV on fertility and how this might change with the introduction of ART.   
2.5.1 Population impact of HIV on fertility   
The population impact of HIV on fertility in sub Saharan Africa has been well 
documented41, 43, 45, 72.   These analyses have demonstrated that the relationship between 
HIV and fertility varies with age. Among the youngest women aged 15-19 years, fertility 
is higher among HIV positive women, due to selection of sexually active women, while 
above age 25 the fertility of HIV positive women becomes increasingly lower than that of 
their HIV negative counterparts, termed ‘HIV associated subfertility’. Population based 
studies have also identified differences in HIV associated subfertility by region43, 45, and 
urban and rural area45 
With the increasing availability of ART, studies have sought to estimate its impact on 
fertility in HIV positive women.  A systematic review by Yeatman et al in 2016 73 
concluded that the evidence indicated that fertility increases after the first year on ART 
but remains lower than in HIV negative women of the same age.  The authors exercise 
caution as the data in the review spans the period of 2005-2010 when ART programs 
were being scaled up.  This systematic review contained studies that can be roughly 
divided into three types.  First, clinic based where the comparison was HIV positive 
women on ART compared to those not on ART, with no HIV negative controls or 
comparisons with HIV positive women who have not attended a care and treatment clinic 
(CTC) groups.  Second are general population studies that compare HIV positive women 
to HIV negative women but do not have individual level data on which women are on 
ART and instead use comparisons of the two groups in a time when ART was not 
available and when it was widely available.  Both these types of studies have limitations, 
which are discussed below.  Finally, there is a group of general population studies that 
include individual level data on ART status. 
Studies that use clinic based data do not necessarily represent the population 
experience.  HIV positive women who attend a care and treatment clinic may be different 
to those who do not and may experience different fertility rates.  This may be particularly 
important in the time when ART was being scaled up as there is more likely to be a 
selection bias in those attending the clinics.  One bias that is particularly problematic is 
that women are often referred to care and treatment through antenatal clinic care: these 
women are therefore fecund at the time of referral, making them possibly less 
representative of HIV positive women in the population. Elul et al found in a study of 26 
HIV clinics in Kenya and Uganda that women who were pregnant at enrolment into care 
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were much more likely to be started on ART than those who were not pregnant74.  As the 
criteria for ART initiation over time has changed, particularly for pregnant women, this 
will change the selection effects.  Over time WHO guidelines for PMTCT have changed. 
Early recommendations named option A and option B, suggested that ART should start 
as soon as a women is diagnosed with a CD4 count of less than 350 and continued for 
life (option A) or for women with a CD4 count above 350 that ART should be given for a 
period around the pregnancy (option B).   New guidelines were introduced in the form of 
option B+ recommending that all women found HIV positive during pregnancy should be 
treated from time of diagnosis for life regardless of CD4 count75, 76.   
This shift in policy implied by option B+ will steadily increase the number of “healthy” 
fecund HIV positive women in the “on ART group” and likely include more young women 
of lower parity.   Another problem this poses is that in the first six months of initiation on 
ART a spike in fertility is seen due to women having the babies from the pregnancy 
during which they were identified as HIV positive and in need of treatment.  But if a 
women’s follow up time starts from the time of delivery the bias will go in the other 
direction as straight after a delivery a woman is less likely to be fecund due to postpartum 
amenorrhea, lactation amenorrhea and active birth spacing.  Elul et al point this out and 
begin follow up time on treatment from the time of delivery for those who were pregnant 
at ART initiation then investigate whether there is an interaction between pregnancy 
status at enrolment in HIV care and ART status with respect to the incidence of 
pregnancy74.  They found evidence for a significant effect; in a model adjusting for other 
factors such as age and time varying CD4 count they found that those women who were 
pregnant at enrolment in HIV Care and on ART had a higher incidence of pregnancy 
than those not on ART even though overall they found no difference in the incidence of 
pregnancy between women in care on ART compared to those not on ART.  This study 
was done at a time prior to option B+, with option B+ the composition on ART will likely 
increase the proportion of women enrolled on treatment when pregnant. 
Three of the studies in the review by Yeatman et al were from general population with 
an HIV negative comparison group77-79.  Two of these studies (one of which is presented 
in this PhD78, Chapter 7) did not have individual level data on treatment status for HIV 
positive women so can only infer that any observed narrowing of the differences in the 
fertility between HIV negative and positive women in the era of ART is due to the impact 
of ART on fertility.   However, this has the benefit of not assuming that the availability of 
ART has only direct effects on those women receiving treatment.  It is possible that with 
increased availability of ART attitudes and beliefs about HIV infection may change, 
thereby possibly changing the fertility of HIV positive women not yet receiving treatment.  
When modelling the HIV epidemic all of these effects must be taken together in order to 
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get the most accurate estimates.  The third population based study was from Gregson 
et al 77 who used data from a general population survey in Zimbabwe with individual level 
information on ART status to look at pregnancy prevalence of women who were HIV 
negative, HIV positive not on ART and HIV positive on ART, at a time after ART was 
scaled up.  They found that the fertility of HIV positive women was 75% lower than that 
of HIV negative women 15-49 years old and that there was no evidence that the fertility 
of HIV positive women on ART differed from those not receiving treatment.   
Since the publication of Yeatman et al there have been two more studies of note45, 80 that 
have looked at the population level effect of HIV on fertility. The first study used data 
from a demographic surveillance site with HIV testing and clinic data in Malawi80 
enabling, as in Gregson et al77, comparison groups to be HIV positive women not on 
treatment in the population, rather than only those in care, and HIV negative women.  
They found a suggestion of an increase in fertility for younger women on ART compared 
to those not on treatment but there was not sufficient power to be confident of this result.  
In this study the fertility of HIV positive women regardless of treatment was nevertheless 
lower than that found in HIV negative women.  The second study by Marston et al45 
(Presented in this PhD, chapter 7) used data from 49 nationally representative surveys 
from sub Saharan Africa spanning a period between 2003 and 2016 that included times 
before and after ART roll out and scale up.  National ART coverage was used as an 
ecological measure to see whether there was an impact on fertility, the paper concluded 
that there did appear to be a slight narrowing of the fertility differences between negative 
and positive women with high national ART coverage; however, this was not as much as 
would be expected if the fertility of women on ART was fully restored to that of HIV 
negative women.  The authors also caution that national ART is an ecological measure 
and could represent other aspects of health and development.  Even though many of the 
DHS surveys were conducted following ART roll-out, only a small number have ART 
coverage above 50% and so on a population level ART coverage may not be high 
enough to cause appreciable differences.  
Most studies looking at the impact of ART on fertility have not been able to determine 
whether their results are due to biological or behavioural factors associated with ART. 
2.5.2 Determinants of HIV subfertility  
The determinants of HIV subfertility are complex and can be both biological and 
behavioural.  This section describes the different possible mechanisms that would tend 
to lower fertility in HIV positive women, and discusses how these can change in era of 
antiretroviral treatment. 
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Biological Mechanisms 
There have been a number of reviews assessing the literature on the biological 
mechanisms of HIV on fertility for females81 and males81, 82.   
HIV in women could affect their fecundity in a number of ways, due to weight loss and 
illness caused by AIDS.  Kushner and Lewis highlight literature showing lengthened 
anovulation and amenorrhea, however they state that once adjusting for other factors 
many studies have found that there is no longer an association81.  Other studies have 
looked at differences in the onset of menopause by HIV status, reviews of which in 200783 
and 201384 both found that the literature was conflicting and that it was not possible to 
distinguish the contribution of HIV to earlier menopause from other risk factors such as 
smoking, drug use and ethnicity. 
HIV positive women are more likely to be infected with another sexually transmitted 
infection which may also have an impact on fertility.  Infections such as Gonorrhoea and 
Chlamydia which cause tubal blockage can decrease fecundity and if scarring occurs 
they may cause secondary sterility85. 
A previous meta-analysis by Brocklehurst et al in 1998 found that HIV positive women 
are more likely to suffer miscarriages and still births, compared with HIV negative 
women86.  This was recently updated with a systematic review and meta-analysis by 
Wedi et al87 who looked at perinatal outcomes associated with maternal HIV infection in 
ART naïve women.  Wedi criticised the inclusion of some abstracts and poor quality 
studies in Brocklehurst et al.   Wedi et al found that HIV infection in women was 
associated with stillbirth with a risk ratio of 1.67 (95%CI 1.05-2.66) looking at two studies 
88, 89
 but found only one study on miscarriage from the USA that found no significant 
difference in miscarriage between HIV positive and HIV negative women 90.   Higher 
rates of stillbirths may be due to HIV infection itself or to co-infection with another sexually 
transmitted infection such as Syphilis91 which is more prevalent in HIV positive women 
than HIV negative women due to similar risk factors.  There is conflicting evidence on 
the effect of ART on birth outcomes and very little on miscarriage and stillbirth alone92, 
93
.  Some of these differences may be due to different ART regimes, with one study 
reporting variation in birth outcomes by ART regime, although all outcomes remained 
less favourable than those of HIV negative women94.  
Male fertility had also been reported to be affected by HIV, with lower semen quality95-97.  
Some studies looked at the association between CD4 count and semen quality and found 
some parameters to be positively correlated indicating that impairment increases with 
disease progression97-99.  There have been conflicting reports on the impact of ART on 
semen quality100-103, and the impact may depend on the drug regime104.  Pilatz at al101 
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found that the semen quality of HIV positive men under stable antiretroviral therapy in an 
outpatient clinic in Germany was impaired for 25% of their prospective cohort of patients 
without HIV co-infections when comparing to the WHO 2010 reference values, data that 
represents distributions of semen characteristics of fertile men for use to evaluate a 
patient’s semen quality and prospect for fertility 105.    
Behavioural Mechanisms  
Behavioural mechanisms impacting on fertility can occur with or without an individual’s 
knowledge of their HIV status.  Prior to the roll out of ART in sub Saharan Africa 
knowledge of HIV status was rare although even without a test result suspicions of HIV 
infection due to bouts of ill health or the ill health or death of a partner could impact on 
behaviour. 
Relationship patterns differ between HIV positive and HIV negative women with 
increased widowhood and marital dissolution in HIV positive women with low rates of 
remarriage106, 107  therefore decreasing their chances to have more children.  Sexual 
activity within and outside stable relationships may decline due to illness108 or,  if HIV 
status is known, a desire not to transmit HIV.  If a woman does not know her status but 
knows or is suspicious of her partner’s HIV status, she may try to prevent being infected 
either through less sexual activity or through use of condoms.  If the individual’s HIV 
status is known or suspected within a community, they may also have less access to 
sexual partners.  
Fertility intentions vary by HIV status with many studies reporting HIV positive women 
less likely to want to have more children compared to HIV negative women109-114, with 
this difference increasing with age114.  However most of these studies do not follow up 
after recording pregnancies or births to see if this translates into lower fertility rates. Taulo 
et al113 found that there was no difference in future pregnancy rates even though there 
was a lower desire for more children amongst HIV positive women; however, they state 
that this could be due to the short follow up time in their study.  Answers to questions on 
intentions are subject to social desirability and it is possible that HIV positive women will 
report intending not to have another child as they feel like that is what they should say.  
Also there is ambiguity to the meanings of desire and intention; someone who desires a 
child may not intend to have one and vice versa115.  With increasing availability of ART, 
many studies have looked at how this changes fertility intentions among HIV positive 
women, giving rise to conflicting evidence.  Some report after adjusting for socio-
demographic factors, women on ART having higher childbearing intentions than those 
not on ART116, 117; however this does not necessarily translate into an increase in 
fertility116.  Other studies reported no change114, 118.  Many of these studies were carried 
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out when ART coverage was still fairly low, therefore it is likely that they are influenced 
by the selection biases in the women who are on ART even when controlling for socio-
demographic factors and restricting to ever pregnant, sexually active women.   
2.5.3 Duration of infection 
A number of studies in sub Saharan Africa have looked at disease progression in relation 
to fertility. A case–control study in Uganda found that high viral load was associated with 
reduced rates of pregnancy and a reduction in live births119, even in women who were 
sexually active and not using contraception.  A clinical cohort found that fertility was 
reduced from the earliest stage of HIV infection with a large reduction in fertility following 
progression to AIDS108 – this finding was adjusted for sexual activity but not for 
contraceptive use. A clinical cohort study in Tanzania also found reduced fertility related 
to clinical stage of HIV120 adjusting for social and demographic characteristics. A multisite 
HIV care and treatment programme analysis showed a strong association between 
disease progression and a reduction in the incidence of pregnancy121.   
Increased subfertility by duration of infection at the population level could be explained 
by both biological and behavioural factors. Biological explanatory factors include markers 
of disease progression in the woman, such as increased viral load or decreased CD4 
cell count.  Explanatory factors relating to their partners could include reduced semen 
quality of HIV-positive partners increasing with time since their infection95, 96, 101, and 
increased illness could impact on their ability to maintain normal levels of sexual activity. 
In terms of behaviour, HIV-positive women are more likely to be widowed106, 107, 122 due 
to having had an HIV-positive partner. Although voluntary testing and counselling was 
rare prior to ART introduction, suspicion of HIV status or illness in a partner with HIV may 
reduce the desire for more pregnancies115, which may be more obvious at longer 
durations of infection and it may also increase divorce or separation, and decrease 
remarriage rates106, 107.  
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3 Net survival of perinatally and postnatally HIV-
infected children 
 
To address the first objective of the PhD: to describe different patterns of Paediatric 
Survival from HIV by timing of HIV infection; an analysis of a pooled dataset of clinical 
trials and cohort studies that provided information on the HIV status of children from birth 
with accurate estimates of the timing of HIV infection was conducted and published in 
the International Journal of Epidemiology:  
 
Marston M, Becquet R, Zaba B, et al. Net survival of perinatally and postnatally HIV-
infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J 
Epidemiology. Apr 2011;40(2):385-396.  
 
Previous estimates of Paediatric Survival with HIV have relied on direct data from fairly 
small cohort studies where the HIV status of the child at birth was known along with 
indirect data from larger cohort studies where the HIV status of the mother was known 
but not that of the child.   Survival estimates of infants and children with HIV grouped all 
positive children together regardless of whether they were infected in utero, intrapartum 
or during breastfeeding.  More data have become available, mainly from control arms of 
clinical trials looking at mother to child transmission, where not only is the HIV status of 
the child known, but also the timing of HIV transmission.  Using these data it was possible 
to improve estimates of paediatric survival with HIV by timing of infection, which improves 
estimates of the prevalence of paediatric HIV.    This work is presented in section 3.1.  
After the publication of this work, and following discussions with the UNAIDS reference 
group on estimates, modelling and projections it was agreed that a finer break down of 
survival patterns by timing of infection was needed.  This additional work was published 
in: 
 
Stover, J., T. Brown, and M. Marston, Updates to the Spectrum/Estimation and 
Projection Package (EPP) model to estimate HIV trends for adults and children. Sex 
Transm Infect, 2012. 88 Suppl 2: p. i11-6. 
 
The relevant extract from this paper (authored by the candidate) is presented in section 
3.2. Finally a further analysis was done to test the assumptions underlying the work on 
paediatric survival from HIV presented in sections 3.1 and 3.2 and the implications of 
these assumptions on estimates of paediatric HIV prevalence.  This was prepared by the 
candidate as a report for UNAIDS and is presented in section 3.3. 
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3.1 PAPER A: Net survival of perinatally and postnatally HIV-
infected children: A pooled analysis of individual data from 
sub-Saharan Africa 
 
Milly Marston 1, Renaud Becquet 2,3, Basia Zaba 1, Lawrence H. Moulton 4, Glenda Gray 5, Hoosen  
Coovadia 6, Max. Essex 7, Didier K. Ekouevi 2,3,8, Debra Jackson 9, Anna Coutsoudis 10, Charles 
Kilewo 11, Valériane Leroy 12, Stefan Wiktor 13, Ruth Nduati 14, Philippe Msellati 15, François Dabis 
2,3, Marie-Louise Newell 16,17, Peter D Ghys 18 
1  London School of Hygiene and Tropical Medicine, London, United Kingdom 
2  INSERM, unité 897, Centre de recherche "Epidémiologie et Biostatistique", Bordeaux, France 
3  Institut de Santé Publique Epidémiologie Développement (ISPED), Université Victor Segalen 
Bordeaux 2, Bordeaux, France 
4  ZVITAMBO trial, Zimbabwe; Johns Hopkins Bloomberg School of Public Health 
5  Petra trial, Tanzania, South Africa and Uganda; Perinatal HIV Research Unit, University of 
Witwatersrand 
6  VTS cohort, South Africa, Universty of KwaZulu-Natal, University of Witwatersrand, South 
Africa 
7  Mashi trial, Botswana; Botswana-Harvard AIDS Institute and Harvard School of Health AIDS 
Initiative 
8  Ditrame Plus cohort, Côte d’Ivoire 
9  Good Start cohort, South Africa; University of the Western Cape, South Africa 
10  Vitamin A trial, South Africa 
11  Mitra Plus cohort, Tanzania 
12  ANRSa trial, Côte d’Ivoire & Burkina Faso 
13  Retro-Ci trial, Côte d’Ivoire; Global AIDS Program, Centers for Disease Control and 
Prevention, Atlana USA. 
14  Nairobi trial, Kenya 
15  ANRSb trial, Côte d’Ivoire & Burkina Faso, UMR 145 IRD/Universite de Montpellier 1, 
montpeillier, France. 
16  Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, 
South Africa 
17  Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, University 
College London, London, United Kingdom 
18  UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland 
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3.1.1 Summary 
 
Background:  Previously HIV epidemic models have used a double Weibull curve to 
represent high initial and late mortality of HIV-infected children, without specifically 
distinguishing timing of infection (peri- or postnatally).  With more data on timing of 
infection, which may be associated with disease progression, a separate representation 
of children infected early and late was proposed. 
 
Methods:  Paediatric survival post-HIV infection without antiretroviral treatment was 
calculated using pooled data from 12 studies with known timing of HIV infection.  Children 
were grouped into perinatally or postnatally infected.  Net mortality was calculated using 
cause-deleted life tables to give survival as if HIV was the only competing cause of death.  
To extend the curve beyond the available data children surviving beyond 2.5 years post 
infection were assumed to have the same survival as young adults.  Double Weibull 
curves were fitted to both extended survival curves to represent survival of children 
infected perinatally or through breastfeeding.   
 
Results:  Those children infected perinatally had a much higher risk of dying than those 
infected through breastfeeding, even allowing for background mortality.   The final fitted 
double Weibul curves gave 75% survival at five months after infection for perinatally-
infected, and 1.1 years for postnatally-infected children.  An estimated 25% of the early 
infected children would still be alive at 10.6 years compared to 16.9 years for those 
infected through breastfeeding.     
  
Conclusions:  The increase in available data has enabled separation of child mortality 
patterns by timing of infection allowing improvement and more flexibility in modelling of 
paediatric HIV infection and survival. 
 
Key messages:  
1) Children infected perinatally with HIV have a much higher risk of dying than those 
infected through breastfeeding   
2) Differences seen in the survival of children infected perinatally with HIV and through 
breastfeeding cannot be explained by differences in background mortality, which is much 
higher in the neonatal period. 
3) The use of two separate curves to describe the net survival from perinatal and 
breastfeeding HIV infection improves the realism of child survival when modeling the HIV 
epidemic.  
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3.1.2 Introduction  
 
Until recently, survival of HIV infected children in the absence of causes of death 
unrelated to HIV has been modelled using a double Weibull curve which represents the 
mortality experienced by HIV-infected children irrespective of their time of infection from 
birth 6, 123. The double Weibull curve has been used as it is one of the few functional 
forms that can describe high initial mortality along with rising mortality at older ages.  
However, in a pooled analysis, Newell et al showed that mortality in the two years 
following infection was lower for children who acquired HIV via breastfeeding (postnatal 
infection) than those with perinatal infection 51.  To improve modelling of the HIV epidemic 
a separate representation of children infected early and late was thus deemed 
appropriate. Indeed, new data have become available from clinical trials which provide 
information on HIV status of children from birth and allow an accurate estimation of age 
at infection and sufficient follow up time to allow assessment of the risk of dying, this data 
is in accordance with the differences shown by Newell et al 12.   
 
It has been suggested that the impact of age at infection may be due to background 
mortality patterns 5. Removing background mortality did have a slightly larger effect in 
those infected at older ages where background mortality is higher but it did not explain 
the differences in survival from age at infection in adults.  However, such effects are 
more extreme in childhood where the differences between neonatal and post-neonatal 
mortality is much greater  than the difference in mortality rates in adults within one month 
or 1-12 months after infection.  Therefore some of the differences in time since infection 
shown by Newell el al 51 might be attributable to background mortality in the neonatal 
period. 
 
This paper investigates the effect of background mortality on survival post-infection of 
children by time of infection for up to 2.5 years following acquisition of infection. In order 
to bridge the gap in the data between children and young adults, survival curves are 
further extended beyond the available data by using survival of young adults and model 
curves fitted to the net survival of each of these groups for use in HIV modelling.   
 
  
55 
 
3.1.3 Methods  
Data 
Data from 12 clinical trials and cohort studies in Southern, Eastern and Western Africa 
(Table 3.1) were included in a pooled analysis where all the data was combined into the 
same dataset.  Interventions in these studies were various peripartum antiretroviral 
prophylactic regimens 14-22, vitamin A 23, and birth canal cleansing 24.  These trials 
represent the vast majority of the clinical research studies performed since the mid 90’s 
on the African continent on prevention of mother-to-child transmission of HIV. Most study 
sites (n = 8) were situated in reference hospitals of capital or large cities; three studies 
were based in antenatal care clinics, or a mixture of the two, and one in a mixture of both 
urban and rural settings. The ZVITAMBO accounted for 51% of the person years of 
exposure for HIV infected children.  The median follow up time ranged from 300 to 1096 
days, and studies tested at regular intervals in the first 18 months.   Some studies 
explicitly stated that they provided free medical treatment at time of follow-up and in 
between follow-up visits.   
Inclusion Criteria  
Data collected in time periods when antiretroviral treatment was widely available cannot 
be used in the analysis as it would not represent the survival from HIV per se. However, 
it would be incorrect to censor children at time of treatment initiation as this would mean 
we were selecting out those who were going to die thereby biasing the results to give 
much lower mortality.    Antiretroviral treatment became available in the MASHI trial on 
the 1st October 2002 so follow up was right censored at this point. Antiretroviral 
Treatment was not available during the time of the other trials.    
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Table 3.1: Summary of trials in the analysis with ART interventions for individual site analysis, numbers are for children of HIV positive mothers, number of deaths are in brackets.  
Trial Arm 
Mother 
PMTCT 
Child 
PMTCT* 
Total 
 Infection Status  
Uninfected Early Late Unknown 
HIV Status 
Unknown/ 
Indeterminant 
ANRS 049a 15 ANRSA_N2 None None 78 (22) 55 (4) 15 (14) 2 (1) 5 (2) 1 (1) 
 ANRSA_N3 None None 123 (30) 79 (4) 11 (9) 7 (2) 11 (6) 15 (9) 
 ANRSA_T2 ZDV None 77 (11) 59 (3) 6 (3) 5 (0) 3 (3) 4 (2) 
 ANRSA_T3 ZDV None 123 (25) 88 (3) 6 (6) 8 (4) 10 (5) 11 (7) 
ANRS 049b 24 ANRSB_N None None 51 (11) 36 (2) . (.) 2 (1) 4 (3) 9 (5) 
 ANRSB_T1 None None 53 (15) 35 (2) 1 (1) 3 (1) 4 (4) 10 (7) 
ANRS 12010 
Ditrame Plus 21 
Diatrame 
Plus 
ZDV+NVP or 
CBV+NVP 
ZDV+NVP 
747 (79) 689 (54) 40 (20) 18(5) 0 (0) 0 (0) 
Good Start 17 Paarl NVP sdNVP 149 (7) 107 (0) 12 (4) 3 (0) 6 (2) 21 (1) 
 Rietvlei NVP sdNVP 192 (34) 80 (0) 23 (13) 8 (0) 11 (1) 70 (20) 
 Umlazi NVP sdNVP 324 (26) 184 (0) 33 (10) 12 (0) 14 (3) 81 (13) 
MASHI 20 MASHI_0 
CBV+NVP, 
ZDV, 
ZDV+sdNVP 
ZDV + 
sdNVP 
600 (42) 551 (30) 26 (9) 11 (3) 4 (0) 8 (0) 
 MASHI_1 
CBV+NVP, 
ZDV, ZDV+sdN 
ZDV + 
sdNVP 600 (43) 541 (33) 30 (8) 16 (2) 0 (0) 13 (0) 
MB 124 MB_N None None 197 (45) 132 (15) 27 (16) 19 (2) 13 (7) 6 (5) 
MITRA Plus 18 MITRA Plus ZDV+3TC+NVP ZDV + 3TC 441 (35) 415 (26) 16 (6) 8 (2) 2 (1) 0(0) 
PETRA 19 PETRA_A ZDV/3TC ZDV/3TC 366 (37) 301 (12) 11 (4) 28 (10) 13 (6) 13 (5) 
 PETRA_B ZDV/3TC ZDV/3TC 371 (52) 294 (21) 24 (8) 21 (9) 14 (8) 18 (6) 
 PETRA_C ZDV/3TC None 368 (47) 286 (15) 37 (14) 20 (4) 10 (5) 15 (9) 
 PETRA_D None None 353 (48) 264 (11) 38 (17) 18 (2) 19 (11) 14 (7) 
RETRO 22 RETRO_N None None 133 (29) 86 (4) 26 (11) 10 (4) 2 (1) 9 (9) 
 RETRO_T1 ZDV  None 128 (10) 96 (1) 15 (8) 13 (0) 2 (0) 2 (1) 
VITA 23 VITA_N None None 325 (23) 239 (5) 58 (14) 8 (1) 4 (0) 16 (3) 
 VITA_T1 None None 335 (26) 245 (6) 53 (15) 14 (2) 6 (1) 17 (2) 
VTS 14 VTS NVP sdNVP 1422 (198) 979 (40) 127 (77) 70 (20) 52 (29) 194 (32) 
Zvitambo 16 Zvitambo None None 4495 (881) 3115 (251) 727 (427) 257 (46) 355 (152) 41 (5) 
*up to 7 days postpartum  ART antitetroviral therapy CBV = Combivir (ZDV + 3TC)  NVP  = nevirapine sdNVP = single-dose NVP ZDV = zidovudine 
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Mortality analysis 
Date of infection was taken to be the midpoint between the last negative test and the first 
positive HIV test (antibody or PCR depending on age).  Where there was no negative 
test for those infected early, the midpoint between birth and first positive test was taken.  
A sensitivity analysis was undertaken to assess how results varied according to the date 
imputed.   
 
Children were grouped by infection status (infected and uninfected) and time of infection 
(perinatal, breastfeeding or postnatal period, status unknown) as defined by Newell et 
al51.  Those with unknown timing of infection were not used in the analysis beyond looking 
at their overall mortality compared to those with known timing of infection.  Kaplan-Meier 
analysis was used to calculate survival curves. Uninfected children of positive mothers 
were used to estimate mortality from non-HIV related causes when calculating net 
survival. 
 
Prior to decisions on pooling data the effect on the mortality hazards of the child receiving 
antiretroviral drugs in the first seven days of life for PMTCT post-exposure prophylaxis 
and possible regional differences a piece-wise Weibull model was constructed adjusting 
for duration of follow-up (to allow for changing compostion due to differing follow up times 
across studies) and study of origin to assess whether data should be excluded or 
analysed separately.  
 
Calculating net survival 
Methods to calculate paediatric survival have been described in detail elsewhere6.  In 
brief the net survival probability, , if HIV-related mortality is the only operative cause 
of death, can be calculated from the proportions of HIV-infected children surviving to age 
x, , and the proportion of uninfected children surviving to age x, , using the 
usual relationship for cause deleted life tables: 
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To make the distribution of the HIV-negative children similar to that of the HIV-infected 
children, the HIV-negative ones were weighted so that their distribution by entry into 
observation, study group, and timing of start of risk exposure matched those of the HIV-
infected children.    
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Newell et al showed that infected infants experience different rates of progression 
through the disease stages leading to AIDS and death, with those who acquired the 
infection in utero experiencing a more rapid progression than those acquiring the 
infection around the time of delivery or during breastfeeding.   
 
As noted, the double Weibull provides a good functional representation of paediatric 
survival curve as it allows for initial high mortality followed by rising mortality at later time 
points 6, 38, taking the form: 
 
[ ]{ } ( ) [ ]{ }21 21 exp1exp)( µµ λpiλpi xxxlA ⋅−⋅−+⋅−⋅=  
 
By studying the empirical curves depicting net survival by time since infection we produce 
two functional representations; one for those with perinatal infection and one for those 
with infection through breastfeeding.    
 
External constraints were introduced to extend the curve beyond the follow-up time 
provided by the studies, and these data were used until 20 subjects were remaining, 
which was deemed as a point at which the results could not be seen as reliable due to 
small numbers.  Recently a pooled study has been published5, 7 showing survival post-
infection in adults by age of infection using data from low and middle-income countries.  
This showed a more favourable survival for those adults infected at a younger age, and 
similar results were found in studies from higher income-countries in the pre-ART era125.  
A reasonable assumption we could thus consider is that the net HIV mortality rates of 
infected children at long durations of infection are no higher than the rates experienced 
by HIV-infected young adults below age 25.  The net survival of adults from HIV is 
described by the single Weibull curve: 
 
 
 
3.1.4 Results 
A total of 1930 infected children with known timing of infection were included in the 
analysis contributing 1576 person years of follow-up. The median age at last follow-up 
or death was 1.0 years (range: fraction of a day to 4.39 years) for infected children and 
1.49 years (range: fraction of a day to 11.39 years) for uninfected children of HIV-positive 
mothers.   Of the 1930 infected children, timing of infection was considered early for 
1340, late for 590 and unknown for 615 (Table 3.2). 
 
[ ]µλ xxlA ⋅−= exp)(
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Table 3.2: Follow up and outcome by child’s HIV infection status and timing of infection 
          Follow Up in years 
    
Number  
at start Total Person-years Deaths Median Maximum 
Infected      
 Perinatally 1340 1095.38 699 0.64 4.39 
 Through breastfeeding 590 480.66 120 0.65 4.17 
 Timing unknown  615 590.34 254 0.86 3.77 
Uninfected      
 Mother positive 8384 11457.84 493 1.49 11.39 
 Mother negative 1584 2633.18 51 1.83 4.48 
Unknown infection Status     
  Mother positive 9484 11296.43 250 1.02 3.28 
 
Figure 3.1 shows the cumulative survival of these children by timing of infection. Median 
age of survival was 348 days for those infected perinatally, but was not reached by 2.0 
years when only 20 subjects remained for those infected through breastfeeding, 
therefore was unable to be calculated. The survival of children for which the mode of 
infection was unknown was intermediate, suggesting that this category was made up of 
children infected perinatally and through breastfeeding.  The mortality hazards of those 
children infected through breastfeeding was 0.39 (95% CI 0.32-0.46), lower than for 
those infected perinatally.  The mortality data of uninfected children which are used to 
compute non-HIV related mortality risks for those infected perinatally, showed, as 
expected, higher mortality and worse survival than that of the uninfected children used 
to compute the equivalent risks for those infected through breastfeeding. Mortality of 
uninfected children included in these trials was very low with an overall infant mortality 
rate of 4 per 1000, i.e. lower than in most sub-Saharan African populations generally. 
Changing the imputed infection date for early infection to be birth for children who only 
had a positive, and no negative, test had almost no effect on the results.  This is also 
true of the later infected children, assuming the date of infection to be the earliest 
possible date (last negative test) or the latest possible date (first positive test) date. 
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Figure 3.1: Survival from time of infection by timing of HIV infection and weighted survival of 
uninfected children. 
 
 
Differentials by region and peripartum antiretroviral treatment 
Differences in survival by region and whether the child received peripartum antiretroviral 
intervention in the first seven days of life were assessed using piece-wise Weibull 
models, these were adjusted for study.  After adjusting for study, no mortality differences 
were seen across the regions or between children who received peri-partum preventative 
antiretroviral treatment in the first seven days of life (Table 3.3).    
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Table 3.3: Hazard ratios (HR) of survival for HIV Infection perinatally and through breastfeeding 
    Perinatal Infection    Infection through breastfeeding  
  
Adjusted for 
duration of follow-
up   
Adjusted for 
duration of follow-
up and Study   
Adjusted for 
duration of follow-
up   
 Adjusted for 
duration of follow-
up and Study 
    HR 95% CI    HR 95% CI    HR 95% CI    HR 95% CI  
Region             
 Eastern Africa 1   1   1   1  
 Southern Africa 1.60 (1.19-2.16)**  1.54 (0.85-2.82)  0.69 (0.44-1.08)  0.59 (0.20-1.73) 
 Western Africa 1.39 (0.96-2.01)  1.67 (0.21-13.03)  0.87 (0.44-1.74)  2.19 (0.37-12.92) 
             
Child PMTCT ARV            
 No 1   1   1   1  
  Yes 1.22 (1.00-1.49)*   1.20 (0.62-2.34)   0.69 (0.47-1.00)*   0.41 (0.16-1.02) 
*p<0.05 
**p<0.01 
ARV antiretroviral prophylaxis   
CI confidence interval 
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Timing of late infection  
The late infection group was split further into four groups.  A  Weibull piece-wise model 
adjusting for duration of follow up and trial showed a decrease in the gross mortality the 
later the child is infected. Figure 3.2 shows the increasing improvement in survival with 
later age at infection.  
 
Table 3.4: Hazard Ratios (HR) for those with late HIV infection 
    
Adjusted for duration of 
follow-up and trial  
    HR 95% CI  
Region   
 Eastern Africa 1  
 Southern Africa 0.57 (0.2-1.67) 
 Western Africa 2.48 (0.42-14.78) 
Peripartum ARV   
 No  1  
 Yes 0.4 (0.16-1.01) 
Age at infection    
 28- 90 Days 1  
 90-180 Days  0.81 (0.52-1.27) 
 180-365 Days 0.53 (0.33-0.85)** 
  365+ 0.16 (0.06-0.42)*** 
**p<0.01 
***p<0.001 
ARV antiretroviral prophylaxis 
 
Figure 3.2: Survival from time of infection by age at infection for those infected through 
breastfeeding 
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Net Survival 
Removing all other causes of mortality to give survival as if HIV was the only cause of 
death only slightly raised survival for both those infected perinatally or through 
breastfeeding (Figure 3.3).  The resulting net survival at one year post-infection for those 
infected perinatally was 52% and for those infected through breastfeeding 78% (Table 
3.5). 
 
Figure 3.3: Net and gross survival from time since infection for infection perinatally and through 
breastfeeding 
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Table 3.5: Probability of survival for HIV infected children and uninfected children to time x by timing of infection. 
    Time x  
    1 day 7 day 28 day 90 days 180 days 1 year 2 years 2.5 years 
Perinatal Infection          
 Uninfected (Weighted) 1 1 0.99 0.96 0.95 0.93 0.92 0.91 
 Infected 1 1 0.98 0.80 0.64 0.49 0.35 0.32 
 Net Survival 1 1 0.99 0.83 0.67 0.52 0.39 0.35 
 Net Weibull 0.99 0.96 0.9 0.79 0.69 0.54 0.37 0.32 
Infection through breastfeeding         
 Uninfected (Weighted) 1 1 1 0.99 0.98 0.97 0.96 0.96 
 Infected 1 1 0.99 0.96 0.88 0.76 0.62 0.58 
 Net Survival 1 1 1 0.97 0.89 0.78 0.64 0.60 
  Net Weibull 1 0.99 0.98 0.94 0.89 0.79 0.63 0.56 
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Extending the observed net curve  
Weibull curves were fitted to the net survival of adults post-infection in East Africa by age 
at infection which gave a median time of survival of 20 years for 15-24 year olds (λ=0.002 
µ=2.195) decreasing to 14 years for ages 35-44 (λ=0.025 µ=1.532) 5.  Assuming that 
children who survive for 2.5 years following perinatal infection and two years following 
infection through breastfeeding (the maximum follow up time with greater than 20 
subjects remaining) do not have a worse survival than young adults at the equivalent 
time post-infection the net curve was extended using the probabilities of dying between 
years since infection x and x+1 for adults at the same point in time.  Double Weibull 
curves were then fitted to the extended net survival (Figure 3.4). 
 
Figure 3.4: Double Weibull curves fitted to extended net survival functions for early and late HIV 
infection.  Curves were fitted using the net probability of survival of adults age 15-24 after 2.5 years 
of follow up for perinatal infection and 2.0 years for those infected through breastfeeding. 
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Table 3.6 gives a summary of the curve fits to the extended net survival.  The final Double 
Weibull curves give a median survival at 1.1 years for perinatal infection and 9.4 years 
for infection through breastfeeding.  It predicts a survival of 33% at five years from time 
of infection for those infected perinatally and 60% for those infected through 
breastfeeding.  At 20 years this is 9% and 16%, respectively.  
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Table 3.6: Summary of curve fits to the extended net survival (using adult survival) for those infected 
with HIV perinatally and through breastfeeding from time of infection  
Time of Infection  Parameters   Percentiles   
Net mortality risks 
(per thousand) 
       75% 50% 25%   1q0 5q0 
Perinatal  0.65 1.34 1.06 0.06 2.19  0.38 1.09 10.61  481 626 
Breastfeeding 0.35 1.03 1.66 0.06 2.19   1.09 9.24 16.91   232 396 
 
3.1.5 Discussion 
The current analysis produced separate survival schedules for children infected 
perinatally and those infected through breastfeeding, with a median survival of 1.1 years 
and 9.4 years, respectively. The use of these updated schedules in mathematical 
modelling of the HIV epidemic among children is expected to constitute a major 
improvement over the past approach with a unique survival schedule applied to all 
children.  This has extended work done by Newell et al suggesting a possible mortality 
difference by timing of vertical infection by adding new data that has become available 
and extending the survival curves using the net survival of young adults from HIV. The 
differences in survival are substantial at five years after infection, with only 33% of those 
infected perinatally surviving compared to 60% of those infected through breastfeeding.  
At 20 years after infection the difference is smaller at 16% compared to 9%, this is mainly 
because in the absence of evidence to suggest that either one should be higher we have 
applied the same mortality schedule to both groups after 2.5 years.   
 
The analysis further shows that there are also differences in survival within those who 
are infected through breastfeeding with a more favourable survival the later the time of 
infection, these differences still persisted after taking into account background mortality.   
 
We found no difference between the survival of those HIV-infected infants treated and 
not treated with peripartum antiretrovirals to prevent mother-to-child transmission and 
therefore included these children in the analysis. We do not question the effectiveness 
of PMTCT interventions to reduce the risk of transmission of HIV. However, our data 
suggest that where an infant acquires infection in spite of PMTCT exposure, mortality 
levels are similar to those infants infected without exposure to PMTCT. Regional 
differences in survival by timing of infection were not seen once heterogeneity between 
trials was accounted for, therefore with this current data we pooled data from all regions 
into the same dataset to generate one curve to represent all children. These data are 
only from sub-Saharan Africa with 51% of the person years of exposure coming from the 
ZVITAMBO trial in Zimbabwe16.  Regional differentials between sub-Saharan Africa and 
pi 1λ 1µ 2λ 2µ
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Thailand were seen in adults 7 therefore adding data from other regions would help 
confirm whether such differences exist for the mortality of HIV positive children, although 
we acknowledge that fewer HIV-exposed  children are breastfed in Asia or South 
America than in sub-Saharan Africa.   
 
Although breastfeeding is an important factor in child survival 126 we have not excluded 
those who were never breastfed.  Without knowing the breastfeeding trends in the 
general population we cannot tell how representative this sample is.  Even if we had 
excluded this 12% from this analysis the impact on the overall highly unfavourable 
survival curve would be minimal.   
 
Background mortality had very little effect on the differences in survival post-infection for 
both early and late infection.  All the data come from clinical trials or research studies 
within which background mortality, taken from the uninfected children of infected 
mothers, apparently was much lower than in the corresponding communities. The overall 
HIV-negative infant mortality rate in the current analysis was 4 per 1000.  The 
Demographic and Health Surveys 127 give infant mortality rates in the 10 years preceding 
each survey.  Estimates for urban areas ranged from 41 per 1000 in South Africa 2003 
to 72 per 1000 in Tanzania in 2004-05, all indicating a much higher mortality in the 
general population in many of the places the trials took place. The difference is evident 
even if we allow for the fact that the DHS figure includes the mortality of HIV-infected 
children and that the studies mainly took place at the later end of these periods (i.e. if 
infant mortality decreases over time we would expect a lower mortality rate in the trial). 
It strongly suggests that the mortality of uninfected children involved in the trials is lower 
than that in the general population, possibly due to increased access to health care 
services due to study participation therefore in the general population one might expect 
to see a larger difference between net and gross mortality.  
 
We have used the mortality of HIV-negative children of positive mothers as a reference 
in this analysis.  Therefore the resulting net mortality does not take into account the 
added negative effect of having an HIV-positive mother. There is evidence to suggest 
that there is a difference in the mortality of HIV-negative children born to HIV-positive 
mothers compared to HIV-negative mothers. The Rakai study 128 found that overall, for 
those under two years of age, C(x<2) = 1.3 where C(x) is the ratio between uninfected 
children of infected mothers compared to those of uninfected mothers at age x, but there 
was some evidence of variation of C(x) with age, with C(x<1) = 1.1, and C(1<x<2) = 1.8.  
A study in Kampala 129 showed a similar pattern with the same overall value for C(x<2) 
= 1.3 and a similar increase with age on subdivision of the interval.   
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The model curves beyond two and a half years rely on what is known about adult survival 
and assume that children are like younger adults with respect to mortality patterns.  
Further investigation is needed about whether this is a valid assumption especially for 
children infected early.  The inclusion of more data from other trials might increase our 
knowledge of net child survival beyond two and a half years and give a more accurate 
picture and more knowledge on how child survival compares to young adult survival.  
However this data is currently scarce and with the increase in antiretroviral treatment in 
children it is unlikely that any further data will become available.  It is possible that data 
on time to treatment need and time to death from treatment by timing of infection might 
help inform us further.   
 
The aim of this analysis was to improve modelling of the HIV epidemic by providing a 
separate representation of children infected perinatally and through breastfeeding. This 
analysis is an update on work done previously6, 123 and has used more detailed data from 
studies that can provide the timing of HIV infection of a child.  
 
The increase in data available and the construction of separate survival curves for 
children infected  perinatally and through breastfeeding allows for a clear improvement 
in the modelling of the HIV epidemic and is being used in the UNAIDS spectrum package 
to project the HIV epidemic 130. 
 
 
Acknowledgments 
This work was funded by the Epidemiology and Analysis Division of UNAIDS (Geneva, 
Switzerland).  
 
Composition of the UNAIDS Child survival group 
 
 Coordination 
Renaud Becquet, François Dabis (INSERM, Unit 897, Bordeaux, France); Milly Marston, 
Basia Zaba (London School of Hygiene and Tropical Medicine, London, UK); Marie-
Louise Newell (Africa Centre for Health and Population Studies, University of KwaZulu 
Natal, South Africa); Peter Ghys (UNAIDS, Epidemiology and Analysis Division, Geneva, 
Switzerland).  
 
 Data management 
Sophie Karcher, Renaud Becquet (INSERM, Unit 897, Bordeaux, France).  
  
70 
 
 Representatives of the participating studies 
Larry Moulton (Zvitambo trial, Zimbabwe); Anna Coutsoudis (Vitamin A trial, South 
Africa); Glenda Gray (Petra trial, Tanzania-SA-Uganda); Charles Kilewo (Mitra cohort, 
Tanzania); Jerry Coovadia (VTS cohort, South Africa); Valériane Leroy (ANRSa trial, 
Côte d’Ivoire); Max Essex (Mashi trial, Botswana); Stephan Wiktor (Retro-Ci trial, Côte 
d’Ivoire); Didier Ekouevi (Ditrame Plus cohort, Côte d’Ivoire); Ruth Nduati (Nairobi trial, 
Kenya); Debra Jackson (Good Start cohort, South Africa); Philippe Msellati (ANRSb trial, 
Burkina Faso).  
 
 Investigators and collaborators of the participating studies 
ANRSa Trial, Côte d'Ivoire  
Investigators. François Dabis, Philippe Msellati, Nicolas Meda, Christiane Welffens-Ekra, 
Bruno You, Olivier Manigart, Valériane Leroy, Arlette Simonon, Michel Cartoux, Patrice 
Combe, Amadou Ouangré, Rosa Ramon, Odette Ky-Zerbo, Crépin Montcho, Roger 
Salamon, Christine Rouzioux, Philippe Van de Perre, Laurent Mandelbrot.  
Other investigators. L Dequae-Merchadou, R Lassalle (Bordeaux Coordination Unit); A 
Bazie, A M Cassel Beraud, B Dao, L Gautier-Charpentier, FD Ky, B Nacro, O Sanou, I 
Sombié, F Tall, S Tiendrebeogo, Y Traore, D Valea, S Yaro (Bobo-Dioulasso Centre); 
and D Bonnard, R Camara, M Dosso, N Elenga, G Gourvellec, J B Kottan, R Likikouet, 
V Noba, M Timité, I Viho. 
Data and safety monitoring board. J-F Delfraissy, D Costagliola, C Chouquet, B Bazin, 
P Lepage, B Masquelier, K Toure Coulibaly. 
 
ANRSb Trial, Burkina Faso  
Biostatistics: R Lassalle, V Leroy, R Salamon. 
Epidemiology:M Cartoux, F Dabis (coordinator of the ANRS 049 trial/DITRAME 
programme), N Meda (coordinator of Bobo-Dioulasso Center), P Msellati (coordinator of 
Abidjan Center), R Ramon. 
Gynaecology-obstetrics: A Bazié, B Dao, R Likikouet, L Mandelbrot (principal 
investigator), C Welffens-Ekra (principal investigator). 
Microbiology: D Bonard, P Combe, M Dosso, L Gautier-Charpentier, F D Ky, A Ouangré, 
T Ouassa, O Sanou, F Sylla-Koko, Y Traore, P Van de Perre. 
Molecular biology: A M Cassel-Beraud, J B Kottan, OManigart, CMontcho, C Rouzioux, 
A Simonon, D Valea, B You. 
Paediatrics: R Camara, N Elenga, B Nacro, F Tall, M Timité. 
Trial monitoring: G Gourvellec, O Ky-Zerbo, V Noba, I Sombié, S Tiendrebeogo, I Viho, 
S Yaro. 
 
71 
 
Nairobi Trial, Kenya  
Ruth Nduati, Barbra A Richardson, Grace John, Dorothy Mbori-Ngacha, Anthony 
Mwatha, Jeckoniah Ndinya-Achola, Job Bwayo, Francis E Onyango, Joan Kreiss.  
 
Petra Trial, Tanzania - South Africa - Uganda  
Trial management committee 
J M A Lange (chair), J Saba (study coordinator), G Gray, J McIntyre, F Mmiro, Ch 
Ndugwa, J Moodley, 
H M Coovadia, D Moodley, Ch Kilewo, A Massawe, P Okong, P Kituuka, H von Briesen, 
J Goudsmit, G Biberfeld, F Mhalu, K Karlson, M Guliano, S Declich, S Clapp, G 
Haverkamp, G J Weverling, D Cooper, A Grulich, D Bray, J Perriens. Representatives of 
People Living with HIV: F Ngobeni, G Baguma, S Kyambadde. 
 
Participating clinical centres 
Uganda: Mulago Hospital, Mulago, Kampala (F Mmiro, Ch Ndugwa, P Musoke, C 
Nakabito, P Bakaki, I Kalyesbula, M Lutajumwa, S Mmiro, R Kato, R Byenkya, S 
Kabenge, R Mulira, R Bagenda, J Matavu, F Kikonyogo, E Kawuki, B Nkoyoyo, N 
Matovu, C Mukasa, C Dukar, M Mubiru, D Bagenda, K Khantaway); St Francis Hospital, 
Nsambya, Kampala (P Okong, P Kituuka, K Kayanja, S Kateera, B Sam, B Sabrina, M 
Ravera, E Omobono, M Magoni). 
Tanzania: Muhimbili General Hospital, Dar es Salaam (Ch Kilewo, A Massawe, F Mhalu, 
E Urassa, F Kalokola, F Phillip, M Giattas, F Temu, K Kallanga, A Mkumbukwa, E 
Lugaiya, S Nyoni, S Haule, 
E Hilbayuded, N Kavugha, I Kayombo, E Lyamuya, E Mbena, V Msangi, C Lema, H 
Matimbwa, I Semali, K Karlsson). 
South Africa: Chris Hani Baragwanath Hospital, Johannesburg (S Johnson, A Violari, L 
Connell, G Nelson, J Moetlo, A Makhofola, B Jivkov, F Ngobeni, M Kunene, G Ngakane, 
G Tshabalala, W Saba, 
P Khela, N Radebe); King Edward VII Hospital, Durban (J Moodley, H M Coovadia, D 
Moodley K Naidoo, M Adhikari, T Moniwa, D Moholo, I Mtshali, C Ngubane, A Mlaba, N 
Mkhize, C Sibiya, 
L Shozi, T Ngubane, V Mkhize, L Madurai, V Gopaul, L Thaver, G Swart, J Thomas). 
 
Trial coordination, central data management and statistical analysis 
Switzerland, Geneva, UNAIDS (J Saba, J Perriens); and International Antiviral Therapy 
Evaluation Center (J M A Lange, G Haverkamp, S Clapp, H Huisman, P Hollak, L 
Hendriks), and Department of Clinical Epidemiology and Biostatistics (G J Weverling), 
Academic Medical Centre, Amsterdam, Netherlands. 
72 
 
Laboratories 
Germany, Frankfurt: Georg-Speyer-Haus (A de Amorim-Nink, H Klunker, L Kurunci, H 
von Briesen, A Simon). Sweden, Stockholm: Swedish Institute for Infectious Disease 
Control and Microbiology and Tumorbiology Center Karolinska Institute (G Biberfeld, K 
Karlsson, E Olausson Hansson, A Östborn). Netherlands, Amsterdam: Academic 
Medical Centre–Department of Human Retrovirology (J Goudsmit, S Jurriaans, E de 
Rooy, M Bakker, N Romp). 
 
Retro-CI Trial, Côte d'Ivoire  
Stefan Z Wiktor, Ehounou Ekpini, John M Karon, John Nkengasong, Chantal Maurice, 
Sibailly T Severin, Thierry H Roels, Moise K Kouassi, Eve M Lackritz, Issa-Malick 
Coulibaly, Alan E Greenberg 
 
Vitamin A Trial, South Africa  
Investigators: Anna Coutsoudis, Kubendran Pillay, Louise Kuhn, Elizabeth Spooner, 
Wei-Yann Tsai and Hoosen M. Coovadia. 
Additional members: Gill Sinclair, Anne Mburu, Nolwandle Mngqundaniso, Kerry Uebel, 
Ingrid Coetzee, Ken Annamalai, Trevor Doorasamy, Ugene Govender, Juana 
Willumsen, Nigel Rollins, Jagidesa Moodley and Daya Moodley.  
Data Safety and Monitoring Board: Salim Abdool Karim, Eleanor Gouws, Jonathan Levin 
and Immo Kleinschmidt. 
 
VTS Cohort, South Africa  
Study investigators: Ruth Bland, Hoosen Coovadia (principal investigator), Anna 
Coutsoudis, Marie-Louise Newell, Nigel Rollins.  
Steering Committee: Janet Darbyshire (chair), Nono Simelela (South African National 
Department of Health), Victoria Sithole (Community Advisory Board) and the study 
investigators.  
Data monitoring and Safety Committee: Cathy Wilfert (chair, Elizabeth Glaser Pediatric 
AIDS foundation), Carl Lombard (statistician, Medical Research Council, South Africa), 
Ames Dhai (Department of Obstetrics and Gynaecology and the Biomedical Ethics Unit, 
University of KwaZulu-Natal, South Africa), Francis Crawley (Good Clinical Practice 
Alliance).  
Data management: Cookie Govender, Londiwe Mthethwa and team.  
Clinical team: Thembi Blose, Nqobile Mkhwanazi, Dumo Mkwanazi and team.  
Field team: Zanele Fakude, Samukelisiwe Dube and team.  
Laboratory team: Johannes Viljoen, Natalie Graham, Siva Davaviah and team. 
 
73 
 
Zvitambo Trial, Zimbabwe  
Investigators: Peter J. Iliff, Ellen G. Piwoz, Naume V. Tavengwa, Clare D. Zunguzac, 
Edmore T. Marinda, Kusum J. Nathoo, Lawrence H. Moulton, Brian J. Ward, Jean H. 
Humphrey 
Additional members: Henry Chidawanyika, John Hargrove, Florence Majo, Kuda 
Mutasa, Mary Ndhlovu, Robert Ntozini and Phillipa Rambanepasi (ZVITAMBO); Agnes 
Mahomva (AIDS and TB Unit, Ministry of Health and Child Welfare, Zimbabwe); Lucie 
Malaba (Faculty of Science, University of Zimbabwe); Michael Mbizvo, Partson 
Zvandasara and Lynn Zijenah (University of Zimbabwe College of Health Sciences); 
Lidia Propper and Andrea Ruff (The Johns Hopkins Bloomberg School of Public Health, 
Department of International Health). 
 
ANRS Ditrame Plus Cohort, Côte d'Ivoire  
Principal Investigators: Francois Dabis, Valériane Leroy, Marguerite Timite-Konan, 
Christiane Welffens-Ekra.  
Coordination in Abidjan: Laurence Bequet, Didier K. Ekouevi, Besigin Tonwe-Gold, Ida 
Viho.  
Methodology, biostatistics and data management: Gérard Allou, Renaud Becquet, Katia 
Castetbon, Laurence Dequae-Merchadou, Charlotte Sakarovitch, Dominique Touchard.  
Clinical team: Clarisse Amani-Bosse, Ignace Ayekoe, Gédéon Bedikou, Nacoumba 
Coulibaly, Christine Danel, Patricia Fassinou, Apollinaire Horo, Ruffin Likikouet, Hassan 
Toure. Laboratory team: André Inwoley, Francois Rouet, Ramata Touré. 
Psycho-social team: Hortense Aka-Dago, Alphonse Sihé.  
Social sciences team: Hélène Agbo, Hermann Brou, Annabel Desgrées-du-Lou , Annick 
Tijou-Traoré, Benjamin Zanou.  
Scientific Committee: Stéphane Blanche, Jean-Francois Delfraissy, Philippe Lepage, 
Laurent Mandelbrot, Christine Rouzioux, Roger Salamon. 
 
Good Start Cohort, South Africa  
Mark Colvin, Mickey Chopra, Tanya Doherty, Debra Jackson, Jonathan Levin, Juana 
Willumsen, Ameena Goga, Pravi Moodley 
 
MASHI Trial, Botswana  
Investigators: Ibou Thior, Shahin Lockman, Laura M. Smeaton, Roger L. Shapiro, 
Carolyn Wester, S. Jody Heymann, MD, Peter B. Gilbert, Lisa Stevens, Trevor Peter, 
PhD, Soyeon Kim, Erik van Widenfelt, Claire Moffat, Patrick Ndase, Peter Arimi, Poloko 
Kebaabetswe, Patson Mazonde, Joseph Makhema, Kenneth McIntosh, Vladimir 
Novitsky, Tun-Hou Lee, Richard Marlink, Stephen Lagakos, Max Essex.  
74 
 
Collaborators: Drs C. Anude and J. Chanda, study physicians; L. Makori, nursing 
diploma, study nurse; J. B. Moorad, T. A. Modise, T. Moyo, and M. Malamba, nursing 
and midwifery diplomas, study nurses; D. Arbi and K. Koloi, nursing diplomas, nurse 
recruiters; L. Dube and T. Mmolotsi, health education diplomas, health educators and 
recruiters; S. Babitseng and D. Mere, nursing diplomas, recruiters (Molepolole site); Dr 
J. Boyle, study physician; J. Magetse, V. Modikwa, and M. Tsuro, nursing and midwifery 
diplomas, study nurses; T. Sekoto, family nurse practitioner diploma, study nurse; L. 
Garebatho, nursing diploma, study nurse; M. Sesinyi and K. Kelebalekgosi, health 
educator diplomas, health educators and recruiters (Mochudi site); Dr Z. Tedla, study 
physician; G. Mayondi, K. Sebinang, J. Setswalo, nursing and midwifery diplomas, study 
nurses; N. Makubate, community health 
nursing and midwifery diploma, study nurse; L. Tsalaile, MSc nursing education, study 
nurse; B. Tsule, nursing diploma, study nurse; I. Thebeetsile, nursing diploma, nurse 
recruiter; I. Leteane and O. Makgabana, health education diplomas, health educators 
and recruiters (Lobatse Site); Drs. M. Mogodi, A. Owor, I. Hove, and A. Asmelash, study 
physicians; T. Kakhu, P. Ramalepa, and J. Lubinda, nursing and midwifery diplomas, 
study nurses; S. Ndebele, F. Modise, C. Bohule, K. Motshabi, and M. Ntshimane, nursing 
diplomas, nurse recruiters; (Gaborone site). 
 
MITRA Cohort, Tanzania  
Investigators: Charles Kilewo, Katarina Karlsson, Augustine Massawe, Eligius Lyamuya, 
Andrew Swai, Fred Mhalu, Gunnel Biberfeld.  
Physicians: N. Hamud, F. Kalokola, G. Msemo, F. Temce, M. Giarttas, J. Methodi. 
Nurses: A. Mkumbukwa, E. Rugaiya, S. Semanini, R. Mwamwembe, N. Makundi, A. 
Temu. 
Laboratory Technologists: E. Mbena, E. Olausson-Hansson, D. Kalovya, V. Msangi, and 
A. O¨ stborn. 
Secretary: C. Lema. 
  
75 
 
   
76 
 
3.2 Extract from “Updates to the Spectrum/Estimation and 
Projection Package (EPP) model to estimate HIV trends for 
adults and children” 
 
3.2.1 Child Survival 
In the previous version of Spectrum two new survival curves for ‘AIDS only’ mortality of 
children were introduced, based on data from 12 sub-Saharan African clinical trials and 
studies: the first to represent children infected at birth, the second to represent those 
infected through breast feeding.13, 130 Further analysis of these data gave strong 
evidence that survival of children infected through breast feeding improved the later 
they were infected. Double Weibull curves were fitted to the data allowing for time of 
infection to give a pattern of survival post infection for four groups: those infected at 
birth, at 28–179 days, 180– 364 days and after 365. Similar curves representing the 
survival of HIV negative children from the equivalent time points were used to remove 
non-AIDS mortality. There is limited information about the survival of HIV infected 
children beyond 2.5 years, so as with the previous estimates it was assumed that 
beyond this point the survival for children would be equivalent to that of young adults 
infected at ages 15–24, with a median survival of 15 years.5 Survival is described as a 
double Weibull curve of the form:  
 
St = (π x eX + (1 – π) x eY) x 100 
Where X = -1 x (λ1 x t)µ1  and Y = -1 x (λ2 x t)µ2 
The parameter values are shown in Table 3.7. The resulting curves give a median AIDS 
only survival of 1.1, 6.4, 11.5 and 14.1 years resulting in 9% survival at 20 years for those 
infected at birth and 14%, 19% and 24% for those infected through breast feeding at 28–
179 days, 180–364 days and after 365 days (Figure 3.5). These changes provide for 
greater accuracy in estimating child survival. They will usually result in higher estimates 
of the number of HIV+ children surviving to age 15.  
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Table 3.7: Parameter values for child survival patterns  
  Time of Infection 
Parameter Perinatal 
Postnatal              
0-180 days 
Postnatal          
181-365 days 
Postnatal          
365+ days 
π 0.646 0.440 0.248 0.048 
λ1 1.336 1.015 1.241 1.873 
µ1 1.062 1.484 2.110 1.708 
λ2 0.058 0.058 0.058 0.058 
µ2 2.195 2.200 2.200 2.200 
 
Figure 3.5: Percentage of HIV+ children surviving by number of years since infection. 
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3.3 Research report for UNAIDS - an update to the paediatric 
curve 
 
Changes to the Paediatric Survival Curve 
Report for UNAIDS – March 2015 
Milly Marston, Basia Zaba, Francesca Cavallaro  
Author contributions:  MM conceived the analysis.  MM prepared and analysed the data 
using clinical cohorts.  FC prepared the DHS data, MM analysed the data.  MM wrote 
the report.  BZ commented and edited drafts 
3.3.1 Background 
Empirical data on the survival of children post infection from HIV in the absence of ART 
only exists for up to two or three years post infection.   In order to create a survival curve 
that represents the whole survival pattern for net paediatric survival from HIV we 
currently make the assumption that the children infected though mother to child 
transmission have the same mortality hazards post infection as those found in young 
adults aged 15-2413, 52.  Data for young adults is taken from Sub Saharan African HIV 
demographic surveillance cohorts which are part of the ALPHA network5, 7.    
Data from the ALPHA network show a clear increase in median survival post infection 
with younger age of infection after taking into account background levels of mortality, 
however these data only include those over the age of 15 so we are unable to see if 
this increase in survival continues into early adolescence and childhood and whether 
there is a minimum age beyond which this negative association between age at 
infection and survival is not observed.  Data from Europe, North America and Australia 
show the same pattern as the African cohorts in adults and also show that 5-14 year 
olds still seem to have a more favourable survival than those aged 15-24 years.  Those 
infected at ages <5 appear to have a similar pattern to those infected at 5-14 years 
(Table 3.6)125 
These findings however may be problematic to apply to populations in Sub Saharan 
Africa.  Firstly although they stem from a time when highly active antiretroviral therapy 
was not widespread children in developed countries are likely to have received much 
more HIV related treatment than available in Sub Saharan Africa.  Secondly the infected 
children are nearly all haemophiliacs whereas the older age groups to whom they are 
compared are more commonly infected through sexual intercourse or injecting drugs, 
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and there is some evidence that these different routes of infection can lead to different 
survival times125.  However studies restricted to Haemophiliacs have shown that age at 
infection continues to be important and show that <15 year olds have a significantly 
longer survival than those infected at older ages131. 
 
Figure 3.6:  Survival post infection by age at sero conversion taken from CASCADE Lancet 2000 
125(Permission to reuse license, see appendix 3) , the under 15 year olds are nearly all Haemophiliacs 
(99%) 
 
3.3.2 Methods 
Data Sources 
Empirical data of the survival of children infected at birth comes from 12 clinical trials and 
cohort studies in Southern, Eastern and Western Africa, the data and resulting net 
paediatric survival from HIV is described elsewhere12, 13.  Data on adult net survival post 
infection comes from three East African community based HIV cohorts who are members 
of the ALPHA network, data and methods are described elsewhere5, 7 
Analysis 
We extrapolate the relationship between age at infection and the parameters of the best 
fitting Weibul curves representing adult net survival post infection from Marston et al5  to 
obtain a Weibul curve that represents the survival of children and young adolescents 
following infection at ages 5-14.  
  
We use the new Weibul curve for those infected at ages 5-14 to represent mortality 
hazards of children after the age point at which empirical data on mortality of children 
infected through mother to child transmission13 runs out (With the assumption that those 
infected at birth should have no worse survival at the point the empirical data runs out 
than those infected between 5-14 years old at the same time post infection).   A double 
[ ]µλ xxlA ⋅−= exp)(
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weibul curve is fitted by timing of infection for perinatal infections, those infected between 
0-180 days, 181-364 days and 365 days plus.  The double Weibul takes the form: 
 
Using the new double Weibul parameters we input the survival estimates into Spectrum 
to see how AIDS deaths and prevalence change over the age groups compared to the 
current Spectrum output.  We run Spectrum using the no EPP adjustment in order to see 
the direct effect vertically transmitted infections have in the older ages groups, using the 
EPP adjustment would mean that Spectrum would make small yearly adjustments to the 
EPP incidence to match the EPP prevalence therefore essentially forcing Spectrum to 
give the same prevalence regardless of how many vertical infections are surviving to 
adulthood.  
HIV prevalence in young adults - Demographic and Health Survey (DHS) Analysis 
We used data from 44 DHS and AIDS indicator survey (AIS) 132 to calculate  
prevalence in young people aged 15 to 24  for comparison to Spectrum outputs.   We 
also looked at evidence of vertical transmission and how much it contributes to overall 
prevalence by calculating prevalence in the 15-19 year olds by whether the respondent 
had reported ever having sex.  We could assume if all reports of never having sex were 
true and in the absence of other sorts of HIV transmission such as  blood transfusions 
and needles, that the prevalence of HIV positive 15-19 year olds who have never had 
sex in the population is a minimum for those who were infected at birth.   
Data analysis was carried out using the statistical package Stata 13.1 SE. 
3.3.3 Results 
The extrapolated weibul to represent children infected between 5-14 years old gives a 
median survival of 16.8 compared to 14.3 in the young adults 15-24 year olds, the curve 
and parameters are shown in Figure 3.7 and Table 3.8. 
[ ]{ } ( ) [ ]{ }21 21 exp1exp)( µµ λpiλpi xxxlA ⋅−⋅−+⋅−⋅=
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Figure 3.7: Weibul curves fitted to net adult survival post HIV infection with projected child net 
survival curve (for those under 15) 
 
 
Table 3.8: Weibul parameters for net survival curves of adults and horizontally infected children and 
adolescents 
    Age at infection Adults 
fitted Weibul 
parameters 
Extrapolated curve 
for 5-14 15-24 25-34 35-44 45+ 
λ 0.0006 0.0019 0.0075 0.0251 0.0114 
μ 2.51 2.19 1.81 1.53 2.20 
 
The parameters for the resulting new double Weibul infant survival curves are shown in 
Table 3.9 and graphed in Figure 3.8, mortality hazards are shown in Figure 3.9.   The 
new double Weibul curves are very similar to the previous ones but yield a longer median 
survival time of between 14.0 and 21.9 years from perinatal infection to those infected 
after their first birthday compared to 10.7 and 19.7 with the curves currently used in 
spectrum (Table 3.10) 
.
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Table 3.9: Parameters of double Weibuls for paediatric net survival from HIV current in spectrum and for the new curves 
  Current Curves by time of infection   New Curves by time of infection 
Double 
Weibul 
parameter 
perinatal 
 0-180 
days 
181-
365 
days 
365+ 
days 
  perinatal 
0-180 
days 
181-
365 
days 
365+ 
days 
π 0.646 0.440 0.248 0.048   0.614 0.436 0.251 0.050 
λ1 1.336 1.015 1.241 1.873  
1.479 1.033 1.205 1.810 
µ1 1.062 1.484 2.110 1.708  
1.132 1.509 2.099 1.691 
λ2 0.058 0.058 0.058 0.058  0.051 0.051 0.051 0.051 
µ2 2.195 2.200 2.200 2.200   2.531 2.531 2.531 2.531 
 
 
Table 3.10: Quartile survival years by time of infection 
  
Current - Quartile survival by time of 
infection   
New curves-Quartile survival by time of 
infection 
Quartiles perinatal 
 0-180 
days 
181-365 
days 
365+ 
days 
  perinatal 
0-180 
days 
181-365 
days 
365+ 
days 
75% 0.35 0.85 1.65 8.95   0.35 0.85 1.75 10.95 
median: 50% 1.05 6.45 11.45 14.15 
 
1.05 8.45 13.65 16.35 
25% 10.65 15.65 18.05 19.65   14.05 17.95 20.15 21.85 
 
83 
 
Figure 3.8: Double Weibul Survival Curves comparing current curves used by Spectrum with new 
curves 
 
 
Figure 3.9: Force of mortality comparing current curves used by Spectrum with new curves 
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3.3.4 Implication for AIDS Deaths and HIV prevalence in young adults 
AIDS Deaths 
Using spectrum to project AIDS deaths over time (with the no EPP adjustment) AIDS 
deaths in the under 15 year olds reduce with the largest reduction in the 5-9 year olds.  
AIDS deaths then increase using the new curve compared to the old in those 15 plus.  
This increase is a deferral effect because under the new assumptions more paediatric 
infections survive to become teenagers.  The increase in AIDS death is at its largest in 
the 15-19 year olds.   Figure 3.10 shows the AIDS deaths by age group and time for 
Kenya which follows a fairly typical pattern, other countries are shown in the appendix in 
Figure 3.20-Figure 3.30 (Botswana, Lesotho, Malawi, Mozambique, Rwanda, South 
Africa, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe)  For the older age groups 
the graphs show all AIDS deaths and also AIDS deaths only due to mother to child 
transmission.  It is interesting to note that this predicts that around half the AIDS deaths 
to 20-24 year olds in Kenya in 2020 will be due to vertical transmission that occurred 
around the year 2000.  
Figure 3.10: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Kenya 
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Prevalence 
Longer survival of paediatric infections implies increases in HIV prevalence in children 
and adolescents.  Proportional increases in HIV prevalence comparing the new 
projections with those currently used in Spectrum are highest in the 10-14 year age group 
at around 1.2 times higher with the differences beginning to fall around 2010 presumably 
due to falling HIV prevalence in the past and the introduction of ART.   For those over 15 
prevalence rises to between 1.1 and 1.2 times  higher using the new child survival curves 
(Figure 3.11).  In absolute terms the prevalences are very close apart from peak times, 
which coincide with the age achieved by the cohort of children who were born during 
peak prevalence years in the population.  Prevalence by age group over time is shown 
in Figure 3.12 for Kenya and for all other countries in Figure 3.31-Figure 3.41 in the 
appendix. 
Figure 3.11: Proportional increase in prevalence by age group in Spectrum comparing projections 
using the new curves to the current curves – Note that the age groups 15-24 include all HIV infections 
(sexual as well as vertical transmission). 
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Figure 3.12: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Kenya 
 
Prevalence comparisons to the DHS 
Since the new child survival curves have increased prevalence slightly in all age groups 
we compared the Spectrum prevalence (without EPP adjustment) to that in the 
demographic household surveys (DHS).  Overall currently in Spectrum the prevalence 
in most countries in the 15-19 year olds is slightly lower in spectrum than reported in the 
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Figure 3.13: Comparison of Prevalence from Spectrum with DHS for 15-19 year olds (using 2014 
country files from UNAIDS with no EPP adjustment) 
 
Figure 3.14: Comparison of Prevalence from Spectrum with DHS for 20-24 year olds (using 2014 
country files from UNAIDS with no EPP adjustment) 
  
 
Using the prevalence produced in Spectrum with the new child survival curves for 
selected countries we can compare whether the new curves generate prevalence 
estimates closer or further away from the survey data.  The number of survey data 
sources for 5-9 and 10-14 year olds are limited compared to those available for ages 
15+.    For 5-9 year olds there is little difference in the two estimates from Spectrum for 
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the years and countries with survey data (Figure 3.15).  For 10-14 year olds the new 
curves bring the prevalence in Spectrum slightly closer to the point estimates from the 
surveys with the exception of Kenya 2012 (Figure 3.16).  For 15-19 year olds there is 
little difference but in general the new prevalence from Spectrum is marginally closer to 
the point estimate (Figure 3.17) and for 20-24 year olds there is very little difference 
(Figure 3.18). 
 
Figure 3.15: Comparison of Prevalence from Spectrum and the prevalence given by the new curve 
compared to survey data  for 5-9 year olds  (using 2014 country files from UNAIDS with no EPP 
adjustment) 
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Figure 3.16: Comparison of Prevalence from Spectrum and the prevalence given by the new curve 
compared to Survey data  for 10-14 year olds  (using 2014 country files from UNAIDS with no EPP 
adjustment) 
 
Figure 3.17: Comparison of Prevalence from Spectrum and the prevalence given by the new curve 
compared to DHS for 15-19 year olds  (using 2014 country files from UNAIDS with no EPP adjustment) 
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Figure 3.18: Comparison of Prevalence from Spectrum and the prevalence given by the new curve 
compared to DHS  for 20-24 year olds  (using 2014 country files from UNAIDS with no EPP 
adjustment) 
 
 
Prevalence in young adults by sexual experience  
Sample size was small when looking at HIV prevalence by whether the respondent 
reported ever having sex.  Figure 3.19 shows the HIV prevalence in 15-19 year olds by 
whether they report ever or never having sex (A possible measure of the minimum 
contribution of vertical transmission to HIV prevalence), corresponding numbers with 
confidence intervals are found in Table 3.11 in the appendix.  Between 4.6% (95% CI 
0.9-20.8%) of HIV positive 15-19 year olds in Liberia 2013 to 78.9% (95% CI 49.6-93.4%) 
in Ethiopia 2011 reported never having sex.  
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Figure 3.19: DHS HIV prevalence in 15-19 year olds by whether they have ever or never had sex.  NB 
Sample size is small see Table 4 in appendix for confidence intervals.   
 
 
3.3.5 Discussion  
We have experimented with a small change to the Paediatric survival curves, retaining 
the same basic assumption that once the empirical data runs out, HIV-related child 
mortality is assumed to follow the same pattern as is seen in adults, however we have 
extrapolated improving survival by age at infection to include children and adolescents 
under 15.  The question still remains, how far do we go back in age before the survival 
post infection becomes less favourable as shown by the empirical evidence for those 
infected under the age of one?    
For those infected after the perinatal period there is an initial short increase in mortality 
followed by a decrease in the empirical data, this could be a biological effect (incubation 
of disease following infection) or an artefact due to the slight uncertainty about the exact 
timing of infection.   
The new curves give a lower number of AIDS deaths in the under 15 year age groups 
but increase the AIDS deaths in the 15-19.  The resulting prevalence of HIV is no more 
inconsistent with the DHS prevalence estimates than before and overall bring them 
marginally closer together.   
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Looking at those who are HIV positive in the DHS but have reported never having sex is 
evidence that a large proportion of 15-19 year olds are infected vertically.  The 
prevalence of those HIV positive and reporting never having sex in the population gives 
an estimated minimum contribution of vertical infected 15-19 year olds, however no 
further conclusions or estimates of the actual contribution to prevalence those vertically 
infected make can be made due to a number of reasons; small sample size, knowing 
how many of those who have had sex were infected vertically and the uncertainty around 
whether the report of never having sex is true or not.  
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3.3.6 Appendix 
Mortality graphs comparing spectrum with new curves 
Figure 3.20: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Botswana 
 
 
Figure 3.21: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Lesotho 
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Figure 3.22: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Malawi 
 
Figure 3.23: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Mozambique 
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Figure 3.24: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. – Rwanda 
 
Figure 3.25: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. – South Africa 
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Figure 3.26: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Swaziland 
 
Figure 3.27: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Tanzania 
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Figure 3.28: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Uganda 
 
Figure 3.29: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Zambia 
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Figure 3.30: AIDS Deaths between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve. - Zimbabwe 
 
Prevalence 
Figure 3.31: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Botswana 
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Figure 3.32: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Lesotho 
 
Figure 3.33: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. -Malawi 
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Figure 3.34: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Mozambique 
 
Figure 3.35: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. -Rwanda 
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Figure 3.36: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. – South Africa 
 
Figure 3.37: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Swaziland 
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Figure 3.38: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Tanzania 
 
Figure 3.39: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Uganda 
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Figure 3.40: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Zambia 
 
Figure 3.41: HIV prevalence between 1990 and 2020 by age group from Spectrum using current 
paediatric survival curve and the new curve (using 2014 country files from UNAIDS with no EPP 
adjustment), note difference y scales. - Zimbabwe 
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Table 3.11: Estimated HIV prevalence for 15-19 year olds in the DHS , Proportion of HIV positives 
reporting never having sex and the prevalence of HIV positive 15-19 year olds who report never having 
sex in the population. 
Survey 
HIV 
Prevalence           
(%) 
Percentage of HIV 
positives who report 
never having sex 
Prevalence of  HIV +ve  15-
19 year olds who have 
never had sex  
Burkina2003 0.8 (0.4-1.5) 59.0 (28.6-83.9) 0.5 (0.2-1.1) 
Burkina2010 0.3 (0.1-0.9) 72.1 (42.8-89.9) 0.2 (0.1-0.5) 
Burundi2010 0.3 (0.1-0.6) 67.7 (30.2-91.1) 0.2 (0.1-0.5) 
Cameroon2004 1.4 (1.0-2.0) 26.6 (14.4-43.8) 0.4 (0.2-0.7) 
Cameroon2011 1.2 (0.9-1.7) 31.6 (17.0-50.9) 0.4 (0.2-0.8) 
Congo2009 1.4 (0.8-2.5) 50.3 (26.9-73.7) 0.7 (0.3-1.7) 
CoteIvoire2005 0.3 (0.1-0.8) 12.4 (2.8-40.7) 0.0 (0.0-0.1) 
DRC2007 1.2 (0.6-2.5) 34.8 (12.4-66.8) 0.4 (0.2-0.9) 
DRC2014 0.5 (0.2-1.3) 37.8 (8.5-80.0) 0.2 (0.1-0.6) 
Ethiopia2005 0.4 (0.2-0.9) 23.9 (6.4-59.1) 0.1 (0.0-0.3) 
Ethiopia2011 0.1 (0.1-0.2) 78.9 (49.6-93.4) 0.1 (0.0-0.2) 
Gabon2012 1.0 (0.4-2.2) 23.1 (3.7-70.3) 0.2 (0.0-1.4) 
Ghana2003 0.3 (0.2-0.7) 26.1 (6.4-64.8) 0.1 (0.0-0.4) 
Guinea2005 0.7 (0.4-1.4) 21.2 (5.1-57.5) 0.2 (0.0-0.6) 
Guinea2012 0.9 (0.5-1.7) 50.7 (23.7-77.3) 0.5 (0.2-1.2) 
Kenya2003 1.6 (1.1-2.4) 42.8 (23.6-64.4) 0.7 (0.3-1.3) 
Kenya2009 1.7 (1.1-2.6) 26.8 (11.9-49.9) 0.5 (0.2-1.1) 
Lesotho2004 5.3 (4.1-6.9) 37.9 (26.2-51.1) 2.1 (1.4-3.2) 
Lesotho2009 3.5 (2.6-4.7) 36.7 (24.3-51.2) 1.3 (0.8-2.1) 
Liberia2007 0.9 (0.5-1.5) 10.2 (2.4-34.6) 0.1 (0.0-0.4) 
Liberia2013 0.6 (0.2-1.4) 4.6 (0.9-20.8) 0.0 (0.0-0.1) 
Malawi2004 2.1 (1.3-3.3) 32.1 (14.2-57.5) 0.7 (0.3-1.6) 
Malawi2010 2.7 (2.0-3.6) 38.5 (25.2-53.7) 1.0 (0.6-1.7) 
Mali2006 0.6 (0.4-1.2) 47.3 (21.0-75.2) 0.3 (0.1-0.8) 
Mali2013 0.6 (0.3-1.2) 54.5 (19.1-85.8) 0.3 (0.1-0.9) 
Mozambique2009 5.0 (3.7-6.6) 14.5 (7.1-27.1) 0.8 (0.4-1.6) 
Rwanda2005 0.5 (0.3-0.9) 53.4 (26.0-78.9) 0.3 (0.1-0.6) 
Rwanda2010 0.5 (0.3-0.8) 69.9 (44.4-87.1) 0.4 (0.2-0.7) 
SaoTome2009 0.7 (0.3-1.6) 70.6 (32.1-92.4) 0.5 (0.2-1.4) 
Senegal2005 0.1 (0.0-0.3) 28.5 (3.3-82.3) 0.0 (0.0-0.2) 
Senegal2011 0.1 (0.0-0.2) 16.5 (2.0-65.1) 0.0 (0.0-0.1) 
SierraLeone2008 0.7 (0.3-1.4) 17.7 (3.7-54.7) 0.1 (0.0-0.5) 
SierraLeone2013 1.1 (0.7-1.7) 33.4 (18.8-52.2) 0.4 (0.2-0.7) 
Swaziland2007 5.8 (4.8-7.0) 34.8 (27.2-43.3) 2.1 (1.5-2.8) 
Tanzania2004 2.1 (1.5-3.0) 41.4 (26.1-58.7) 0.9 (0.5-1.4) 
Tanzania2008 1.0 (0.7-1.5) 46.3 (26.9-66.9) 0.5 (0.2-0.9) 
Tanzania2012 1.0 (0.7-1.5) 57.2 (37.7-74.8) 0.6 (0.3-1.1) 
Uganda2011 2.4 (1.8-3.0) 45.7 (36.3-55.4) 1.1 (0.8-1.5) 
Zambia2007 4.7 (3.7-5.9) 40.7 (31.9-50.2) 2.0 (1.4-2.7) 
Zimbabwe2006 4.6 (3.8-5.6) 45.3 (35.7-55.2) 2.2 (1.6-2.8) 
Zimbabwe2011 3.8 (3.1-4.6) 62.8 (52.8-71.8) 2.4 (1.9-3.1) 
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4 PAPER B: Is the risk of HIV acquisition increased 
during and immediately after pregnancy?  A secondary 
analysis of pooled HIV community-based studies from 
the ALPHA network. 
For objective 2 of the PhD: to investigate population level risk of acquisition of HIV in 
pregnant women; an analysis was conducted using data from the ALPHA network and 
published in:  
Marston, M; Newell, ML; Crampin, A; Lutalo, T; Musoke, R; Gregson, S; Nyamukapa, C; 
Nakiyingi-Miiro, J; Urassa, M; Isingo, R; Zaba, B. (2013) Is the Risk of HIV Acquisition 
Increased during and Immediately after Pregnancy? A Secondary Analysis of Pooled HIV 
Community-Based Studies from the ALPHA Network. PLoS One, 8 (12).  
4.1 Introduction to paper 
Differences in the rate of acquisition of HIV in pregnancy or in the postpartum period 
compared to non-pregnant non-postpartum time are important to consider when estimating 
mother to child transmission, as the increased viral load in recent infection would expose 
the foetus to higher risk of in utero mother-to-child transmission, or a breastfeeding infant to 
a higher risk of postpartum transmission.  Apart from one, all of the previous studies on HIV 
acquisition in pregnancy were not from a general population, which is an important limitation, 
as in the general population HIV acquisition in pregnancy depends not only on biological 
mechanisms for the transmission of HIV and sexual behaviour but also on the level of HIV 
discordance amongst partners.   
Therefore for estimates of paediatric HIV incidence at a population level, an analysis of 
population level data is required.  Population-based HIV cohort studies are ideally placed to 
provide generalisable estimates of the risk of HIV acquisition during pregnancy in the 
community; this paper uses data from six such cohorts from eastern and southern Africa 
which are part of the ALPHA network. The paper assesses the population-level HIV 
incidence during pregnancy and the post-partum period, adjusting for age. 
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4.2 Abstract 
Background 
Previous studies of HIV acquisition in pregnancy have been in specific population groups, 
such as sero-discordant couples which have shown an increased risk of HIV acquisition 
during pregnancy  and studies of sexually active women where the results have been 
ambiguous.  However these studies are unable to tell us what the overall impact of 
pregnancy is on HIV acquisition in the general population.    
 
Methods 
Data from six community-based HIV cohorts were pooled to give 2,628 sero-conversions 
and a total of 178,000 person years of observation.  Multiple imputation was used to allow 
for the uncertainty of exact sero-conversion date in surveillance intervals greater than the 
length of a pregnancy.  Results were combined using Rubin’s rules to give appropriate error 
bounds.  The analysis was stratified into two periods: pre- and post- widespread availability 
of prevention of mother-to-child HIV transmission services. This allows us to assess whether 
there is reporting bias relating to a person’s knowledge of their own HIV status which would 
become more widespread in the latter time period.   
 
Results 
Results suggest that women while pregnant have a lower risk of acquiring HIV infection over 
all periods (HRR 0.79, 95%CI 0.70-0.89) than women who were not pregnant.  There is no 
evidence for a difference in the rate of HIV acquisition between postpartum and non-
pregnant women (HRR 0.92 95%CI 0.84-1.03).  
 
Discussion  
Although there may be immunological reasons for increased risk of HIV acquisition during 
pregnancy, at a population level this study indicates a lower risk of HIV acquisition for 
pregnant women.  Pregnant women may be more likely to be concordant with their current 
sexual partner than non-pregnant women, i.e. either already HIV positive prior to the 
pregnancy or if negative at the time of becoming pregnant more likely to have a negative 
partner.   
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4.3 Introduction 
Fertility rates are high in many sub-Saharan African countries and, thus, a significant 
proportion of woman-years are spent pregnant 53.  Evidence regarding the risk of acquisition 
of HIV infection at and shortly after the time of pregnancy is conflicting 54-60.  An increased 
risk of HIV acquisition in pregnant women has implications for health services as the 
increased viral load in acute infection would expose the fetus to higher risk of in utero 
mother-to-child transmission61.  This would also have implications for HIV epidemic 
modelling as estimates for paediatric HIV would need to be revised upwards. 
A number of prospective studies from Eastern and Southern Africa have assessed the risk 
of HIV incidence during pregnancy.  A multisite study of sero-discordant couples found that 
HIV incidence was, in univariate analysis, two-fold higher in pregnant than in not-pregnant 
women;  however, after adjusting for age, any unprotected sex in last month, and 
contraceptive use, the risk difference was reduced and no longer statistically significant 57.   
A similar study in Uganda restricted to married sero-discordant couples reported a non-
significant increase in the HIV acquisition rate in pregnant women 54.   Other studies included 
women regardless of the partners’ HIV status; in a Ugandan study of sexually-active women 
the risk of HIV-1 acquisition was doubled during pregnancy 54.  However, in an HIV 
prevention trial enrolling women from a number of health services and community venues 
in southern Africa there was no increased risk of HIV-1 in pregnant women 59.   A study in 
Uganda and Zimbabwe, in which women from family planning sites were enrolled, found no 
increased risk of HIV acquisition in pregnant women in the pooled analysis overall, and 
actually showed some evidence of a protective pregnancy effect in one of the sites in the 
study after adjusting for covariates 56.  Further studies have shown a possible increased HIV 
incidence during pregnancy 62-64, others showed a risk comparable to the general population 
of a similar age 65, 66.  
A number of studies have investigated HIV incidence in the postpartum period, again with 
somewhat conflicting results.  In Malawi, a prospective study of women enrolled after 
delivery found  HIV acquisition was increased in the first year postpartum decreasing 
subsequently 60; this was also the case in Zimbabwe 58 and Rwanda 55. The authors of the 
latter study suggested that the decrease could be partly due to a cohort selection bias with 
those remaining uninfected for longer having a lower risk of  infection .  Other studies have 
not reported an increased risk in the postpartum period 54, 67.   
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The rate of HIV acquisition and differences between pregnant, postpartum and non-pregnant 
women at a population level will depend not only on the risk of infection per sexual act with 
an HIV positive partner, but also on the level of discordance in pregnant and non-pregnant 
couples and the differences in sexual behaviour between these groups.  Therefore results 
from the studies outlined above cannot be generalised to the general population. 
Population-based HIV cohort studies are ideally placed to provide generalisable estimates 
of the risk of HIV during pregnancy in the community; this paper uses data from six such 
cohorts from eastern and southern Africa.  We aim to assess the population-level HIV 
incidence during pregnancy and the post-partum period, adjusting for age.   The results will 
inform organisations that provide estimates to health services providers.     
4.4 Methods 
4.4.1 Data 
Data come from six sites: Karonga (Karonga prevention study), Kisesa (TAZAMA), Masaka 
(UK Medical Research Council and  Uganda Virus Research Institute), Rakai (Rakai Health 
Sciences), Manicaland (Imperial College London and the Biomedical Research and Training 
Institute) and uMkhanyukude (Africa Centre).  Data collection was sufficiently similar to allow 
pooled analyses, with allowance for unobserved heterogeneity between sites. 
 
The Karonga Demographic Surveillance Study (DSS) is located in rural northern Malawi; it 
was established in 2002 and has a total population of around 35,000,  population-based HIV 
testing in the DSS was undertaken in four annual rounds from  2007-2011 25 and average 
adult HIV prevalence between these dates was 8% 26.  The Kisesa cohort study is situated 
in rural north-west Tanzania, it was established in 1994 and has a population of around 
30,000  it contains  a small trading centre located on the main road from Mwanza town to 
the border of Kenya which runs through the centre of the study area, average HIV 
prevalence between 1994 and  2010 was 6% 27, 133.  The Masaka DSS is located in rural 
south west Uganda and was established in 1989.  Its initial population was around 10,000 
which then increased to 18,000 when 10 villages were added to the census area 31.  Average 
HIV prevalence between 1989 and 2011 was 8% 32. The Rakai Health Sciences Program 
runs the Rakai Community Cohort Study (RCCS), with an adult population of between 
12,000-16,000. For this analysis, data were collected from  1999 with 2002/03 adult HIV 
prevalence reported to be 11.4 % 33. The Manicaland study was established in 1993. A 
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prospective household census (population size approximately 37,000) and general 
population cohort survey (10,000-12,000) were initiated in 12 locations spread across three 
districts in 1998, with follow-ups being conducted every 2 or 3 years. They comprise two 
small towns, four agricultural estates, two roadside settlements and four subsistence farming 
areas. Overall adult HIV prevalence has fallen in these areas from 24% in the late 1990s to 
14% at the end of the 2010s 134.  The Africa Centre Surveillance study was established in 
2000 in uMkhanyakude, in rural KwaZulu-Natal, South Africa; each round covers 
approximately 90,000 resident and non-resident household members in approximately 
12,000 households, with a key-household respondent 34, an individual HIV surveillance for 
resident adults (≥15 years) was added in 2003 and adult HIV prevalence in 2012 was around 
28% and annual incidence in the 15-50 year age group for women was about 5% 35.   
 
4.4.2 Ethics statement 
Each of the six sites contributing data to the pooled analysis has received ethical clearance 
from the appropriate local ethics review bodies, and from the corresponding Institutional 
Review Boards for studies which had collaborating partnerships with Northern Universities.   
uMkhanyakude:  Annually re-certified ethics permission for the Africa Centre DSS and 
nested individual HIV surveillance among consenting adults obtained from the Biomedical 
Research Ethics Committee at the Nelson Mandela School of Medicine, University of 
KwaZulu-Natal.   Detailed written informed consent obtained for participation in the HIV 
surveillance.   Karonga: Ethical approval granted by the National Health Sciences Research 
Committee of Malawi and the ethics Committee of the London School of Hygiene and 
Tropical Medicine. Written informed consent obtained for HIV testing.  Kisesa: Ethical 
approval for each survey round of the Kisesa cohort study granted by the Tanzanian Medical 
Research Coordinating Committee and the Ethics Committee of the London School of 
Hygiene and Tropical Medicine. Prior to 2006, verbal consent obtained directly from all study 
participants (aged 15 and over), due to low literacy rates among the study population. 
Consent witnessed and documented for each study participant by a member of the sero-
survey team. From 2006 onward, consent was again obtained directly from all study 
participants, however written consent option introduced, for those able to provide this.    
Manicaland:   All respondents (all aged 15 years and older) provided written informed 
consent at each survey round prior to completing survey and providing a blood sample for 
HIV testing. For respondents under age 18 years, written informed consent was also 
provided by parent/guardian. Ethical approval for Manicaland HIV/STD Prevention Project 
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provided by Medical Research Council of Zimbabwe and St. Mary’s Research Ethics 
Committee, London.  Masaka:  The MRC DSS approved by the Uganda Virus Research 
Institute (UVRI) Science and Ethics Committee (SEC) and the Uganda National Council of 
Science and Technology (UNCST).  Study participants provided written consent to 
participate in any part of the study. Rakai: The Rakai Community Cohort Survey approved 
by the UVRI SEC andUNCST.  Literate participants provided written consent while those 
unable to read or write had a witness sign on their behalf. 
 
4.4.3 Identifying pregnancy periods 
For all the sites, in the absence of active pregnancy reporting, pregnancy periods can be 
identified from the date of birth of a child.  This information either comes from a mother-child 
data link or from a women reporting that she gave birth.  All studies apart from Karonga and 
Africa Centre also collect routine data on current pregnancy status, giving limited information 
on pregnancy periods that do not result in a live birth.  Such pregnancies are harder to 
identify for a number of reasons: firstly women rarely report a pregnancy in the first trimester; 
secondly many DSS use proxy respondents so it is possible that they will not know the 
women in their household is pregnant until sometime past the first trimester.   Pregnancies 
ending in early miscarriage are thus rarely captured.  Rakai is a partial exception as they 
have done routine hCG (human chorionic gonadotropin) testing if the last menstrual period 
was delayed or the woman was unsure of her pregnancy status 54.  Pregnancies ending in 
stillbirth may be captured either by asking direct questions about stillbirths since the last 
DSS round, or by noting reported pregnancies that did not result in a live birth in a later 
round.  However only those DSS which have consistently maintained a short time gap 
between survey rounds (ideally ≤4 months) can be reasonably certain of interviewing women 
after the first trimester but before the stillbirth occurs.    Early miscarriage and abortion are 
estimated to make up a fairly small proportion of total time pregnant therefore missing a 
large fraction of these would be unlikely to affect the results.  
 
4.4.4 Analysis methods 
Women of reproductive age (15- 49 years old) were eligible for inclusion in the analysis.  
Person-years of observation for each woman were split into time not-pregnant, pregnant and 
one year postpartum.  For a woman to be included in the analysis she must have had at 
least two HIV tests, the first of which must have been negative to allow observation of any 
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sero-conversion. Follow-up time started from the date of the first negative test and lasted 
until exit at the date of their last test or at the date of sero- conversion, if earlier.    
 
Time between HIV surveillance tests varies across the different sites ranging from annual to 
three year inter-test intervals; further, a person might miss a surveillance round thus 
extending the period between tests.  For all study sites, the interval between HIV tests is 
longer than a full gestation pregnancy, and we cannot be sure whether the sero-conversion 
occurred before, during or after the pregnancy period.  To allow for this uncertainty, the 
analysis was repeated 100 times, each time with the estimated sero-conversion date 
assigned at a random point between the last negative and first positive dates, rates and 
crude and adjusted hazard rate ratios (HRR) were calculated using piecewise exponential 
regression, so that age (grouped into conventional five year age groups), pregnancy status 
and calendar time could be treated as time-varying factors.  Rates and the log of the hazard 
rate ratios from the imputations were combined using Rubin’s rules 39 to give confidence 
intervals that reflect the uncertainty about the exact date of sero-conversion.  The crude 
hazard rate ratios converged at around 20 imputations with the adjusted rate ratios taking 
30 to 40 imputations to converge to stable values.  
 
Since the introduction of widespread voluntary counselling and testing and the roll-out of 
antiretroviral treatment (ART) in sub-Saharan Africa, it is possible that the composition of 
those who do not consent to test/participate in surveillance has changed, potentially biasing 
results.  For example, people who know they are HIV-positive may be less likely to consent 
to participate in an HIV surveillance round 26, 135, 136,  this would be especially pertinent for 
women who are HIV tested in antenatal care (ANC) clinics in the context of prevention of 
mother-to-child transmission (PMTCT) services.  Women who are not pregnant may have 
less exposure to HIV testing, although community-based HIV testing is becoming more 
widespread.  The possibility of bias after PMTCT programmes were introduced (post-
PMTCT period) is addressed by stratifying the data by the pre- and post-PMTCT periods.   
Post-PMTCT is defined from the point when PMTCT became available and accessible to 
the populations.  In some studies, this time preceded introduction of HIV treatment 
programmes (Masaka, Rakai and uMkhanyakude).   
 
Surveillance data from the Kisesa, Masaka, Manicaland and Rakai studies all include a 
period before PMTCT was widely available at ANC.  For Karonga and uMkhanyakude HIV 
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surveillance data are only available after introduction of widespread PMTCT services (Table 
4.1).    
 
Table 4.1: Data available from sites by periods in which availability of PMTCT was low medium and high  
Site Availability of data by level of PMTCT 
services  
 None/Very low Some/Widespread 
Karonga No data available 2007-2011 
Kisesa 1994-May2007 June 2007-2010 
Manicaland 1998-2008 No data available 
Masaka 1989-Mar2002 April 2002-2010 
Rakai 1999-May2004 June 2004-2011 
uMkhanyakude No data available 2001-2011 
 
 
This paper investigates the risk of HIV acquisition during pregnancy and in the postpartum 
period in both the pre- and post-PMTCT period.  For the pre-PMTCT period person years 
are censored at date of last test prior to widespread PMTCT.  The post-PMTCT period 
includes all the person years from the date PMTCT began to be more widely available in 
each site.   
 
4.5 Results 
Table 4.2 and Table 4.3 show site specific and pooled rates before and after introduction of 
PMTCT.   Overall there were 2628 sero-conversions and a total of 178 thousand person 
years contributing to the analysis.  The number of person years and sero-conversions in the 
pre-PMTCT period is lower than in the post-period, partly due to fewer study sites 
contributing and partly due to the strict censoring at last test prior to PMTCT beginning in 
each site.   uMkhanyakude contributes around two-thirds of the sero-conversions in the post-
PMTCT period, but only a sixth of the person-years due to its relatively high incidence and 
low fertility setting.  Karonga only provides a small number of sero-conversions and few 
person-years due to a shorter follow-up time. Using the mean of the imputation runs 304 
sero-conversions occurred in the 25,000 person years spent pregnant.    
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Table 4.2: Sero-conversion and person years contributing to the analysis for each period (mean of imputation runs).  Note that the uMkhanyakude and Karonga 
site only contributes to the post PMTCT period.   
   
All* 
 (Six Sites)   
Pre PMTCT  
(Four sites)   
Post PMTCT 
 (Five sites) 
 
Pregnancy and 
Maternity Status 
SC 1000 PY 
Rate 
 /1000 
PY 
 
SC 1000 PY 
Rate 
/1000 
PY 
 
SC 
1000 
PY 
Rate 
/1000 
PY 
Maternity Status            
 
Not pregnant  1861 121.10 15.37 
 
271 28.33 9.57 
 
1245 68.43 18.20 
 Pregnant 304 24.75 12.28  62 6.65 10.32  169 12.52 13.46 
 
<1 year post partum 463 31.49 14.70 
 
81 8.30 8.87 
 
262 16.52 15.86 
Pregnancy Status 
           
 Not pregnant  2324 152.57 15.23  345 36.63 9.41  1507 84.95 17.74 
  Pregnant 304 24.75 12.28   69 6.65 10.32   169 12.52 13.46 
*Note that all is not the sum of pre and post- PMTCT due to the nature of censoring for the pre-PMTCT group 
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Table 4.3: : Number of Sero-conversions (SC) and person years (PY) contributing to the analysis for each site by period (mean of imputation runs). Note that 
each site covers a different period of calendar time. 
 
   Karonga Kisesa Manicaland Masaka Rakai uMkhanyakude 
 
Pregnancy and 
Maternity Status 
SC 
1000 
PY   
Rate 
per 
1000 
PY SC 
1000 
PY   
Rate 
per 
1000 
PY SC 
1000 
PY   
Rate 
per 
1000 
PY SC 
1000 
PY   
Rate 
per 
1000 
PY SC 
1000 
PY   
Rate 
per 
1000 
PY SC 
1000 
PY   
Rate 
per 
1000 
PY 
Pre PMTCT 
                  
 
Not pregnant  - - - 57 6.30 9.06 84 6.08 13.80 65 9.16 7.05 65 6.80 9.57 - - - 
 
Pregnant - - - 12 2.06 5.85 10 0.55 18.31 11 1.88 5.84 36 2.18 16.55 - - - 
 
<1 year post partum - - - 17 2.64 6.50 7 0.74 9.99 13 2.30 5.54 36 2.63 13.88 - - - 
Post PMTCT 
                  
 
Not pregnant  34 8.15 4.22 19 3.13 5.93 41 3.70 11.10 83 13.43 6.16 230 20.43 11.26 841 19.70 42.69 
 
Pregnant 9 1.73 4.99 3 0.65 3.99 1 0.34 1.75 16 2.42 6.44 36 5.31 6.80 105 2.04 51.43 
 
<1 year post partum 9 2.46 3.55 6 0.94 6.77 2 0.44 4.24 20 3.22 6.19 80 6.64 11.98 146 2.75 52.88 
All Years 
                  
 
Not pregnant  34 8.15 4.22 170 17.33 9.78 241 16.95 14.20 175 25.51 6.88 401 33.44 11.99 841 19.70 42.69 
 
Pregnant 9 1.73 4.99 36 5.19 6.84 23 1.55 14.65 31 4.84 6.40 100 9.40 10.64 105 2.04 51.43 
  <1 year post partum 9 2.46 3.55 53 6.52 8.10 39 2.11 18.46 38 6.17 6.20 178 11.47 15.55 146 2.75 52.88 
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In the pooled data, the crude analysis showed no evidence of different risks of HIV 
acquisition between pregnant or postpartum women and non-pregnant women in the pre-
PMTCT era (Table 4.4).  After adjusting for age, the rate ratios showed a protective effect 
for pregnant and postpartum women compared to those who were not pregnant, although 
this did not reach statistical significance for pregnant women (HRR 0.85, 95%CI 0.63-1.13 
and  HHR 0.75 95%CI 0.57-0.98, respectively). In the post-PMTCT period, there was 
evidence of a protective effect against HIV acquisition in both pregnant and postpartum 
women when adjusted for age (HHR 0.60, 95%CI 0.50-0.71 and HHR 0.71 95%CI 0.62-0.82 
respectively (Table 4.5)).   After adjusting for study site the evidence became of borderline 
statistical significance for postpartum women.    
 
Table 4.4: Incident rate ratio comparing pregnancy status for pre PMTCT period 
Pregnancy and 
Maternity Status 
Crude   Adjusted Age    
Adjusted Age and 
Site 
 HRR 95% CI 
 
HRR 95% CI 
 
HRR 95% CI 
Maternity Status         
  Not pregnant  1 
  
1 
  
1 
 
  Pregnant 1.08 (0.82-1.42)  0.85 (0.64-1.13)  0.89 (0.67-1.19) 
  <1 year postpartum 0.93 (0.71-1.21) 
 
0.75 (0.57-0.98) 
 
0.78 (0.59-1.03) 
Pregnancy Status 
        
  Not pregnant 1   1   1  
  Pregnant 1.10 (0.84-1.43)   0.93 (0.71-1.22)   0.96 (0.73-1.26) 
 
 
Table 4.5: Incident rate ratio comparing pregnancy status for the period post widespread PMTCT   
Pregnancy and 
Maternity Status 
Crude   Adjusted Age    
Adjusted Age and 
Site 
 HRR 95% CI 
 
HRR 95% CI 
 
HRR 95% CI 
Maternity Status 
        
  Not pregnant  1 
  
1 
  
1 
 
  Pregnant 0.74 (0.63-0.87)  0.60 (0.50-0.71)  0.75 (0.64-0.89) 
  <1 year postpartum 0.87 (0.76-1.00) 
 
0.71 (0.62-0.82) 
 
0.89 (0.77-1.02) 
Pregnancy Status 
        
  Not pregnant 1   1   1  
  Pregnant 0.76 (0.64-0.89)   0.65 (0.55-0.76)   0.77 (0.65-0.91) 
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Combining all data from all periods gave results very similar to those in the post-PMTCT 
period: with a rate ratio comparing pregnant to non-pregnant women adjusted by age of 0.69 
(95%CI 0.61-0.78), indicating a lower HIV acquisition risk during pregnancy (Table 4.6).  This 
effect remained when adjusting by study site.   
 
Table 4.6: Incident rate ratio comparing pregnancy status for all periods 
Pregnancy and 
Maternity  Status 
Crude   Adjusted Age    
Adjusted Age and 
Site 
 HRR 95% CI  HRR 95% CI  HRR 95% CI 
Maternity Status         
  Not pregnant  1 
  
1 
  
1 
 
  Pregnant 0.80 (0.71-0.90) 
 
0.64 (0.57-0.73) 
 
0.77 (0.68-0.88) 
  <1 year postpartum 0.96 (0.86-1.06) 
 
0.78 (0.70-0.87) 
 
0.92 (0.84-1. 03) 
Pregnancy Status         
  Not pregnant 1 
  
1 
  
1 
 
  Pregnant 0.81 (0.71-0.91)   0.69 (0.61-0.78)   0.79 (0.70-0.89) 
 
There was evidence of an interaction between age and pregnancy status indicating that the 
protective effect did not apply to the 15-24 year old age group (all periods pooled HRR 0.84 
95%CI 0.50-1.41), this effect remained significant excluding the uMkhayakude which 
contributes the most data.  There was no evidence of interaction between pregnancy status 
and study site.   The analysis was repeated on individual site data combining the pre- and 
post-PMTCT periods (Table 4.7); both the  Kisesa and Rakai studies individually showed a 
significant  decrease in HIV acquisition rates comparing  pregnant to non-pregnant women 
when adjusted for age  (HRR 0.57, 95%CI 0.37-0.87 and HRR 0.71 , 95%CI 0.57-0.89 
respectively).    Masaka and Manicaland showed a non-significant decrease in HIV 
acquisition, Karonga and Africa Centre showed no evidence for any difference between HIV 
acquisitions in pregnant women compared to non-pregnant women; however, the 
confidence intervals in Karonga are very wide due to the small sample.    Kisesa showed a 
significant decrease and Masaka a borderline significant decrease in HIV acquisition in 
postpartum compared to non-pregnant women; the other sites showed no evidence for any 
difference between the two groups. 
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Table 4.7: Incident rate ratio adjusted for age comparing pregnancy status for all periods by study site 
 Karonga Kisesa Manicaland Masaka Rakai uMkhanyakude 
Pregnancy and 
Maternity Status HRR 95% CI HRR 95% CI HRR 95% CI HRR 95% CI HRR 95% CI HRR 95% CI 
Maternity Status             
  Not pregnant  1 
 
1 
 
1 
 
1 
   
1 
 
  Pregnant 1.17 (0.49-2.79) 0.70 (0.47-1.03) 1.02 (0.62-1.68) 0.93 (0.62-1.39) 0.89 (0.71-1.11) 1.20 (0.97-1.48) 
  <1 year postpartum 0.82 (0.33-2.04) 0.83 (0.60-1.14) 1.29 (0.90-1.86) 0.90 (0.63-1.29) 1.30 (1.08-1.55) 1.24 (1.03-1.48) 
Pregnancy Status 
            
  Not pregnant 1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
  Pregnant 1.21 (0.51-2.86) 0.66 (0.43-0.99) 0.98 (0.60-1.62) 0.95 (0.64-1.40) 0.82 (0.66-1.03) 1.17 (0.95-1.44) 
             
Adjusted             
 Karonga Kisesa Manicaland Masaka Rakai uMkhanyakude 
Pregnancy and 
Maternity Status HRR 95% CI HRR 95% CI HRR 95% CI HRR 95% CI HRR 95% CI HRR 95% CI 
Maternity Status             
  Not pregnant  1 
 
1 
 
1 
 
1 
   
1 
 
  Pregnant 0.97 (0.40-2.40) 0.56 (0.38-0.84) 0.81 (0.49-1.34) 0.76 (0.50-1.15) 0.73 (0.58-0.92) 0.91 (0.73-1.12) 
  <1 year postpartum 0.67 (0.26-1.72) 0.68 (0.48-0.95) 1.04 (0.72-1.50) 0.74 (0.51-1.09) 1.08 (0.89-1.30) 0.94 (0.78-1.13) 
Pregnancy Status 
            
  Not pregnant 1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
  Pregnant 1.08 (0.45-2.60) 0.57 (0.37-0.87) 0.80 (0.48-1.33) 0.82 (0.55-1.23) 0.71 (0.57-0.89) 0.92 (0.74-1.13) 
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4.6 Discussion 
This study is the first to look at risk of HIV acquisition during pregnancy at a population 
level, without restricting the analysis to sexually active women or to sero-discordant 
couples.   These data show some evidence that, in the whole population, pregnant 
women have a lower risk of HIV acquisition during pregnancy than women who are not 
pregnant and no evidence that postpartum women have a different risk of HIV acquisition 
in the first year post-pregnancy compared to non-pregnant women.   
A study by Mugo et al. found an unadjusted rate ratio of 2.34 (95% CI 1.33-4.09) 
comparing pregnant to non-pregnant women 57, however, this study enrolled sero-
discordant couples with at least three reported episodes of vaginal intercourse during 
the three months prior to screening and who intended to remain a couple and thus were 
a selected population.  In the population overall, pregnancy is more likely to be desired 
in a stable partnership such as marriage.  Being in a stable partnership would imply that 
the couple have had sex on a frequent basis, and, therefore by the time of a pregnancy, 
will be more likely to be sero-concordant with their partner.   The higher the parity of the 
birth, the more likely the couple are to be HIV concordant (if the births have occurred 
within the same partnership) as they will have had a longer period of sexual partnership.    
Assuming that a higher proportion of pregnant women are in stable partnerships than 
non-pregnant women, it is likely that a higher proportion of pregnant women have sero-
negative partners compared to the non-pregnant women.  This is because those already 
concordant-positive will not be at risk of infection and therefore will be excluded from the 
analysis.  The interaction evidence that the slight protective effect is not seen in the 
youngest age group might go further to support this theory as they have had less time to 
become concordant with their partner.  Also those who have never had a sexual partner, 
a relatively large fraction of the under-20 age group, will not be at risk of infection and 
will not be pregnant.   
 
Studies of sexually active women are less selective than sero-discordant couple studies 
but could still be different to those based on the whole population.    The definition of 
sexually active women varies across studies, some exclude all women who report no 
sexual activity in the intervals between survey rounds, which may cause the exclusion of 
women who report no sexual activity during or immediately after pregnancy 54,  some 
exclude only women who did not have a partner in the last 12 months 59, and some 
exclude those who were not sexually active at enrolment 56 with the time reference period 
left unspecified.   If all sexually inactive women in both the non-pregnant and pregnant 
groups were excluded, differences in the age-specific proportion sexually inactive in the 
two groups could give rise to spurious results.  Pregnant women or those who had 
recently given birth might be less sexually active due to the pregnancy, especially in 
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cultures where prolonged post-partum abstinence is the cultural norm 137.  Non-pregnant 
women may be excluded because they have never had a sexual partner – in these two 
cases the excluded women are at lower risk of infection.    But in other cases, exclusion 
of women retrospectively reporting no recent sexual activity may lead to excluding high 
risk groups: e.g. women whose marriages have recently broken up due to widowhood 
and separation (these events occur more frequently among women with HIV positive 
partners 106); or women who live apart from their partners because of the nature of their 
employment 138.  The prospective behaviour of women who have recently experienced a 
period without sexual activity may also place them at high risk in the near future e.g. at 
the time of first sex or when acquiring a new partner 139.   
 
Using sexually active women from sites in Uganda and Zimbabwe Morrison et al 56  
overall found no difference between the pregnant and not pregnant women (HRR 0.56 
95% CI 0.30-1.05); however, they did find evidence for an interaction with site; the 
Zimbabwean site showed a lower risk of HIV acquisition in pregnant women (HR 0.26; 
95% CI 0.10-0.68).  As with this study they also found some evidence of interaction with 
age, with no difference in HIV acquisition for younger women (HRR 1.14; 95% CI 0.47-
2.80) but a lower risk during pregnancy for older women (HRR 0.37 95% CI 0.13-1.09); 
however, this was not statistically significant.  A further prospective study found no 
increased risk 59.  Only one prospective study of sexually active women in Uganda found 
a significant increased risk in HIV transmission during pregnancy (HRR 2.03 95% CI% 
1.33-3.11) unadjusted and a similar result after adjusting for covariates 54. The study 
shows that when stratifying by age the rate ratio only remains statistically significant for 
those 15-19 years old, showing a similar age effect to this study and to the study by 
Morrison et al 56.   The Ugandan study sample of sexually active women 54 came from 
the same population as the Rakai study in this analysis at an earlier time period but gives 
an increased risk of HIV acquisition in pregnant women rather than the decreased risk 
we see in this analysis when using the whole population.    
 
In this analysis overall, we find no evidence of increased HIV incidence in the post-
partum period when compared to non-pregnant and non-postpartum periods.  There was 
some evidence of a decreased risk in this period once adjusted for age; however, 
statistical significance was lost when also adjusting for site indicating heterogeneity 
between study sites.  To be consistent with studies that found a higher incidence 
immediately postpartum followed by a decrease over time, we would expect to see a 
significantly higher incidence in women in the post-partum period than in women who 
were neither pregnant nor post-partum.   There are a number of differences in the studies 
cited above: those noting an increase in risk are not from the general population but from 
 122 
 
antenatal clinics or hospital delivery wards, therefore restricting the analysis to women 
who have given birth, whereas in this study the non-pregnant non-postpartum women 
may never have given birth or last gave birth a long time ago.  Also it is possible, as 
Leroy et al suggest 55, that studies noting a decrease in incidence over time could be 
affected by a cohort selection effect whereby high risk sub-groups sero-convert early on, 
leaving the  cohort survivors composed mainly of low risk sub-groups.  Finally, the 
incident rate confidence intervals in these studies either overlapped between groups 55 
or are not shown 60; therefore, the results give weak but inconclusive evidence.  Our 
results here are consistent with a study of sexually active women in Uganda 54 which 
showed no significant difference in those women breastfeeding compared to those not 
pregnant and non-lactating. 
 
The major strength of this study is that it is population-based rather than selected from 
clinics or hospitals, therefore we are able to assess the population risk of HIV 
transmission during pregnancy.  Also we have pooled data from six different study sites 
that contribute 178,000 person years of data which makes this study much larger than 
previous studies on this topic.  
 
Four sites were able to contribute to the pre-PMTCT period, where there is less 
possibility of bias due to those who know they are infected being less likely to agree to 
testing, however the results from the pre- and post-analysis were consistent although the 
pre-PMTCT period did not reach statistical significance because of the limited sample 
size available.  If there was a bias in the post-PMTCT period it would have to be very 
large to overturn the protective effect of pregnancy shown in this study (HRR 0.65; 
95%CI 0.61-0.78) and generate an increased risk of around two as seen in the sero-
discordant couple studies.  Kisesa, one of the study sites that, on its own, showed a 
lower risk of HIV acquisition during pregnancy, actually had one of the shortest periods 
where PMTCT was available, therefore it is less likely to be biased due to differences 
between pregnant and non-pregnant women knowing their HIV status and their 
subsequent participation in the surveillance study.    
 
The major limitation of this analysis is the source of HIV test data from surveillance 
rounds that may be two or three years apart giving long sero-conversion intervals.  Thus, 
we only know that a woman was pregnant at some point during the interval but do not 
know if the sero-conversion occurred before, during, or immediately after, the pregnancy.  
The imputation method used enables us to allow for this uncertainty and to generate 
confidence intervals to reflect this.  When restricting the analysis to shorter sero-
conversion intervals, the results did not change.  The identification of a pregnancy 
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interval may also lead to uncertainty, pregnancies that end in miscarriage are rarely 
reported in these studies, stillbirths are also often not captured, therefore some of the 
pregnancy person years will be miscategorised as not pregnant.  However these person-
years will be small in comparison with all the pregnancies identified by live births and 
those pregnancies that are captured with a pregnancy report.  HIV infected women suffer 
more miscarriages and stillbirths than their uninfected counterparts 86 however this 
decrease in viability of pregnancy is associated with longer duration of infection 119, there 
are no studies that suggest an association of sero-conversion with pregnancy loss. 
 
Although there might be immunological reasons for increased risk of HIV acquisition 
during pregnancy, at a population level this study indicates a lower risk of HIV acquisition 
in pregnant women.  This is probably due to a range of socio-behavioural characteristics 
of women and their partners that determine which women are most likely to become 
pregnant and which women will become infected, and these factors could be investigated 
in further analyses. 
 
This study furthers understanding of the population risk of HIV acquisition during 
pregnancy and in the first year postpartum.  The results can inform modellers and help 
health care providers with decisions on the kinds of interventions that would do most to 
help prevent the spread of HIV.     
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5 Paper C: Measuring the Impact of antiretroviral 
therapy roll-out on population level fertility in three 
African countries 
 
For objective 3 of the PhD: to investigate whether there is an impact of ART on fertility 
at the population level; an analysis was conducted using longitudinal data from the 
ALPHA network and published in:  
 
Marston, M; Nakiyingi-Miiro, J; Hosegood, V; Lutalo, T; Mtenga, B; Zaba, B; ALPHA 
network; (2016) Measuring the Impact of Antiretroviral Therapy Roll-Out on Population 
Level Fertility in Three African Countries. PLoS One, 11 (3).  
 
5.1 Introduction to paper 
Fertility of HIV positive women compared to HIV negative women is a key input into 
estimates of the number of children born to HIV positive women, therefore it is essential 
to understand what impact ART will have.  The majority of the work comparing 
differences in fertility between HIV positive and negative women was carried out before 
ART was available.  In the presence and increased coverage of ART, it has been 
speculated that the fertility of HIV positive women on ART will become the same as 
fertility of HIV negative women, due to improved health and changes in the desire for 
children.  Many of the studies in the ALPHA network have fertility data that span the pre- 
and post-ART era.  If ART influences fertility we would expect to see a narrowing of the 
gap in fertility levels between HIV positive and negative women once ART had been 
rolled out.   
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5.2 Abstract 
 
Background   
UNAIDS official estimates of national HIV prevalence are based on trends observed in 
antenatal clinic surveillance, after adjustment for the reduced fertility of HIV positive 
women. Uptake of ART may impact on the fertility of HIV positive women, implying a 
need to re-estimate the adjustment factors used in these calculations. We analyse the 
effect of antiretroviral therapy (ART) provision on population-level fertility in Southern 
and East Africa, comparing trends in HIV infected women against the secular trends 
observed in uninfected women. 
Methods  
We used fertility data from four community-based demographic and HIV surveillance 
sites: Kisesa (Tanzania), Masaka and Rakai (Uganda) and uMkhanyakude (South 
Africa).  All births to women aged 15–44 years old were included in the analysis, 
classified by mother’s age and HIV status at time of birth, and ART availability in the 
community. Calendar time period of data availability relative to ART introduction varied 
across the sites, from 5 years prior to ART roll-out, to 9 years after.  Calendar time was 
classified according to ART availability, grouped into pre ART, ART introduction  
(available in at least one health facility serving study site) and ART available (available 
in all designated health facilities serving study site). We used Poisson regression to 
calculate age adjusted fertility rate ratios over time by HIV status, and investigated the 
interaction between ART period and HIV status to ascertain whether trends over time 
were different for HIV positive and negative women.    
Results  
Age-adjusted fertility rates declined significantly over time for HIV negative women in all 
four studies.  However HIV positives either had no change in fertility (Masaka, Rakai) or 
experienced a significant increase over the same period (Kisesa, uMkhanyakude). HIV 
positive fertility was significantly lower than negative in both the pre ART period (age 
adjusted fertility rate ratio (FRR) range 0.51 95%CI 0.42-0.61 to 0.73 95%CI 0.64-0.83) 
and when ART was widely available (FRR range 0.57 95%CI 0.52-0.62 to 0.83 95%CI 
0.78-0.87), but the difference has narrowed. The interaction terms describing the 
difference in trends between HIV positives and negatives are generally significant. 
Conclusions  
Differences in fertility between HIV positive and HIV negative women are narrowing over 
time as ART becomes more widely available in these communities. Routine adjustment 
of ANC data for estimating national HIV prevalence will need to allow for the impact of 
treatment. 
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5.3 Background   
There has been a rapid scale up in the provision of Antiretroviral therapy (ART) in Sub 
Saharan Africa in the last decade with more than 7.5 million people receiving treatment 
by the end of 2012140 this comes hand in hand with increased access to HIV testing and 
therefore knowledge of HIV status.  A large proportion of those with HIV in sub Saharan 
Africa are women of reproductive age who are routinely tested for HIV at antenatal care 
clinics (ANC) in order to try to prevent mother to child transmission and those testing 
positive are referred to clinics for treatment141. 
 
Official estimates of national HIV prevalence by UNAIDS are currently based on trends 
observed in antenatal clinic surveillance142 and far more ANC data are becoming 
available due to routine reports from PMTCT programs.  ANC prevalence trends are then 
adjusted to match prevalence levels estimated from national population surveys 143.  Part 
of this adjustment accounts for the reduced fertility of HIV positive women 72, 144 , however  
increased access to care and treatment services and uptake of antiretroviral therapy may 
impact on the fertility of HIV positive women for biological and  behavioural reasons, 
implying a need to re-estimate the adjustment factors used in these calculations.    
There have been no longitudinal studies in Sub-Saharan Africa that have looked at the 
population level impact of ART on fertility.  A few studies have measured fertility or 
incidence of pregnancy in women on ART116, 119, 121, 145 but these lack suitable 
comparators (HIV negative women in the same community) and may not be 
representative of all HIV positive women.  A cross sectional comparison using Malawian 
Demographic and Health Survey data (DHS) found an increased probability of giving 
birth for HIV positive women relative to HIV negative women between 2004 and 2010 79 
which is attributed to the increase in access to mother to child transmission and ART 
services in Malawi.  We analyse the effect of antiretroviral therapy provision on 
population-level fertility in four cohort studies in Southern and East Africa, comparing 
trends in HIV infected women against the secular trends observed in uninfected women. 
 
5.4 Methods  
5.4.1 Sites and setting 
Fertility data that span the pre-ART era and the time of introduction and widespread use 
of ART are available from four community-based demographic and HIV surveillance 
sites: Kisesa (managed by the National Institute of Medical Research Mwanza in 
Northern Tanzania), Masaka (MRC/UVRI Uganda Research Unit on AIDS), Rakai (Rakai 
Health Sciences) – both in South-west Uganda, and uMkhanyukude (Africa Centre, in 
KwaZulu-Natal, South Africa).   These sites belong to the network for analysing 
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longitudinal population based data on HIV in Africa (ALPHA)9, 146 and have been 
described in detail elsewhere 27, 31, 32, 35, 147-149.  
 
5.4.2 Data, HIV and ART provision 
The ALPHA network standardises site-specific data to a common format to enable joint 
analysis.  In brief, each study records demographic data including dates of birth (of 
mothers and infants).  The studies also collect data on HIV status and provide dates of 
testing and test results for their populations.  In Kisesa, Rakai, and uMkhanyakude, the 
HIV surveys were done separately to the demographic surveillance rounds, and data 
were linked afterwards using unique identifiers.  In Masaka, HIV testing was done 
immediately after demographic surveillance rounds which were used to list those eligible 
for HIV testing.  HIV testing took place in the home for all sites apart from Kisesa where 
temporary village clinics are used to which people are transported from their homes.  
Prior to the availability of antiretroviral therapy, testing protocols used informed consent 
without disclosure, so that participants did not learn the results of the HIV research tests, 
however with the advent of ART, sites began to offer full pre-test and post-test 
counselling to the participants during the data collection round.  Participants are still not 
obliged take part in the counselling or to learn their results.  In Rakai the samples taken 
in the home were tested at the field laboratory and then returned by a community based 
counsellor to those participants requesting the results. 
 
The introduction and level of uptake of ART in the different studies varies.  ART was 
introduced in the study areas between 2004 and 2005, when selected clinics were 
allowed to administer drugs and people were mobilised to make them aware of the new 
services.  Further details of ART introduction and uptake are described elsewhere150-153.   
 
5.4.3 Study Population 
The population included in this analysis is women of reproductive age (15-44) living in 
the surveillance areas between the time point corresponding to five years before ART 
was introduced, to the last date for which data were available for each site up to 2015.  
Table 5.1 shows prevalence for each site in pre and post ART years for women aged 15-
49.      
 
All live births to women aged 15–44 years old while under observation in the study were 
included in the analysis, classified by mother’s age, area of residence and HIV status at 
time of the birth, and by ART availability in the community.   We did not include 45-49 
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year olds to create the standard fertility analysis grouping of 15-49 years as there were 
very few births to HIV positive women at this age.   
 
Table 5.1: HIV prevalence of women aged 15-49 in Study sites 
Study Site, Round (years) ART 
period 
N Prevalence (95% CI) 
Kisesa 4 (2003-2004) Pre ART 3369 5.11 (4.36 - 5.85) 
Kisesa 6 (2010-2010) Post ART 2445 7.08 (6.06 - 8.09) 
Manicaland 3 (2003-2005) Pre ART 8273 20.45 (19.58 - 21.32) 
Manicaland 5 (2009-2011) Post ART 6150 17.54 (16.59 - 18.50) 
Masaka 14 (2002-2003) Pre ART 2361 14.06 (12.66 - 15.46) 
Masaka 16 (2004-2005) Post ART 2485 17.99 (16.48 - 19.50) 
Rakai 9 (2002-2003) Pre ART 3708 13.65 (12.54 - 14.75) 
Rakai 12 (2006-2008) Post ART 4507 14.98 (13.93 - 16.02) 
uMkhanyakude 1 (2002-2005) Pre ART 6533 27.2 (26.12 - 28.28) 
uMkhanyakude 4 (2007-2008) Post ART 3604 27.58 (26.12 - 29.04) 
 
All sites are predominately rural, though most contain areas with local markets, health 
and education facilities.  Area of residence is classified differently for each site. The 
Masaka DSS is divided into two areas: old villages where surveillance began in 1989; 
and new villages where surveillance began in November 1999.  In Kisesa sub-villages 
are classified according to their distance from the small trading centre on the main road.  
In Rakai the peri urban group comprises trading towns, villages along secondary roads 
and fishing communities and the rural category are communities beyond those located 
along secondary roads.  uMkhanyakude is predominantly rural but also includes an small 
town and peri-urban densely populated areas.   
5.4.4 Measures 
HIV Status was classified as negative, positive and unknown.  Negative person time was 
defined as the time between first testing negative and last testing negative, also included 
in negative time was a site specific time following the last negative test, this was allocated 
according to the HIV incidence rates in the sites, the cut off for post negative time was 
taken as the time at which the cumulated probability of becoming infected following the 
last test reached 5%. This cut-off point was five years in Kisesa, Masaka and Rakai and 
two years in uMkhanyakude.  HIV positive time was all the person time after the first 
positive test.  The sero conversion interval was calculated as the mid point between first 
positive and last negative test and positive and negative time was assigned accordingly.  
Interval censoring was invoked if the midpoint of the sero conversion interval was longer 
than the site specific post negative time – in that case only the post negative time was 
assigned to negative and one year pre positive time was assigned to positive, the 
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remainder of the interval was designated unknown.  The composition of the unknown 
group over time changes due to the different ways HIV positive and HIV negative time is 
allocated and is also affected by participation changes in testing26, 136 therefore we do 
not present results from this group.  No pressure was put on participants to receive their 
HIV status as part of research survey procedures, therefore we would not expect a link 
between participation in testing and fertility. 
 
Calendar time period of data availability relative to ART introduction varied across the 
sites (Figure 5.1), from 5 years prior to ART roll-out, to 9 years after.  Calendar time was 
classified according to ART availability, grouped into pre ART, ART Introduction 
(introduced in at least one of the health facilities serving the community) and ART 
available (available in all the health facilities serving the community that were designated 
as ART providers according to national guidelines).  We limit results  presented for the 
short ART roll out period to just the age specific rates, as this time period is relatively 
short and is different in each site depending on the speed and nature of the roll out 
therefore tells us little about general patterns and trends.   
 
5.4.5 Analysis 
We used Poisson regression to calculate age adjusted fertility rate ratios over time by 
HIV status, and investigated the interaction between ART period and HIV status to 
ascertain whether trends over time were different for HIV positive and negative women.   
We adjust for age and area of residence in this analysis to control for any changes in the 
composition of the study site that may have occurred between the pre and post ART 
periods.   The analysis was performed separately for each site and pooled across sites 
where appropriate, the pooled results were adjusted by study site. 
 
At ages under 20, HIV infection and fertility are highly correlated as many teenagers will 
not yet have had sex, and only those who have had sex are at risk of becoming pregnant 
or acquiring HIV. Therefore fertility in the 15-19 year old age group is almost always 
higher in HIV positive women144. We therefore stratify our analysis to look at 15-19 year 
olds and 20-44 year olds separately. 
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5.5 Ethics statements 
Each of the six sites contributing data to the pooled analysis has received ethical 
clearance from the appropriate local ethics review bodies, and from the corresponding 
Institutional Review Boards for studies which had collaborating partnerships with 
Northern Universities.  
 
uMkhanyakude 
Annually re-certified ethics permission for the Africa Centre DSS and nested individual 
HIV surveillance among consenting adults is obtained from the Biomedical Research 
Ethics Committee at the Nelson Mandela School of Medicine, University of KwaZulu-
Natal.  Detailed written informed consent obtained for participation in the HIV 
surveillance. 
 
Kisesa 
Ethical approval for each survey round of the Kisesa cohort study granted by the 
Tanzanian Medical Research Coordinating Committee and the Ethics Committee of the 
London School of Hygiene and Tropical Medicine.  Prior to 2006, verbal consent was 
obtained directly from all study participants (aged 15 and over), due to low literacy rates 
among the study population.  Consent was witnessed and documented for each study 
participant by a member of the sero-survey team or senior person from the community.  
From 2006 onward, consent was again obtained directly from all study participants, 
however a written consent option was introduced, for those able to provide this and 
written parental consent for those under 18 years was also obtained. 
 
Masaka 
The MRC DSS is approved by the Uganda Virus Research Institute (UVRI) Science and 
Ethics Committee (SEC) and the Uganda National Council of Science and Technology 
(UNCST).  Study participants provided written consent to participate in all parts of the 
study. 
 
Rakai 
The Rakai Community Cohort Survey is approved by the UVRI SEC and UNCST.  
Literate participants provided written consent while those unable to read or write had a 
witness sign on their behalf.  Those unable to read or write used a thumbprint to 
document consent and a witness would also sign as evidence that the consent had been 
read to the participant who had understood and consented to participate. 
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Figure 5.1.  Dates of ART Periods included in the analysis  
 
 
5.6 Results  
Overall crude and age specific fertility rates fell or remained the same between the pre 
and post ART periods for all sites (Table 5.2-Table 5.5).   Classifying the crude fertility 
rates by HIV status shows that overall fertility declined in the HIV negative but remained 
more or less the same or increased slightly for the HIV positive (For the HIV positive in 
Rakai this is true if we exclude 15-19 year olds).  Age specific rates by HIV status follow 
this general trend for all sites apart from slight increases in HIV negative 25-34 year olds 
in Masaka, 35-39 year olds in Rakai and 15-19 year olds in uMkhanyakude.  Overall 
fertility is higher in the rural areas for all sites. 
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Table 5.2: Fertility of women aged 15-44 years old, by calendar time period and stratified by individual HIV status for Kisesa. 
        All   HIV-Negative   HIV-Positive 
        Births 
Person 
Years 
Rate 
/1000   Births 
Person 
Years 
Rate 
/1000   Births 
Person 
Years 
Rate 
/1000 
Kisesa             
 
ART Period            
   
Pre ART 5253 26.2 200.1  4108 17.6 233.1  132 1.0 126.9 
   ART Introduction 3715 19.5 190.6  2763 12.6 218.4  106 0.8 132.0 
   ART available 5895 37.2 158.3  2924 15.4 190.3  195 1.4 144.2 
 Age            
  
15-19            
   
Pre ART 846 6.2 136.6  584 3.6 160.2  12 0.1 197.6 
   ART Introduction 518 4.8 108.3  308 2.9 107.3  8 0.0 232.3 
   ART available 792 9.5 83.6  335 3.6 93.3  4 0.0 81.5 
  20-24            
   
Pre ART 1461 5.4 270.8  1117 3.4 325.8  23 0.2 144.7 
   ART Introduction 952 3.8 250.7  714 2.3 309.2  9 0.1 97.5 
   ART available 1475 7.2 205.1  637 2.7 237.1  24 0.1 193.6 
  25-29            
   
Pre ART 1294 4.9 264.1  1002 3.2 311.7  44 0.3 157.6 
   ART Introduction 897 3.3 270.1  676 2.1 315.3  34 0.2 202.7 
   ART available 1402 6.3 223.9  693 2.4 285.1  40 0.2 185.5 
  30-34            
   
Pre ART 877 4.0 221.3  705 2.8 254.3  38 0.3 143.7 
   ART Introduction 746 3.1 237.7  563 2.1 272.0  32 0.2 133.3 
   ART available 1131 5.6 200.5  621 2.4 254.7  66 0.3 197.1 
  35-39            
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Pre ART 569 3.3 173.6  510 2.6 198.8  13 0.2 80.4 
   ART Introduction 426 2.4 180.9  356 1.7 212.8  16 0.2 102.2 
   ART available 805 5.0 162.5  454 2.3 201.2  55 0.4 131.9 
  40-44            
   
Pre ART 206 2.5 81.8  190 2.0 95.0  2 0.1 17.3 
   ART Introduction 176 2.1 83.9  146 1.6 92.3  7 0.1 62.6 
   ART available 290 3.7 78.1  184 2.0 93.7  6 0.2 28.3 
 Residence            
  
Rural            
   
Pre ART 3125 13.4 233.2  2564 10.1 254.2  71 0.4 171.0 
   ART Introduction 2295 9.9 232.0  1805 7.2 252.4  54 0.3 162.7 
   ART available 3453 17.9 193.0  1932 8.9 215.9  103 0.6 164.3 
  Peri Urban/Urban            
   
Pre ART 2128 12.8 165.7  1544 7.5 204.8  61 0.6 97.6 
   ART Introduction 1420 9.6 147.9  958 5.5 174.2  52 0.5 110.4 
      ART available 2442 19.3 126.3   992 6.4 154.6   92 0.7 126.8 
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Table 5.3: Fertility of women aged 15-44 years old, by calendar time period and stratified by individual HIV status for Masaka. 
        All   HIV-Negative   HIV-Positive 
        Births 
Person 
Years 
Rate 
/1000   Births 
Person 
Years 
Rate 
/1000   Births 
Person 
Years 
Rate 
/1000 
Masaka            
 
ART Period          
  
Pre ART 2524 14.8 170.1 2285 12.8 179.2 117 1.0 115.2 
  
ART Introduction 510 3.3 153.6 466 2.8 164.0 21 0.3 83.8 
  
ART available 4185 28.0 149.7 3672 23.3 157.4 281 2.3 119.7 
Age            
  
15-19            
   
Pre ART 490 4.6 107.0 448 4.2 106.9 14 0.1 205.3 
  
ART Introduction 101 1.0 105.3 91 0.9 102.3 2 0.0 112.2 
  
ART available 665 8.5 78.5 593 7.6 77.6 25 0.2 159.4 
 
20-24          
  
Pre ART 766 2.9 261.3 701 2.5 277.6 32 0.2 185.3 
  
ART Introduction 155 0.6 245.1 145 0.5 266.8 3 0.0 77.3 
  
ART available 1115 4.9 226.6 1005 4.1 242.6 58 0.3 186.8 
 
25-29          
  
Pre ART 562 2.4 231.9 497 2.0 252.0 38 0.3 136.5 
  
ART Introduction 126 0.5 229.9 115 0.4 260.9 6 0.1 101.3 
  
ART available 1012 4.3 237.1 884 3.5 256.1 71 0.4 163.7 
 
30-34          
  
Pre ART 357 1.9 192.4 316 1.5 211.9 20 0.2 88.8 
  
ART Introduction 69 0.4 154.4 63 0.4 175.6 4 0.1 69.3 
  
ART available 786 4.0 195.3 680 3.2 215.4 71 0.5 133.5 
 
35-39          
  
Pre ART 263 1.7 152.8 241 1.4 168.4 11 0.2 62.7 
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ART Introduction 38 0.4 98.4 32 0.3 100.4 5 0.0 117.7 
  
ART available 466 3.3 139.6 387 2.6 149.6 47 0.5 92.1 
 
40-44          
  
Pre ART 86 1.3 64.9 82 1.1 71.7 2 0.1 20.9 
  
ART Introduction 21 0.3 60.4 20 0.3 68.9 1 0.0 29.0 
  
ART available 141 2.9 48.1 123 2.3 52.6 9 0.4 22.2 
Residence          
 
Original Study 
Villages          
  
Pre ART 1989 11.3 175.5 1820 9.9 183.6 81 0.7 116.5 
  
ART Introduction 382 2.4 158.1 347 2.1 164.8 16 0.2 97.8 
  
ART available 3003 19.5 153.7 2675 16.6 161.4 182 1.5 121.4 
 
New villages          
  
Pre ART 535 3.5 152.7 465 2.8 163.8 36 0.3 112.4 
  
ART Introduction 128 0.9 141.6 119 0.7 161.6 5 0.1 57.4 
      ART available 1182 8.4 140.5   997 6.8 147.6   99 0.8 116.7 
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Table 5.4: Fertility of women aged 15-44 years old, by calendar time period and stratified by individual HIV status for Rakai. 
        All   HIV-Negative   HIV-Positive 
        Births 
Person 
Years 
Rate 
/1000   Births 
Person 
Years 
Rate 
/1000   Births 
Person 
Years 
Rate 
/1000 
Rakai             
 
ART Period          
  
Pre ART 6598 51.8 127.3 5805 35.9 161.8 495 5.5 90.2 
  
ART Introduction 2598 23.1 112.5 2304 15.5 148.5 201 2.3 88.6 
  
ART available 6634 68.7 96.6 5736 42.8 134.0 547 6.9 79.3 
Age            
  
15-19            
   
Pre ART 1220 13.4 91.3 1119 8.1 137.3 38 0.3 131.0 
  
ART Introduction 310 5.7 54.8 273 3.0 90.7 7 0.1 83.9 
  
ART available 674 17.4 38.8 601 9.2 65.2 17 0.2 90.8 
 
20-24          
  
Pre ART 2320 12.8 181.4 2090 9.6 217.9 137 1.1 127.4 
  
ART Introduction 872 5.4 161.6 799 3.8 208.7 50 0.4 129.5 
  
ART available 1953 14.8 131.8 1651 9.0 183.0 125 0.9 139.0 
 
25-29          
  
Pre ART 1713 10.3 166.7 1460 7.3 199.5 183 1.6 116.7 
  
ART Introduction 791 4.8 165.2 693 3.5 199.0 80 0.6 133.4 
  
ART available 1992 13.7 145.9 1641 8.6 190.0 178 1.6 112.6 
 
30-34          
  
Pre ART 830 6.4 128.8 684 4.4 156.5 96 1.3 74.6 
  
ART Introduction 425 3.4 124.9 369 2.4 155.8 40 0.6 65.0 
  
ART available 1309 10.9 119.7 1077 6.8 158.5 131 1.7 75.4 
 
35-39          
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Pre ART 382 4.8 79.0 331 3.4 96.4 36 0.8 45.4 
  
ART Introduction 155 2.0 76.0 130 1.5 88.9 19 0.3 55.1 
  
ART available 572 7.1 80.3 458 4.3 106.1 65 1.3 50.8 
 
40-44          
  
Pre ART 133 4.1 32.4 121 3.0 40.2 5 0.5 10.5 
  
ART Introduction 45 1.8 24.9 40 1.4 29.3 5 0.2 21.0 
  
ART available 134 4.8 28.1 116 2.9 40.3 7 0.8 8.4 
Residence          
 
Rural          
  
Pre ART 5483 41.2 133.2 4872 29.3 166.4 390 4.2 91.9 
  
ART Introduction 2200 18.2 121.1 1979 12.6 157.3 157 1.7 91.7 
  
ART available 5156 49.7 103.7 4459 31.7 140.8 400 4.7 85.9 
 
Peri Urban/Urban          
  
Pre ART 1115 10.7 104.5 933 6.6 141.4 105 1.2 84.3 
  
ART Introduction 398 4.9 80.7 325 2.9 110.7 44 0.6 79.1 
      ART available 1401 18.5 75.7   1019 8.9 114.7   118 1.8 65.1 
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Table 5.5: Fertility of women aged 15-44 years old, by calendar time period and stratified by individual HIV status for uMkhanyakude. 
        All   HIV-Negative   HIV-Positive 
        Births 
Person 
Years 
Rate 
/1000   Births 
Person 
Years 
Rate 
/1000   Births 
Person 
Years 
Rate 
/1000 
uMkhanyakude            
 
ART Period            
   
Pre ART 3337 31.8 104.8  1550 14.0 110.7  297 3.0 98.3 
   ART Introduction 3899 33.7 115.7  1887 15.3 123.6  581 4.9 119.1 
   ART available 11601 119.5 97.0  4741 41.0 115.7  2264 23.7 95.4 
 Age            
  
15-19            
   
Pre ART 794 9.3 85.2  485 5.9 82.6  45 0.4 120.7 
   ART Introduction 1019 9.8 104.2  664 6.4 103.4  85 0.4 196.8 
   ART available 2836 32.8 86.4  1639 17.3 94.5  217 1.4 159.3 
  20-24            
   
Pre ART 1014 6.6 154.5  435 2.4 182.2  95 0.7 138.7 
   ART Introduction 1262 7.4 169.6  589 3.2 182.4  211 1.1 184.9 
   ART available 3749 25.2 149.0  1631 9.3 175.4  587 4.2 140.2 
  25-29            
   
Pre ART 653 4.8 135.3  209 1.3 167.0  77 0.7 116.3 
   ART Introduction 689 4.9 139.5  228 1.3 170.4  133 1.0 129.4 
   ART available 2398 20.3 118.2  661 4.5 145.5  680 5.6 122.0 
  30-34            
   
Pre ART 491 4.1 121.0  206 1.2 168.9  47 0.5 86.7 
   ART Introduction 505 4.2 119.5  184 1.2 158.3  95 0.9 103.1 
   ART available 1487 15.9 93.8  397 3.0 132.4  483 5.1 94.7 
  35-39            
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Pre ART 284 3.6 79.9  154 1.5 104.6  27 0.4 64.8 
   ART Introduction 301 3.7 80.6  148 1.4 106.0  43 0.8 57.0 
   ART available 880 13.5 65.2  305 3.1 99.0  240 4.2 56.8 
  40-44            
   
Pre ART 101 3.5 28.7  61 1.8 34.0  6 0.3 17.4 
   ART Introduction 123 3.6 34.3  74 1.7 42.9  14 0.6 23.3 
   ART available 251 11.9 21.1  108 3.7 29.2  57 3.3 17.3 
 Residence            
  
Rural            
   
Pre ART 2069 18.9 109.8  1076 9.6 112.2  165 1.6 100.3 
   ART Introduction 2382 19.8 120.2  1288 10.3 124.9  335 2.7 123.9 
   ART available 6955 66.2 105.1  3220 26.8 120.4  1190 12.2 97.7 
  Peri Urban/Urban            
   
Pre ART 1192 12.2 97.5  452 4.2 107.1  126 1.3 95.0 
   ART Introduction 1387 12.6 110.0  548 4.6 118.9  234 2.0 114.8 
      ART available 4476 48.4 92.5   1486 13.7 108.3   1048 10.8 97.1 
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Fertility rates in HIV positive women are consistently lower than those of HIV negative 
women apart from the youngest age group of 15-19 years olds (Figure 5.2).  For all sites 
apart from uMkhanyakude fertility rates  in HIV positive women aged over 20 are around 
half those of the negatives in the pre ART period and  0.73 (95%CI 0.64-0.83) times the 
negative rates in uMkhanyakude.  In the post ART period overall the differences between 
positive and negative are smaller, with rate ratios ranging from 0.57 (95%CI 0.52-0.62) 
in Rakai to 0.83 (95%CI 0.78-0.87) in uMkhanyakude.  In both periods fertility differences 
between positive and negative women become greater as age increases.  
Figure 5.2. Unadjusted fertility rate ratios by age and ART period comparing positives to negatives 
 
 
For all women aged 15-44 years old, age and residence adjusted fertility rates declined 
significantly over time, driven by the significant decline in fertility among HIV negative 
women in all four studies (Table 5.6). For HIV positive women in Kisesa and Masaka 
there is a fertility increase of borderline significance of 1.21(95%CI 0.99-1.49) and 
1.16(95%CI 0.96-1.41) respectively, and no change in uMkhanyakude and Rakai. The 
interaction between HIV Status and ART period was significant for all sites apart from 
uMkhanyakude showing that the changes in fertility over the two ART periods are 
significantly different for HIV positive and HIV negative women.    Excluding 15-19 year 
olds (Table 5.7) whose fertility rates are determined largely by patterns of sexual debut, 
yields an overall reduction in fertility in HIV negative women in all sites and increases 
among HIV positive women in Kisesa and Masaka with rate ratios of 1.29 (95%CI 1.04-
1.59) and 1.21 (95%CI 0.99-1.47) respectively, and no change in uMkhanyakude and 
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Rakai.  In this narrower age range the interaction terms between HIV Status and ART 
period were significant for all sites apart from Rakai.   
Table 5.6: Fertility Rate Ratio (FRR) for 15-44 year olds comparing ART period with pre ART adjusted 
for by age and residence 
  ART Period 
HIV Negative HIV Positive Interaction 
p-value* FRR (95% CI) FRR (95% CI) 
Kisesa           
 Pre-ART 1  1   
 
ART Available 0.84 ( 0.81- 0.88) 1.21 ( 0.99- 1.49) 0.001 
Masaka      
 
Pre-ART 1  1   
 
ART Available 0.90 ( 0.86- 0.94) 1.16 ( 0.96- 1.41) 0.010 
uMkhanyakude      
 
Pre-ART 1  1   
 
ART Available 0.98 ( 0.93- 1.03) 1.04 ( 0.92- 1.16) 0.363 
Rakai       
 
Pre-ART 1  1   
 
ART Available 0.84 ( 0.81- 0.86) 0.96 ( 0.86- 1.08) 0.020 
*Interaction between ART period and HIV status 
Table 5.7: Fertility Rate Ratio (FRR) for 20-44 year olds comparing ART period with pre ART adjusted 
for by age and residence 
  
ART Period 
HIV Negative HIV Positive 
Interaction 
p-value* 
 FRR (95% CI) FRR (95% CI)  
Kisesa           
 Pre-ART 1  1   
 
ART Available 0.89 ( 0.86- 0.93) 1.29 ( 1.04- 1.59) 0.001 
Masaka      
 
Pre-ART 1  1.00   
 
ART Available 0.94 ( 0.90- 0.99) 1.21 ( 0.99- 1.47) 0.016 
uMkhanyakude      
 
Pre-ART 1  1   
 
ART Available 0.90 ( 0.84- 0.95) 1.04 ( 0.92- 1.17) 0.033 
Rakai       
 
Pre-ART 1  1   
 
ART Available 0.93 ( 0.90- 0.96) 1.00 ( 0.89- 1.12) 0.252 
*Interaction between ART period and HIV status 
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The data for 20-44 year olds were pooled for the comparison of the period when ART 
was available with the pre ART period, giving overall rate ratios of 0.9 (95%CI 0.89-0.92) 
for HIV negative women and 1.08 (95%CI 1.01-1.16) for HIV positive women adjusted 
for age, residence and study site, with a significant interaction (p<0.001) between HIV 
status and ART period.    Focussing on 15-19 year olds (Table 5.8), there has been a 
significant reduction in fertility for HIV negative women in all sites apart from 
uMkhanyakude where the relative increase was 1.11 (95%CI 1.01-1.22).  The confidence 
intervals for the rate ratios for the HIV positive are very large, so no real pattern can be 
determined.   
 
Table 5.8: Fertility Rate Ratio (FRR) for 15-19 year olds comparing ART period with pre ART adjusted 
for by age and residence 
  ART Period 
HIV Negative HIV Positive Interaction 
p-value* FRR (95% CI) FRR (95% CI) 
Kisesa           
 Pre-ART 1  1   
 
ART Available 0.56 ( 0.49- 0.64) 0.40 ( 0.14- 1.12) 0.524 
Masaka      
 
Pre-ART 1  1   
 
ART Available 0.75 ( 0.67- 0.85) 0.73 ( 0.41- 1.32) 0.936 
uMkhanyakude      
 
Pre-ART 1  1   
 
ART Available 1.11 ( 1.01- 1.22) 1.32 ( 0.97- 1.79) 0.278 
Rakai       
 
Pre-ART 1  1   
 
ART Available 0.49 ( 0.44- 0.53) 0.66 ( 0.38- 1.13) 0.277 
*Interaction between ART period and HIV stat 
 
For the two sites with data available (Kisesa and Masaka) in the 5-10 years prior to ART 
there was no evidence of any interaction between HIV status and period when comparing 
the periods 0-5 years and 5-10 years prior to ART (Not shown).  
 
Person years with unknown HIV status were lowest in Masaka at 7.2% in the pre ART 
period and 8.2% in the post ART period, in Rakai they were 20.2% and 27.7%, Kisesa 
28.9% and 52.0%, uMkhanyakude 46.5% and 38.3% respectively.  The HIV status 
unknown category includes the unclassified post negative time intervals and time before 
the first HIV test. 
  
 145 
 
5.7 Discussion 
This analysis uses community based cohort studies to look at the population impact of 
ART on fertility.  We have shown that changes in fertility have been different in HIV 
positive women compared to the HIV negative over the pre and post ART Period - 
representing a discontinuity since the pre ART era.  This would indicate that the 
introduction of ART is narrowing the gap in fertility rates between the HIV positive and 
negative.  These results are similar to those found in the cross sectional study using the 
Malawi DHS 79 which showed a decrease over two surveys in the relative difference in 
fertility comparing the HIV positive and HIV negative at the time of the survey.  Since our 
longitudinal data can accurately measure HIV status at the time of birth these results are 
a strong affirmation of the cross-sectional findings. 
Fertility dynamics, HIV and changes due to ART are complex and can be both biological 
and behavioural.  Earlier studies showed that HIV positive women with further disease 
progression have lower fertility than the uninfected and those more recently infected 119, 
121, 154
.  Women with HIV also have increased risk of spontaneous abortion and still birth 
86
 which lower their fertility.  It is possible that the improved health of women on ART 
increases their fecundity although one study found an increase in still births for HIV 
positive women on ART compared to those not on ART92.   
Relationship dynamics may also change: studies from the pre ART era have shown an 
increased risk of widowhood and marital dissolution for HIV positive women and low 
rates of remarriage107, 155, therefore decreasing their chances to bear more children.  In 
the era of ART the risk of widowhood will decrease and marital dissolution rates may 
change leading to more opportunity for childbearing.   
Fertility intentions are likely also to change, HIV positive women are more likely to report 
desiring fewer births than those uninfected115 but some studies that compared fertility 
intentions of HIV positive women on treatment to those not on treatment found an 
increase in desire for children with increasing duration on ART 116, 117, 145.  It is unclear 
whether these intentions translate into actual increases in fertility.   A cross sectional 
study from a perinatal HIV Research Unit in Soweto found no difference in fertility 
intentions between those on ART or not114 – however all participants were attending the 
HIV clinic so according to the authors, the intentions of those not yet on treatment may 
have been shaped by the knowledge that ART was available when needed.    A 
multicounty HIV care and treatment program cohort study in sub-Saharan Africa reported 
HIV positive women on treatment having 1.74(95%CI 1.19-2.54) higher incidence of 
pregnancy than those not on treatment121.  The study was unable to determine the factors 
underlying the results with both biological and behavioural factors being possible. 
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This analysis shows the extent of changes in fertility trends at the population level which 
is important for modellers and policy makers.  It does not tell us how much of the change 
is attributable to biological factors directly associated with improved health of those 
receiving ART, psychological changes that alter fertility intentions, or social changes in 
marital dynamics and stigma.  It is important to note that in the pre ART era most people 
in these studies would not have known their HIV status so reasons for low fertility in the 
HIV positives would not include a conscious desire for fewer children motivated by 
knowledge of status.   These topics need further analysis with individual linkage to clinic 
data to classify time on treatment, to investigate biological factors, and more detailed 
demographic and behavioural background characteristics. 
Differences in fertility between HIV positive and HIV negative women are narrowing over 
time as ART becomes more widely available in these communities. Routine adjustment 
of ANC data for estimating national HIV prevalence will need to allow for the impact of 
treatment.  Given the profound differences between fertility rate ratios and trends in 
infected and uninfected women under 20 with those aged 20 and over, it would be useful 
to classify ANC data on HIV prevalence by age, reporting separately on those under 20. 
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6 Paper D: The effects of HIV on fertility by infection 
duration: evidence from African population cohorts 
before ART availability 
 
For objective 4 of the PhD: to estimate the population impact of HIV on fertility and to 
examine the effect of duration of infection on fertility and whether this is independent of 
age using longitudinal data from the ALPHA network; was published in:  
 
Marston, M; Nakiyingi-Miiro, J; Kusemererwa, S; Urassa, M; Michael, D; Nyamukapa, C; 
Gregson, S; Zaba, B; Eaton, JW; ALPHA network; (2017) The effects of HIV on fertility 
by infection duration: evidence from African population cohorts before 
antiretroviral treatment availability. AIDS, 31 Suppl 1  
 
6.1 Introduction to paper 
The age specific differences in the effects of HIV on fertility have been well documented, 
showing increasing subfertility amongst HIV positive women compared to negative 
women as age increases.  An exception is seen in the youngest women 15-19 where 
selection effects cause the fertility to be higher in HIV positive women than negative 
women.  However there are no estimates of the independent effect of duration of 
infection.  This could be important in estimates of changes due to HIV epidemic duration, 
because increased HIV subfertility at older ages may be due to longer duration of 
infection, so subfertility may change over different epidemic stages.  Earlier in the 
epidemic women are more likely to be more recently infected than later in the epidemic.  
Longer survival of infected women on ART further increases the mean duration since 
infection.   
 
Previous estimates of age specific HIV subfertility have mainly relied on retrospective 
data that may be subject to a number of biases.  Survivorship bias arises because 
women who have died in the period before the survey are not included.  These women 
are more likely to have had longer duration of infection and lower fertility, therefore their 
exclusion causes over estimates of HIV positive fertility.  Measurement bias arises 
because HIV status is measured at the time of the survey, therefore those who sero 
converted in the reference period before the survey analysis contribute some HIV 
negative exposure time which is wrongly allocated to the HIV positive group.   
Longitudinal community-based studies are well placed to assess the level of these 
possible biases in the analysis of the impact of HIV on fertility.  
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6.2 Abstract  
Objectives: To estimate the relationship between  HIV natural history and fertility by 
duration of infection in East and Southern Africa before the availability of antiretroviral 
therapy, and assess potential biases in estimates of age-specific sub-fertility when using 
retrospective birth histories in cross-sectional studies.   
 
Design: Pooled analysis of prospective population-based HIV cohort studies in Masaka 
(Uganda) Kisesa (Tanzania), and Manicaland (Zimbabwe). 
 
Methods: Women aged 15-49 who had ever tested for HIV were included. Analyses 
were censored at antiretroviral treatment roll out.  Fertility rate ratios were calculated to 
see the relationship of duration of HIV infection on fertility, adjusting for background 
characteristics. Survivorship and misclassification biases on age-specific subfertility 
estimates from cross-sectional surveys were estimated by reclassifying person time from 
the cohort data to simulate cross-sectional surveys and comparing fertility rate ratios to 
true cohort results. 
 
Results: HIV negative and positive women contributed 15,440 births and 86320 person 
years; and 1,236 births and 11240 thousand person years respectively to the final 
dataset. Adjusting for age, study site and calendar year, each additional year since HIV 
sero conversion was associated with a 0.02 (95%CI 0.01-0.03) relative decrease 
infertility for HIV-positive women. Survivorship and misclassification biases in simulated 
retrospective birth histories resulted in modest underestimates of sub-fertility by 2-5% for 
age groups 20-39y.   
 
Conclusion:   Longer duration of infection is associated with greater relative fertility 
reduction for HIV-positive women. This should be considered when creating estimates 
for HIV prevalence among pregnant women and PMTCT need over the course of the 
HIV epidemic and ART scale-up.  
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6.3 Introduction  
The effects of HIV infection on fertility have been extensively studied in generalized HIV 
epidemic settings in sub-Saharan Africa 41, 72, 107, 119, 156, 157. This was of interest for two 
reasons: firstly, to forecast the demographic impacts of hyper-endemic HIV 158, 159 and, 
secondly, because HIV prevalence among pregnant women was widely used for 
estimating general population HIV prevalence levels and trends142, 143, 160. More recently, 
the need to plan and evaluate prevention of mother-to-child transmission (PMTCT) 
programmes has further increased the importance of accurate predictions of fertility of 
HIV-positive women and changes therein. 
Existing literature, largely based on analysis of cross-sectional data, has demonstrated 
that the relationship between HIV infection and fertility depends strongly on age. Among 
young women (age 15–19 years) ANC prevalence is higher than general population 
prevalence because both pregnancy and HIV risk occur among the subset of women 
who are sexually active, but among older age groups the fertility rate ratio among HIV-
positive women becomes increasingly lower relative to HIV-negative women 41, 144, 161. 
Presently, the Spectrum model uses estimates of the fertility rate ratio (FRR) for HIV-
positive to HIV-negative women by age-group estimated by Chen and Walker 41 to 
generate estimates of HIV prevalence among pregnant women and need for PMTCT. 
However, rather than a direct effect of age, the lower prevalence among older pregnant 
women may primarily be associated with reduced fertility during later stages of HIV 
infection108, 119-121, 154. This distinction is potentially important because of its interaction 
with the stages of the HIV epidemic—during the early exponential growth period of the 
epidemic, many more women are recently infected, and so HIV-related subfertility will be 
lower than later in the epidemic, even among older women.  Moreover, antiretroviral 
treatment (ART) is disproportionately provided to those infected the longest and 
experiencing the most serious clinical symptoms—those who are expected to experience 
the greatest fertility reductions. If the effects of HIV on fertility are strongly related to the 
duration of infection, then these two effects may contribute to biased predictions about 
need for PMTCT services as ART programmes scale-up. 
Finally, the hypothesised relationship between duration of HIV infection and fertility may 
influence our ability to estimate the relationship between HIV and fertility. Widely used 
estimates of age-specific fertility rate ratios (FRR) by HIV status rely on cross-sectional 
Demographic and Health Survey data to compare fertility over the previous three years 
among HIV-positive and HIV-negative women 41.  This poses two potential biases (Figure 
6.1). First, it excludes women who do not survive the three-year period preceding the 
survey. If duration of infection influences fertility, then this survivorship bias would 
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exclude women with the lowest fertility, resulting in an underestimate of subfertility based 
on cross sectional surveys. Second, retrospective analyses assume the HIV status at 
the time of the survey is unchanged over the previous three years. For women who 
seroconverted during the three years prior to the survey, this misclassifies some HIV-
negative person-time as HIV-positive, again potentially overestimating the true fertility of 
HIV-positive women.  
Figure 6.1: Survivorship and misclassification bias  
 
 
In this analysis, we estimate the relationship between the imputed duration of HIV 
infection and fertility using data from three prospective general-population open cohorts 
in Uganda, Tanzania and Zimbabwe – all members of the ALPHA network9.  The 
objective of this analysis is to estimate the relationship of HIV natural history and fertility 
in the absence of treatment, and as such we censor the cohort data at the time when 
ART became available in the population (population-wide fertility trends in these cohorts 
since ART scale-up have been described elsewhere78). We use the prospective 
demographic and HIV surveillance data to empirically quantify the expected magnitude 
of survivorship and misclassification biases on age specific subfertility from cross 
sectional surveys.  
 
6.4 Methods  
6.4.1 Sites and setting 
Data come from three community-based demographic and HIV open cohort studies. 
Kisesa (managed by the National Institute for Medical Research Mwanza) located in 
north western Tanzania, was established in 1994 and has a population of around 34,000. 
It is predominately rural with a small trading centre on the main road. The average HIV 
prevalence between 1994 and 2010 was 6% 27. The Manicaland study (managed by the 
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Biomedical Research and Training Institute and Imperial College London) in Zimbabwe 
was established in 1998. A prospective household census (population size 
approximately 37,000) and general population cohort survey (10,000-12,000) were 
initiated in 12 geographically distinct study sites spread across three districts, with follow-
up rounds conducted every 2 or 3 years. The Manicaland study sites comprise two small 
towns, four agricultural estates, two roadside settlements and four subsistence farming 
areas. Overall adult HIV prevalence was around 25% in the late 1990s and has declined 
steadily to around 15% in 2012-13 28. Masaka (managed by MRC/UVRI Uganda 
Research Unit on AIDS) is situated in rural south west Uganda and was established in 
1989. Its initial population was around 10,000 which then increased to 18,000 when 10 
villages were added to the census area in 2000. Average HIV prevalence between 1989 
and 2011 was 8%32.    
6.4.2 Fertility data 
In Kisesa there are two sources of data that are used to estimate fertility.   At each 
demographic surveillance round conducted one to two times per year a proxy respondent 
is asked whether each woman in the household gave birth since the previous round and 
the birth outcome.  Also all new members of the household, including newborns are 
linked to their mother if she lives in the household.  These two pieces of information are 
reconciled to give the date of delivery of each birth observed in the DSS.   
 
In Masaka there are four sources of data for estimating fertility. At each annual census, 
women of child bearing age are asked whether they were pregnant in the previous 12 
months and the birth outcome. The names and identification number of the child are 
recorded on the mother’s record. Secondly, each new member of the household is 
enumerated during the annual census and the reasons for joining obtained. If the reason 
is new born, the mother’s identification number is recorded on the child’s census record. 
Thirdly, village leaders are asked to report all births in their village on a monthly basis to 
the study clerks. This information is entered and any child reported by these recorders 
but not on census is added to the census file. Fourth, every 3 years, all children aged 
<18 years are asked about their parents to establish/confirm who they are and their vital 
status.  
 
In the Manicaland study, survey rounds are conducted every two to three years. At each 
survey round, eligible women are enumerated in a household census and invited to 
participate in an open cohort study. Participants report all births since the previous survey 
round through a structured questionnaire. For women who die between survey rounds, 
any births occurring since the previous survey round are recorded in a verbal autopsy 
interview with the next of kin. 
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6.4.3 HIV data  
In Kisesa, the HIV surveys were carried out separately to the demographic surveillance 
rounds every two to three years, and data were linked afterwards using unique personal 
identifiers.  In Masaka, HIV testing was done immediately after demographic surveillance 
rounds which were used to list those eligible for HIV testing.  HIV testing took place in 
the home for all sites apart from Kisesa where temporary village clinics are used, to which 
people are transported from their homes.    Prior to the availability of antiretroviral 
therapy, testing protocols used informed consent without disclosure, so that participants 
did not learn the results of the HIV research tests. In Manicaland, following household 
census enumeration, research assistants interview eligible individual participants to 
collect dried blood spot samples, which are transported to and analysed in an offsite 
laboratory.  
6.5 Statistical Analysis  
6.5.1 Imputation of date of seroconversion 
Calculating the fertility rate by duration of HIV infection requires data about when a 
woman seroconverted, which is not exactly observed. We generated 100 imputations for 
the date of seroconversion for each HIV-positive woman. For women who are observed 
HIV-negative in one survey round and HIV-positive in a subsequent round 
(‘seroconverters’), we imputed dates of seroconversion from a uniform distribution 
between the dates of the last negative and first HIV positive test.  
 
For women who were already HIV positive the first time they were tested in the cohort 
(‘prevalent cases’), we imputed 100 seroconversion dates from a distribution determined 
by the convolution of the age-specific HIV incidence rates and the probability of surviving 
from seroconversion until the woman’s latest age at interview.  
6.5.2 Fertility rate ratio by duration of infection 
Person time and live births of women of reproductive age (15- 49 years old) who had 
ever tested for HIV in the studies were eligible for inclusion in the analysis.  HIV negative 
person-time for women with no subsequent positive test was assumed to last for up to 
five years past their last negative test, the exact cut-off point was determined by the HIV 
incidence rates in the sites, defined as the time at which the cumulated probability of 
becoming infected following the last negative test reached 5%.  Data for each cohort 
were censored at the start of ART introduction (Kisesa March 2005, Masaka January 
2004, Manicaland June 2005), in order to estimate the intrinsic relationship between HIV 
and fertility before the availability of antiretroviral therapy.  For women ever testing HIV 
positive imputed seroconversion dates were used to assign person-time by HIV status.  
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The imputed duration of infection is defined as 0 for HIV-negative, and is treated as a 
continuous variable in years following sero-conversion. Fertility rate ratios (FRR) by HIV 
status and duration of infection are calculated using piecewise exponential regression 
allowing for clustering of births in each women, adjusting for age-specific fertility in each 
site and a log-linear trend in fertility over calendar time centred on the year 2001.   The 
analysis was repeated 100 times using independently imputed sero conversion dates.  
The log of the hazard rate ratios from the imputations were combined using Rubin’s rules 
39
 to give confidence intervals that reflect the uncertainty about the exact date of sero-
conversion.  Older age at infection pre ART is associated with a shorter survival time 7 
independent of current age 5. We investigated whether this could also have an effect on 
subfertility classified by duration of infection (model not shown)   
6.5.3 The effects of survivorship and misclassification bias in 
retrospective survey analysis 
We quantified the potential magnitude of survivorship and misclassification biases when 
estimating age specific subfertility from cross sectional surveys by using the population 
cohort data to simulate the three-year retrospective fertility history analysis and 
compared the resulting age-specific FRRs to the true FRRs observed in the cohorts. 
Person time was classified in three year intervals 2000-2002 and 2003-2005 then 
aggregated over the six-year period.  We calculated actual sub-fertility by age (adjusted 
for study site, residence and calendar time), then calculated sub-fertility by age as 
assumed in cross-sectional studies by allocating all the person time of women who were 
positive at the end of the time period to HIV positive for the whole period (simulating 
misclassification) and removing any person time and births to women who died in the 
period (simulating survivorship bias).   
 
All analysis was done using Stata 14.1. 
 
6.6 Ethics statement 
Each of the three sites contributing data to the pooled analysis received ethical clearance 
from the appropriate local ethics review bodies, and from the corresponding Institutional 
Review Boards at relevant collaborating partner universities.  
 
6.7 Results  
6.7.1 Estimates of HIV subfertility by duration of infection  
The dataset compiled for women aged 15-49 years contained 15,451 births and 86280  
person years to HIV negative women; 993 births and 9580 person years to HIV positive 
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women; and 315 births and 2510 person years with HIV status unknown.  Prior to 
imputation the latter group comprised the time before a first positive test and person time 
in the sero conversion interval (Table 6.1). Kisesa contributed the most births (54%) and 
person years (42%) (Table 1). Manicaland contributed the highest number of births and 
person years to HIV positive women (477 births 5750 person years) due to the higher 
HIV prevalence in Zimbabwe.   After imputation of sero conversion dates HIV negative 
and positive women contributed 15,440 births and 86320 person years; and 1,236 births 
and 11240 person years respectively.  The total fertility rate over the pre ART time period 
used was highest in Kisesa at 6.2 followed by Masaka at 5.2 and lowest in Manicaland 
at 3.1. 
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Table 6.1: Births and person years by HIV status and study site for women aged 15-49 who ever tested for HIV 
  Kisesa   Manicaland   Masaka   All sites 
HIV Status Births 
Person 
Years per 
1000   Births 
Person 
Years per 
1000   Births 
Person 
Years per 
1000   Births 
Person 
Years per 
1000 
Negative 8581 38.11   2003 19.87   4867 28.30   15451 86.28 
Positive 284 2.17  381 4.93  328 2.48  993 9.58 
Unknown 162 1.12   96 0.85   57 0.54   315 2.51 
Note for those HIV negative women were included up to 5 years post last negative test  
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Crude fertility rates patterns were broadly similar in the observed prevalent positive 
person time compared to the imputed positive person time with the rates slightly higher 
in the imputed positive person time, consistent with imputed positive being biased 
towards earlier duration after sero conversion (not shown).   Crude rates show a 
decrease in fertility by duration of infection (Table 6.2). 
 
Compared to HIV-negative women, the relative fertility of HIV-positive 20-24 year-olds 
was 0.72 (95%CI 0.66-0.79), and relative fertility further reduced with age (Table 6.3, 
Model 1).  The 15-19 year old HIV-positive women have higher fertility compared to those 
who are uninfected due to the fact that many women in this age-group are not sexually 
active and therefore are not exposed to HIV.   
 
Including duration of infection in the model showed that each additional year since 
seroconversion was associated with a 0.979 (95%CI 0.965-0.995) times reduction in 
fertility for HIV-positive women, adjusted for age, the effect of age at sero-conversion, 
study site and calendar year (Model 2, Table 6.3). Accounting for duration attenuated 
the relative fertility of positive women compared to negative women to 0.78 (95%CI 0.70-
0.88) and similarly for other age groups (Model 2, Table 6.3).  
 
Restricting the model to HIV positive women (Not shown) shows that with increasing 
year of age at sero conversion there is an increase in the effect of duration on subfertility 
(FFR 0.997 95%CI 0.994-0.999).   
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Table 6.2: Crude rates with imputed data by HIV status . 
 
  
HIV Negative Imputed Positive All imputed data 
    Births 
Person 
Years 
per 1000 
Fertility 
Rate per 
1000 Births 
Person 
Years 
per 1000 
Fertility 
Rate per 
1000 Births 
Person 
Years 
per 1000 
Fertility 
Rate per 
1000 
Age Group           
15-19  2683.47 21.98 122.07 122 0.70 173.47 2806 22.69 123.66 
20-24  4445.68 15.40 288.66 381 1.97 193.19 4826 17.37 277.83 
25-29  3505.11 12.83 273.12 393 2.69 146.36 3898 15.52 251.18 
30-34  2485.16 11.03 225.41 209 2.29 91.31 2694 13.31 202.35 
35-39  1592 9.72 163.76 106 1.66 63.72 1698 11.39 149.14 
40-44  621.26 8.53 72.87 21 1.25 16.53 642 9.78 65.66 
45-49  106.89 6.83 15.66 4 0.67 6.11 111 7.50 14.80 
HIV status           
Negative  15440 86.32 178.87    15440 86.32 178.87 
Positive     1236 11.24 109.98 1236 11.24 109.98 
Duration of infection         
1 year     130 0.81 160.13 130 0.81 160.13 
1-2 years     265 1.87 142.15 265 1.87 142.15 
3-4 years     252 1.87 135.13 252 1.87 135.13 
5-6 years      205 1.68 121.66 205 1.68 121.66 
7-8 years     145 1.39 104.62 145 1.39 104.62 
9+ years      226 3.56 63.52 226 3.56 63.52 
Study Site           
Kisesa  8582.09 38.16 224.89 389 2.78 139.75 8971 40.94 219.10 
Manicaland  2002.82 19.89 100.67 477 5.75 82.97 2480 25.65 96.70 
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Masaka  4854.66 28.26 171.78 370 2.70 136.78 5224 30.96 168.73 
Calendar Year          
1990  185.89 1.08 171.57 20 0.13 148.61 206 1.22 169.06 
1991  335.79 1.61 209.15 34 0.19 179.94 370 1.80 206.05 
1992  322.34 1.66 193.84 34 0.18 184.99 356 1.85 192.97 
1993  232.02 1.68 138.42 36 0.18 197.64 268 1.86 144.22 
1994  587.16 2.98 197.17 44 0.27 164.69 631 3.25 194.48 
1995  1109.32 4.93 225.06 60 0.40 151.54 1170 5.33 219.56 
1996  1079.8 5.02 214.92 61 0.41 149.27 1141 5.43 210.00 
1997  1111.19 5.11 217.29 65 0.43 152.19 1176 5.54 212.30 
1998  919.17 5.16 178.27 37 0.42 88.61 956 5.57 171.58 
1999  1369.48 7.02 195.03 104 0.96 107.58 1473 7.98 184.49 
2000  1562.19 9.17 170.37 155 1.48 104.97 1718 10.65 161.28 
2001  1684.16 9.72 173.25 145 1.46 99.67 1829 11.18 163.65 
2002  1711.85 10.23 167.27 169 1.49 113.05 1881 11.73 160.37 
2003  1750.11 10.97 159.58 130 1.56 82.92 1880 12.53 150.02 
2004  1242.34 7.92 156.90 108 1.26 86.04 1351 9.18 147.16 
2005   236.76 2.06 115.13 34 0.42 81.86 271 2.48 109.51 
Births and person years are averaged over 100 datasets 
 162 
 
Table 6.3: Effects of HIV on fertility by age and duration of infection  
  Model 1 - No duration   
Model 2 - With 
duration 
  
    FRR 95%CI   FRR 95%CI   
        
Duration of infection  
   0.979 (0.964-0.995)    
      
HIV status    
  
 
 
HIV Negative 1   1   
 
HIV Positive 0.72 (0.66-0.79)  0.78 (0.70-0.88)  
        
Effects of HIV by age 
      
 
15-19,HIV Positive 2.02 (1.67-2.45)  1.95 (1.60-2.38)  
 
20-24,HIV Positive 1   1   
 
25-29,HIV Positive 0.86 (0.75-0.98)  0.90 (0.78-1.03)  
 
30-34,HIV Positive 0.69 (0.58-0.81)  0.74 (0.62-0.89)  
 
35-39,HIV Positive 0.73 (0.58-0.92)  0.81 (0.63-1.03)  
 
40-44,HIV Positive 0.46 (0.28-0.76)  0.52 (0.32-0.87)  
 
45-49,HIV Positive 0.90 (0.27-2.99)  1.01 (0.30-3.39)  
 
 
        
      
Age Group 
      
 
15-19 0.50 (0.47-0.54)  0.50 (0.47-0.54)  
 
20-24 1   1   
 
25-29 0.96 (0.92-1.01)  0.96 (0.92-1.01)  
 
30-34 0.81 (0.77-0.85)  0.81 (0.77-0.85)  
 
35-39 0.63 (0.59-0.67)  0.63 (0.59-0.67)  
 
40-44 0.31 (0.28-0.35)  0.31 (0.28-0.35)  
 
45-49 0.09 (0.07-0.12)  0.09 (0.07-0.12)  
Study Site 
      
 
Kisesa 1   1   
 
Manicaland 0.66 (0.62-0.71)  0.67 (0.62-0.71)  
 
Masaka 0.87 (0.82-0.92)  0.87 (0.82-0.92)          
Calendar Year 0.99 (0.99-1.00)   0.99 (0.99-1.00)   
Results from exponential regression of fertility rates as a function of HIV status, age and duration 
of infection controlling for interaction between study site and age (not shown), study site and 
calendar year (not shown).  Calendar year is centred at 2001, age at sero conversion is centred 
at age 25. .Pooled results based on 100 datasets for imputed date of sero conversion.   
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6.7.3 Estimates of survivorship bias in retrospective surveys 
Age specific subfertility was larger in the ALPHA sites compared to that found by Chen 
and Walker41  apart from the 15-19 year age group (Figure 6.2a). The reduction in fertility 
was 3-12% greater in the age groups 20-34 years, and somewhat larger at the oldest 
age groups, for example 41% lower in the 40-44 year age group.  However, confidence 
intervals encompassed Chen and Walker  estimates apart from the 40-44 year old age 
group. Figure 6.2 b compares the observed subfertility by age in the cohorts (red dots) 
to the subfertility estimates when analysed using the assumptions of a retrospective 
cross-sectional survey (blue triangles). Estimates with simulated misclassification and 
survivorship bias attenuated the subfertility by age by between 2-5% in the age groups 
between 20 and 39 years old and 22% in the 40-44 year age group.  
 
There was some evidence for variation of age specific subfertility by study site with 
subfertility in Manicaland lower than in Masaka and Kisesa  
 
6.8 Discussion 
These data show that longer duration of HIV infection is associated with increased 
subfertility.  Estimating age specific HIV subfertility using retrospective cross sectional 
surveys underestimates subfertility, particularly for older ages, due to survivorship bias 
being more important at longer duration of infection which corresponds to greater fertility 
reducing effects of HIV infection.   
  
Many studies have documented the effect of HIV on fertility and on age-specific 
subfertility41, 72, 144, 161 at the population level during the pre-ART period.  A number of 
studies in sub-Saharan Africa have looked at disease progression in relation to fertility, 
a case control study in Uganda found that high viral load was associated with reduced 
rates of pregnancy and a reduction in live births119, despite being sexually active and not 
using contraception.  Also a clinical cohort found that fertility is reduced from the earliest 
stage of HIV infection with a large reduction in fertility following the progression to AIDS 
108
 – this finding was adjusted for sexual activity but not for contraceptive use.  A clinical 
cohort study in Tanzania also found reduced fertility related to clinical stage of HIV 120 
adjusting for social and demographic characteristics.  A multi-site HIV care and treatment 
programme analysis showed a strong association between disease progression and a 
reduction in the incidence of pregnancy121.   
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Figure 6.2: a) Fertility rate ratio from Chen and Walker – Survivorship bias b) Age specific Fertility 
rate ratio (HIV positive/HIV negative) by study site compared to Chen and Walker 
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Increased subfertility by duration of infection at the population level could have both 
biological and behavioural factors.  Biologically, as well as increases in viral load or 
decreases in CD4 count as explanatory factors, the semen quality of HIV positive 
partners could be reduced over the time of their infection 95, 96, 101 or their increased illness 
could impact on their sexual activity.  In terms of behaviour, HIV positive women are 
more likely to be widowed107, 122, 155 due to having had an HIV positive partner.  Although 
voluntary testing and counselling was rare in these sites prior to ART introduction, 
suspicion of HIV status or illness in a partner with HIV may reduce the desire for more 
pregnancies 115 which may be more obvious at longer durations of infection and it may 
also increase divorce or separation 107, 155 
 
Increased age at seroconversion accelerated the effects of infection duration on 
subfertility.  Older age at infection leads to shorter survival post infection5, 7, so a shorter 
duration to low CD4 count and higher viral load which have been shown to reduce fertility.  
Also at older ages of sero conversion it is more likely the partner (who is more likely to 
be older) has been infected for a longer duration therefore there is a higher chance of 
widowhood early on in the women’s HIV infection lowering her changes of pregnancy.  
Finally, older women are likely to have higher parity and therefore may have lower 
desires for more children than a younger woman who has none or few children. 
 
Compared to the DHS analysis by Chen and Walker 41, ALPHA cohorts showed greater 
fertility reductions among HIV-positive women by five year age group, particularly in the 
older age groups. Around half of this discrepancy was explained by biases inherent in 
estimating subfertility from cross sectional data due to not including the person years 
and births of those who died prior to interview and classifying all person years according 
to the HIV status at time of interview.   
 
Residual differences between our findings and those of Chen and Walker 41 could have 
a number of causes.  This DHS analysis uses countries across South, East and Western 
Africa, whereas our analysis uses study sites from East and Southern Africa where 
Manicaland, Zimbabwe showed lower subfertility than the two east Africa sites (although 
confidence intervals overlapped) which may indicate some differences in subfertility and 
duration of infection in different settings as found in previous studies 107, 157.  Modern 
contraceptive use by all women is much higher in Zimbabwe at 40.1% in 2005-06 
compared to Tanzania and Uganda, 22.5% in 2004-05 and 19.6% in 2006 respectively 
162
 which may contribute to these differences 107.    Deliveries and the deaths of children 
dying in early infancy (particularly in the neonatal period) could be underreported in the 
ALPHA studies due to recall bias or lack of knowledge on the part of a proxy respondent, 
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which would affect HIV positive women disproportionally due to the high infant mortality  
of children infected through vertical transmission 13. This could artificially increase 
subfertility estimates in the cohort studies.  The DHS will be prone to more recall bias 
than the cohort studies, however, if analysis is limited to the first few years prior to the 
interview, and the respondent is the women rather than a proxy it is possible this will lead 
to less bias in reporting of births to infants who have died in DHS compared to ALPHA 
studies. We find that subfertility increases with duration of HIV infection in the absence 
of ART.  This has two important implications that should be considered in future HIV 
epidemic estimates and the estimates of need for PMTCT. Firstly, over the course of the 
epidemic the distribution of duration of infection changes. During the exponential growth 
phase a higher proportion of women will be recently infected, and as incidence declines 
average duration of infection will become longer. This means that the population-level 
effects of HIV on fertility, and hence the relationship between HIV prevalence measured 
among pregnant women and general population prevalence, will change.  
 
Second, initiation of anti-retroviral treatment has been disproportionately among women 
in later stages of infection who might be expected to have the lowest fertility rates. Thus, 
following ART scale-up, not only might women on ART have increased fertility 73, but 
also the fertility of untreated HIV-positive women may be higher because those who 
would have the lowest fertility are selectively removed into the treatment group.  
Implementation of Option B+ over the past several years, in which all pregnant women 
are initiated on lifelong ART, will further change these dynamics. In light of the 
demonstrated association between duration of infection and fertility reduction, we 
recommend that model-based approaches account for not only age but also stage of 
infection and ART status when estimating HIV prevalence among pregnant women and 
PMTCT need. 
 
Our results also imply that there are differences in fertility by setting. This underscores 
that, where possible, locally available data such as prevalence from routine HIV testing 
of pregnant women should be used in place of default model values to inform appropriate 
model assumptions about subfertility when generating estimates of PMTCT need.  
Finally, it is worth noting that survivorship bias will be less important in the era of ART, 
as HIV mortality is lower.  The assumption that women who are HIV positive at the time 
of interview have been infected for at least 3 years will also become more realistic as 
longer durations of infection become more common in the era of ART.  These factors 
should also be considered when interpreting changes over time in the relationship 
between HIV and fertility from cross-sectional surveys.   
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7 PAPER E: The relationship between HIV and fertility 
in the era of antiretroviral therapy in sub Saharan 
Africa – Evidence from 48 Demographic & Health 
Surveys 
 
7.1 Introduction to chapter 
 
For objective 5 of the PhD: to estimate the population impact of HIV on fertility and 
investigate if there are variations by region, urban and rural residence and ART coverage 
using cross sectional data from demographic and health surveys; an analysis was 
conducted using data from demographic and health surveys and published in:  
 
Marston, M., B. Zaba, and J.W. Eaton, The relationship between HIV and fertility in the 
era of antiretroviral therapy in sub-Saharan Africa: evidence from 49 Demographic and 
Health Surveys. Trop Med Int Health, 2017. 22(12): p. 1542-1550. 
 
Understanding the fertility of HIV positive women has been of central importance to the 
HIV response in sub-Saharan Africa for planning and evaluating programmes to prevent 
mother-to-child HIV transmission (PMTCT).  Conversely, understanding differences in 
HIV prevalence in pregnant women and the general female population is vital for the 
interpretion HIV prevalence trends observed among pregnant women, and extrapolation 
of these trends to estimate prevalence in the general population. 
 
An earlier systematic review and an updated search showed that there are few 
population-based studies in the era of ART73.  One study looked at HIV subfertility using 
demographic and health surveys (DHS) prior to ART roll out41. Another focused on DHS 
from Malawi pre and post ART roll out79. Two studies used community-based cohort 
studies, one comparing pre and post ART periods78, the other using only the period 
before ART roll out43.  All studies found lower fertility in HIV positive women in general, 
and both studies looking at the pre and post ART periods found some evidence for a 
narrowing of the differences in fertility in the period after ART roll out.   
 
This paper uses data from 48 demographic and health surveys (DHS) and AIDS indicator 
surveys (AIS) from 27 countries in sub-Saharan Africa from 2003 through to 2015. This 
greatly expands a previous analysis of 16 surveys in Sub Saharan African from 2003 
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through 2007, and in particular extends the analysis into the ART era. This larger dataset 
is also used to examine regional, urban/rural and temporal differences. 
 
For the purposes of this PhD, appendix 1 of the paper is presented in an expanded 
format in section 7.2 and appendix 2 has been incorporated into the main text in section 
7.2.   
 
For objective 6 of the PhD: to investigate possible biases affecting the analysis of the 
impact of HIV on fertility that arise from the use of retrospective data such as DHS or 
prospective data; an analysis was carried out using DHS and ALPHA network data.  Part 
of this work was published as supplementary material to paper E (Appendix 1) 
 
The work presented here (section 7.2) is broader than that published in the 
supplementary material to paper E, and not only covered biases when using 
retrospective data such as DHS but also looks at biases that arise when using 
longitudinal data from the ALPHA network.  It assesses whether we can attribute the 
higher HIV subfertility at younger ages found in ALPHA network sites (paper D) 
compared to those using DHS studies (paper E) to biases inherent in the analyses of 
these two data sources.   
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7.1.1 Abstract  
 
Objectives  
Describe regional differences in the relative fertility of HIV positive women compared to 
negative women and changes as antiretroviral treatment (ART) is scaled-up, in order to 
improve estimates of predicted need for and coverage of prevention of mother-to-child 
transmission services at national and subnational levels.   
 
Methods 
We analysed 48 nationally representative household surveys in sub-Saharan Africa 
between 2003 and 2015 to estimate fertility rate ratios of HIV positive and HIV negative 
women by age using exponential regression, and test for regional and urban/rural 
differences.  We estimated the association between national ART coverage and the 
relationship between HIV and fertility. 
 
Results 
Significant regional differences exist in HIV and fertility relationships, with less HIV-
associated subfertility in Southern Africa. Age patterns of relative fertility are similar.  HIV 
impact on fertility is weaker in urban than rural areas. For women below age 30, regional 
and urban/rural differences are largely explained by differences in age at sexual debut. 
Higher levels of national ART coverage appear to slightly attenuate the relationship 
between HIV and fertility.  
 
Conclusions 
Regional differences in HIV-associated subfertility and urban/rural differences in age 
patterns of relative fertility should be accounted for when predicting need for and 
coverage of PMTCT services at national and subnational level. Although HIV impacts on 
fertility are somewhat reduced at higher levels of national ART coverage, differences in 
fertility between HIV positive and negative remain, and fertility of women on ART should 
not be assumed to be the same as HIV-negative women. 
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7.1.2 Introduction  
Elimination of mother-to-child transmission of HIV (MTCT) through provision of 
antiretroviral treatment (ART) to all HIV positive pregnant women is a major policy 
objective for national HIV programmes, The Joint United Nations Programme on 
HIV/AIDS (UNAIDS), and the U.S. President’s Emergency Plan for AIDS Relief 
(PEPFAR) 1. Accurate estimates of the number of HIV-positive pregnant women at the 
national and sub-national level are essential for planning and allocating resources 
needed for services to prevent mother-to-child transmission (PMTCT), calculating 
coverage and unmet need of existing services, and evaluating progress towards 
elimination targets 2. Estimates of PMTCT need, coverage, and MTCT rates are key 
outputs of official annual national HIV programme reports, generated with support from 
UNAIDS163. HIV prevalence in antenatal care and PMTCT settings is the main indicator 
of national HIV epidemic trends, but in order to interpret it correctly as a guide to 
prevalence in the general population we need to understand the relative incidence of 
pregnancy in HIV positive and negative women.  
 
Coverage and unmet need for PMTCT services are estimated by dividing number of 
pregnant women receiving PMTCT services from routine programmatic data (the 
numerator) by a modelled estimate of the number of HIV positive pregnant women (the 
denominator). Estimating the number of HIV positive pregnant women, and hence need 
for PMTCT services, relies on information about (1) age- and sex-specific HIV 
prevalence in the population, (2) age-specific fertility rates, and (3) the fertility of HIV-
positive women relative to HIV-negative women. Existing literature about the effects of 
HIV status on fertility emphasises a changing relationship with age41, 43, 72, 144, 164. At the 
youngest ages HIV-positive women, relative to HIV negative women have higher fertility 
due to selection of sexually active women. The fertility of HIV positive women relative to 
HIV negative women steadily declines with age, due to both biological effects of HIV on 
fecundity 108, 144, 165 and differences in exposure to pregnancy including factors such as 
higher divorce and widowhood in HIV positive women155. A few studies have suggested 
regional differences in HIV-related subfertility 43, 78, 157 although regional variation is not 
systematically accounted for in current estimates of PMTCT need.  
 
It is widely anticipated that ART scale-up will ameliorate the subfertility of HIV positive 
women, which would affect the number of HIV positive pregnant women, although 
evidence of this is limited 73. In the era of ART most studies of the impact of ART on 
pregnancy or fertility have been clinic based 73 which have shown some evidence that 
fertility increases after the first year on ART but still remains lower than HIV negative 
women. Elul et al 74 have criticised existing evidence from clinical cohorts which do not 
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account for the effect of pregnancy status at enrolment. Allowing for this in an analysis 
of 26 clinics in East Africa, they found little evidence that ART initiation is associated with 
an increased risk of pregnancy in women who enrol in HIV care. A number of population 
level studies have shown evidence of a narrowing of fertility differences between HIV 
positive and HIV negative women78, 79 in the era of ART.    
 
This study aims to improve the characterization of the relative fertility of HIV positive 
women to HIV negative women by region and place of residence, and update widely 
used estimates with data from the ART era.  
  
7.1.3 Methods 
Data  
We used data from 48 Demographic and Health Surveys (DHS) and AIDS indicator 
surveys (AIS) conducted in 27 sub-Saharan African countries between 2003 and 2016 
in which both full birth histories and HIV testing outcomes were available 40. National 
ART coverage estimates for adult women were taken from UNAIDS estimates 166 and 
ranged from none in the earlier years to 72% in Zimbabwe in 2015 (Table 7.1).  
 
DHS and AIS are nationally representative household surveys 40. All analyses account 
for the two-stage cluster sampling survey design and use the HIV weights provided by 
DHS. In pooled analysis, surveys are re-weighted so that each survey contributes equally 
toward the analysis. 
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Table 7.1: Demographic and Health Surveys with HIV women testing population samples by September2017 
Region Survey Year n 
HIV prevalence 
Women 15-49 
 (95% CI)* 
Estimated 
female adults 
15+  ART 
coverage(%)† 
(%)†166 
Median age at first sex 25-29 
year olds‡ 
Urban Rural All 
Southern Africa         
  
Lesotho 2004 3030 26.3 (24.5-28.2) 1 (1-1) 19.0 18.6 18.7 
  Lesotho 2009 3778 26.7 (25.0-28.6) 27 (25-29) 18.9 18.3 18.5 
  Lesotho 2014 3175 29.7 (27.7-31.8) 40 (37-43)] 18.8 18.3 18.5 
  Namibia 2013 4051 16.9 (15.4-18.4) 62 (50-70) 19.0 18.3 18.8 
  Swaziland 2006-07 4424 31.1 (29.4-32.9) 10 (8-11) 18.6 17.9 18.1 
  Zimbabwe 2005-06 6947 21.1 (19.7-22.6) 2 (2-3) 19.7 18.4 18.9 
  Zimbabwe 2010-11 7313 17.7 (16.6-18.8) 31 (24-38) 20.5 18.6 19.3 
  Zimbabwe 2015 8667 16.7 (15.6-17.8) 72 (57-84) 20.0 17.9 18.6 
East and Mid Africa         
  
Burundi 2010 4533 1.7 (1.4-2.1) 33 (26-40) 20.7 19.9 19.9 
  Kenya 2003 3151 8.7 (7.6-10.0) 0 (0-0) 18.9 17.6 18.0 
  Kenya 2008-09 3641 8.0 (6.8-9.3) 16 (15-18) 19.5 17.7 18.3 
  Malawi 2004 2686 13.3 (12.0-14.8) 1 (1-2) 18.2 17.4 17.5 
  Malawi 2010 7091 12.9 (11.8-14.1) 31 (29-33) 17.9 17.1 17.3 
 
 
Malawi 2015-16 7737 10.8 (9.9-11.7) 66 (63-71) 18.1 16.9 17.2 
  Rwanda 2005 5641 3.6 (3.1-4.2) 9 (8-11) 20.3 19.9 20.0 
  Rwanda 2010 6917 3.7 (3.3-4.2) 45 (39-51) 21.5 21.3 21.3 
  Rwanda 2014-15 6752 3.6 (3.2-4.1) 67 (59-76) 21.4 21.5 21.5 
  Tanzania 2007-08 8179 6.6 (5.9-7.4) 10 (8-12) 18.2 17.3 17.5 
  Tanzania 2011-12 9756 6.2 (5.6-6.8) 24 (18-28) 18.3 17.3 17.9 
  Zambia 2007 5502 16.1 (14.7-17.5) 20 (19-22) 17.9 17.0 17.4 
  Zambia 2013-14 14719 15.1 (14.2-16.0) 53 (50-56)] 18.3 16.9 17.5 
West and Central Africa and Ethiopia        
  
Burkina 2003 4086 1.5 (1.2-2.0) 1 (1-1) 18.4 17.3 17.4 
  Burkina 2010 8298 1.2 (0.9-1.5) 32 (25-40) 18.6 17.3 17.6 
  Cameroon 2004 5128 6.6 (5.9-7.4) 2 (2-3) 17.1 15.8 16.5 
  Cameroon 2011 7221 5.6 (5.0-6.3) 18 (15-20) 17.7 16.5 17.3 
  Chad 2014-15 5656 1.8 (1.4-2.2) 50 (42-59) 16.7 16.1 16.2 
  Cote Ivoire 2005 4413 6.4 (5.5-7.5) 6 (5-7) 16.9 16.1 16.4 
  Cote Ivoire 2011-12 4509 4.6 (3.9-5.4) 25 (22-27) 17.6 16.3 16.9 
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  DRC 2007 4492 1.6 (1.2-2.2) 5 (4-6) 17.4 16.4 16.9 
  DRC 2013-14 9264 1.6 (1.2-2.2) 24 (19-29) 17.4 16.4 16.8 
  Ethiopia 2005 5736 1.9 (1.4-2.4) 2 (2-3) 20.7 16.1 16.6 
  Ethiopia 2011 14695 1.9 (1.5-2.3) 41 (32-51) 18.3 17.2 17.4 
  Gabon 2012 5459 5.8 (4.7-7.1) 32 (26-38) 17.1 16.7 17.1 
  Gambia 2013 4089 2.1 (1.6-2.8) 24 (18-30) 20.6 18.0 19.3 
  Ghana 2003 5097 2.3 (1.9-2.8) 0 (0-0) 19.4 17.9 18.3 
  Guinea 2005 3742 1.9 (1.4-2.6) 2 (1-2) 16.7 15.9 16.0 
  Guinea 2012 4622 2.1 (1.7-2.6) 28 (21-34) 17.6 15.7 16.3 
  Liberia 2007 6382 1.8 (1.4-2.1) 3 (2-3) 16.6 16.1 16.3 
  Liberia 2013 4397 2.0 (1.5-2.8) 19 (15-24) 16.6 16.0 16.4 
  Mali 2006 4528 1.4 (1.0-2.0) 8 (6-10) 16.8 15.9 16.2 
  Mali 2012-13 4806 1.3 (1.0-1.8) 32 (24-40)] 18.0 16.5 16.8 
  Niger 2006 4406 0.6 (0.4-0.9) 3 (2-4) 17.9 15.6 15.8 
  Niger 2012 5000 0.4 (0.2-0.5) 27 (20-32) 18.7 15.8 16.0 
  Sao Tome 2009 2378 1.3 (0.8-2.0) . 17.6 17.3 17.5 
  Senegal 2005 4229 0.7 (0.4-1.0) 0 21.2 17.5 19.3 
  Senegal 2010-11 5326 0.6 (0.4-0.8) 33 (25-40) 21.1 17.9 19.4 
  Sierra Leone 2008 3448 1.7 (1.3-2.3) 4 (3-5) 16.7 15.7 16.0 
  Sierra Leone 2013 7695 1.7 (1.3-2.0) 21 (13-29) 17.0 16.0 16.4 
    Togo 2013-14 4737 3.1 (2.6-3.7) 37 (27-49) 18.6 17.4 18.1 
* Estimated HIV prevalence, see methods section 
† http://aidsinfo.unaids/, accessed  07 September 2017.  Note for those surveys running over two years the earlier year is given 
‡ICF International, 2015. The DHS Program STATcompiler. http://www.statcompiler.com. September 07 2017 
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Calculating age specific fertility rates 
Each woman respondent was asked birth history questions for up to 20 births, beginning 
with the most recent. Dates of birth of the women and children are given in months and 
years, we assigned the day of birth to be the midpoint of the month.  
 
We initially analysed fertility rates by HIV status during the three years prior to the 
interview. This cut-off was used in previous studies41, 42 to balance the benefits of 
maximizing the person-years of observation while seeking to minimize maternal 
survivorship bias, recall bias and misclassification of HIV status over the three preceding 
years43. However, we report results adjusted for the first year prior to the survey due to 
evidence of persistence of these biases when using data from longer than a year prior 
to the survey (see section 7.2, which shows the analysis). We used the standard 
demographic definition of age-specific fertility rates (ASFR):  
 
— =

		ℎ						 + 4

			 	!	 					 + 4
 
 
we then estimated the fertility rate ratios in the general population.  Subsequently, we 
restricted the analysis to person years after first sex to assess the extent to which 
variation in age at first sex explains fertility differences among HIV positive women and 
HIV negative women in the younger age groups. We assumed sexual debut occurred on 
the date corresponding to the midyear of the reported age at first sex (which is reported 
as an integer age). Age at first sex was changed to nine months before the reported date 
of first birth if this was earlier than the midpoint of reported age at first sex. 
 
Other Variables 
Other variables included women’s HIV status at the time of the survey, calendar year, 
ART coverage, region, and place of residence (urban/rural). Those infected with HIV-2 
and whose HIV test was indeterminate were excluded from the analysis (0.04%).  
 
Countries were grouped into regions as follows: Southern (Zimbabwe, Lesotho, 
Swaziland and Namibia), East and mid- Africa (Tanzania, Kenya, Uganda, Rwanda, 
Burundi, Malawi and Zambia) and West and Central Africa with Ethiopia (Table 7.1). HIV 
epidemics in the East and Mid African countries occurred earlier than in Southern Africa. 
West and central Africa along with Ethiopia have lower prevalence and HIV transmission 
is likely more concentrated.  
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ART coverage estimates were taken from UNAIDS estimates167 of national female adult 
ART coverage at the time of each survey were stratified into categories <20%, 20-49%, 
and >50% (Table 7.1).  For surveys that ran over two different years a midpoint of the 
estimated coverage in both years was taken.  
Analysis  
We used exponential regression to investigate the interaction between HIV status and 
five-year age group, place of residence, region and ART coverage with respect to their 
impacts on fertility. Each analysis was adjusted for country and survey year. The analysis 
was repeated excluding person time prior to first sex. The multivariate Wald test was 
used to assess significance of interaction terms. The first model includes only the 
interaction between age and HIV status controlled for country and year of survey. 
Subsequent models include the effect of place of residence, region and national ART 
coverage and the interactions between them and age and HIV status.  
All models included the three-way interaction between year before the survey, five year 
age group and HIV status. Results are reported for the first year before the interview 
date.  
Analyses were conducted using Stata version 14.1  
7.1.4 Results 
Pooled analysis of DHS surveys 
Model 1 (Table 7.2) estimated the crude fertility rate ratio (FRR) for HIV positive women 
relative to HIV negative women by five-year age group across all countries and surveys, 
adjusted only for calendar year and country. In the 15-19 year age group, fertility was 
1.38 (95% CI 1.19-1.61) times higher in HIV positive women compared to HIV negative 
women, consistent with the fact that for younger ages many women have not yet been 
exposed to sex therefore are also not exposed to HIV. Thereafter, fertility of HIV positive 
relative to HIV negative women decreased with age from a FRR of 0.93 (95%CI 0.85-
1.03) in 20 to 24 year olds to  0.29 (95CI 0.13-0.66) in 45-49 year olds (Figure 7.1, show 
stratum specific ratios derived from Table 7.2, Model 1 along with estimates made by 
Chen and Walker 41).   
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Table 7.2: Adjusted fertility rate ratios for all women aged 15-49 
  Model 1   Model 2 
    FRR 95 %CI   FRR 95 %CI 
HIV status       
 
HIV negative 1
 
1 
 
HIV Positive 0.70(0.63-0.78)  0.62 (0.53-0.73) 
Effects of HIV by age      
 
15-19, HIV positive 1.92(1.59-2.32)  2.39 (1.86-3.08) 
 20-24, HIV positive 1.32(1.15-1.52)  1.54 (1.29-1.85) 
 25-29, HIV positive 1.14(0.99-1.30)  1.31 (1.08-1.59) 
 30-34, HIV positive 1  1 
 
35-39, HIV positive 0.76(0.63-0.92)  0.80 (0.62-1.04) 
 40-44, HIV positive 0.62(0.43-0.87)  0.67 (0.41-1.09) 
 45-49, HIV positive 0.41(0.18-0.95)  0.10 (0.01-0.94) 
Effects of HIV by Place of residence      
 Urban, HIV positive     1 
 
Rural, HIV positive    1.18 (1.02-1.36) 
Effects of Place of residence on age and HIV status interaction   
 
Rural, HIV positive,15-19    0.71 (0.56-0.89) 
 Rural, HIV positive,20-24    0.77 (0.65-0.92) 
 Rural, HIV positive,25-29    0.78 (0.65-0.92) 
 Rural, HIV positive,30-34    1 
 
Rural, HIV positive,35-39    0.91 (0.71-1.16) 
 Rural, HIV positive,40-44    0.91 (0.57-1.44) 
 Rural, HIV positive,45-49    4.71 (0.60-36.8) 
Effects of HIV by Region      
 
Southern, HIV positive    1.12 (1.05-1.20) 
 Eastern, HIV positive     1 
 Western, HIV positive    0.99 (0.91-1.08) 
Effects of HIV by ART Coverage      
 <20%, HIV positive     1 
 
20-49%, HIV positive    1.05 (0.98-1.11) 
 >50%, HIV positive    1.09 (1.01-1.18) 
Age Group       
 
15-19 0.57(0.55-0.60)  0.50 (0.47-0.53) 
 20-24 1.08(1.04-1.12)  0.98 (0.93-1.03) 
 25-29 1.13(1.09-1.17)  1.11 (1.05-1.16) 
 30-34 1  1 
 
35-39 0.76(0.73-0.80)  0.69 (0.65-0.74) 
 40-44 0.33(0.31-0.36)  0.26 (0.23-0.29) 
 45-49 0.09(0.07-0.10)  0.06 (0.05-0.08) 
Place of residence      
 
Urban    1 
 
Rural    1.37 (1.32-1.42) 
Effects of age by Place of residence      
 
Rural, 15-19    1.25 (1.18-1.32) 
 Rural, 20-24    1.18 (1.13-1.23) 
 Rural, 25-29    1.04 (1.00-1.09) 
 Rural, 30-34    1 
 
Rural, 35-39    1.13 (1.06-1.20) 
 Rural, 40-44    1.36 (1.21-1.53) 
 Rural, 45-49    1.58 (1.21-2.06) 
Region        
 
Southern    0.67 (0.64-0.70) 
 Eastern    1 
 
Western    0.72 (0.68-0.77) 
ART Coverage      
 
<20%    1 
 
20-49%    0.96 (0.93-1.00) 
  >50%       0.77 (0.73-0.82) 
Results from exponential regression of fertility rates as a function of HIV status, age controlling for Country and 
calendar year. Also not shown is the additional interaction between years before the survey, HIV status and age 
group.   Model 2 has an additional interaction between place of residence, age group and HIV status, region and 
HIV status, and ART coverage and HIV status. 
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Figure 7.1: Age specific fertility rate ratio comparing HIV positive to HIV negative women in the year 
before the survey, adjusting for country and year and the interaction between years before survey 
and HIV status,  compared to Chen and Walker estimates. 
 
Variation by region and place of residence   
There was a significant interaction between HIV status and region (Table 2, Model 2). In 
Southern Africa, the relative fertility rate of HIV positive compared to HIV negative 
women was 1.12 (95%CI 1.05-1.20) times higher than in the Eastern region (Table 7.2, 
Model 2). West and Central countries were similar to East and Mid Africa (RR 0.99, 95% 
CI 0.91-1.08; Table 7.2, Model 2 and Figure 7.2a). There was no significant interaction 
between region, five-year age group, and HIV status (Wald test F=1.37, p=0.173), 
indicating lack of evidence of regional difference in the relative age pattern of HIV 
subfertility. 
 
For all surveys except two, fertility rates are higher in rural areas than urban areas for 
15-49 year old women whilst HIV prevalence is lower in rural areas compared to urban 
areas (Table 7.3). The statistically significant effect of place of residence on the 
relationship between HIV and fertility (Table 7.2, Model 2) indicates that these 
systematic urban/rural differences in fertility and HIV partially explains the overall lower 
fertility of HIV positive women. In contrast to region, place of residence did significantly 
affect the age-pattern of relative fertility (Wald test F=2.80, p=0.010), with a steeper 
gradient in urban areas than in rural areas (Figure 7.2a). Among 30-34 year olds, the 
relative fertility of women in rural areas was 1.18 (95%CI 1.02-1.36)  times greater than 
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in urban areas, while among 15-19 year olds relative fertility of HIV-positive women 
was 0.83 (95%CI 0.69-0.995) times lower in rural areas than urban.    
 
Figure 7.2: Adjusted Age specific fertility rate ratios comparing HIV positive women to negative 
women by region and Urban and Rural residence (Adjusted for Region, place of residence, the 
effect of five year age group on HIV status and place of residence, ART coverage, Country, 
Calendar year) using all women person years (a) and excluding person years prior to first sex (b) 
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Figure 7.3: Urban, rural fertility rate ratio for HIV negative women (left) and  HIV prevalence urban 
rural ratio (right) on the log scale. In all regions, HIV prevalence was higher while fertility was lower  
in urban areas than rural. This suggests that the lower fertility among HIV positive women may be 
partially confounded by urban/rural differences in fertility and HIV. 
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ART coverage and HIV subfertility   
The fertility differences between HIV positive and HIV negative women slightly reduced 
as ART coverage increased.  With ART coverage at over 50% the fertility rate ratio was 
1.09 times higher (95% CI 1.01-1.18), compared to when ART coverage was below 20%. 
However, overall the fertility of HIV positive women remained significantly lower than that 
of HIV-negative women in recent surveys with high ART coverage. For example in urban 
Southern Africa the fertility rate ratio increased from 0.70 (95%CI 0.59-0.82) in 30-34 
year olds in a time with less than 20% national ART coverage to 0.76 (95%CI 0.64-0.91) 
when there was 50% ART coverage (Figure 7.4, Table 7.2;  Table 7.3). There was no 
evidence that the level of ART coverage affected the age-pattern of relative fertility (Wald 
test F=1.23, p=0.253) 
 
Figure 7.4: Adjusted Age specific fertility rate ratios for Southern Africa comparing HIV positive 
women to negative women by region and National ART coverage  (Adjusted for Region, place of 
residence, the effect of five year age group on HIV status and place of residence, ART coverage, 
Country, Calendar year) 
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Table 7.3: Adjusted age specific fertility rate ratio comparing HIV positive to HIV negative women. 
    Southern Africa   East and Mid Africa   West and Central Africa 
    <20%   20-49%   >50%   <20%   20-49%   >50%   >20%   20-49% 
Urban                               
 15-19  1.65 (1.36- 2.01)   1.72 (1.41- 2.11)   1.84 (1.51- 2.24)   1.48 (1.22- 1.80)   1.55 (1.27- 1.89)   1.65 (1.35- 2.01)   1.48 (1.21- 1.80)   1.54 (1.26- 1.88) 
 20-24  1.07 (0.93- 1.22)   1.11 (0.96- 1.29)   1.19 (1.03- 1.36)   0.96 (0.84- 1.09)   1.00 (0.87- 1.15)   1.07 (0.93- 1.21)   0.96 (0.83- 1.09)   1.00 (0.86- 1.15) 
 25-29  0.90 (0.79- 1.02)   0.94 (0.81- 1.07)   1.00 (0.87- 1.14)   0.80 (0.71- 0.91)   0.84 (0.73- 0.96)   0.89 (0.78- 1.02)   0.80 (0.70- 0.91)   0.84 (0.73- 0.96) 
 30-34  0.69 (0.58- 0.81)   0.72 (0.60- 0.86)   0.76 (0.65- 0.90)   0.62 (0.53- 0.72)   0.64 (0.54- 0.76)   0.68 (0.58- 0.80)   0.61 (0.52- 0.72)   0.64 (0.54- 0.76) 
 35-39  0.53 (0.42- 0.67)   0.56 (0.44- 0.70)   0.59 (0.47- 0.74)   0.48 (0.38- 0.60)   0.50 (0.40- 0.63)   0.53 (0.42- 0.67)   0.48 (0.38- 0.60)   0.50 (0.39- 0.63) 
 40-44  0.44 (0.28- 0.69)   0.46 (0.29- 0.72)   0.49 (0.31- 0.77)   0.39 (0.25- 0.62)   0.41 (0.26- 0.65)   0.44 (0.28- 0.69)   0.39 (0.25- 0.62)   0.41 (0.26- 0.65) 
 45-49  0.07 (0.01- 0.61)   0.07 (0.01- 0.64)   0.07 (0.01- 0.68)   0.06 (0.01- 0.55)   0.06 (0.01- 0.57)   0.07 (0.01- 0.61)   0.06 (0.01- 0.55)   0.06 (0.01- 0.57) 
Rural                
 15-19  1.40 (1.19- 1.66)   1.46 (1.23- 1.74)   1.56 (1.31- 1.85)   1.26 (1.06- 1.49)   1.31 (1.11- 1.56)   1.40 (1.18- 1.66)   1.25 (1.05- 1.49)   1.31 (1.09- 1.56) 
 20-24  0.98 (0.88- 1.10)   1.02 (0.91- 1.15)   1.09 (0.97- 1.23)   0.88 (0.79- 0.98)   0.92 (0.82- 1.04)   0.98 (0.87- 1.10)   0.88 (0.77- 1.00)   0.92 (0.80- 1.04) 
 25-29  0.83 (0.75- 0.91)   0.86 (0.78- 0.96)   0.92 (0.82- 1.02)   0.74 (0.67- 0.82)   0.77 (0.70- 0.86)   0.82 (0.74- 0.92)   0.74 (0.65- 0.84)   0.77 (0.68- 0.87) 
 30-34  0.81 (0.73- 0.91)   0.85 (0.75- 0.96)   0.90 (0.80- 1.02)   0.73 (0.65- 0.82)   0.76 (0.68- 0.86)   0.81 (0.72- 0.92)   0.73 (0.64- 0.83)   0.76 (0.67- 0.86) 
 35-39  0.60 (0.50- 0.71)   0.62 (0.53- 0.74)   0.66 (0.56- 0.79)   0.54 (0.45- 0.63)   0.56 (0.47- 0.66)   0.60 (0.50- 0.71)   0.53 (0.44- 0.64)   0.56 (0.47- 0.67) 
 40-44  0.49 (0.35- 0.70)   0.51 (0.36- 0.73)   0.55 (0.39- 0.77)   0.44 (0.31- 0.63)   0.46 (0.32- 0.65)   0.49 (0.34- 0.70)   0.44 (0.31- 0.63)   0.46 (0.32- 0.66) 
  45-49  0.39 (0.17- 0.87)    0.41 (0.18- 0.91)    0.43 (0.19- 0.97)    0.35 (0.16- 0.78)    0.36 (0.16- 0.82)    0.39 (0.17- 0.87)    0.35 (0.15- 0.78)    0.36 (0.16- 0.82) 
Model:   hivstatusXagegrp hivstatusXagegrpXresidence  coverageXhivstatus epigrpXhivstatus yearbeforeXi.hivstatusXagegrp_fiveyr year country  
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HIV and fertility among women who have ever had sex 
Across surveys, we observed consistently higher median age at first sex among young 
women in urban areas compared to rural areas and in southern African countries 
compared to east Africa and west and central Africa (Table 7.1). This suggests that some 
of the variation in the relative fertility of HIV positive women at the youngest ages (Figure 
7.2a) may be attributable to systematic differences in the age at sexual debut.  We 
replicated the above models, excluding person years prior to first sex (Table 7.4).  
Removing the person years of women who had not become sexually active completely 
explained the higher fertility among HIV positive women aged under 25 compared to HIV 
negative women (figure 1b shows the stratum specific rate ratios derived from Table 7.4, 
model 2). In all regional, place of residence and ART coverage groups, the fertility of HIV 
positive women aged 15-19 was not significantly different to that of HIV negative women 
when excluding person time prior to first sex (Table 7.4, Figure 7.2b; Table 7.5). 
Excluding person time prior to first sex gave a relative fertility rate ratio of 0.92 (95% CI 
0.76-1.11) for 15-19 year old women in urban areas, compared to 1.49 (95% CI 1.22-
1.82) when analysing all women. Similarly, in rural areas the FRR for 15-19 year olds 
was 0.89 (95%CI 0.76-1.05) after excluding person years prior to first sex, compared to 
1.23 (95%CI 1.04-1.47) for all person years. For 20-24 year olds, the relative fertility of 
HIV positive women fell, and in many cases was significantly lower than that of HIV-
negative women (p<0.05) when restricted to sexually active women (Figure 7.2b; Table 
7.5). The effect of age on the interaction between place of residence remained but was 
reduced at younger ages. After restricting to person years for women after first sex, the 
differences in the relative fertility for women under age 25 by place of residence and 
differences by region were substantially reduced (Figure 7.2b; Table 7.3 and Table 7.5). 
For example for 15-19 year olds the relative fertility rate ratio was the same in the urban 
and rural areas (interaction term 0.95, 95%CI 0.80-1.13 compared to 0.83, 95%CI 0.69-
0.995 when including all women’s person time).  
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Table 7.4: Adjusted fertility rate ratios for those women aged 15-49 excluding person years prior to 
first sex  
  Model 1   Model 2 
    FRR 95 %CI   FRR 95 %CI 
HIV status       
 
HIV negative 1 
 
1 
 
HIV Positive 0.69 (0.62-0.77)  0.59 (0.51-0.69) 
Effects of HIV by age      
 
15-19, HIV positive 1.33 (1.11-1.60)  1.55 (1.21-1.98) 
 20-24, HIV positive 1.20 (1.05-1.38)  1.36 (1.13-1.63) 
 25-29, HIV positive 1.12 (0.97-1.29)  1.29 (1.06-1.56) 
 30-34, HIV positive 1  1 
 
35-39, HIV positive 0.77 (0.63-0.92)  0.81 (0.62-1.04) 
 40-44, HIV positive 0.62 (0.44-0.88)  0.67 (0.41-1.10) 
 45-49, HIV positive 0.42 (0.18-0.96)  0.10 (0.01-0.96) 
Effects of HIV by Place of residence      
 Urban, HIV positive     1 
 
Rural, HIV positive    1.21 (1.05-1.40) 
Effects of Place of residence on age and HIV status interaction   
 
Rural, HIV positive,15-19    0.78 (0.63-0.98) 
 Rural, HIV positive,20-24    0.82 (0.69-0.98) 
 Rural, HIV positive,25-29    0.78 (0.65-0.93) 
 Rural, HIV positive,30-34    1 
 
Rural, HIV positive,35-39    0.90 (0.71-1.16) 
 Rural, HIV positive,40-44    0.90 (0.57-1.42) 
 Rural, HIV positive,45-49    4.65 (0.6-36.32) 
Effects of HIV by Region      
 
Southern, HIV positive    1.09 (1.02-1.16) 
 Eastern, HIV positive     1 
 Western, HIV positive    1.05 (0.96-1.14) 
Effects of HIV by ART Coverage      
 <20%, HIV positive     1 
 
20-49%, HIV positive    1.04 (0.98-1.11) 
 >50%, HIV positive    1.13 (1.05-1.22) 
Age Group       
 
15-19 1.20 (1.15-1.24)  1.16 (1.10-1.22) 
 20-24 1.22 (1.17-1.26)  1.16 (1.10-1.22) 
 25-29 1.15 (1.11-1.20)  1.14 (1.08-1.20) 
 30-34 1  1 
 
35-39 0.76 (0.73-0.80)  0.69 (0.64-0.74) 
 40-44 0.33 (0.31-0.35)  0.25 (0.23-0.28) 
 45-49 0.08 (0.07-0.10)  0.06 (0.04-0.07) 
Place of residence      
 
Urban    1 
 
Rural    1.32 (1.27-1.37) 
Effects of age by Place of residence      
 
Rural, 15-19    1.05 (1.00-1.10) 
 Rural, 20-24    1.08 (1.04-1.13) 
 Rural, 25-29    1.03 (0.98-1.08) 
 Rural, 30-34    1 
 
Rural, 35-39    1.13 (1.06-1.21) 
 Rural, 40-44    1.37 (1.22-1.53) 
 Rural, 45-49    1.59 (1.22-2.07) 
Region        
 
Southern    0.74 (0.71-0.77) 
 Eastern    1 
 
Western    0.72 (0.68-0.76) 
ART Coverage      
 
<20%    1 
 
20-49%    0.96 (0.92-0.99) 
  >50%       0.76 (0.72-0.80) 
Results from exponential regression of fertility rates as a function of HIV status, age controlling for Country and calendar year.  Also not shown is the 
additional interaction between years before the survey, HIV status and age group.    Model 2 has an additional interaction between place of residence, 
age group and HIV status, region and HIV status, and ART coverage and HIV status. 
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Table 7.5: Adjusted age specific fertility rate ratio comparing HIV positive to HIV negative excluding person time prior to first sex. 
Sexually Southern Africa   East and Mid Africa   West and Central Africa 
Active <20%   20-49%   >50%   <20%   20-49%   >50%   >20%   20-49% 
Urban                               
 15-19 0.99 (0.82-1.20)  1.02 (0.84-1.24)  1.13 (0.93-1.37)  0.92 (0.76-1.11)  0.95 (0.78-1.15)  1.05 (0.86-1.27)  0.97 (0.80-1.17)  1.00 (0.83-1.21) 
 20-24 0.87 (0.76-0.99)  0.90 (0.77-1.04)  0.99 (0.86-1.13)  0.81 (0.71-0.91)  0.83 (0.72-0.96)  0.92 (0.81-1.04)  0.85 (0.74-0.97)  0.88 (0.76-1.01) 
 25-29 0.82 (0.72-0.93)  0.84 (0.74-0.97)  0.93 (0.82-1.06)  0.76 (0.67-0.86)  0.78 (0.68-0.89)  0.86 (0.76-0.98)  0.80 (0.70-0.91)  0.83 (0.72-0.94) 
 30-34 0.63 (0.54-0.75)  0.66 (0.55-0.78)  0.72 (0.61-0.85)  0.59 (0.50-0.69)  0.61 (0.51-0.72)  0.67 (0.57-0.78)  0.62 (0.53-0.73)  0.64 (0.54-0.76) 
 35-39 0.50 (0.40-0.62)  0.51 (0.41-0.64)  0.56 (0.45-0.70)  0.46 (0.37-0.58)  0.48 (0.38-0.60)  0.52 (0.42-0.66)  0.48 (0.39-0.61)  0.50 (0.40-0.63) 
 40-44 0.41 (0.26-0.64)  0.42 (0.27-0.66)  0.46 (0.30-0.73)  0.38 (0.24-0.59)  0.39 (0.25-0.62)  0.43 (0.27-0.68)  0.40 (0.25-0.63)  0.41 (0.26-0.65) 
 45-49 0.06 (0.01-0.58)  0.06 (0.01-0.60)  0.07 (0.01-0.66)  0.06 (0.01-0.54)  0.06 (0.01-0.56)  0.07 (0.01-0.62)  0.06 (0.01-0.57)  0.06 (0.01-0.59) 
Rural                
 15-19 0.96 (0.82-1.13)  0.99 (0.84-1.17)  1.10 (0.93-1.29)  0.89 (0.76-1.05)  0.92 (0.78-1.09)  1.02 (0.86-1.20)  0.94 (0.80-1.11)  0.97 (0.82-1.15) 
 20-24 0.86 (0.78-0.96)  0.89 (0.80-1.01)  0.99 (0.88-1.11)  0.80 (0.72-0.89)  0.83 (0.74-0.93)  0.91 (0.81-1.03)  0.85 (0.75-0.96)  0.88 (0.77-0.99) 
 25-29 0.77 (0.70-0.85)  0.79 (0.72-0.88)  0.88 (0.79-0.98)  0.71 (0.64-0.79)  0.74 (0.67-0.82)  0.81 (0.73-0.91)  0.75 (0.66-0.85)  0.78 (0.69-0.88) 
 30-34 0.77 (0.69-0.86)  0.80 (0.71-0.90)  0.88 (0.78-0.99)  0.72 (0.64-0.80)  0.74 (0.66-0.83)  0.81 (0.72-0.92)  0.75 (0.66-0.86)  0.78 (0.69-0.89) 
 35-39 0.55 (0.47-0.66)  0.57 (0.48-0.68)  0.63 (0.53-0.75)  0.51 (0.43-0.61)  0.53 (0.45-0.63)  0.59 (0.49-0.70)  0.54 (0.45-0.65)  0.56 (0.47-0.67) 
 40-44 0.46 (0.32-0.65)  0.47 (0.33-0.67)  0.52 (0.37-0.74)  0.42 (0.30-0.60)  0.44 (0.31-0.62)  0.48 (0.34-0.69)  0.45 (0.31-0.64)  0.46 (0.32-0.66) 
  45-49 0.37 (0.17-0.83)   0.39 (0.17-0.86)   0.42 (0.19-0.95)   0.35 (0.15-0.78)   0.36 (0.16-0.80)   0.39 (0.18-0.88)   0.36 (0.16-0.82)   0.38 (0.17-0.85) 
Model:   hivstatusXagegrp hivstatusXagegrpXresidence  coverageXhivstatus epigrpXhivstatus yearbeforeXi.hivstatusXagegrp_fiveyr year country if sexually active   
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7.1.5 Discussion 
This analysis has shown that overall subfertility attributable to HIV is slightly less 
pronounced than previously thought, and we find that it varies across settings. Consistent 
regional and urban/rural differences have been found, which are largely explained by 
variation in age at first sex. The fertility differential between HIV positive and HIV negative 
women appears to have narrowed in recent years as ART coverage has increased, 
however caution is required in attributing this directly to ART.    
 
We corroborated patterns found in previous studies showing increasing HIV-associated 
subfertility with age41, 43, 72. Also consistent with these other studies, we find that in the 
youngest age group HIV positive women have higher fertility than their HIV negative 
counterparts as many women in this age group are not sexually active and therefore are 
not exposed to either HIV or pregnancy. Chen and Walker reported a strong relationship 
between the percentage of 15-19 year olds who are sexually active and the fertility rate 
ratio among this age group41. We extended this to show that when restricting analysis of 
fertility to women who had sexually debuted there was no difference in the fertility of HIV-
positive and HIV-negative women, suggesting that selection for sexually active women 
completely explains the increased fertility of HIV positive women in this age group. 
Variation in age at first sex largely explained regional and place of residence differences 
in relative fertility.  West and Central Africa overall have a much lower median age at first 
sex than both East and Southern Africa at around 15-16 years old compared to 18-19 
years old in the Southern African countries (Table 1).  The median age at sexual debut 
is higher in urban compared to rural areas (Table 1), and again, once person years before 
sexual debut are removed from the analysis there is no significant difference in relative 
fertility between urban and rural residency for women under 30. At older ages, HIV-
associated subfertility is more pronounced in the urban areas. This could be explained 
by differences in sexual activity between rural and urban areas168, influenced by 
differences in social norms, desired family size, knowledge of HIV status and access to 
services that may influence contraceptive use or abstinence from sex. In addition to 
systematic differences in sexual debut, regions also differed in the scale of HIV 
epidemics and the stage of the epidemic at the time when surveys have been collected.   
This analysis suggests that the relationship between HIV and fertility has attenuated 
slightly since the introduction of ART, but overall fertility remains significantly lower 
among HIV positive women than HIV negative women. These reductions are somewhat 
less dramatic than predicted by current estimates of PMTCT need published by UNAIDS 
using the Spectrum model, which assumes that women on ART for more than six months 
have the same fertility as HIV negative women of the same age. For example, under this 
assumption a 50% increase in ART coverage would attenuate the overall FRR of HIV 
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positive women from 0.7 times that of HIV negative women to 0.85. This is an increase 
of 1.21 times, somewhat greater than the 1.11 times increase that we estimated for 
survey periods with ART coverage >50% compared to those <20%. There was no 
evidence that the effect of ART coverage on HIV subfertility varied by age. Since the 
differences in HIV-associated subfertility by national ART coverage are small it is 
possible that we did not have the power to detect any further differences by age.  National 
ART coverage is an ecological variable. It does not measure individual exposure to 
treatment, and hence we are cautious about attributing causality, for example countries 
with better roll out of ART may also have other things in common such as good health 
systems, with better provision of family planning services. 
 
We find substantially less HIV-associated subfertility compared to Chen and Walker41 in 
women aged below 35 and more HIV-associated subfertility at older ages.  A number of 
factors can explain these differences. Chen and Walker had fewer surveys than were 
used in this analysis and did not adjust for place of residence or region, which we showed 
confounds the relationship between HIV and fertility because of systematically lower 
fertility in urban areas which also have higher HIV prevalence. The surveys used in the 
Chen and Walker analysis were predominantly from East, West and Central Africa where 
HIV-associated subfertility is more pronounced than in Southern Africa. We looked at 
data for the three years prior to the survey when constructing our models as did Chen 
and Walker, however we only report results from the first year before the survey due to 
evidence that using data beyond one year exaggerated the HIV-associated subfertility in 
younger women (see document, Supplemental Digital Content 1). We also find 
substantially lower subfertility using the DHS data than we did using data from the 
demographic surveillance sites in Eastern and Southern Africa43. Much of these DSS 
data are from rural populations around Lake Victoria in East Africa that experienced early 
and severe HIV epidemics, all factors that we expect to be associated with greater 
subfertility based on this multi-country analysis.  
 
There are a number of recommendations arising from these analyses for improving 
estimates and predictions of need for PMTCT services. We found evidence for variation 
across regions, with less HIV associated sub fertility in Southern Africa, but no evidence 
of differences by age pattern. This suggests that scaling the estimated age pattern of 
relative fertility of HIV-positive women to reflect overall prevalence among pregnant 
women observed through routine HIV testing may be a reasonable approach to 
calibrating and reflecting variation across countries and settings.  There are significant 
differences in the pattern of relative fertility by urban/rural residency, which appeared to 
be largely explained by older sexual debut in urban areas. This should be accounted for 
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in planning and allocating resources for PMTCT at the subnational level and evaluating 
local progress towards MTCT elimination. Finally, the relationship between HIV and 
fertility has attenuated slightly since ART has been introduced, supporting the current 
practice to account for ART coverage when predicting fertility of HIV positive women and 
need for PMTCT. However, overall the reductions are somewhat less dramatic than 
predicted by current Spectrum assumptions and fertility remains lower among HIV 
positive women than HIV negative women at older ages. Overall, we have characterised 
the fertility patterns of HIV positive women over time and across regions in sub-Saharan 
Africa as ART scaled up from the mid 2000s through 2015. However, they could continue 
to evolve rapidly as HIV treatment and prevention programmes enter a new era. 
Improving timely data about the fertility patterns of HIV positive women and deeper 
understanding of the mechanisms underlying changes will be important to plan and 
evaluate PMTCT policy and monitor epidemic trends.        
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7.2 Possible biases in the analysis of HIV and fertility (Appendix 
one of PAPER E expanded) 
 
7.2.1  Introduction 
Analysis of population level effects of HIV on fertility has relied on two types of studies, 
first retrospective data from demographic and health surveys (DHS)1 with HIV testing2, 
second data from community based HIV cohort studies3, 4.  Demographic and Health 
Surveys have the advantage that they are large nationally representative surveys across 
sub Saharan Africa whereas community based cohort studies are usually not nationally 
representative and do not cover much of sub-Saharan Africa.   However, community 
based HIV cohort studies could be seen as the gold standard as they prospectively test 
participants for HIV and record births and other demographic characteristics.  This 
means that HIV status of the mother at the birth of the child is known, in contrast to using 
retrospective data, which requires us to assume that the HIV status of the women at time 
of interview is the same as her HIV status in the time prior to the survey.  Retrospective 
surveys are also subject to survivorship bias, since not all women of childbearing age in 
the sample households survive to time of interview.  Women who die prematurely are 
likely to have experienced a serious illness, such as AIDS, and during the time of serious 
illness they are likely to have low fertility.    Both data sources can be affected by 
underreporting of young infant deaths, which are more likely to occur to HIV positive 
women, due to recall bias 5.  However if we use only the most recent years before the 
surveys it is possible that DHS data are less affected by this bias as they directly ask the 
woman herself about her births as opposed to community based cohort studies which 
often use proxy respondents to report experiences of family members.   
 
7.2.2  Methods 
Identifying biases in retrospective data used to analyse HIV subfertility  
We started the analysis reported in the manuscript using the standard cut off of three 
years prior to the survey.  This standard is used by DHS in reporting general fertility 
rates6, and was adopted by previous studies of HIV and fertility2.  This cut off for fertility 
analysis is chosen to balance the desire for maximizing the retrospective person years 
of observation while minimizing biases from using retrospective data.  Table A1 
summarises the potential biases that are known to occur in using retrospective birth 
reports to analyse fertility, many of which vary with age. 
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Using the same methods as outlined in the main paper we used exponential regression 
to estimate the interaction between single years before the survey and its effect on the 
age pattern of HIV subfertility.  The model included HIV status and five year age group, 
single years before the survey and adjusted for country and survey year.  
 
Using DHS data to model the possible extent of bias in DSS data due to under-reporting 
of early infant deaths. 
Whereas all the bias categories listed in Table 7.6 can affect retrospective fertility data 
collected in DHS, only the last one (under-reporting of births leading to infant deaths) 
can occur in prospectively collected data, such as are obtained in demographic 
surveillance systems (DSS).  This kind of under-reporting will occur if the birth and the 
subsequent infant death occur within the same inter-survey interval, and may be more 
severe if proxy reporting is allowed, rather than obtaining reports from the mother herself.  
Early infant deaths will disproportionality affect HIV positive women due to high mortality 
of children who are vertically infected with HIV13, and this concentration of infant deaths 
would be more pronounced in the years prior to antiretroviral treatment given for the 
prevention of mother to child transmission (PMTCT).   
 
We ran our analysis using a similar model to Marston et al43 allowing for interaction 
between HIV status and five-year age group and adjusting for place of residence, country 
and calendar year.  We used data for only one year before the DHS survey simulating a 
DSS survey with an inter survey interval of one year, with no key informant reporting 
events during the inter-survey interval.  We ran the model to simulate a total lack of 
reporting of births resulting in neonatal deaths and then more extreme scenarios, 
excluding any birth than resulted in a death within half a year and within one year.   
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Table 7.6: Biases affecting the use of retrospective data to measure HIV-associated subfertility 
Nature of bias Direction of bias Age groups affected 
Survivorship bias: women who have been infected for longer are 
more likely to have died before being interviewed.  They are also 
more likely to have much lower fertility due to illness, but are not 
included in the analysis  
 
Fertility of HIV positive 
women is over-
estimated,    so HIV-
associated sub-fertility 
is understated 
More in older women as they are more likely to have 
been infected for longer and are thus at higher risk of 
dying 
Age eligibility: survey eligibility is limited to ages of 15-49, therefore 
women aged 47+ in the three years prior to the survey may no 
longer be eligible to participate on the survey date.  The 
composition of the oldest age group skews to the younger ages, 
where fertility is higher.  
 
Fertility of HIV positive 
women is over-
estimated,    so HIV-
associated sub-fertility 
is understated  
Only the 45-49 year old age group is affected 
HIV status miss-classification (i): women who sero-convert in the 
analysis interval, and who have a birth before sero-conversion will 
be wrongly classified as contributing births (and person-years) to HIV 
positive fertility 
Fertility of HIV positive 
women is over-
estimated,    so HIV-
associated sub-fertility 
is understated  
This bias would be greatest at ages in which HIV 
incidence is highest, generally ages 20-34.  
HIV status miss-classification (ii): women who sero-convert in the 
analysis interval, and who have a birth after sero-conversion will 
have too many person-years (but not too few births) classified as 
contributing to HIV positive fertility 
Fertility of HIV positive 
women is under-
estimated,    so HIV-
associated sub-fertility 
is exaggerated 
This bias will be greatest if sero-conversion occurs 
close to the age of sexual debut, or formation of first 
regular sexual union, when births are more likely to 
occur after sero-conversion, so the age group most 
strongly affected will be 15-24 
 194 
 
Nature of bias Direction of bias Age groups affected 
HIV status miss-classification (iii): Women who sero-convert in the 
analysis interval, and who have no birth will have too many person-
years classified as contributing to HIV positive fertility.  
 
 
 
Fertility of HIV positive 
women is under-
estimated,    so HIV-
associated sub-fertility 
is exaggerated 
This bias would be greatest at ages in which HIV 
incidence is highest, generally ages 20-34.  
Under-reporting of births of infants who die:  Births that result in 
early neonatal and infant deaths tend to be underreported 
especially those which occurred further back in time.   Since children 
of HIV positive women have higher mortality, especially before 
PMTCT services were widespread, this kind of under-reporting will 
be more frequent in HIV positive women 
Fertility of HIV positive 
women is under-
estimated, so HIV-
associated sub-fertility 
is exaggerated  
Affects all age groups, but likely to diminish in 
importance over time, as roll-out of PMTCT services 
improves mortality of children of HIV positive mothers 
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7.2.3  Results 
Analysis of biases using retrospective data to analyse HIV subfertility  
First, we investigated possible biases in using the retrospective data for three years prior 
to the survey.  We fitted a simple model with HIV status, age group and the interaction 
between the two, adjusted for country and calendar year as shown in section 7.1  (Table 
7.2, Model 1).   We introduced the variable representing the first, second and third year 
before the survey and tested it’s interaction with HIV status, this showed a significant 
decrease in the fertility rate ratio comparing HIV positive women to HIV negative women 
of 0.91 (0.85-0.98) and 0.94 (0.87-1.01) times in the second and third year compared to 
the first year respectively (Wald test for interaction p=0.073).   
 
We also looked at how age affected the interaction between years before the survey and 
HIV status (Table 7.7, model 1).  We found that the interaction between HIV status and 
years before the survey appeared to work in different directions.  For women under 30 
years HIV-associated subfertility was more pronounced if we used data further back than 
one year compared to the first year.  The fertility rate ratio comparing positives to 
negatives decreasing by 0.86 (95%CI 0.79-0.94) and 0.89 (95%CI 0.81-0.97) in the 2nd 
and 3rd year respectively (Table 7.7, Model 2).   For those aged 30 years and over, HIV-
associated subfertility was less pronounced as a result of using data going back further 
than one year, although this was not significant (Table 7.7, Model 3). Table 7.8 and 
Figure 7.5 show the resultant adjusted age specific rate ratios by years used prior to the 
survey.   
 
Analysis of possible biases in DSS due to under reporting of births ending in early infant 
deaths  
Births that occurred in the year before the surveys ended in death for a higher percentage 
of HIV positive women compared to HIV negative women.   Excluding deaths occurring 
to children born in the interval before the age of six months, the effects were largest in 
the women aged 25-29 years, with 10.2% of births excluded in HIV positive women 
compared to 3.3% in HIV negative women (Table 7.9).  The exclusion of births that ended 
in neonatal death gave an increase in subfertility of 5.5% in the youngest age group and 
was lowest at 1.1% in the 20-24 year old age group.  The extreme of excluding any birth 
that ended in a death in the interval gave an 11% increase in subfertility in the 15-19 year 
olds, 8.2% in the 30-34 year olds and between 3-6% in the remaining groups (Table 7.9).  
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Table 7.7: Adjusted fertility rate ratios for all women, women under 30 and women over 30 to demonstrate the significant decrease in HIV subfertility in women under 30 
when looking beyond one year prior to the survey. 
  All women   All women   Women <30   Women 30+ 
    FRR 95 %CI Wald   FRR 95 %CI Wald   FRR 95 %CI Wald   FRR 95 %CI Wald 
HIV status                 
 HIV negative     1   1   1  
 HIV Positive 0.74(0.68-0.79) >0.001  0.70 (0.63-0.78) >0.001  0.77(0.71-0.82) >0.001 0.73(0.67-0.80) >0.001 
Age group              
15-19 0.59(0.57-0.60)  0.57 (0.55-0.59)  0.51(0.50-0.52)     
20-24 1.12(1.10-1.14)  1.08 (1.04-1.12)  0.97(0.95-0.99)     
25-29 1.15(1.13-1.17)  1.13 (1.09-1.17)  1.00 >0.001    
30-34 1  1     1  
35-39 0.76(0.75-0.78)  0.77 (0.73-0.80)     0.76(0.75-0.78)  
40-44 0.35(0.34-0.36)  0.33 (0.31-0.36)     0.35(0.34-0.36)  
45-49 0.11(0.10-0.12) >0.001 0.09 (0.07-0.10) >0.001     0.11(0.10-0.12) >0.001 
Effects of HIV by age             
15-19, HIV positive 1.83(1.66-2.03)  1.97 (1.64-2.37)  1.79(1.62-1.97)     
20-24, HIV positive 1.22(1.12-1.32)  1.33 (1.16-1.53)  1.18(1.09-1.27)     
25-29, HIV positive 1.03(0.95-1.11)  1.13 (0.98-1.29)  1 >0.001    
30-34, HIV positive 1  1     1  
35-39, HIV positive 0.81(0.73-0.91)  0.75 (0.62-0.91)     0.81(0.73-0.91)  
40-44, HIV positive 0.65(0.53-0.78)  0.60 (0.43-0.85)     0.65(0.53-0.78)  
45-49, HIV positive 0.41(0.24-0.69) >0.001  0.41 (0.18-0.94) >0.001     0.41(0.25-0.69) >0.001 
Year before survey             
1st 1  1  1  1  
2nd 0.94(0.92-0.96)  0.89 (0.86-0.94)  0.96(0.94-0.98)  0.90(0.87-0.93)  
3rd 0.95(0.94-0.97) >0.001  0.94 (0.90-0.98) >0.001  0.96(0.94-0.98) >0.001 0.95(0.91-0.98) >0.001 
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Effects of HIV by years before survey             
2nd  year, HIV positive 0.92(0.86-0.99)  0.96 (0.81-1.15)  0.87(0.79-0.95)  1.03(0.91-1.18)  
3rd year, HIV positive 0.94(0.88-1.01) 0.073  1.05 (0.90-1.21) 0.639  0.89(0.82-0.97) 0.003  1.04(0.93-1.17) 0.764 
Effects of yearbefore on age and HIV status interaction             
2nd  year, HIV positive, 15-19  0.94 (0.71-1.24)         
2nd  year, HIV positive, 20-24  0.90 (0.72-1.13)         
2nd  year, HIV positive, 25-29  0.89 (0.71-1.11)         
 2nd  year, HIV positive, 30-34  1         
 2nd  year, HIV positive, 35-39  1.29 (0.96-1.73)         
 2nd  year, HIV positive, 40-44  1.03 (0.63-1.69)         
 2nd  year, HIV positive, 45-49  1.66 (0.54-5.06)         
 3rd year, HIV positive, 15-19  0.86 (0.67-1.11)         
 3rd year, HIV positive, 20-24  0.85 (0.70-1.03)         
 3rd year, HIV positive, 25-29  0.85 (0.70-1.05)         
 3rd year, HIV positive,30-34  1         
 3rd year, HIV positive, 35-39  0.99 (0.76-1.29)         
 3rd year, HIV positive, 40-44  1.20 (0.76-1.90)         
  3rd year, HIV positive, 45-49    0.34 (0.06-2.07) 0.146                 
Note: The country and calendar year variables are not shown 
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Table 7.8: Fertility rate ratios by five year age group and year before the survey from exponential 
regression model using all women in Table 7.7 
Age group 
Year before the survey 
1st year  2
nd year  3
rd year 
FRR 95% CI   FRR 95% CI   FRR 95% CI 
15-19 1.38 (1.19-1.61)   1.25 (1.08-1.44)   1.25 (1.09-1.43) 
20-24 0.93 (0.85-1.03)  0.81 (0.73-0.89)  0.83 (0.75-0.91) 
25-29 0.79 (0.72-0.86) 
 
0.68 (0.61-0.74) 
 
0.71 (0.63-0.79) 
30-34 0.70 (0.63-0.78) 
 
0.68 (0.59-0.77) 
 
0.73 (0.66-0.82) 
35-39 0.53 (0.45-0.62) 
 
0.65 (0.55-0.77) 
 
0.55 (0.47-0.64) 
40-44 0.42 (0.30-0.59)  0.42 (0.30-0.58)  0.53 (0.40-0.71) 
45-49 0.29 (0.13-0.66)   0.46 (0.22-0.97)   0.10 (0.02-0.52) 
 
 
 
Figure 7.5: Fertility rate ratios by five year age group and year before the survey from exponential 
regression model using all women in Table 7.7 
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Table 7.9: Change in Age Specific fertility rate ratio if and birth ending in neonatal, less than six or twelve months in the previous year to the survey was missed.   
Womens 
age  
No exclusion  Neonatal deaths   Deaths before six months   Deaths before one year   
FRR 95% CI 
Births 
excluded (%) 
FRR 95% CI 
Decrease 
in FRR 
Births 
excluded (%) 
FRR 95% CI 
decrease in 
FRR 
Births 
excluded (%) 
FRR 95% CI 
Decrease in 
FRR 
HIV 
 -ve 
HIV 
+ve 
(%) 
HIV 
 -ve 
HIV 
+ve 
(%) 
HIV 
 -ve 
HIV 
+ve 
(%) 
15-19 1.41 (1.22-1.64) 4.1 9.2 1.33 (1.14-1.56) 5.5 5.1 12.8 1.30 (1.11-1.52) 8.2 5.1 12.8 1.26 (1.07-1.48) 11.0 
20-24 0.98 (0.89-1.08) 3.0 3.9 0.97 (0.87-1.07) 1.1 3.8 6.9 0.94 (0.85-1.05) 3.2 3.8 6.9 0.94 (0.85-1.04) 3.8 
25-29 0.84 (0.77-0.92) 2.6 6.0 0.81 (0.74-0.89) 3.6 3.3 10.2 0.78 (0.71-0.85) 7.4 3.3 10.2 0.77 (0.70-0.85) 8.2 
30-34 0.75 (0.68-0.84) 3.1 4.2 0.74 (0.67-0.83) 1.4 4.1 8.2 0.72 (0.64-0.80) 4.5 4.1 8.2 0.71 (0.64-0.79) 5.8 
35-39 0.57 (0.49-0.67) 4.0 6.3 0.56 (0.47-0.65) 2.6 4.7 9.0 0.54 (0.46-0.64) 4.9 4.7 9.0 0.54 (0.46-0.64) 4.8 
40-44 0.45 (0.33-0.62) 4.2 6.6 0.44 (0.31-0.62) 2.7 5.6 6.6 0.44 (0.32-0.62) 1.5 5.6 6.6 0.43 (0.30-0.61) 4.9 
45-49 0.30 (0.13-0.68) 11.3 0.0 0.34 (0.15-0.77) -12.4 14.1 0.0 0.35 (0.15-0.79) -16.0 14.1 0.0 0.35 (0.15-0.79) -15.8 
Model: hivstatusXagegrp_fiveyr resid year country if yearbefore==1 
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7.2.4 Discussion 
We found evidence of biases when using retrospective data for analysis of subfertility.   
Using data beyond one year increased the subfertility in younger women and slightly 
increased it for older women although this was not significant.  Older women are likely 
to have been infected with HIV for longer than younger women –  this means that 
survivorship bias would be greater for older women, as with longer duration of infection 
they are likely to be less fertile 4 and less likely to survive to be interviewed.   For younger 
women the assumption that they have been HIV positive for several years before the 
survey will be less true than for older women who are more likely to have sero converted 
long ago.  Therefore the assumption of constant retrospective HIV status at younger 
ages would be expected to cause a larger misclassification of person years by HIV 
status: more negative person years will be wrongly classified as HIV positive in younger 
women, which would tend to decrease the apparent extent of their subfertility.  However, 
we found the overall bias in the measurement of subfertility in younger women related to 
increasing the number of years of retrospective data used in the analysis went in the 
opposite direction.  One possible reason for this is that the HIV negative time for younger 
women immediately prior to sero conversion is dominated by time prior to entry into first 
sexual union, or indeed prior to sexual debut, when women are not yet exposed to risk 
of conception or HIV acquisition.  This coupled with all the person years when a women 
does not have a birth during a sero conversion interval being assigned to HIV positive 
women, would tend to exaggerate the extent of subfertility in the HIV positive group 
mirroring our observations.    
 
Researchers should be aware of the many possible biases when analysing population 
based data on HIV and fertility, and try to minimise them.  The biases found in this study 
show that biases in estimates of HIV sub fertility are strongly influenced by the age of 
the woman, and can be minimised by curtailing the analysis to the year immediately 
preceding the survey.      
 
We also used the DHS data to investigate the impact of missing neonatal and young 
infant deaths in when using Demographic Surveillance to estimate the extent of HIV-
associated subfertility.  Our modelling showed that such omissions cannot explain the 
differences in the estimates obtained from the present analysis of the pooled DHS data 
to the estimates obtained in the analysis of community based cohort studies by Marston 
et al 43 
  
 201 
 
 
8 PAPER F: Relative patterns of sexual activity and 
fertility among HIV positive and negative women – 
evidence from 46 DHS 
 
For objective 7 of the PhD: To identify how behaviour contributes to HIV subfertility in 
order to gain a better understanding of the contribution it makes to differences in fertility 
by HIV status; an analysis was conducted using data from demographic and health 
surveys and has been submitted to PLoS ONE:  
 
8.1 Introduction to paper 
Both papers C and E found at the population level only a slight narrowing of the 
differences between HIV positive and HIV negative women in the era of ART.   This along 
with a systematic review73 which concluded that that evidence indicated that fertility 
increases after the first year on ART but remains lower than in HIV negative women of 
the same age, stimulated a call for more research to try to understand the mechanisms 
behind the differences in fertility by HIV status.  This is necessary in order to better 
estimate and project the number of pregnant women in need of PMTCT services and to 
estimate the incidence and prevalence of paediatric HIV48.  Paper E provided evidence 
of regional and urban and rural variation in HIV subfertility.  It also showed that these 
differences at younger ages could be largely be explained by varying age at sexual 
debut, demonstrating that at young ages sexual behaviour has an impact on fertility 
differentials by HIV status. In order to shed more light on the mechanisms for the 
differences in fertility by HIV status it is important to assess how much of the HIV 
subfertility seen in populations with generalised HIV epidemics could be directly due to 
sexual behaviour. 
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8.2 Abstract  
 
Objectives  
Projections of fertility of HIV positive women as ART scales up are needed to plan 
prevention of mother-to-child transmission (PMTCT) services. We describe differences 
in exposure to pregnancy between HIV positive and HIV negative women by age, region 
and national ART coverage to evaluate the extent to which behavioural differences 
explain lower fertility among HIV positive women and assess whether exposure to 
pregnancy has changed with antiretroviral treatment (ART) scale-up.   
Methods 
We analysed 46 nationally representative household surveys in sub-Saharan Africa 
conducted between 2003 and 2015 to estimate risk of exposure to recent sex and 
pregnancy of HIV positive and HIV negative women by age using a log Poisson model. 
We tested for regional and urban/rural differences and associations with national ART 
Coverage.  We estimated an adjusted fertility rate ratio of HIV positive to HIV negative 
women adjusting for differences in exposure to pregnancy.   
Results 
Exposure to pregnancy differs significantly between HIV positive and negative women 
by age, modified by region.  Younger HIV positive women have a higher exposure to 
pregnancy that HIV negative women and the opposite is true at older ages. The switch 
occurs at 25-29 for rural women and 30-34 for urban women. There was no evidence 
that exposure to pregnancy of HIV positive women have changed as national ART 
coverage increased.  The inferred rate of fecundity of HIV positive women when adjusted 
for differences in exposure to pregnancy were lower than unadjusted fertility rate ratios 
in women aged 20-29 and 20-24 in urban and rural areas respectively varying between 
0.6 and 0.9 over regions.   
Discussion  
The direct effects of HIV on fertility are broadly similar across ages, while the dramatic 
age gradient that has frequently been observed is largely attributable to variation in 
relative sexual exposure by age. 
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8.3 Background 
Numerous studies have demonstrated that the relationship between HIV and fertility 
varies with age. Among the youngest women aged 15-19 years, fertility is higher among 
HIV positive women, while above age 25 the fertility of HIV positive women becomes 
increasingly lower than that of their HIV negative counterparts, termed ‘HIV associated 
subfertility’. Population based studies have also identified differences in HIV subfertility 
by region43, 45, urban and rural area45 and speculated whether changes are associated 
with increased antiretroviral treatment (ART) roll out 45, 79, 169.   
 
Accurate short-term projections for the number of HIV positive women are important for 
HIV surveillance and policy, for example to plan local provision of prevention of mother-
to-child transmission (PMTCT) services and interpret HIV surveillance data for pregnant 
women to infer wider epidemic trends. Beyond documenting the empirical relationships 
between HIV and fertility, such projections require characterization of the mechanisms 
that explain the complex relationship between HIV and fertility in order to predict how 
this will change as the epidemic context evolves, in particular with the rapid scale-up of 
ART and changes in eligibility policy. The Spectrum model supported by UNAIDS 
currently assumes that the fertility of women on ART for longer than six months is the 
same fertility as HIV-negative women of the same age. A number of cohort studies have 
reported high rates of conception among women on long-term treatment121, 152.  However, 
direct comparisons with fertility of HIV-negative women in the same population are not 
readily available. A recent systematic review concluded that evidence was scant, but 
suggested lower fertility in HIV positive women on ART 73. Marston et al 45 estimated that 
with national ART coverage at high levels, the gap between fertility of HIV positive and 
HIV negative women has narrowed, but that fertility of HIV positive women remained 
lower than would be expected if HIV positive women on ART had the same fertility as 
HIV negative women. 
 
A variety of biological and socio-behavioural explanations have been hypothesised to 
explain HIV subfertility, and, as ART roll out increases, both causes of HIV subfertility 
could be affected.  The physiological and immunological fertility reducing effects of HIV 
could be attenuated if ART lessens the severity of women’s HIV disease. Reduced 
widowhood and divorce together with increased sexual activity due to improved health 
could increase exposure to pregnancy for HIV positive women compared to the pre-ART 
era. 
 
It is well documented that at younger ages, age at sexual debt largely explains the 
relatively higher fertility in HIV positive women compared to their HIV negative 
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counterparts41, 43, 72, 144.   However, at older ages the contribution of differences in sexual 
behaviour to lower fertility in HIV positive women has been less thoroughly analysed.  
Sexual intercourse has been reported as less frequent in HIV positive women compared 
to HIV negative women 107, 108  but also modern contraceptive use is generally lower107, 
170
.  The proximate determinants of fertility through which behavioural factors must act 
are (i) sexual intercourse and (ii) non-use of contraception.  Therefore, quantifying the 
differences between HIV positive and HIV negative women’s exposure to sex without the 
use of contraceptives and a comparison of the ensuing pregnancy rates sheds light on 
the contribution of sexual behaviour to HIV subfertility, and may explain some regional 
differences in HIV subfertility and predict how this could change in the era of ART. 
 
We use 46 nationally representative surveys from sub-Saharan Africa to estimate levels 
and trends of exposure to sex and to pregnancy outcome comparing HIV positive women 
to HIV negative women by region, place of residence and national ART coverage to 
assess how much of the HIV subfertility seen in these populations could be directly due 
to sexual behaviour. 
 
8.4 Methods 
 
Figure 8.1 describes a simple conceptual framework for the possible effects of HIV on 
fertility. In this analysis, we aim to estimate the extent to which lower fertility is attributable 
to lower exposure to pregnancy due to behaviour modification associated with HIV, 
compared to biological factors decreasing fecundity which could potentially be directly 
ameliorated by successful ART. The ideal study to evaluate this would be to analyse 
individual-level conception rates during periods of exposure to pregnancy for HIV positive 
and HIV negative women. This is not possible in survey data because sexual activity and 
contraceptive use are only measured at the time of the survey, not over the duration of 
exposure to pregnancy.   
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Figure 8.1: A simple Conceptual framework for pathways to lower fertility in HIV positive women 
 
Instead, to assess the contribution of differences in sexual behaviour (coital frequency 
and contraceptive use) to lower fertility in HIV positive women, we evaluate the 
relationship between age-specific exposure to recent sex (defined as sex in the last four 
weeks) and age-specific fertility rates of HIV positive women compared to HIV negative 
women. We work with the hypothesis that at the population level, exposure to recent sex 
is a measure of direct behavioural actions that lead to the possibility of a pregnancy.  
Therefore, if behavioural differences were the only factor determining differences in 
fertility, we would expect the relative rate of recent sex by HIV status to be the same as 
the relative fertility rates. On the other hand, if biological effects of HIV completely 
explained differences in fertility, we expect to see no difference in recent sexual activity 
between HIV positive and HIV negative women.   Since contraceptive use may differ 
between HIV positive and HIV negative women we also study exposure to recent sex 
without contraceptive use.  We make the following assumptions:  
 
• The relationship between the binary measure of sex in the last four weeks 
(yes/no) and an integer measure of coital frequency is the same for HIV positive 
and HIV negative women at the population level  
• For an individual current contraceptive use is equivalent to contraceptive use in 
the last four weeks 
• Contraceptive use efficacy is equal for HIV positive and HIV negative women.   
We test our assumptions about recent sex as a proxy for coital frequency by repeating 
the analyses outlined below restricting it to married women, as marital status would likely 
 208 
 
 
affect the relationship between recent sex and coital frequency, so if marital patterns are 
different by HIV status, this relationship may also differ. 
 
Data 
We analysed data from 46 Demographic and Health surveys (DHS) and AIDS indicator 
surveys (AIS) from 26 countries in sub-Saharan Africa that included both HIV testing 
data and questions about recent sexual intercourse and current contraceptive use (Table 
8.1).  Four surveys with HIV testing (Tanzania 2008 and 2012, Cote D’Ivoire 2005 and 
Uganda 2011) were excluded as they did not include questions on current contraceptive 
use. 
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Table 8.1: Summary of Demographic and Health surveys used  
Region Survey Year n  
HIV prevalence 
Women 15-49         
(95% CI)* 
Estimated 
female adults 
15+  ART 
Southern Africa       
  
Lesotho 2004 3030 26.3 (24.5-28.2) 1 (1-1) 
  Lesotho 2009 3778 26.7 (25.0-28.6) 27 (25-29) 
  Lesotho 2014 3175 29.7 (27.7-31.8) 40 (37-43) 
  Namibia 2013 4051 16.9 (15.4-18.4) 62 (50-70) 
  Swaziland 2006-07 4424 31.1 (29.4-32.9) 10 (8-11) 
  Zimbabwe 2005-06 6947 21.1 (19.7-22.6) 2 (2-3) 
  Zimbabwe 2010-11 7313 17.7 (16.6-18.8) 31 (24-38) 
  Zimbabwe 2015 8667 16.7 (15.6-17.8) 72 (57-84) 
East and Mid Africa       
  
Burundi 2010 4533 1.7 (1.4-2.1) 33 (26-40) 
  Kenya 2003 3151 8.7 (7.6-10.0) 0 (0-0) 
  Kenya 2008-09 3641 8 (6.8-9.3) 16 (15-18) 
  Malawi 2004 2686 13.3 (12.0-14.8) 1 (1-2) 
  Malawi 2010 7091 12.9 (11.8-14.1) 31 (29-33) 
  Malawi 2015-16 7737 10.8 (9.9-11.7) 66 (63-71) 
  Rwanda 2005 5641 3.6 (3.1-4.2) 9 (8-11) 
  Rwanda 2010 6917 3.7 (3.3-4.2) 45 (39-51) 
  Rwanda 2014-15 6752 3.6 (3.2-4.1) 67 (59-76) 
  Zambia 2007 5502 16.1 (14.7-17.5) 20 (19-22) 
  Zambia 2013-14 14719 15.1 (14.2-16.0) 53 (50-56)] 
West and Central Africa and Ethiopia      
  
Burkina 2003 4086 1.5 (1.2-2.0) 1 (1-1) 
  Burkina 2010 8298 1.2 (0.9-1.5) 32 (25-40) 
  Cameroon 2004 5128 6.6 (5.9-7.4) 2 (2-3) 
  Cameroon 2011 7221 5.6 (5.0-6.3) 18 (15-20) 
  Chad 2014-15 5656 1.8 (1.4-2.2) 50 (42-59) 
  Cote Ivoire 2011-12 4509 4.6 (3.9-5.4) 25 (22-27) 
  DRC 2007 4492 1.6 (1.2-2.2) 5 (4-6) 
  DRC 2013-14 9264 1.6 (1.2-2.2) 24 (19-29) 
  Ethiopia 2005 5736 1.9 (1.4-2.4) 2 (2-3) 
  Ethiopia 2011 14695 1.9 (1.5-2.3) 41 (32-51) 
  Gabon 2012 5459 5.8 (4.7-7.1) 32 (26-38) 
  Gambia 2013 4089 2.1 (1.6-2.8) 24 (18-30) 
  Ghana 2003 5097 2.3 (1.9-2.8) 0 (0-0) 
  Guinea 2005 3742 1.9 (1.4-2.6) 2 (1-2) 
  Guinea 2012 4622 2.1 (1.7-2.6) 28 (21-34) 
  Liberia 2007 6382 1.8 (1.4-2.1) 3 (2-3) 
  Liberia 2013 4397 2 (1.5-2.8) 19 (15-24) 
  Mali 2006 4528 1.4 (1.0-2.0) 8 (6-10) 
  Mali 2012-13 4806 1.3 (1.0-1.8) 32 (24-40)] 
  Niger 2006 4406 0.6 (0.4-0.9) 3 (2-4) 
  Niger 2012 5000 0.4 (0.2-0.5) 27 (20-32) 
  Sao Tome 2009 2378 1.3 (0.8-2.0) . 
 
  
Senegal 2005 4229 0.7 (0.4-1.0) 0 (0-0) 
  Senegal 2010-11 5326 0.6 (0.4-0.8) 33 (25-40) 
  Sierra Leone 2008 3448 1.7 (1.3-2.3) 4 (3-5) 
  Sierra Leone 2013 7695 1.7 (1.3-2.0) 21 (13-29) 
    Togo 2013-14 4737 3.1 (2.6-3.7) 37 (27-49) 
 * Estimated HIV prevalence, see methods section     
† http://aidsinfo.unaids/, accessed  07 September 2017.  Note for those surveys running over two years the earlier 
year is given   
‡ICF International, 2015. The DHS Program STATcompiler. http://www.statcompiler.com. September 07 2017 
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Outcome variables  
Exposure to sex: We created a binary variable “had recent sexual intercourse” defined 
as reporting having had sexual intercourse in the last four weeks.   
 
Married: Marital status was defined as a binary variable: currently married (including 
cohabiting couples) and not currently married. 
 
Current modern Contraceptive use: Modern contraceptive use conformed to the DHS 
definition and included the pill, IUD, injections, diaphragm, condom, female sterilization, 
male sterilization, implants, female condom, Foam/Jelly and lactational amenorrhea. 
 
Exposure to pregnancy: A binary outcome “exposure to pregnancy” was defined as those 
who reported recent intercourse and reported not to be currently using any modern 
contraceptive. This definition assumes that current contraceptive use was constant in the 
4 weeks prior to the survey.   
 
Condom use: This binary outcome defined as women reporting currently using condoms 
among women who had reported recent sex and currently using a modern contraceptive. 
 
Fertility Rates: This is measured using the retrospective birth histories and calculated as 
births per person year in the three years preceding the survey. 
 
Other Variables 
Other variables included  women’s HIV status at the time of the survey, five-year age 
group at time of survey, calendar year, place of residence (urban/rural), ART coverage 
using UNAIDS estimates167 of national female adult ART coverage at the time of each 
survey stratified into categories <20%, 20-49%, and >50%,  and Region.  Region was 
grouped into Southern (Zimbabwe, Lesotho, Swaziland and Namibia), East and Mid 
Africa (Tanzania, Kenya, Uganda, Rwanda, Burundi, Malawi and Zambia) and West and 
Central Africa with Ethiopia (Table 1). HIV epidemics in the East and Mid African 
countries occurred earlier than in Southern Africa. West and central Africa along with 
Ethiopia have lower prevalence and their HIV transmission is likely to be more 
concentrated in high risk groups.  
Women who were pregnant at the time of the survey (0.9%); those infected with HIV-2 
(0.9%); and those whose HIV test was indeterminate (0.04%) were excluded from the 
analysis.  
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Data analysis  
For each outcome variable, we used log Poisson regression to estimate the interaction 
between HIV status and five-year age group, place of residence, region and national 
ART coverage for the outcome variables recent sex, recent exposure to pregnancy, and 
fertility rate45. Each model was adjusted for country and survey year.  Relative exposure 
to pregnancy by HIV status were compared to the fertility rate ratios by HIV status in 
order to estimate how much of the reduced fertility in HIV positive women compared to 
HIV negative women at the population level could be attributed to less exposure to sex. 
For regressions of fertility rate, fertility data for the three years before the survey were 
modelled, with an additional categorical variable for each year before the survey 
interacted with the age groups below 25 years and above 25 years45. Estimated fertility 
rate ratios by HIV status pertain to estimated fertility rate for the year preceding the 
survey.  
 
We further analysed the outcomes of modern contraceptive use and marital status using 
the same log Poisson regression models in order to evaluate the extent to which 
differences in exposure to pregnancy between HIV positive and HIV negative women 
were mediated by differences in these intermediate outcomes. Finally, we investigate 
differences in contraceptive type between HIV positive and HIV negative women and the 
potential implications of this for contraceptive efficacy.  We assess differences in type of 
modern contraceptives used between HIV positive and HIV negative women by 
analysing differences in condom use among women who reported having recent sex and 
currently using a modern contraceptive.   
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Decomposition of fertility differences 
Due to the cross-sectional nature of the data we are unable to directly measure the 
contribution of recent sex to differences in fertility by HIV status as the outcome. The 
only possible measures of fertility relate to births in the years before the survey, so they 
come before the exposure, sex in the last four weeks.   Instead, we have estimated 
relative fertility rates and relative exposure to pregnancy between HIV positive and HIV 
negative women within a given age, location, and time period. Comparing these risk 
ratios allows us to decompose the fertility differences by HIV status into differences in 
exposure to pregnancy and inferred differences in fecundity, as shown below. 
The probability of having a live birth for an HIV negative women is: 
"#$ = %"#$ × '"#$ 
∴ 	'"#$ =
"#$
%"#$	
																	(1) 
Where %"#$ is  the probability of being sexually exposed to pregnancy and '"#$  the 
probability of becoming pregnant and having a live birth given exposure. 
 
For an HIV positive women 
#$ = %#$ × '#$ 
#$ = %#$ × '"#$ × ,	       (2) 
Where , is the additional risk factor of being HIV positive.  
Rearranging (2) and substituting in (1) 
, =
#$
%#$	 × '"#$
=	
#$ × %"#$
"#$ × %#$
 
≈
. 			(+//−/)
2					! 	(+//−/)
 
 
 
To obtain estimates of the relative difference in fecundity for HIV positive women, we use 
the risk ratios of being exposed to pregnancy analysed in this analysis along with the 
fertility rate ratios from Marston et al 45 .    
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8.5 Ethical Approval 
Ethical approval was obtained from the London School of Hygiene and Tropical Medicine 
ethics committee 2nd May 2017. DHS obtained the required local ethical approval and 
permission for each survey. 
 
8.6 Results 
Recent sex by HIV status 
In Eastern, Mid and Southern Africa the median percentage of women reporting recent 
sex across the 46 surveys was around 25% at age 15-19. This peaked in the age range 
25-34 at around 70% in HIV negative women and 50% in HIV positive women and then 
declined after this age.   For West and Central Africa the peak occurred at slightly older 
ages, in 30-39 year olds (Figure 8.2). 
 
Figure 8.2: Cross-survey median percentages for recent sex, Exposure to Pregnancy (Exposed) and 
being married by HIV status (blue negative, red positive) by HIV status and region.  Also shown is 
the interquartile range and the 10th to 90th percentile range.  
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Differences in recent sex between HIV positive and HIV negative women varied with age, 
residence and region, although the general patterns are similar.  Younger HIV positive 
women were more likely to have had recent sex compared to HIV negative women. This 
switched at around 20-24 for rural women and 25- 29 for urban women after which HIV 
positive women had a lower risk of recent sex than HIV negative women (See Table 8.2, 
model 2,  Figure 8.3 and appendix Table 8.5).  In southern Africa, the difference between 
HIV positive and HIV negative women was smaller (interaction term 1.06 95%CI 1.01-
1.12).  For example, in the 30-34 year age group, East and Mid African HIV positive 
women in urban areas were 0.90 (95%CI 0.85-0.96) less likely to have had recent sex 
compared to 0.96 (95%CI 0.89-1.02) in Southern Africa.  There was no evidence of 
variation of an interaction between HIV status and region by age.  There was no evidence 
of any change in the relative probability of recent sex between HIV positive women to 
HIV negative women by ART coverage (Table 8.2, model 3).    
 
Figure 8.3: Adjusted Risk ratio for recent sex and exposure to a live birth, comparing HIV positive 
women to negative women with Fertility rate ratio  
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Table 8.2: Adjusted Risk ratios of recent sex, using Log Poisson model  
 Model 1   Model 2   Model 3  
   RR 95 %CI   RR 95 %CI   RR 95 %CI 
HIV status         
 
HIV negative 1
 
1
 
1  
 
HIV Positive 0.85(0.82-0.89)  0.90(0.85-0.94)  0.90(0.85-0.96) 
Effects of HIV by age         
 
15-19, HIV positive 1.72(1.51-1.95)  1.72(1.51-1.95)  1.53(1.23-1.92) 
 20-24, HIV positive 1.25(1.17-1.33)  1.25(1.17-1.33)  1.31(1.19-1.44) 
 25-29, HIV positive 1.11(1.05-1.17)  1.10(1.04-1.17)  1.10(1.01-1.19) 
 30-34, HIV positive 1  1  1  
 
35-39, HIV positive 0.93(0.87-0.99)  0.93(0.88-0.99)  0.88(0.80-0.96) 
 40-44, HIV positive 0.86(0.80-0.93)  0.87(0.81-0.93)  0.81(0.72-0.91) 
 45-49, HIV positive 0.74(0.67-0.81)  0.74(0.68-0.81)  0.69(0.59-0.81) 
Effects of HIV by Place of residence       
 
rural, HIV positive    0.88(0.85-0.92)  0.85(0.78-0.92) 
Effects of Place of residence on age and HIV status interaction     
 
rural, HIV positive,15-19      1.27(0.97-1.67) 
 rural, HIV positive,20-24      0.96(0.85-1.10) 
 rural, HIV positive,25-29      1.04(0.93-1.16) 
 rural, HIV positive,30-34      1  
 
rural, HIV positive,35-39      1.13(1.00-1.27) 
 rural, HIV positive,40-44      1.16(1.00-1.35) 
 rural, HIV positive,45-49      1.14(0.94-1.39) 
Effects of HIV by Region        
 
Southern, HIV positive   1.06(1.01-1.11)  1.06(1.01-1.11) 
 Eastern, HIV positive   1  1  
 
Western, HIV positive   1.03(0.98-1.09)  1.03(0.98-1.09) 
Effects of HIV by ART Coverage       
 
<20%, HIV positive       1  
 
20-49%, HIV positive      1.01(0.96-1.06) 
 >50%, HIV positive       0.99(0.94-1.05) 
Age Group         
 
15-19 0.29(0.28-0.30)  0.29(0.28-0.30)  0.26(0.25-0.27) 
 20-24 0.74(0.73-0.76)  0.75(0.73-0.76)  0.68(0.66-0.70) 
 25-29 0.94(0.93-0.96)  0.94(0.93-0.96)  0.90(0.88-0.93) 
 30-34 1  1  1  
 
35-39 1.01(0.99-1.02)  1.01(0.99-1.02)  1.00(0.97-1.03) 
 40-44 0.99(0.97-1.01)  0.99(0.97-1.00)  0.95(0.91-0.98) 
 45-49 0.90(0.88-0.92)  0.90(0.88-0.91)  0.87(0.84-0.91) 
Place of residence         
 
urban       1  
 
rural    1.08(1.06-1.09)  1.01(0.98-1.04) 
Effects of age by Place of residence       
 
rural, 15-19       1.16(1.09-1.24) 
 rural, 20-24       1.15(1.11-1.20) 
 rural, 25-29       1.06(1.03-1.10) 
 rural, 30-34       1  
 
rural, 35-39       1.01(0.97-1.05) 
 rural, 40-44       1.05(1.01-1.10) 
 rural, 45-49       1.04(0.99-1.09) 
Region          
 
Southern    0.92(0.87-0.98)  0.93(0.86-1.00) 
 Eastern    1  1  
 
Western    0.78(0.73-0.84)  0.78(0.72-0.85) 
ART Coverage         
 
<20%       1  
 
20-49%       0.92(0.87-0.98) 
  >50%             0.93(0.84-1.02) 
 *All models also adjusted for calendar year (categorical) and country 
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Differences in modern contraceptive use for those who have had recent sex    
Among women who reported recent sex, overall HIV positive women were less likely to 
report current use of modern contraceptives (appendix Table 8.6, Figure 8.6).  However, 
these differences varied by age, region and place of residence.  In urban areas for 
Southern and East and Mid Africa HIV positive women under 35 years old reported lower 
modern contraceptive use than HIV negative women (aRR ranging from 0.63, 95%CI 
0.56-0.71 to 0.87, 95%CI 0.82-0.93).  This pattern was similar in East and Mid Africa for 
older women but in Southern African women over 35 years old there was little or no 
difference in contraceptive use. In West and Mid Africa there was no evidence of a 
difference between current modern contraceptive use comparing HIV positive women to 
HIV negative women.  In rural areas the pattern is different. Among younger women 
there was very little evidence of any difference between HIV positive and negative 
women’s current contraceptive use.  For East and Mid Africa the risk ratios were below 
one for all ages indicating lower use of modern contraceptives among HIV positive 
women but this only reaches statistical significance (p<0.05) at ages 30 to 34 years.   
Among rural women older than 35 in southern Africa, HIV positive women are more likely 
to be currently using modern contraceptives than HIV negative women (for example 35-
39 year old aRR is 1.15 (95%CI 1.06-1.25) (see appendix Table 8.6-Table 8.7,Figure 
8.6).  
 
Differences in condom use amongst modern contraceptive users 
Of the women reporting having had recent sex and currently using modern 
contraceptives, HIV positive women were more likely to be using condoms than HIV 
negative women at all ages. The magnitude of this different varied by age, region and 
rural and urban residency (Appendix, Figure 8.7)   
 
Recent exposure to pregnancy 
Relative differences in recent exposure to pregnancy between HIV positive and HIV 
negative women were different from the relative patterns in recent sex, due to HIV 
positive women in many exposure groups having lower use of modern contraceptives 
than their HIV negative counterparts.  Figure 8.2 shows the cross-survey median 
percentages of exposure to pregnancy by HIV status and region.  
 
Rural HIV positive women aged 15-24 had a higher risk of recent exposure to pregnancy 
compared to HIV negative women (Table 8.3, model 7 and Figure 8.3). This switched 
around age 25-34 where HIV positive women are less exposed to pregnancy than the 
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HIV negative women with a general trend of an increase in this gap with age. There was 
some evidence for regional variation with a slightly increased difference in recent 
exposure to pregnancy between HIV positive and HIV negative women Southern African 
and Western African HIV positive women with interaction terms 0.95 (95%CI 0.87-1.04) 
and 0.91 (95%CI 0.84-0.99).  There was no evidence of a variation of region and HIV by 
age, though statistical power was limited to detect such an interaction.   Young urban 
women also had higher exposure to pregnancy at young ages and lower exposure at 
older ages, but the crossover occurred at an older age group of around age 30-39, with 
some regional variation. There was no evidence of change in the relationship of HIV 
positive women to HIV negative women’s exposure to pregnancy by ART coverage 
(Table 8.3, model 6).    
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Table 8.3: Risk ratios of exposure to pregnancy, using Log Poisson model  
 Model 4   Model 5   Model 6 
   RR 95 %CI   RR 95 %CI   RR 95 %CI 
HIV status         
 
HIV negative 1 
 
1
 
1  
 
HIV Positive 0.91 (0.84-0.98)  1.03(0.91-1.17)  1.03(0.90-1.18) 
Effects of HIV by age         
 
15-19, HIV positive 1.86 (1.54-2.25)  1.79(1.25-2.55)  1.79(1.25-2.55) 
 20-24, HIV positive 1.30 (1.16-1.46)  1.39(1.16-1.66)  1.39(1.16-1.66) 
 25-29, HIV positive 1.12 (1.01-1.25)  1.25(1.06-1.48)  1.25(1.06-1.48) 
 30-34, HIV positive 1  1  1  
 
35-39, HIV positive 0.85 (0.76-0.95)  0.78(0.65-0.93)  0.78(0.65-0.93) 
 40-44, HIV positive 0.91 (0.80-1.03)  0.83(0.68-1.02)  0.83(0.67-1.02) 
 45-49, HIV positive 0.82 (0.71-0.94)  0.73(0.57-0.94)  0.73(0.57-0.94) 
Effects of HIV by Place of residence       
 
rural, HIV positive    0.91(0.78-1.06)  0.91(0.78-1.06) 
Effects of Place of residence on age and HIV status interaction     
 
rural, HIV positive,15-19   1.09(0.72-1.66)  1.09(0.72-1.66) 
 rural, HIV positive,20-24   0.91(0.72-1.14)  0.91(0.72-1.14) 
 rural, HIV positive,25-29   0.82(0.66-1.02)  0.82(0.66-1.02) 
 rural, HIV positive,30-34   1  1  
 
rural, HIV positive,35-39   1.16(0.92-1.46)  1.16(0.92-1.46) 
 rural, HIV positive,40-44   1.16(0.89-1.50)  1.16(0.89-1.50) 
 rural, HIV positive,45-49   1.20(0.89-1.62)  1.20(0.89-1.62) 
Effects of HIV by Region         
 
Southern, HIV positive    0.95(0.87-1.04)  0.95(0.86-1.04) 
 Eastern, HIV positive    1  1  
 
Western, HIV positive    0.91(0.84-0.99)  0.91(0.83-1.00) 
Effects of HIV by ART Coverage        
 
<20%, HIV positive       1  
 
20-49%, HIV positive       1.04(0.96-1.14) 
 >50%, HIV positive       0.96(0.86-1.08) 
Age Group         
 
15-19 0.33 (0.32-0.34)  0.28(0.26-0.30)  0.28(0.26-0.30) 
 20-24 0.75 (0.73-0.77)  0.66(0.62-0.70)  0.66(0.62-0.70) 
 25-29 0.93 (0.91-0.96)  0.87(0.83-0.92)  0.87(0.83-0.92) 
 30-34 1  1  1  
 
35-39 1.08 (1.05-1.11)  1.10(1.04-1.16)  1.10(1.04-1.16) 
 40-44 1.14 (1.11-1.17)  1.13(1.07-1.20)  1.13(1.07-1.20) 
 45-49 1.16 (1.13-1.19)  1.15(1.09-1.23)  1.15(1.09-1.23) 
Place of residence         
 
urban    1  1  
 
rural    1.24(1.18-1.29)  1.24(1.18-1.29) 
Effects of age by Place of residence       
 
rural, 15-19    1.28(1.18-1.4)  1.28(1.18-1.4) 
 rural, 20-24    1.23(1.16-1.31)  1.23(1.16-1.31) 
 rural, 25-29    1.11(1.05-1.18)  1.11(1.05-1.18) 
 rural, 30-34    1  1  
 
rural, 35-39    0.97(0.91-1.03)  0.97(0.91-1.03) 
 rural, 40-44    0.98(0.92-1.05)  0.98(0.92-1.05) 
 rural, 45-49    0.99(0.93-1.06)  0.99(0.93-1.06) 
Region          
 
Southern    0.38(0.34-0.42)  0.38(0.34-0.42) 
 Eastern    1  1  
 
Western    0.95(0.84-1.08)  0.95(0.84-1.08) 
ART Coverage         
 
<20%       1  
 
20-49%    0.88(0.79-0.99)  0.88(0.79-0.99) 
  >50%       0.81(0.70-0.95)   0.81(0.69-0.95) 
 *All models also adjusted for calendar year and country 
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Estimating fertility rate ratios if exposure was the same for recent sex and exposure to 
pregnancy 
Figure 8.4 shows the inferred relative fecundity of HIV positive women compared to HIV 
negative, when adjusted for differences in exposure to pregnancy.  The estimated 
fecundity for HIV positive women under 35 was between 0.6 and 0.9 compared to that 
of HIV negative women.  This varied by place of residence and region with greater 
reductions in fertility in urban areas compared to rural areas.  The estimated fecundity 
reduction was less in Southern Africa compared to the two other regions.  After the age 
of 35 the estimated fecundity reduction intensified gradually as age increases.    
 
Figure 8.4: Adjusted Fertility rate ratios (FRR) with adjusted fertility rate ratios adjusted for exposure 
to pregnancy (FRR/RR) 
 
 220 
 
 
Marriage  
Figure 8.2 shows the median percentage married across surveys by age, HIV status and 
region.  These showed a slightly higher or similar median percentage of women married 
among HIV positive women up to the ages of 20-24.  After this age HIV negative women 
were more likely to be married with the gap increasing with age.   
 
Rural HIV positive women aged 20-49 are less likely to report being currently married 
compared to HIV negative women with this difference widening as age increases 
(appendix, Table 8.10 and Table 8.11, Figure 8.10). For example in Southern Africa, the 
relative probability of being married for HIV positive women was 0.88 (95% CI 0.84-0.94) 
at 20-24 years old to 0.62 (95% CI 0.57-0.68) at age 45-49.  Young urban HIV positive 
women below the age of 30 have a higher or similar risk of being married compared to 
their HIV negative counterparts but after 30 their probability of marriage becomes lower 
than that of HIV negative women, with the relative difference increasing with age.  There 
is some regional variation with Western and Central Africa having a slightly reduced 
difference.  There is some evidence that the gap between positive and negative women 
has narrowed with increased ART coverage.   
 
Married women differences between recent sex and exposure to pregnancy 
The analysis of recent sex and exposure to pregnancy among married women only was 
restricted to 20-44 year olds due to very small sample size for married HIV positive 
women in the 15-19 and 45-49 year age group.  When restricted to married women only, 
differences in recent sexual activity were much smaller between HIV positive women and 
HIV negative women than when considering all women (Appendix,Table 8.12-Table 
8.15, Figure 8.11-Figure 8.14).  For rural married women there was no evidence of a 
difference by HIV status for ages 20-34 and a slightly lower risk of recent sex for HIV 
positive married women aged 35-44.  However, for rural HIV positive women there was 
a higher risk of exposure to a pregnancy for women of all ages apart from 35-39 year 
olds. For West Africa the pattern was the same but differences were not statistically 
significant.   For urban married women aged 20-34 in Southern Africa there was evidence 
of an increased risk of recent sex compared to HIV negative married women, with no 
evidence of a difference at older ages 35-44.  This pattern was the same in the other 
regions but did not reach statistical significance. 
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Estimating the fecundity reduction for married women 
Estimates of the fecundity reduction estimated among married women only gave broadly 
similar results as for all women although implying slightly larger fecundity reduction for 
HIV positive    rural women in Eastern and Mid and Southern Africa (appendix, Figure 
8.15 and Figure 8.16).  Detailed results are further reported in the appendix, including all 
models, stratified rate ratios and graphs. 
 
8.7 Discussion  
This analysis has shown that patterns of sexual exposure between HIV positive and HIV 
negative women by age, region and place of residence strongly mirror the patterns of 
relative fertility rates between the two groups.   We have also shown that after adjusting 
for differences in exposure to recent sexual activity, young HIV positive women may have 
somewhat lower rates of conception and fertility than HIV negative counterparts, similar 
to that observed among women in older age groups.   
 
Many studies have found higher fertility rates in young HIV positive women 15-19 
compared to HIV negative women. This is due to selection effects where women who 
begin sexual activity are exposed to both the risk of pregnancy and HIV41, 45, 72, 171 Where 
median age at first sex is higher these selection effects can also have some impact in 
the 20-24 year age group45.  Others have shown that some HIV subfertility is due to 
widowhood and separation from a partner, or lower sexual activity due to illness107 – it is 
speculated that declines in coital frequency are larger with increases in age. This 
analysis confirms both these aspects of behaviour.  Rural HIV positive women have an 
increasingly lower probability of recent sex as age increases and urban HIV positive 
women have a higher risk of recent sex in 20-24 year olds followed by a lower risk after 
the age of 30. A different pattern emerges when examining exposure to pregnancy, 
taking into account modern contraceptive use.  Modern contraceptive use is lower among 
HIV positive women, resulting in much higher exposure to pregnancy for younger HIV 
positive women compared to HIV negative women up to the age of around 25 years old 
for rural areas and 30 for urban areas.  For older women the exposure to pregnancy 
remains lower for HIV positive women than HIV negative women although their risk of 
recent exposure to pregnancy was slightly closer than their risk of recent sex. These 
differences in recent exposure to pregnancy appear to disguise the direct effects of HIV 
on fertility.  With the assumptions that the relationship between recent sex and coital 
frequency is the same at population level for HIV positive and HIV negative women and 
that the effectiveness of contraceptive use is the same across the two groups, we 
estimate that the impact of HIV on fecundity is much higher in younger women than might 
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be gauged from HIV-associated subfertility measured in general populations, without 
taking into account sexual behaviour 41, 45, 72 and slightly lower in older women.  Taken 
together, this suggests that the direct effects of HIV on fertility are more similar across 
ages, while the dramatic age gradient that has frequently been observed is largely 
attributable to variation in relative sexual exposure by age.  We estimate that in these 
younger women, if biological factors impacting fecundity were the only effect on fertility, 
the fertility risk ratio comparing HIV positive women to HIV negative women would be 
around 0.7 to 0.9.  This appears to vary by region and urban and rural residency, with a 
greater estimated biological impact on fecundity in urban areas and a lower estimated 
biological impact in Southern Africa.   
 
A possible explanation for a biological impact of HIV on fecundity in women at the earlier 
stages of HIV infection may be co-infection or past infection with other sexually 
transmitted infections (STI).  The role of STIs in HIV subfertility has been discussed 
previously172-174.  HIV positive women are more likely to be infected with another STI than 
HIV negative women as STI have similar risk factors to HIV.  STI such as Chlamydia and 
Gonorrhoea cause Pelvic inflammatory disease that can impair fertility soon after 
infection and if left untreated can then go on to cause permanent infertility due to tubal 
damage85.   Other STI such as syphilis are linked to adverse fetal outcomes: miscarriage 
and still birth91.  These STIs in women are generally asymptomatic175 and therefore may 
go untreated, but also lack of access to health facilities or social stigma may contribute 
to lack of treatment.  Variation in biological subfertility by place of residence and region 
may be explained by the prevalence and type of STIs and access to treatment.   
 
These results also shed light on the persistent fertility differences between HIV positive 
and HIV negative women in the era of ART45, 73, 74.  Although it is possible that high 
coverage has not been sustained for long enough to observe a dramatic recovery in 
fertility yet, it is also possible that although ART improves the health of HIV positive 
women, it may not immediately change their prospects for sexual activity and exposure 
to pregnancy, or it may not ameliorate the long-term impacts of previous STIs on 
impaired fertility. There was no evidence of an effect of ART coverage or timing of ART 
roll-out in this analysis indicating that the relative difference in recent exposure to 
pregnancy between HIV positive and HIV negative women has not changed over time.  
There are few DHS studies in countries that have achieved a high ART roll out for a 
sustained amount of time, therefore it is possible that it is too soon to detect behavioural 
changes due to the presence of ART.    
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As this analysis uses cross sectional data we are unable to model sexual behaviour as 
an explanatory factor for individual-level fertility outcomes. Our measure of fertility comes 
from birth histories in the year before the survey, the explanatory variable recent sex 
relates to the four weeks prior to the survey, and current contraceptive use is measured 
at the time of the survey.  Therefore our estimates of the biological effect of HIV on 
fecundity are indirect, depending on ratio comparisons of fertility rates and rates of 
exposure to unprotected sex. 
 
For this analysis we assume that the relationship between recent sex and coital 
frequency is the same by HIV status of the women.  However, apart from 15-19 year 
olds, HIV positive women were generally less likely to be married than HIV negative 
women, therefore we might find that the relationship between recent sex and coital 
frequency may be different if the latter were to be measured directly. To reduce the 
possibility of this biasing our analysis, we also restricted the analysis to married women 
only, which yielded broadly similar results for the estimated effect of HIV on fertility.  
However coital frequency may also be determined by a variety of other factors such as 
partner mobility, polygamy, duration of marriage and desire for children which we have 
not yet investigated. 
 
We used reported current modern contraceptive use as a proxy for the contraceptive 
behaviour during the four weeks prior to the survey.  Although this may be a reasonable 
assumption it is possible that consistency and contraceptive efficacy varies by type of 
contraceptives.  Of the women who had reported recent sex and currently using modern 
contraceptives, HIV positive women were more likely to be using condoms than HIV 
negative women. Condom are both less effective than other modern contraceptives as 
they are more likely to be incorrectly used and used differently with different partners so 
may be less likely to have been used consistently over the previous four weeks.  With 
condom use more prevalent in HIV positive women it is possible that they have a higher 
exposure to pregnancy risk relative to HIV negative women, even if the exposure to 
pregnancy variable used in this analysis is similar.   This may have more of an effect in 
areas where prevalence of condom use is higher.  
 
We have shown that differences in sexual activity between HIV positive and HIV negative 
women by age largely explain the steep gradient in fertility rate ratios by age that has 
been previously described, as well as regional and urban/rural differences in relative 
fertility. Moreover, recent sexual activity and exposure to pregnancy for HIV positive 
women has not increased significantly since ART was scaled-up. This may go some way 
explain why we have not observed the rapid increases in fertility of HIV positive women 
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that would be predicted by mathematical models which assume women on ART will have 
the same fertility as HIV negative women of the same age. We also hypothesize that 
long-term fertility impairment due to other STIs or lasting immunological effects of HIV 
may contribute to the continuing lower average fertility of HIV positive women. These 
dynamics could continue to evolve as both women and men initiate ART earlier, 
widowhood and marriage dissolution decrease, and norms around sexual behaviour and 
HIV continue to change.  
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8.8 Appendix  
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Recent sex by HIV status 
Table 8.4: Risk ratios of recent sex, using Log Poisson model 
 Model 1   Model 2   Model 3    Model 4  
    FRR 95 %CI   FRR 95 %CI   FRR 95 %CI   FRR 95 %CI 
HIV status            
 
HIV negative 1
 
1
 
1
 
1
 
HIV Positive 0.85(0.82-0.89)  0.90(0.85-0.94)  0.90(0.85-0.96)  0.90(0.84-0.97) 
Effects of HIV by age            
 
15-19, HIV positive 1.72(1.51-1.95)  1.72(1.51-1.95)  1.53(1.23-1.92)  1.54(1.23-1.92) 
 20-24, HIV positive 1.25(1.17-1.33)  1.25(1.17-1.33)  1.31(1.19-1.44)  1.31(1.19-1.44) 
 25-29, HIV positive 1.11(1.05-1.17)  1.10(1.04-1.17)  1.10(1.01-1.19)  1.10(1.01-1.19) 
 30-34, HIV positive 1  1  1  1
 
35-39, HIV positive 0.93(0.87-0.99)  0.93(0.88-0.99)  0.88(0.80-0.96)  0.88(0.80-0.96) 
 40-44, HIV positive 0.86(0.80-0.93)  0.87(0.81-0.93)  0.81(0.72-0.91)  0.81(0.72-0.91) 
 45-49, HIV positive 0.74(0.67-0.81)  0.74(0.68-0.81)  0.69(0.59-0.81)  0.69(0.59-0.81) 
Effects of HIV by Place of residence          
 
rural, HIV positive    0.88(0.85-0.92)  0.85(0.78-0.92)  0.85(0.78-0.92) 
Effects of Place of residence on age and HIV status interaction        
 
rural, HIV positive,15-19      1.27(0.97-1.67)  1.27(0.97-1.67) 
 rural, HIV positive,20-24      0.96(0.85-1.10)  0.96(0.85-1.10) 
 rural, HIV positive,25-29      1.04(0.93-1.16)  1.04(0.93-1.16) 
 rural, HIV positive,30-34      1  1
 
rural, HIV positive,35-39      1.13(1.00-1.27)  1.13(1.00-1.27) 
 rural, HIV positive,40-44      1.16(1.00-1.35)  1.16(1.00-1.35) 
 rural, HIV positive,45-49      1.14(0.94-1.39)  1.14(0.94-1.39) 
Effects of HIV by Region           
 
Southern, HIV positive   1.06(1.01-1.11)  1.06(1.01-1.11)  1.06(1.01-1.11) 
 Eastern, HIV positive   1  1  1
 
Western, HIV positive   1.03(0.98-1.09)  1.03(0.98-1.09)  1.03(0.97-1.09) 
Effects of HIV by ART Coverage          
 
<20%, HIV positive       1  1
 
20-49%, HIV positive      1.01(0.96-1.06)  1.01(0.97-1.06) 
 >50%, HIV positive       0.99(0.94-1.05)  0.99(0.94-1.05) 
Age Group            
 
15-19 0.29(0.28-0.30)  0.29(0.28-0.30)  0.26(0.25-0.27)  0.26(0.25-0.27) 
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 20-24 0.74(0.73-0.76)  0.75(0.73-0.76)  0.68(0.66-0.70)  0.68(0.66-0.70) 
 25-29 0.94(0.93-0.96)  0.94(0.93-0.96)  0.90(0.88-0.93)  0.90(0.88-0.93) 
 30-34 1  1  1  1
 
35-39 1.01(0.99-1.02)  1.01(0.99-1.02)  1.00(0.97-1.03)  1.00(0.97-1.03) 
 40-44 0.99(0.97-1.01)  0.99(0.97-1.00)  0.95(0.91-0.98)  0.95(0.91-0.98) 
 45-49 0.90(0.88-0.92)  0.90(0.88-0.91)  0.87(0.84-0.91)  0.87(0.84-0.91) 
Place of residence            
 
urban       1  1
 
rural    1.08(1.06-1.09)  1.01(0.98-1.04)  1.01(0.98-1.04) 
Effects of age by Place of residence          
 
rural, 15-19       1.16(1.09-1.24)  1.16(1.09-1.24) 
 rural, 20-24       1.15(1.11-1.20)  1.15(1.11-1.20) 
 rural, 25-29       1.06(1.03-1.10)  1.06(1.03-1.10) 
 rural, 30-34       1  1
 
rural, 35-39       1.01(0.97-1.05)  1.01(0.97-1.05) 
 rural, 40-44       1.05(1.01-1.10)  1.05(1.01-1.10) 
 rural, 45-49       1.04(0.99-1.09)  1.04(0.99-1.09) 
Region             
 
Southern    0.92(0.87-0.98)  0.93(0.86-1.00)  0.93(0.86-1.00) 
 Eastern    1  1  1
 
Western    0.78(0.73-0.84)  0.78(0.72-0.85)  0.78(0.72-0.85) 
ART Coverage            
 
<20%       1  1
 
20-49%       0.92(0.87-0.98)  0.92(0.87-0.97) 
  >50%             0.93(0.84-1.02)   0.93(0.84-1.02) 
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Table 8.5: Stratum specific risk ratios from Model 2, recent sex  
recent sex - nopreg   
    Southern Africa   
East and 
Mid   West and central 
Urban             
 15-19 1.46 (1.16-1.83)  1.39 (1.11-1.74) 1.44 (1.15-1.80) 
 20-24 1.28 (1.18-1.39)  1.22 (1.12-1.33) 1.26 (1.16-1.37) 
 25-29 1.05 (0.98-1.13)  1.01 (0.94-1.08) 1.04 (0.97-1.12) 
 30-34 0.96 (0.89-1.02)  0.91 (0.85-0.97) 0.94 (0.88-1.01) 
 35-39 0.83 (0.77-0.90)  0.79 (0.73-0.86) 0.82 (0.75-0.89) 
 40-44 0.76 (0.68-0.86)  0.73 (0.65-0.82) 0.75 (0.67-0.85) 
 45-49 0.64 (0.55-0.76)  0.61 (0.52-0.72) 0.63 (0.54-0.75) 
Rural       
 
15-19 1.25 (0.98-1.59)  1.19 (0.93-1.52) 1.23 (0.96-1.56) 
 20-24 1.09 (0.97-1.23)  1.04 (0.93-1.17) 1.08 (0.95-1.22) 
 25-29 0.90 (0.81-1.00)  0.86 (0.77-0.95) 0.89 (0.80-0.99) 
 30-34 0.82 (0.77-0.87)  0.78 (0.73-0.83) 0.80 (0.75-0.87) 
 35-39 0.71 (0.63-0.80)  0.68 (0.60-0.76) 0.70 (0.62-0.79) 
 40-44 0.65 (0.57-0.75)  0.62 (0.54-0.72) 0.64 (0.56-0.74) 
  45-49 0.55 (0.46-0.66)   0.52 (0.44-0.63) 0.54 (0.45-0.65) 
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Figure 8.5: Risk ratio of recent sex, comparing HIV positive women to HIV negative women  
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Differences in modern contraceptive use for those who have had recent sex  
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Table 8.6: Risk of using a current modern use of contraceptives for those who have had recent sex, comparing HIV positive to HIV negative women 
 
Model 1   Model 2   Model 3    Model 4 
RR 95 %CI   RR 95 %CI   RR 95 %CI   RR 95 %CI 
HIV status            
 
HIV negative 1 
 
1 
 
1
 
1 
 
HIV Positive 0.92 (0.87-0.97)  0.63 (0.56-0.71)  0.66(0.58-0.75)  0.66 (0.57-0.75) 
Effects of HIV by age            
 
15-19, HIV positive 0.98 (0.81-1.19)  1.31 (0.92-1.87)  1.11(0.72-1.71)  1.11 (0.72-1.71) 
 20-24, HIV positive 0.96 (0.88-1.05)  1.19 (1.00-1.41)  1.16(0.96-1.41)  1.17 (0.96-1.41) 
 25-29, HIV positive 0.99 (0.91-1.07)  1.14 (0.96-1.35)  1.00(0.83-1.21)  1.01 (0.84-1.21) 
 30-34, HIV positive 1  1  1  1 
 
35-39, HIV positive 1.12 (1.03-1.22)  1.21 (1.02-1.43)  1.20(1.00-1.45)  1.20 (0.99-1.45) 
 40-44, HIV positive 1.06 (0.96-1.18)  1.17 (0.96-1.42)  1.13(0.89-1.42)  1.12 (0.89-1.41) 
 45-49, HIV positive 1.21 (1.05-1.40)  1.16 (0.87-1.55)  1.02(0.73-1.43)  1.01 (0.72-1.42) 
Effects of HIV by Place of residence       
 
rural, HIV positive   1.22 (1.15-1.29)  1.13(1.02-1.25)  1.13 (1.02-1.26) 
Effects of Place of residence on age and HIV status interaction      
 
rural, HIV positive,15-19    1.27(0.86-1.87)  1.26 (0.86-1.86) 
 rural, HIV positive,20-24    1.01(0.85-1.20)  1.01 (0.85-1.20) 
 rural, HIV positive,25-29    1.25(1.08-1.46)  1.25 (1.08-1.46) 
 rural, HIV positive,30-34    1 1 
rural, HIV positive,35-39    1.01(0.86-1.19)  1.01 (0.86-1.19) 
 rural, HIV positive,40-44    1.07(0.87-1.31)  1.07 (0.87-1.32) 
 rural, HIV positive,45-49    1.19(0.88-1.62)  1.20 (0.89-1.63) 
Effects of HIV by Region        
 
Southern, HIV positive  1.38 (1.21-1.58)  1.37(1.20-1.56)  1.38 (1.21-1.58) 
 Western, HIV positive  1.37 (1.02-1.85)  1.30(0.96-1.77)  1.34 (0.99-1.83) 
Effects of Region on age and HIV status interaction       
 
Southern Africa, Positive, 15-19  0.68 (0.44-1.04)  0.70(0.45-1.07)  0.70 (0.45-1.07) 
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 Southern Africa, Positive, 20-24  0.75 (0.61-0.92)  0.76(0.62-0.93)  0.76 (0.62-0.93) 
 Southern Africa, Positive, 25-29  0.81 (0.67-0.98)  0.82(0.68-0.99)  0.82 (0.68-0.99) 
 Southern Africa, Positive, 30-34  1  1  1 
 
Southern Africa, Positive, 35-39  0.90 (0.74-1.09)  0.90(0.74-1.09)  0.90 (0.74-1.09) 
 Southern Africa, Positive, 40-44  0.82 (0.64-1.03)  0.82(0.65-1.04)  0.82 (0.65-1.04) 
 Southern Africa, Positive, 45-49  1.01 (0.72-1.42)  1.04(0.74-1.46)  1.05 (0.75-1.47) 
 West and Central Africa, Positive, 15-19 1.09 (0.56-2.13)  1.17(0.59-2.33)  1.16 (0.59-2.30) 
 West and Central Africa, Positive, 20-24 0.98 (0.65-1.46)  1.05(0.70-1.58)  1.04 (0.70-1.57) 
 West and Central Africa, Positive, 25-29 0.93 (0.63-1.37)  1.04(0.70-1.54)  1.03 (0.69-1.53) 
 West and Central Africa, Positive, 30-34 1  1  1 
 
West and Central Africa, Positive, 35-39 0.99 (0.65-1.52)  1.04(0.68-1.61)  1.04 (0.67-1.60) 
 West and Central Africa, Positive, 40-44 1.11 (0.68-1.82)  1.14(0.69-1.90)  1.15 (0.69-1.91) 
 West and Central Africa, Positive, 45-49 0.67 (0.27-1.69)  0.53(0.19-1.44)  0.53 (0.20-1.46) 
Effects of HIV by ART Coverage       
 
20-49%, HIV positive      0.96 (0.89-1.04) 
 >50%, HIV positive      1.04 (0.97-1.12) 
Age Group        
 
15-19 0.86 (0.82-0.90)  0.68 (0.62-0.75)  0.82(0.74-0.92)  0.82 (0.74-0.92) 
 20-24 1.00 (0.97-1.04)  0.90 (0.85-0.95)  0.96(0.90-1.03)  0.96 (0.90-1.03) 
 25-29 1.00 (0.97-1.03)  0.95 (0.90-1.00)  1.01(0.95-1.08)  1.01 (0.95-1.08) 
 30-34 1  1  1  1 
 
35-39 0.89 (0.85-0.92)  0.93 (0.88-0.99)  0.94(0.87-1.01)  0.94 (0.87-1.01) 
 40-44 0.77 (0.74-0.80)  0.85 (0.80-0.91)  0.85(0.78-0.93)  0.85 (0.78-0.93) 
 45-49 0.52 (0.49-0.55)  0.59 (0.54-0.65)  0.70(0.62-0.79)  0.70 (0.62-0.79) 
Place of residence        
 
urban   1  1  1 
 
rural   0.68 (0.67-0.70)  0.71(0.68-0.75)  0.71 (0.68-0.75) 
Effects of age by Place of residence       
 
rural, 15-19     0.75(0.69-0.83)  0.75 (0.69-0.83) 
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 rural, 20-24     0.92(0.86-0.98)  0.92 (0.86-0.98) 
 rural, 25-29     0.93(0.88-0.99)  0.93 (0.88-0.99) 
 rural, 30-34     1  1 
 
rural, 35-39     0.98(0.91-1.05)  0.98 (0.91-1.05) 
 rural, 40-44     0.98(0.90-1.07)  0.98 (0.90-1.07) 
 rural, 45-49     0.80(0.71-0.89)  0.80 (0.71-0.89) 
Region         
 
Southern   1.59 (1.41-1.79)  1.54(1.22-1.93)  1.54 (1.22-1.94) 
 Eastern   1  1  1 
 
Western   0.55 (0.48-0.63)  0.54(0.43-0.69)  0.54 (0.43-0.69) 
Effects of age by Region        
 
Southern Africa, 15-19   1.22 (1.09-1.37)  1.19(1.06-1.34)  1.19 (1.06-1.34) 
 Southern Africa, 20-24   1.10 (1.03-1.17)  1.08(1.01-1.15)  1.08 (1.01-1.15) 
 Southern Africa, 25-29   1.06 (0.99-1.12)  1.04(0.98-1.10)  1.04 (0.98-1.10) 
 Southern Africa, 30-34   1  1  1 
 
Southern Africa, 35-39   0.94 (0.88-1.01)  0.94(0.88-1.01)  0.94 (0.88-1.01) 
 Southern Africa, 40-44   0.94 (0.87-1.02)  0.94(0.86-1.02)  0.94 (0.86-1.02) 
 Southern Africa, 45-49   0.96 (0.85-1.08)  0.93(0.82-1.05)  0.93 (0.82-1.04) 
 West and Central Africa, 15-19  1.46 (1.30-1.64)  1.40(1.24-1.57)  1.40 (1.24-1.57) 
 West and Central Africa, 20-24  1.19 (1.10-1.29)  1.16(1.07-1.26)  1.16 (1.07-1.26) 
 West and Central Africa, 25-29  1.04 (0.96-1.12)  1.01(0.94-1.09)  1.01 (0.94-1.09) 
 West and Central Africa, 30-34  1  1  1 
 
West and Central Africa, 35-39  0.93 (0.85-1.01)  0.92(0.85-1.00)  0.92 (0.85-1.00) 
 West and Central Africa, 40-44  0.83 (0.75-0.92)  0.83(0.75-0.93)  0.83 (0.75-0.93) 
 West and Central Africa, 45-49  0.77 (0.67-0.88)  0.74(0.64-0.85)  0.74 (0.64-0.85) 
ART Coverage            
 
<20%       1  1 
 
20-49%       1.17 (1.01-1.37)  1.18 (1.02-1.38) 
  >50%             1.14 (0.85-1.53)   1.14 (0.85-1.53) 
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Table 8.7: Stratified rate ratios for the risk of using a current modern use of contraceptives for those who have had recent sex, comparing HIV positive to HIV negative 
women 
 
Risk ratios by region 
Southern Africa   East and Mid   West and central 
Urban             
 15-19 0.77 (0.61-0.98)  0.82 (0.59-1.15) 1.23 (0.75-2.01) 
 20-24 0.77 (0.71-0.85)  0.75 (0.65-0.85) 1.00 (0.78-1.29) 
 25-29 0.81 (0.75-0.87)  0.72 (0.63-0.82) 0.91 (0.73-1.15) 
 30-34 0.87 (0.82-0.93)  0.63 (0.56-0.71) 0.86 (0.66-1.14) 
 35-39 0.95 (0.87-1.03)  0.76 (0.68-0.86) 1.04 (0.79-1.37) 
 40-44 0.83 (0.74-0.93)  0.73 (0.62-0.86) 1.12 (0.78-1.61) 
 45-49 1.02 (0.86-1.22)  0.73 (0.56-0.95) 0.68 (0.29-1.56) 
Rural       
 
15-19 0.94 (0.74-1.19)  1.00 (0.72-1.40) 1.50 (0.91-2.45) 
 20-24 0.94 (0.86-1.03)  0.91 (0.80-1.03) 1.21 (0.94-1.57) 
 25-29 0.98 (0.91-1.05)  0.87 (0.77-0.99) 1.11 (0.89-1.39) 
 30-34 1.06 (0.99-1.13)  0.77 (0.68-0.87) 1.05 (0.80-1.38) 
 35-39 1.15 (1.06-1.25)  0.93 (0.82-1.04) 1.26 (0.96-1.66) 
 40-44 1.01 (0.90-1.13)  0.89 (0.76-1.05) 1.36 (0.95-1.95) 
  45-49 1.24 (1.05-1.48)   0.89 (0.69-1.16) 0.82 (0.36-1.91) 
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Figure 8.6: Risk ratio of currently using modern contraceptives for women reporting recent sex, comparing HIV positive women to HIV negative women  
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Figure 8.7: Risk ratio of using a condom for women who report having recent sex and currently using a modern contraceptive (HIV+ve/HIV-ve) 
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Recent exposure to pregnancy 
Table 8.8: Risk ratios of recent exposure to a live birth, using Log Poisson model 
Exposed - nopreg Model 5   Model 6   Model 7   Model 8 
    FRR 95 %CI   FRR 95 %CI   FRR 95 %CI   FRR 95 %CI 
HIV status            
 
HIV negative 1
 
1  1  1
 
HIV Positive 0.91(0.84-0.98)  1.03(0.90-1.16)  1.03(0.91-1.17)  1.03(0.90-1.18) 
Effects of HIV by age            
 
15-19, HIV positive 1.86(1.54-2.25)  1.78(1.24-2.54)  1.79(1.25-2.55)  1.79(1.25-2.55) 
 20-24, HIV positive 1.30(1.16-1.46)  1.40(1.17-1.67)  1.39(1.16-1.66)  1.39(1.16-1.66) 
 25-29, HIV positive 1.12(1.01-1.25)  1.25(1.06-1.48)  1.25(1.06-1.48)  1.25(1.06-1.48) 
 30-34, HIV positive 1  1  1  1
 
35-39, HIV positive 0.85(0.76-0.95)  0.78(0.65-0.93)  0.78(0.65-0.93)  0.78(0.65-0.93) 
 40-44, HIV positive 0.91(0.80-1.03)  0.82(0.67-1.01)  0.83(0.68-1.02)  0.83(0.67-1.02) 
 45-49, HIV positive 0.82(0.71-0.94)  0.72(0.56-0.94)  0.73(0.57-0.94)  0.73(0.57-0.94) 
Effects of HIV by Place of residence          
 
rural, HIV positive    0.92(0.79-1.07)  0.91(0.78-1.06)  0.91(0.78-1.06) 
Effects of Place of residence on age and HIV status interaction        
 
rural, HIV positive,15-19   1.08(0.71-1.65)  1.09(0.72-1.66)  1.09(0.72-1.66) 
 rural, HIV positive,20-24   0.90(0.71-1.13)  0.91(0.72-1.14)  0.91(0.72-1.14) 
 rural, HIV positive,25-29   0.83(0.67-1.03)  0.82(0.66-1.02)  0.82(0.66-1.02) 
 rural, HIV positive,30-34   1  1  1
 
rural, HIV positive,35-39   1.16(0.92-1.46)  1.16(0.92-1.46)  1.16(0.92-1.46) 
 rural, HIV positive,40-44   1.17(0.90-1.51)  1.16(0.89-1.50)  1.16(0.89-1.50) 
 rural, HIV positive,45-49   1.20(0.89-1.63)  1.20(0.89-1.62)  1.20(0.89-1.62) 
Effects of HIV by Region            
 
Southern, HIV positive    0.95(0.87-1.04)  0.95(0.87-1.04)  0.95(0.86-1.04) 
 Eastern, HIV positive    1  1  1
 
Western, HIV positive    0.91(0.84-0.99)  0.91(0.84-0.99)  0.91(0.83-1.00) 
Effects of HIV by ART Coverage           
 
<20%, HIV positive          1
 
20-49%, HIV positive          1.04(0.96-1.14) 
 >50%, HIV positive          0.96(0.86-1.08) 
Age Group            
 
15-19 0.33(0.32-0.34)  0.28(0.26-0.30)  0.28(0.26-0.30)  0.28(0.26-0.30) 
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 20-24 0.75(0.73-0.77)  0.66(0.62-0.69)  0.66(0.62-0.70)  0.66(0.62-0.70) 
 25-29 0.93(0.91-0.96)  0.87(0.83-0.92)  0.87(0.83-0.92)  0.87(0.83-0.92) 
 30-34 1  1  1  1
 
35-39 1.08(1.05-1.11)  1.09(1.03-1.16)  1.10(1.04-1.16)  1.10(1.04-1.16) 
 40-44 1.14(1.11-1.17)  1.15(1.09-1.21)  1.13(1.07-1.20)  1.13(1.07-1.20) 
 45-49 1.16(1.13-1.19)  1.15(1.08-1.22)  1.15(1.09-1.23)  1.15(1.09-1.23) 
Place of residence            
 
urban    1  1  1
 
rural    1.22(1.17-1.27)  1.24(1.18-1.29)  1.24(1.18-1.29) 
Effects of age by Place of residence          
 
rural, 15-19    1.29(1.18-1.41)  1.28(1.18-1.40)  1.28(1.18-1.4) 
 rural, 20-24    1.24(1.16-1.32)  1.23(1.16-1.31)  1.23(1.16-1.31) 
 rural, 25-29    1.11(1.05-1.18)  1.11(1.05-1.18)  1.11(1.05-1.18) 
 rural, 30-34    1  1  1
 
rural, 35-39    0.98(0.92-1.04)  0.97(0.91-1.03)  0.97(0.91-1.03) 
 rural, 40-44    0.98(0.92-1.04)  0.98(0.92-1.05)  0.98(0.92-1.05) 
 rural, 45-49    1.01(0.94-1.08)  0.99(0.93-1.06)  0.99(0.93-1.06) 
Region             
 
Southern    0.38(0.35-0.43)  0.38(0.34-0.42)  0.38(0.34-0.42) 
 Eastern    1  1  1
 
Western    1.00(0.89-1.12)  0.95(0.84-1.08)  0.95(0.84-1.08) 
ART Coverage            
 
<20%          1
 
20-49%       0.88(0.79-0.99)  0.88(0.79-0.99) 
  >50%             0.81(0.70-0.95)   0.81(0.69-0.95) 
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Table 8.9: Stratum specific risk ratios from Model 5, exposure to live birth 
   
    Southern Africa   
East and 
Mid   West and central 
Urban             
 15-19 1.73 (1.24-2.42)  1.82 (1.30-2.54) 1.66 (1.19-2.31) 
 20-24 1.36 (1.16-1.60)  1.43 (1.23-1.67) 1.31 (1.13-1.52) 
 25-29 1.22 (1.06-1.41)  1.29 (1.13-1.47) 1.17 (1.04-1.33) 
 30-34 0.97 (0.86-1.11)  1.03 (0.90-1.16) 0.93 (0.83-1.06) 
 35-39 0.76 (0.66-0.89)  0.80 (0.69-0.93) 0.73 (0.63-0.84) 
 40-44 0.80 (0.66-0.97)  0.84 (0.70-1.01) 0.77 (0.64-0.92) 
 45-49 0.71 (0.55-0.90)  0.74 (0.58-0.95) 0.68 (0.53-0.86) 
Rural       
 
15-19 1.72 (1.40-2.13)  1.81 (1.47-2.23) 1.65 (1.34-2.03) 
 20-24 1.13 (1.00-1.27)  1.18 (1.05-1.33) 1.08 (0.96-1.22) 
 25-29 0.93 (0.84-1.04)  0.98 (0.88-1.10) 0.90 (0.80-1.00) 
 30-34 0.90 (0.80-1.01)  0.94 (0.85-1.06) 0.86 (0.77-0.97) 
 35-39 0.81 (0.72-0.92)  0.86 (0.76-0.96) 0.78 (0.69-0.88) 
 40-44 0.86 (0.75-0.98)  0.91 (0.80-1.03) 0.83 (0.72-0.94) 
  45-49 0.78 (0.68-0.91)   0.82 (0.71-0.95) 0.75 (0.65-0.87) 
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Figure 8.8: Risk ratio of exposure to pregnancy, comparing HIV positive women to HIV negative women 
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Figure 8.9: Adjusted Risk ratio for recent sex and exposure to a live birth, comparing HIV positive women to negative women with Fertility rate ratio  
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Married  
Table 8.10: Risk ratios of being married using Log Poisson model 
 
Model 1   Model 2   Model 3  
RR 95 %CI   RR 95 %CI   RR 95 %CI 
HIV status         
 
HIV negative 1   1   1  
 
HIV Positive 0.78 (0.76-0.81)  0.79 (0.75-0.84)  0.77 (0.72-0.82) 
Effects of HIV by age         
 
15-19, HIV positive 1.80 (1.61-2.01)  2.14 (1.73-2.65)  2.15 (1.74-2.66) 
 20-24, HIV positive 1.19 (1.13-1.26)  1.37 (1.25-1.51)  1.39 (1.26-1.53) 
 25-29, HIV positive 1.10 (1.05-1.14)  1.18 (1.10-1.27)  1.19 (1.11-1.28) 
 30-34, HIV positive 1   1   1  
 
35-39, HIV positive 0.92 (0.88-0.97)  0.88 (0.81-0.96)  0.89 (0.81-0.96) 
 40-44, HIV positive 0.86 (0.81-0.92)  0.84 (0.75-0.93)  0.84 (0.75-0.94) 
 45-49, HIV positive 0.78 (0.73-0.84)  0.75 (0.66-0.87)  0.76 (0.66-0.87) 
Effects of HIV by Place of residence       
 
rural, HIV positive    0.99 (0.93-1.06)  0.99 (0.93-1.06) 
Effects of Place of residence on age and HIV status interaction     
 
rural, HIV positive,15-19   0.80 (0.62-1.02)  0.80 (0.63-1.03) 
 rural, HIV positive,20-24   0.82 (0.73-0.92)  0.82 (0.73-0.92) 
 rural, HIV positive,25-29   0.89 (0.82-0.97)  0.88 (0.81-0.96) 
 rural, HIV positive,30-34   1   1  
 
rural, HIV positive,35-39   1.07 (0.97-1.19)  1.07 (0.96-1.18) 
 rural, HIV positive,40-44   1.04 (0.92-1.18)  1.03 (0.91-1.17) 
 rural, HIV positive,45-49   1.04 (0.88-1.23)  1.03 (0.87-1.21) 
Effects of HIV by Region        
 
Southern, HIV positive   1.01 (0.98-1.05)  1.02 (0.98-1.05) 
 Western, HIV positive   1.06 (1.01-1.10)  1.07 (1.02-1.12) 
Effects of HIV by ART Coverage       
 
<20%, HIV positive       1  
 
20-49%, HIV positive      1.03 (0.99-1.07) 
 >50%, HIV positive       1.06 (1.02-1.11) 
Age Group         
 
15-19 0.26 (0.26-0.27)  0.18 (0.17-0.19)  0.18 (0.17-0.19) 
 20-24 0.73 (0.73-0.74)  0.60 (0.58-0.61)  0.59 (0.58-0.61) 
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 25-29 0.95 (0.94-0.95)  0.89 (0.87-0.91)  0.89 (0.87-0.91) 
 30-34 1   1   1  
 
35-39 1.01 (1.00-1.02)  1.04 (1.02-1.06)  1.04 (1.02-1.06) 
 40-44 0.97 (0.96-0.98)  1.00 (0.98-1.02)  1.00 (0.98-1.02) 
 45-49 0.92 (0.91-0.93)  0.93 (0.90-0.95)  0.93 (0.90-0.95) 
Place of residence         
 
urban    1   1  
 
rural    1.13 (1.11-1.15)  1.13 (1.11-1.15) 
Effects of age by Place of residence       
 
rural, 15-19    1.73 (1.62-1.85)  1.72 (1.61-1.85) 
 rural, 20-24    1.37 (1.33-1.41)  1.38 (1.34-1.42) 
 rural, 25-29    1.09 (1.07-1.12)  1.10 (1.08-1.12) 
 rural, 30-34    1   1  
 
rural, 35-39    0.96 (0.94-0.98)  0.96 (0.94-0.98) 
 rural, 40-44    0.95 (0.93-0.98)  0.96 (0.93-0.98) 
 rural, 45-49    0.98 (0.95-1.01)  0.98 (0.95-1.01) 
Region          
 
Southern    1.03 (0.99-1.08)  1.02 (0.97-1.08) 
 Eastern    1   1  
 
Western    1.19 (1.13-1.24)  1.20 (1.13-1.26) 
ART Coverage         
 
<20%       1  
 
20-49%       1.05 (1.02-1.09) 
  >50%             1.05 (0.99-1.13) 
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Table 8.11: Stratum specific risk ratios of being married comparing HIV positive women to HIV negative women. 
 
Risk ratios by region 
Southern Africa   East and Mid   West and central 
Urban             
 15-19 1.71(1.38-2.12)  1.70(1.37-2.10)  1.79(1.44-2.23) 
 20-24 1.12(1.02-1.22)  1.11(1.01-1.21)  1.17(1.07-1.28) 
 25-29 0.96(0.90-1.01)  0.95(0.90-1.00)  1.00(0.95-1.06) 
 30-34 0.80(0.76-0.85)  0.80(0.75-0.85)  0.84(0.80-0.90) 
 35-39 0.71(0.66-0.77)  0.71(0.66-0.76)  0.75(0.70-0.81) 
 40-44 0.67(0.61-0.74)  0.67(0.60-0.74)  0.71(0.64-0.78) 
 45-49 0.59(0.51-0.68)  0.59(0.51-0.68)  0.62(0.54-0.72) 
Rural       
 
15-19 1.33(1.17-1.51)  1.32(1.16-1.50)  1.40(1.22-1.59) 
 20-24 0.88(0.84-0.94)  0.88(0.83-0.93)  0.93(0.87-0.99) 
 25-29 0.84(0.80-0.88)  0.83(0.80-0.87)  0.88(0.84-0.93) 
 30-34 0.79(0.76-0.83)  0.79(0.75-0.82)  0.83(0.79-0.87) 
 35-39 0.75(0.72-0.79)  0.75(0.71-0.79)  0.79(0.75-0.83) 
 40-44 0.70(0.65-0.74)  0.69(0.65-0.74)  0.73(0.68-0.78) 
  45-49 0.62(0.57-0.68)   0.62(0.57-0.67)   0.65(0.60-0.71) 
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Figure 8.10: Adjusted Risk ratio for being married, comparing HIV positive women to negative women. 
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Married recent sex and exposure to pregnancy 
Table 8.12: Risk ratios of recent sex for married women, using Log Poisson model 
 
Model 1   Model 2   Model 3    Model 4 
RR 95 %CI   RR 95 %CI   RR 95 %CI   RR 95 %CI 
HIV status            
 
HIV negative 1 
 
1 
 
1
 
1 
 
HIV Positive 1.00 (0.96-1.04)  0.99 (0.95-1.04)  0.99(0.94-1.03)  1.06 (0.99-1.12) 
Effects of HIV by age            
 
15-19, HIV positive 1.09 (0.98-1.22)  1.11 (0.99-1.23)  1.11(1.00-1.24)  0.87 (0.72-1.06) 
 20-24, HIV positive 1.05 (0.99-1.12)  1.06 (0.99-1.12)  1.06(1.00-1.12)  1.01 (0.93-1.11) 
 25-29, HIV positive 1.03 (0.98-1.08)  1.03 (0.98-1.09)  1.03(0.98-1.09)  0.98 (0.91-1.05) 
 30-34, HIV positive 1  1  1  1 
 
35-39, HIV positive 0.96 (0.91-1.01)  0.96 (0.92-1.02)  0.97(0.92-1.02)  0.94 (0.87-1.02) 
 40-44, HIV positive 0.95 (0.90-1.01)  0.96 (0.91-1.02)  0.96(0.91-1.02)  0.91 (0.83-1.00) 
 45-49, HIV positive 0.92 (0.85-1.00)  0.93 (0.86-1.01)  0.93(0.86-1.01)  0.86 (0.74-0.99) 
Effects of HIV by Place of residence       
 
rural, HIV positive   0.95 (0.92-0.99)  0.96(0.92-1.00)  0.88 (0.81-0.94) 
Effects of Place of residence on age and HIV status interaction      
 
rural, HIV positive,15-19       1.45 (1.15-1.83) 
 rural, HIV positive,20-24       1.07 (0.95-1.20) 
 rural, HIV positive,25-29       1.10 (0.99-1.22) 
 rural, HIV positive,30-34       1 
 
rural, HIV positive,35-39       1.07 (0.96-1.20) 
 rural, HIV positive,40-44       1.12 (0.99-1.28) 
 rural, HIV positive,45-49       1.17 (0.98-1.40) 
Effects of HIV by Region        
 
Southern, HIV positive   1.04 (1.00-1.08)  1.04(1.00-1.08)  1.04 (0.99-1.08) 
 Western, HIV positive   1.01 (0.95-1.06)  1.01(0.96-1.07)  1.00 (0.94-1.06) 
Effects of HIV by ART Coverage       
 
20-49%, HIV positive       0.99 (0.94-1.03) 
 >50%, HIV positive       0.95 (0.91-1.00) 
Age Group        
 
15-19 0.87 (0.85-0.89)  0.88 (0.85-0.90)  0.87(0.85-0.89)  0.96 (0.91-1.01) 
 20-24 0.94 (0.93-0.96)  0.95 (0.93-0.96)  0.94(0.93-0.96)  0.99 (0.96-1.01) 
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 25-29 0.98 (0.97-0.99)  0.98 (0.96-0.99)  0.98(0.96-0.99)  0.98 (0.95-1.01) 
 30-34 1  1  1  1 
 
35-39 1.01 (1.00-1.03)  1.01 (1.00-1.03)  1.01(0.99-1.03)  0.99 (0.96-1.02) 
 40-44 1.02 (1.01-1.04)  1.03 (1.01-1.04)  1.03(1.01-1.04)  0.97 (0.94-1.01) 
 45-49 0.99 (0.97-1.01)  0.99 (0.97-1.01)  0.99(0.98-1.01)  0.97 (0.93-1.01) 
Place of residence        
 
urban   1  1  1 
 
rural   0.92 (0.91-0.93)  0.91(0.90-0.93)  0.92 (0.90-0.95) 
Effects of age by Place of residence       
 
rural, 15-19       0.88 (0.82-0.94) 
 rural, 20-24       0.94 (0.91-0.97) 
 rural, 25-29       0.99 (0.96-1.03) 
 rural, 30-34       1 
 
rural, 35-39       1.03 (0.99-1.07) 
 rural, 40-44       1.08 (1.03-1.12) 
 rural, 45-49       1.03 (0.99-1.08) 
Region         
 
Southern   0.99 (0.96-1.02)  0.99(0.96-1.02)  0.99 (0.97-1.02) 
 Eastern   1  1  1 
 
Western   0.91 (0.85-0.98)  0.91(0.85-0.98)  0.91 (0.85-0.98) 
ART Coverage            
 
<20%       1  1 
 
20-49%       0.99 (0.93-1.06)  0.99 (0.93-1.06) 
  >50%             0.98 (0.89-1.08)   0.99 (0.90-1.09) 
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Table 8.13: Risk ratios of exposure to a live birth, for married women,, using Log Poisson model 
 
Model 1   Model 2   Model 3    Model 4 
RR 95 %CI   RR 95 %CI   RR 95 %CI   RR 95 %CI 
HIV status            
 
HIV negative 1 
 
1 
 
1
 
1 
 
HIV Positive 1.09 (1.01-1.17)  1.19 (1.08-1.32)  1.20(1.09-1.32)  1.25 (1.10-1.42) 
Effects of HIV by age            
 
15-19, HIV positive 1.18 (0.99-1.40)  1.19 (1.00-1.42)  1.19(1.00-1.42)  0.99 (0.74-1.34) 
 20-24, HIV positive 1.08 (0.97-1.21)  1.08 (0.97-1.21)  1.07(0.96-1.20)  1.03 (0.87-1.23) 
 25-29, HIV positive 1.00 (0.90-1.11)  1.00 (0.90-1.11)  1.00(0.90-1.10)  1.06 (0.90-1.24) 
 30-34, HIV positive 1  1  1  1 
 
35-39, HIV positive 0.87 (0.78-0.97)  0.87 (0.78-0.98)  0.87(0.78-0.98)  0.82 (0.69-0.97) 
 40-44, HIV positive 1.00 (0.89-1.12)  1.00 (0.89-1.12)  1.01(0.90-1.13)  0.95 (0.78-1.14) 
 45-49, HIV positive 0.98 (0.86-1.11)  0.97 (0.85-1.11)  0.98(0.86-1.12)  0.90 (0.71-1.15) 
Effects of HIV by Place of residence       
 
rural, HIV positive   0.98 (0.91-1.05)  0.97(0.90-1.04)  0.93 (0.80-1.07) 
Effects of Place of residence on age and HIV status interaction      
 
rural, HIV positive,15-19       1.32 (0.91-1.92) 
 rural, HIV positive,20-24       1.02 (0.80-1.29) 
 rural, HIV positive,25-29       0.88 (0.70-1.10) 
 rural, HIV positive,30-34       1 
 
rural, HIV positive,35-39       1.12 (0.89-1.42) 
 rural, HIV positive,40-44       1.06 (0.82-1.37) 
 rural, HIV positive,45-49       1.08 (0.80-1.45) 
Effects of HIV by Region        
 
Southern, HIV positive   0.95 (0.86-1.05)  0.95(0.87-1.05)  0.94 (0.86-1.04) 
 Western, HIV positive   0.86 (0.79-0.94)  0.86(0.79-0.94)  0.84 (0.77-0.93) 
Effects of HIV by ART Coverage       
 
20-49%, HIV positive       0.99 (0.91-1.07) 
 >50%, HIV positive       0.96 (0.87-1.06) 
Age Group        
 
15-19 1.02 (0.98-1.06)  1.01 (0.98-1.05)  1.01(0.97-1.04)  1.05 (0.97-1.14) 
 20-24 0.96 (0.94-0.99)  0.96 (0.93-0.98)  0.96(0.93-0.98)  0.97 (0.92-1.02) 
 25-29 0.98 (0.96-1.00)  0.98 (0.96-1.00)  0.98(0.96-1.00)  0.96 (0.91-1.01) 
 30-34 1  1  1  1 
 
35-39 1.08 (1.05-1.10)  1.07 (1.05-1.10)  1.07(1.05-1.10)  1.08 (1.02-1.14) 
 40-44 1.17 (1.14-1.20)  1.16 (1.13-1.19)  1.16(1.13-1.19)  1.14 (1.08-1.21) 
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 45-49 1.26 (1.23-1.29)  1.25 (1.22-1.29)  1.25(1.22-1.28)  1.26 (1.19-1.33) 
Place of residence        
 
urban   1  1  1 
 
rural   1.12 (1.10-1.14)  1.13(1.10-1.15)  1.13 (1.08-1.18) 
Effects of age by Place of residence       
 
rural, 15-19       0.95 (0.87-1.03) 
 rural, 20-24       0.99 (0.93-1.05) 
 rural, 25-29       1.03 (0.97-1.09) 
 rural, 30-34       1 
 
rural, 35-39       0.99 (0.94-1.06) 
 rural, 40-44       1.01 (0.95-1.08) 
 rural, 45-49       0.99 (0.93-1.06) 
Region         
 
Southern   0.57 (0.53-0.61)  0.60(0.56-0.65)  0.60 (0.56-0.65) 
 Eastern   1  1  1 
 
Western   1.90 (1.71-2.12)  1.90(1.70-2.12)  1.90 (1.70-2.12) 
ART Coverage            
 
<20%       1  1 
 
20-49%       0.84 (0.76-0.94)  0.85 (0.76-0.94) 
  >50%             0.76 (0.66-0.87)   0.76 (0.66-0.88) 
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Table 8.14: Stratum specific risk ratios, recent sex, married women, exclude pregnancy 
 
  
Southern Africa   East and Mid   West and central 
Urban             
 15-19 1.14 (1.02-1.27)  1.10 (0.98-1.22) 1.10 (0.99-1.23) 
 20-24 1.09 (1.03-1.15)  1.05 (0.99-1.11) 1.05 (0.99-1.12) 
 25-29 1.07 (1.02-1.12)  1.02 (0.98-1.07) 1.03 (0.98-1.09) 
 30-34 1.03 (0.98-1.08)  0.99 (0.95-1.04) 1.00 (0.94-1.06) 
 35-39 1.00 (0.95-1.05)  0.96 (0.91-1.00) 0.96 (0.91-1.02) 
 40-44 0.99 (0.94-1.05)  0.95 (0.90-1.01) 0.96 (0.90-1.02) 
 45-49 0.96 (0.89-1.05)  0.93 (0.85-1.00) 0.93 (0.85-1.02) 
Rural       
 
15-19 1.09 (0.98-1.21)  1.05 (0.94-1.17) 1.05 (0.95-1.17) 
 20-24 1.04 (0.99-1.09)  1.00 (0.95-1.06) 1.01 (0.94-1.07) 
 25-29 1.02 (0.97-1.06)  0.98 (0.93-1.02) 0.99 (0.93-1.04) 
 30-34 0.99 (0.94-1.03)  0.95 (0.90-0.99) 0.95 (0.90-1.01) 
 35-39 0.95 (0.91-1.00)  0.91 (0.87-0.96) 0.92 (0.87-0.98) 
 40-44 0.95 (0.90-1.00)  0.91 (0.86-0.96) 0.92 (0.86-0.98) 
  45-49 0.92 (0.85-0.99)   0.88 (0.82-0.96) 0.89 (0.82-0.97) 
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Table 8.15: Stratum specific risk ratios, Exposed, married women, exclude pregnancy 
Exposed - Married 
Women 
  
Southern Africa   East and Mid   West and central 
Urban             
 15-19 1.33 (1.12-1.59)  1.42 (1.20-1.68) 1.24 (1.06-1.46) 
 20-24 1.21 (1.07-1.37)  1.29 (1.16-1.44) 1.13 (1.02-1.25) 
 25-29 1.12 (1.01-1.26)  1.20 (1.09-1.32) 1.05 (0.96-1.15) 
 30-34 1.12 (1.01-1.25)  1.19 (1.08-1.32) 1.04 (0.95-1.15) 
 35-39 0.98 (0.87-1.09)  1.04 (0.94-1.16) 0.91 (0.82-1.01) 
 40-44 1.12 (0.99-1.27)  1.20 (1.07-1.34) 1.05 (0.94-1.16) 
 45-49 1.09 (0.95-1.26)  1.16 (1.02-1.32) 1.02 (0.89-1.16) 
Rural       
 
15-19 1.30 (1.10-1.54)  1.39 (1.18-1.64) 1.21 (1.03-1.43) 
 20-24 1.18 (1.06-1.31)  1.26 (1.14-1.39) 1.10 (0.99-1.22) 
 25-29 1.10 (1.00-1.21)  1.17 (1.07-1.28) 1.02 (0.93-1.12) 
 30-34 1.09 (1.00-1.20)  1.17 (1.06-1.28) 1.02 (0.93-1.12) 
 35-39 0.95 (0.86-1.06)  1.02 (0.92-1.12) 0.89 (0.80-0.99) 
 40-44 1.09 (0.98-1.22)  1.17 (1.05-1.29) 1.02 (0.92-1.13) 
  45-49 1.06 (0.94-1.21)   1.14 (1.01-1.28) 0.99 (0.88-1.13) 
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Figure 8.11: Adjusted Risk ratio for recent sex,, comparing HIV positive women to negative women with Fertility rate ratio for married women 
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Figure 8.12: Risk ratio of currently using modern contraceptives for married women reporting recent sex, comparing HIV positive women to HIV negative women  
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Figure 8.13: Adjusted Risk ratio for exposure to pregnancy, comparing HIV positive women to negative women with Fertility rate ratio for married women 
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Figure 8.14: Adjusted Risk ratio for recent sex and exposure to a live birth, comparing HIV positive women to negative women with Fertility rate ratio for married women 
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Figure 8.15: Adjusted Fertility rate ratio (FRR/RR) for married women 
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Figure 8.16: Comparing fertility rate ratios adjusted for exposure to pregnancy for all women to married women 
  
15-19 20-24 25-29 30-34 35-39 40-44 45-49
Five Year Age Group
All Women
Married
Rural, East and Mid Africa
15-19 20-24 25-29 30-34 35-39 40-44 45-49
Five Year Age Group
All Women
Married
Rural, Southern Africa
15-19 20-24 25-29 30-34 35-39 40-44 45-49
Five Year Age Group
All Women
Married
Rural, West and Central Africa
15-19 20-24 25-29 30-34 35-39 40-44 45-49
Five Year Age Group
All Women
Married
Urban, East and Mid Africa
15-19 20-24 25-29 30-34 35-39 40-44 45-49
Five Year Age Group
All Women
Married
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model: hivstatusXageagroup residXi.hivstatusXagegroup  regionXhivstatus year country
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9 Final Discussion  
 
The overall aim of this PhD was to improve empirical evidence to inform estimates of 
Paediatric HIV.   This discussion is divided into three sections on the three distinct topics 
of this PhD.  First paediatric survival from HIV, second the acquisition of HIV in pregnancy 
and third the impact of HIV on fertility. Each section summarises the key findings, 
discusses the implications of these findings and make recommendations for future 
research. The final section is an overall summary.  Table 9.1 at the end of this section 
gives an overview of the main findings from each paper long with how it has influenced 
estimates of paediatric HIV. 
 
9.1 Paediatric HIV survival 
9.1.1 Summary of findings  
• Children infected perinatally with HIV have a much higher risk of dying than those 
infected through breastfeeding   
• Differences seen in the survival of children infected perinatally with HIV and 
through breastfeeding cannot be explained by differences in background 
mortality, which is much higher in the neonatal period. 
• The use of four variants to describe net survival by timing of HIV infection 
(perinatal and at different breastfeeding durations) improves the realism of child 
survival when modeling the HIV epidemic.  
 
9.1.2 How has this informed estimates of Paediatric HIV 
The work contained in this PhD on Paediatric survival (chapter 3) has been incorporated 
into models to estimate paediatric HIV, including the Spectrum model used by UNAIDS. 
 
9.1.3 Discussion  
Since ART is now widely available, no new data has or will become available on the 
survival of children infected from HIV in the absence of ART.  This means that the study 
presented in the PhD is the final evidence on the natural history of paediatric survival 
with HIV.   
 
Limitations of the final estimated double Weibull function are that the survival of children 
after 2 years old is based on young adult survival patterns.  Section 3.3 investigated how 
changing these assumptions based on data from a European cohort showing more 
favourable survival in 10-14 year olds compared to 15-19 year olds might change the 
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paediatric estimates.  It concluded that the main effect was to lower AIDS deaths in the 
10-14 year olds and increase them in the 15-19 year olds.  Matching the resulting 
estimated prevalence from Spectrum with these new assumptions did not improve its fit 
to empirical estimates using data from national surveys.  After some discussion at the 
UNAIDS reference group on estimates, projections and modelling as to whether the data 
from the European cohort (which at young ages was based on Haemophiliacs) should 
be used to represent African populations it was decided to keep the estimates that were 
presented in Paper A and section 3.2. 
 
9.2 HIV incidence in pregnancy 
9.2.1 Summary of findings  
At a population level, pregnancy is protective for the acquisition of HIV compared to non-
pregnant and non-postpartum periods.  There is no evidence for a difference in the 
acquisition of HIV in the postpartum period and in non-pregnant periods.   
 
9.2.2 How has this informed estimates of Paediatric HIV 
There was a concern that if HIV acquisition in pregnancy had been higher than in non-
pregnant women, then estimates of vertical transmission would need to be re-evaluated 
as in the period immediately after infection viral load is initially high, implying that mother 
to child transmission is more likely.   With evidence from the work presented in this PhD 
showing that at a population level pregnancy appeared to be protective against HIV 
acquisition it was decided that a  higher  rate  of  incidence  among  pregnant  women  
should  not  be  assumed  in Spectrum.   
 
9.2.3 Discussion  
HIV acquisition in pregnancy has continued to be a concern and area of investigation.  
Shortly after the paper presented in this PhD was published a systematic review was 
prepared by Drake et al70.  The authors found five studies that looked at HIV acquisition 
in pregnancy56, 57, 59, 176, 177 compared to non-pregnant time;  two showed evidence of an 
increased risk57, 177 and three showed no evidence of a difference56, 59, 176.  Based on the 
meta-analysis of these studies, there was no evidence that pregnancy increased the risk 
of HIV acquisition (pooled hazard ratio=1.3, 95% CI: 0.5-1.6).  However the authors failed 
to consider the radically different populations these studies were implemented in, which 
would affect the interpretation of the hazard ratio.  Of the two studies that showed 
evidence for an increased risk in pregnancy one was from a study of serodiscordant 
couples57 in which there is an increased risk of the woman’s exposure to HIV.  The other 
studies were studies of HIV negative sexually active women, some of whom were at 
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moderate or high risk of HIV but were not identified as specifically having an HIV positive 
partner.   Therefore these should not have been put into a meta-analysis together. In the 
study presented in this PhD (not included in Drake at al due to similar publication timing) 
the population at risk is all HIV negative women in the population regardless of risk of 
HIV.   
 
Most recently a study of serodiscordant couples by Thomson et al178 gives evidence of 
an increased risk of HIV per condomless coital act during pregnancy compared to non-
pregnant periods, this study included data from the previous serodiscordant study57.  This 
led to a commentary piece in the same journal71 which finishes with the statement:  
 
“These data serve to emphasize that HIV-seronegative pregnant and postpartum women 
in HIV-endemic areas need to be considered key populations at high risk for HIV 
acquisition, requiring urgent attention to the development of interventions to detect HIV 
seroconversion and initiate ART to prevent transmission to their infants and sexual 
partners, and even more critically, to maintain their HIV-seronegative status.” – 
Mofenson, 2018, Journal of Infectious diseases.  
 
While it is indeed important to prevent mother to child transmission and help a woman 
retain her seronegative status it is also important to put this study in the context of the 
general population where only a small proportion of couples are serodiscordant.  It is 
possible that women who are pregnant (especially those who have been pregnant 
before) are more likely to be concordant with their partner as they are likely to have had 
a fairly long sexual history with the father of their child, increasing the risk of HIV 
transmission prior to the current pregnancy.  The study presented in this PhD (Paper B) 
gave evidence that on a population level pregnancy was actually protective, with the 
likely explanation that couples were more likely to be concordant during pregnancy.   
Further work to estimate the number of serodiscordant couples during pregnancy 
compared to non-pregnant time would enable us to connect up the findings from 
Thomson et al and the work presented in this PhD to help policy makers understand 
where best to allocate resources for prevention of HIV infection and mother to child 
transmission.   
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9.3 The impact of HIV on fertility  
9.3.1 Summary of findings  
Key findings from this PhD that inform the differential in fertility among HIV positive and 
HIV negative women 
• Differences in fertility rate comparing HIV positive to HIV negative women at 
younger ages may be less than previously thought 
• There are regional variations in HIV associated subfertility  
• Duration of infection is independent of age in its impact on fertility  
• Differences in sexual activity and exposure to pregnancy largely explain the steep 
gradient seen by age in the fertility rate ratios comparing HIV positive to HIV 
negative women   
• After accounting for differences in exposure to pregnancy (defined as recent 
sexual intercourse without use of contraception), HIV positive women under the 
age of 30 in urban areas and under 25 in rural areas have a much lower fertility 
rate than their HIV negative counterparts than previously seen when this 
exposure was not considered.   
• Scale up of ART does not appear to have caused HIV positive women to attain 
fertility levels similar to HIV negative women. 
• Scale up of ART does not appear to have changed the relative differences in  
exposure to pregnancy between HIV positive and negative women 
 
9.3.2 How has this informed estimates of Paediatric HIV 
Work on the impact of HIV on fertility is still being evaluated, however in the last few 
years the new assumptions about the fertility level discount applied to HIV positive 
women and the impact of ART on fertility have been implemented in UNAIDS models.  
The following paragraphs discuss the progress made in improving assumptions about 
HIV and fertility and include recommendations for further work.    
 
Estimates of fertility rate ratios comparing HIV positive to HIV negative women 
Previously the fertility rate ratios used in Spectrum for estimating fertility reduction in HIV 
positive women came from Chen and Walker41.  Work from this PhD has re-evaluated 
these estimates, both their magnitude and how they are implemented in Spectrum.   
There was concern that the Chen and Walker analysis, based on retrospective data, 
could be biased due to both misclassification of HIV status and survivorship bias, 
whereby women who die in the analysis period cannot report on their fertility (and are 
more likely to be HIV positive and have lower fertility due to illness).  General population 
cohort data such as ALPHA data should be free of these biases and therefore may be 
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seen as a gold standard.  However these data can also be prone to different biases due 
to missed early infant deaths: a birth and infant death that occur between DSS rounds 
(typically 6 to 12 months apart in ALPHA sites) may be missed by surveys, and since 
these are more likely to occur to HIV positive women this would increase the apparent 
HIV subfertility.    Work done in parallel to paper D in this PhD (section 6) calculated age-
specific fertility rate ratios using ALPHA network data from four sites. These estimates 
were then used in later versions of Spectrum from 2017. This initially caused a problem 
with the estimates which suggested fewer women in need of PMTCT than observed. 
Therefore, in the light of evidence of heterogeneity by region (seen in Paper D and initial 
work presented in Paper E, Section 7) a fitting tool was incorporated into the procedure, 
allowing a scaling of the fertility rate ratios to fit to the number of directly observed 
pregnant women at ANC when assessing the need for PMTCT. 
 
Following this, paper E of this PhD (Section 7) updated the work of Chen and Walker 
using 49 DHS and AIS from sub Saharan Africa. This work confirmed that estimates of 
fertility using the DHS were biased when using data further than one year prior to the 
survey.  The direction of the bias resulted in a higher level of HIV subfertility in younger 
women and lower level in older women.  The analysis in paper E showed that differences 
in fertility at the population level between HIV positive and HIV negative women at 
younger ages are small and in some regions negligible, importantly it also showed that 
there were regional and urban and rural differences in levels of HIV subfertility which had 
also been noted in paper D, using ALPHA data.  The new estimates from paper E were 
slightly at odds with the fertility rate ratios newly implemented in Spectrum from ALPHA 
data showing much less HIV subfertility at younger ages.  The work expanding on the 
appendix for paper E in this PhD explored whether biases in either data source could 
explain the differences and concluded that the number of infant deaths required to be 
missed in the DSS to explain the differences between the estimates was not plausible.  
Since it has been demonstrated that there are regional differences one possible 
explanation is that it is regional differences that explain the differences between DHS 
data and ALPHA data; the sites used from ALPHA were predominately from rural East 
Africa which showed the greatest sub fertility.  In addition, ALPHA study sites are not 
nationally representative and may be located in areas that have even higher subfertility. 
 
In the light of this work it was agreed that the regional specific fertility rate ratios derived 
from Paper E will be used in the next update of Spectrum. 
 
Paper F in this PhD (section 8) demonstrated that the patterns of HIV subfertility change 
when considering sexual exposure. Adjusting for behavioural exposure to pregnancy risk 
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increased HIV subfertility at younger ages and decreased it at older ages, thereby 
removing the steep gradient seen in typical patterns of HIV subfertility by age.  The 
resulting differences in fertility after adjusting for exposure to pregnancy may be 
attributable to direct biological impacts of HIV if we assume there are no other residual 
confounders.   
 
If this were the case there are two main things to note, firstly the immediate discount in 
fertility at young ages occur at a time when the women are likely to be more recently 
infected; secondly the differences in the levels of fertility impacts over regions.  Ross et 
al108 found a reduction in fertility from the earliest asymptomatic stage of infection when 
controlling for age, frequency of sexual intercourse (although not contraceptive use) 
along with other factors, which corresponds to the findings in Paper F.  This could imply 
the HIV virus itself causes an immediate reduction in fertility.  But another biological effect 
may be due to other Sexually Transmitted Infections (STI), since HIV positive women 
are more likely to have or have had another STI179 they could be infertile or sterile from 
previous or repeated infections. STIs are often more prevalent in younger age groups180.    
 
The impact STIs might have on the lower fertility of HIV positive women depends on both 
the prevalence of STIs in the population and differences in STI prevalence between HIV 
positive and HIV negative women, these two factors may not be correlated. In 
populations where an STI is very prevalent the differences by HIV status may be lower 
than in a population with lower prevalence where HIV transmission and STI infection is 
more strongly associated with higher behavioural risk groups.  Published data showing 
STI prevalence by HIV status in general populations is sparse, and there is very little 
data on the overall prevalence of STIs in general populations in Sub Saharan Africa.  
Most data on STI prevalence comes from antenatal clinic settings and studies of 
pregnant women180-183.  Data that compare STI prevalence in HIV positive and negative 
women in antenatal clinics would underestimate the population differences in STI 
prevalence by HIV for STIs such as Gonorrhoea and Chlamydia which cause infertility 
leading to fewer women with these infections being found at ANC.   
 
Overall prevalence of STIs in populations varies widely by region180, 182 which could partly 
explain differences in the estimated subfertility when accounting for exposure to 
pregnancy by region, and in urban and rural settings.   It would be a useful exercise to 
try to model the impact of fertility with different levels and differentials in STI prevalence 
between HIV negative and HIV positive women to see if these could have a significant 
impact on fertility differentials by HIV status.    Recently a study assessed the prevalence 
of STIs in young people in South Africa184. The study was nested in a demographic 
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surveillance site that is also part of the ALPHA Network.  The authors suggested that 
this proof of concept for population based STI surveillance could be conducted in other 
similar study sites such as those from the ALPHA network.  Since the sites that are part 
of the ALPHA network have rich longitudinal data on sexual behaviour, HIV status and 
fertility, nesting STI surveillance within them would not only inform STI prevalence but 
also enrich studies looking at the impact of STIs on HIV and fertility.   
 
A women’s ability to become pregnant also depends on the fertility of her partner.  In the 
absence of ART there is evidence of lower fertility in HIV positive men95-97, therefore for 
young HIV positive women with concordant partners this may also impact on their fertility.   
 
The impact of duration of infection  
Following evidence that duration of infection has an impact on fertility independent of 
age it was agreed that parameters for subfertility by stage of infection be incorporated in 
the Spectrum model.  This was in order to take into account the changing composition 
of duration of infection in each age group as the epidemic matures.     
 
The impact of ART on fertility 
Discussions still continue on the impact of ART on fertility, this is a key factor in the 
current estimates of paediatric HIV and in the future as ART is further scaled up.  With 
most countries now adopting option B+76 a large proportion of HIV positive women will 
be on ART therefore the impact of assumptions about their fertility will have a larger 
impact on Paediatric HIV estimates.  In the current version of Spectrum (V5.63) it is 
assumed that after 6 months an HIV positive women’s fertility is the same as HIV 
negative fertility, this is then scaled up or down to match directly observed ANC data 
where available.  Evidence from this PhD in papers C and E (sections 5 and 7) show that 
on a population level although there may be a slight narrowing of the differences in fertility 
between HIV positive and HIV negative women this is not as large as would be expected 
if it were assumed that HIV positive women on ART have fertility equivalent to their HIV 
negative counterparts.  This is consistent with the systematic review by Yeatman et al73 
concluding that the evidence indicated that fertility increases after the first year on ART 
but remains lower than in HIV negative women of the same age. 
 
There are many reasons to explain why there is little evidence to support the current 
assumption that women on ART have the same fertility as HIV negative women.  First, 
there are other biological factors that ART does not influence, such as coinfection with 
STIs or sterility due to past infection.  Secondly a women’s ability to become pregnant 
also depends on the fertility of her partner.  In the absence of ART there is evidence of 
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lower fertility in HIV positive men.  ART coverage is higher in women than men so even 
if a women was on ART her partner may not be.  There is evidence that HIV positive 
men have lower fertility due to lower quality semen that HIV negative men81.  Thirdly, 
different drug regimes may also effect fertility in different ways and these have changed 
over time, for example one of the current recommended first line treatments include 
Efavirenz185 for which there is evidence that it can lessen contraceptive efficacy of 
hormonal implants186 and may decrease fertility in men104. 
 
Paper F (section 8) shows no evidence of a change in exposure to pregnancy between 
HIV positive and HIV negative women with higher national ART coverage indicating that 
the behavioural component of HIV-associated subfertility has not changed.   Paper F 
found no evidence of a change in the differences in marriage between HIV positive and 
HIV negative women with increased national ART coverage.   There is lower coverage 
of ART in men compared to women, implying that widowhood would not necessarily be 
reduced as much as might be expected from overall national ART coverage levels.  
Separation and divorce may not necessarily change, particularly if the women’s partner 
is HIV negative.   HIV positive women who attend CTC may be more likely to have access 
to family planning due to being in contact with a health facility, and to being counselled 
about family planning.  So it is possible that even if HIV positive women’s fecundity 
improves on ART this is counteracted by more widespread use of contraceptives.  
However Paper F found no evidence for a change in the relative difference between HIV 
positive and HIV negative women in modern contraceptive use for those who had 
reported recent sex  
 
Since around 2005 when ART began to be scaled up in sub Saharan Africa the 
underlying population on ART has changed and so have recommended drug regimes.  
Along with this the proportion of HIV positive women with knowledge of their HIV status 
is increasing.  All these changes cause problems when trying to estimate paediatric HIV 
as estimation of the impact of ART on fertility itself appears to be a moving target.    
 
For estimating the number of children born to HIV positive mothers on or off ART, there 
are three groups of HIV positive women, those who have not attended CTC, those in 
CTC but not on ART and finally those on ART.  Since there are major selection effects 
when considering women on ART we also need to consider the women in the general 
population who are not on treatment.  These women could be healthy and possibly not 
aware of their HIV status, they could be ill and not have been able to seek treatment, or 
they could be less fertile or sterile due to HIV and STI co infections and thus not have 
been referred through ANC.  Therefore in estimating fertility differences, assuming an 
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increase in the fertility of HIV positive women on ART may imply a need to decrease it 
for infected women who are not on ART.    An ideal place to compare these three groups 
of HIV positive women along with HIV negative women is to use data from the ALPHA 
network: two of these study sites have already looked at this77, 80 and found no evidence 
of a difference between fertility of HIV positive women on ART compared to those not on 
treatment.  Increasing the number of sites and follow up time would help us understand 
the fertility in the different populations and enable us to investigate the inherent biases 
in these analyses.   
 
The composition of the population on ART could vary in a number of ways over time. 
Initially as ART is introduced it is likely that there is a high proportion of women on ART 
who initiated treatment at an advanced stage of disease because they are identified as 
in need of treatment due to illness.  The other important group will be women who are 
referred from ANC and found to have a CD4 count below the WHO cut off at the time.  
As scale up of ART continues, the composition will change: firstly because women not 
coming via ANC referral will have a larger range of disease stages at ART initiation due 
to increased coverage of VCT.  As WHO guidelines change with the introduction of option 
B+ pregnant women who initiate ART will initially present at a wide range of ages and 
parities.  This will increase the proportion of healthier women on ART, and possibly the 
proportions of younger, lower parity women who would have been above the CD4 cut-
off under options A and B.   After option B+ has been in operation over a longer period, 
the composition of women of child bearing ages on ART should gradually stabilise, 
although there may be changes in the number of referrals through VCT of infertile women 
and those prior to child bearing, which could change the age composition. Understanding 
the composition of women on ART, by age, CD4 count, pregnancy status at initiation, 
how they were referred at initiation, and how these factors change over time could help 
us understand reasons for the fertility differences (or lack of difference) between women 
on and off ART. It would also help us infer how the population not at CTC clinics might 
be changing.  Networks such as the IeDEA network (International Epidemiology 
Databases to Evaluate AIDS) 187 which is an international network of care and treatment 
clinics including Sub Saharan Africa, are ideally placed to look at such data.   
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Table 9.1:  Summary of main findings and how there have informed estimates of paediatric HIV. 
 Paper Title Main finding  How has this informed estimates of paediatric HIV? 
A Net survival of perinatally 
and postnatally HIV-infected 
children: A pooled analysis of 
individual data from sub-
Saharan Africa 
Those children infected perinatally had a 
much higher risk of dying than those infected 
through breastfeeding, even allowing for 
background mortality.   The final fitted double 
Weibul curves gave 75% survival at five 
months after infection for perinatally-
infected, and 1.1 years for postnatally-
infected children.  An estimated 25% of the 
early infected children would still be alive at 
10.6 years compared to 16.9 years for those 
infected through breastfeeding.     
 
For modelling of paediatric HIV, the increase in available data has 
enabled separation of child mortality patterns by timing of infection 
allowing improvement and more flexibility in modelling of paediatric 
HIV infection and survival.  This work has been incorporated into 
models to estimate paediatric HIV, including the Spectrum model 
used by UNAIDS.  Previously the single curve used to describe 
survival post infection of children assumed they would all die before 
the age of 15.  These curves reduced the HIV mortality in the 10-14 
year olds and cause a large increase in the proportion of HIV positive 
women in the 15-24 year old age groups who were infected through 
mother to child transmission.   
 Research (report for 
UNAIDS) an update to the 
paediatric curve 
Changing the assumption of child survival 
from HIV where there is no empirical data 
available deferred AIDS deaths to older 
ages.  
This paper demonstrated possible ways in which the paediatric 
survival from HIV used in HIV modelling could be changed.  The 
current decision is that, in the absence of more empirical evidence 
the original estimates from paper A should continue to be used.  
 
B “Is the risk of HIV acquisition 
increased during and 
immediately after 
pregnancy?  A secondary 
analysis of pooled HIV 
community-based studies 
from the ALPHA network”. 
Although there may be immunological 
reasons for increased risk of HIV acquisition 
during pregnancy, at a population level this 
study indicates a lower risk of HIV acquisition 
for pregnant women and a similar risk in the 
first year post partum.  
For modelling of Paediatric HIV, this suggests that is no need to 
increase the proportion of HIV positive women who are considered 
an incident infection.   
 
When planning policies relating to higher transmission of HIV in 
pregnancy and the postpartum period, the population level should be 
considered to estimate how many women may be at risk and whether 
targeting them is the most cost effect way of preventing MTCT.  
   
C  “Measuring the Impact of 
antiretroviral therapy roll-out 
on population level fertility in 
three African countries” 
Differences in fertility between HIV positive 
and HIV negative women are narrowing over 
time as ART becomes more widely available 
in these communities.  
 
This provides evidence that routine adjustment of ANC data for 
estimating national HIV prevalence will need to allow for the impact 
of treatment.  
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Table 9.1: continued 
 Paper Title Main finding  How has this informed estimates of paediatric HIV? 
D “The effects of HIV on fertility 
by infection duration: 
evidence from African 
population cohorts before 
ART availability”   
Longer duration of infection is associated 
with greater relative fertility reduction for HIV-
positive women.  
This should be considered when creating estimates for HIV 
prevalence among pregnant women and PMTCT need over the 
course of the HIV epidemic and ART scale-up.  Duration of infection 
has now been incorporated into the Spectrum model used by 
UNAIDS. 
E  “The relationship between 
HIV and fertility in the era of 
antiretroviral therapy in sub 
Saharan Africa – Evidence 
from 49 Demographic & 
Health Surveys” 
Significant regional differences exist in HIV 
and fertility relationships, with less HIV-
associated subfertility in Southern Africa. 
Age patterns of relative fertility are similar.  
HIV impact on fertility is weaker in urban than 
rural areas. For women below age 30, 
regional and urban/rural differences are 
largely explained by differences in age at 
sexual debut. Higher levels of national ART 
coverage appear to slightly attenuate the 
relationship between HIV and fertility.  
Regional differences in HIV-associated subfertility and urban/rural 
differences in age patterns of relative fertility should be accounted for 
when predicting need for and coverage of PMTCT services at 
national and subnational level. Although HIV impacts on fertility are 
somewhat reduced at higher levels of national ART coverage, 
differences in fertility between HIV positive and negative remain, and 
fertility of women on ART should not be assumed to be the same as 
HIV-negative women.   The new estimates from this paper about the 
fertility level discount applied to HIV positive women and the impact 
of ART on fertility have been implemented in UNAIDS models.   
 
F  “Relative patterns of sexual 
activity and fertility among 
HIV positive and negative 
women – evidence from 46 
DHS” 
Exposure to pregnancy differs significantly 
between HIV positive and negative women 
by age, modified by region.  Younger HIV 
positive women have a higher exposure to 
pregnancy that HIV negative women and the 
opposite is true at older ages. The switch 
occurs at 25-29 for rural women and 30-34 
for urban women.  The direct effects of HIV 
on fertility are broadly similar across ages, 
while the dramatic age gradient that has 
frequently been observed is largely 
attributable to variation in relative sexual 
exposure by age. 
 
For modelling of the epidemic, consideration should be given to 
possible changes in sexual activity in the era of ART that may change 
the differences in fertility in HIV positive women compared to HIV 
negative women.  Also there is some evidence that the discount in 
HIV positive women’s fertility may be seen start after infection when 
accounting for sexual activity, this could suggest that some of the 
subfertility seen in HIV positive women may be due to other factors 
such as STIs or a reduction in their partners fertility if they are HIV 
positive.  Since ART in women cannot improve these determinants 
of lower fertility, it is possible that we will not see a large improvement 
at a population level of the fertility in HIV positive women with 
increased ART roll out.  
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9.4 Key strengths and weaknesses of data sources 
This PhD uses data from a number of sources, clinical cohort studies, cross sectional 
nationally representative surveys with retrospective reporting and community based 
demographic and HIV surveillance sites.  Each has its strengths and weaknesses in 
relation to the analyses in this PhD which are discussed in the individual chapters, the 
key issues are discussed below.   
 
The clinical cohort studies used in this PhD (section 3) have significant strength in being 
able to accurately identify the timing of HIV infection in infants born to HIV positive 
mothers using frequent testing from birth, this enabled me to look at survival post 
infection by timing of infection.  One of the weaknesses of these studies is that the follow 
up time is very short, and there is only follow up to around 2.5 years post infection for 
perinatally infected children and only 1.5 years for those infected during breastfeeding.   
Another weakness with clinical cohort studies is the increase the participants may have 
in contact with medical services compared to if they were not part of the trial.  Indeed 
some of the studies explicitly stated that they provided medical care to the participants16.   
This may mean that they do not reflect the experience of the general population.  I 
calculated the net survival to remove this bias, as it takes into account the lower 
background mortality experienced by trial participants, however if treatment averts the 
death of an HIV positive child with a condition that an HIV negative child would have 
survived from, the bias may persist and cause an underestimate in paediatric survival 
from HIV.  
 
There is great strength in community based demographic and HIV surveillance sites such 
as those from the ALPHA network9 as they represent the experience of a general 
population.  The longitudinal nature of the data allows for knowledge of timing of events 
such as HIV acquisition and births.  There are a number of weaknesses using this data 
when analysing pregnancy or birth data, these vary across the study sites depending on 
data collection methods.  One is that for many of the studies either since inception or for 
significant time periods, demographic data has only been collected annually9 which 
means that it is possible events are missed such as early infant deaths as they are born 
and die in the inter census period.  This could cause an underestimation of fertility. Some 
studies use village informers to capture inter census events at the time of the event to 
go some way to minimise this problem25.  Often proxy respondents are used to answer 
questions on pregnancies in the household which may mean underreporting.   Another 
issue is that the source of HIV test data from surveillance rounds may be two or three 
years apart9 giving long sero-conversion intervals.  Thus, for the analysis of HIV 
acquisition in pregnancy we only know that a woman was pregnant at some point during 
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the interval but do not know if the sero-conversion occurred before, during, or 
immediately after, the pregnancy.  However the imputation method I used enabled me 
to allow for this uncertainty and to generate confidence intervals to reflect this.   
 
Demographic and health surveys offer nationally representative data and the core 
questionnaire has been standardised to ensure comparability across populations and 
over time36.  There are a number of limitations this data has for the analyses in this PhD, 
one major limitation in the analysis of HIV and fertility is the cross sectional nature of the 
survey.   In these analysis we use retrospective reporting of births, therefore the time 
period is prior to the survey.  We know HIV status at the time of the survey but do not 
know when the women sero-converted, therefore we must make an assumption of a 
women’s HIV status prior to the survey.  An HIV negative women will be HIV negative 
but an HIV positive women will only have been positive since sero-conversion which is 
an unknown time point.  Therefore the more person years we go back prior to the survey 
assuming an HIV positive women was still positive the more there will be wrongly 
attributed negative person years contributing to this group.  Analysis of this bias 
concluded that going further than one year prior to the survey biased the data enough 
that it should not be included (section 7.2). 
 
For two of the studies (Papers E and F) in the absence of any other information  I used 
estimates of ART coverage in adult women from UNAIDS estimates167.   Therefore the 
national ART coverage used is an ecological variable. It does not measure individual 
exposure to treatment, and hence we have to be cautious about attributing causality, for 
example countries with better roll out of ART may also have other things in common such 
as good health systems, with better provision of family planning services.  One benefit 
of an ecological measure is has the potential to include the indirect effects of ART on 
HIV positive women in the ART era that individual ART usage will not.  For example it 
may be possible that knowledge of ART availability may increase the desire to have 
another child even if the women is not on treatment. 
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9.5 Conclusions 
The work in this PhD has informed estimates of paediatric HIV through providing 
empirical evidence upon which assumptions can be based.  It has provided:   
• estimates of paediatric HIV survival in the absence of ART,  
• evidence that at the population level there is no indication of an increased risk of HIV 
acquisition during pregnancy and the postpartum period that is seen in studies of 
selected populations such as serodiscordant couples,  
• improved estimates of age specific subfertility due to accounting for bias in the data,  
• evidence that there are regional and urban rural differentials in HIV subfertility 
• added to the body of evidence that although the fertility differentials between HIV 
positive and HIV negative women appear to be narrowing slightly in the era of ART 
this is not enough to assume that an HIV positive women on ART’s fertility returns to 
that of her HIV negative counterparts.    
 
Empirical evidence is essential to validate estimates of paediatric HIV.  Understanding 
the underlying mechanisms of population effects of HIV on fertility is essential in order to 
understand what might happen as ART is scaled up in populations.  This PhD work 
provides evidence that sexual activity, which is highly age-dependant, plays a large part 
in HIV subfertility and may mask biological impacts that vary relatively little by age.       
 
Along with the importance of informing paediatric HIV estimates, this work also highlights 
the need for more data on STIs and family planning that need to be collected in general 
population studies in order to understand more the role of behavioural factors such as 
family planning and sexual activity and bio-medical factors such as the role of co-
infection with other STIs and the direct impact of HIV infection on fertility. 
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